

P1 1141165

RECEIVED

10 MAR 2004

WIPO

PCT

THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

**UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office**

March 05, 2004

**THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM
THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK
OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT
APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A
FILING DATE.**

APPLICATION NUMBER: 60/486,713

FILING DATE: July 11, 2003

RELATED PCT APPLICATION NUMBER: PCT/US03/41273

**By Authority of the
COMMISSIONER OF PATENTS AND TRADEMARKS**



M. Sias
**M. SIAS
Certifying Officer**

**PRIORITY
DOCUMENT**
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1 (a) OR (b)

17169 U.S. PTO
07/11/03

ATTORNEY DOCKET NO. TPIP029C+

IN THE U.S. PATENT AND TRADEMARK OFFICE
Provisional Application Cover Sheet.

COMMISSIONER FOR PATENTS
Washington, D.C. 20231

Sir:

This is a request for filing a PROVISIONAL APPLICATION under 37 CFR 1.53(c).

INVENTOR(S)/APPLICANT(S)

Last Name	First Name, MI	Residence (City and Either State or Foreign Country)
Tawa	Mark	Brighton, MA
Almarsson	Orn	Shrewsbury, MA
Remenar	Julius	Framingham, MA

TITLE OF THE INVENTION

PHARMACEUTICAL COMPOSITIONS

CORRESPONDENCE ADDRESS

Customer No. 34846
John Lucas
Transform Pharmaceuticals, Inc.
29 Hartwell Avenue
Lexington, MA

ENCLOSED APPLICATION PARTS (check all that apply)

- (X) Specification *Number of Pages* 639
(X) Drawing(s) *Number of Pages* 20
() Power of Attorney
() Additional inventors are being named on separately numbered sheets attached hereto.

METHOD OF PAYMENT

A check in the amount of \$ 80.00 to cover the filing fee is enclosed.

Charge \$ _____ to Deposit Account _____.

"Express Mail" label no. EV331911915US

Date of Deposit: July 11, 2003

I hereby certify that this is being deposited with the United States Postal Service 'Express Mail Post Office to Addressee' service under 37 CFR 1.10 on the date indicated above and is addressed to the Commissioner for Patents, Washington, D.C. 20231.

By

Jacquie M. Vo
Typed Name: Jacquie M. Vo

Respectfully submitted,

John Lucas

John Lucas
Attorney/Agent for Applicant(s)
Reg. No. 43373

Date: July 11, 2003

Telephone No.: 781-674-7852

16235 U.S. PTO
60/486713

Attorney Docket No. TPIP029C+

158
259
216
633

PHARMACEUTICAL COMPOSITIONS

Inventors: Mark Tawa
111 Kenrick Street
Brighton, MA 02135
Citizenship: USA

Om Almarsson
22 Farmington Drive
Shrewsbury, MA 01545
Citizenship: Iceland

Julius Remenar
9 Eaton Road
Framingham, MA 01701
Citizenship: USA

Pharmaceutical Compositions

INCORPORATION BY REFERENCE

The content of US application nos. 60/437,516, filed December 30, 2002; and US application no. 60/441,335 filed January 21, 2003 are incorporated herein by reference in its entirety.

FIELD OF THE INVENTION

The present invention relates to drug-containing compositions, pharmaceutical compositions comprising such drugs, and methods for preparing same.

BACKGROUND OF THE INVENTION

Drugs in pharmaceutical compositions can be prepared in a variety of different forms. Such drugs can be prepared so as to have a variety of different chemical forms including chemical derivatives or salts. Such drugs can also be prepared to have different physical forms. For example, the drugs may be amorphous or may have different crystalline polymorphs, perhaps existing in different solvation or hydration states. By varying the form of a drug, it is possible to vary the physical properties thereof. For example, crystalline polymorphs typically have different solubilities from one another, such that a more thermodynamically stable polymorph is less soluble than a less thermodynamically stable polymorph. Pharmaceutical polymorphs can also differ in properties such as shelf-life, bioavailability, morphology, vapor pressure, density, color, and compressibility. Accordingly, variation of the solvation state of a drug is one of many ways in which to modulate the physical properties thereof.

A solvate may be defined as a compound formed by solvation, for example as a combination of solvent molecules with molecules or ions of a solute. Well known solvent molecules include water, alcohols and other polar organic solvents. Alcohols include methanol, ethanol, n-propanol, isopropanol, n-butanol, isobutanol, and t-butanol. Alcohols also include polymerized alcohols such as polyalkylene glycols (e.g.,

polyethylene glycol, polypropylene glycol). The best-known and preferred solvent is typically water, and solvate compounds formed by solvation with water are termed hydrates.

Propylene glycol (1,2-propanediol) is a known substance which is a liquid at ambient temperature. As far as the applicants are aware, propylene glycol is not generally well-known for use in the formation of solvates. US Pat. No. 3,970,651 does disclose the use of propylene glycol in the formation of a crystalline cephalosporin derivative. According to this disclosure a propylene glycolate derivative of a specific cephalosporin zwitterion may be formed in the presence of propylene glycol at acidic pH. This disclosure indicates that the propylene glycol derivative is more stable in solid form than the corresponding ethanolate, especially having excellent colour stability and thermal stability. No other solvates are disclosed in this US patent other than the specific solvate of cephalosporin.

In pharmaceutical formulations certain chemical classes of drugs pose particular problems in preparing pharmaceutical formulations for medical use. One such problem arises in the case of hygroscopic drugs, which tend to absorb water from the air. This is disadvantageous because it makes storage of the drug difficult and can cause degradation of the drug in some cases. Such compounds must be handled in controlled humidity environments during manufacture in order to prevent potency errors due to the changing weight of the drug. The final product must be packaged in individual moisture resistant blisters in order to prevent changes in or degradation of the product. Another problem arises from variable hydration states: molecules may change to a more or less stable form as water, a volatile liquid, is lost. Such changes have been known to cause some hydrates to become amorphous. Likewise, absorption of water by a hygroscopic molecule can plasticise the system and lead to recrystallization as a less stable polymorph.

SUMMARY OF THE INVENTION

Solvates are rarely used in pharmaceuticals because the solvents are usually volatile thus making it difficult to maintain the solvent in the crystal. If one were to desolvate a

pharmaceutical solvate or if it desolvated due to storage conditions or otherwise, it could lead to the formation of multiple polymorphs or complete collapse of the crystal structure, forming an amorphous compound with different physical properties. Obviously, this batch-to-batch variability and questionable shelf life is undesired. Typically people find solvates of common solvents, such as propanol and ethanol. Propylene glycol is similar in structure to propanol, but is not thought of as a solvent. Propylene glycol solvates of the present invention desolvate only at considerably higher temperatures and harsher conditions than traditional solvates. Propylene glycol solvates are also pharmaceutically acceptable in much larger amounts than one would expose people to with a traditional solvate. Thus, the propylene glycol solvates of the present invention have characteristics that are vastly superior to traditional solvates.

It has now been found that amorphous, crystalline, hygroscopic, or poorly soluble drugs can be made more soluble, more stable, and less hygroscopic and can be prepared simply, reliably and inexpensively.

In a first aspect, the present invention provides a pharmaceutical composition comprising a propylene glycol solvate of a drug which is hygroscopic or has low aqueous solubility. It has surprisingly been found that by using propylene glycol to form a solvate of a hygroscopic drug, the hygroscopicity of the drug is decreased and/or the stability and aqueous solubility is increased. The drug is therefore much easier to formulate and store than its counterpart untreated or hydrated form.

A number of advantages have been found from the use of propylene glycol in this way. First of all, a higher temperature is required to remove propylene glycol as compared with water or ethanol. This therefore results in an increased thermal stability. Thus the invention further relates to methods of making a pharmaceutical solvate more stable at high temperatures by making a PG solvate of the drug. Secondly, propylene glycol solvates are generally more pharmaceutically acceptable than other common solvates, including those formed from alcohols other than ethanol. It has further been found that

the PG solvates of the present invention have fewer solvation states than hydration states. This is beneficial because production and quality of a drug can be more predictable and consistent. Thus an aspect of the present invention relates to methods of reducing the number of hydration states by making a PG solvate of a drug. PG solvates are also beneficial in addressing the problem of polymorphism. Thus an aspect of the present invention relates to methods of reducing the rate and extent a drug changes form and methods of reducing the chance of making an unwanted form because the PG solvates drive production of a single form. Another aspect of the present invention relates to changing the crystal habit of the drug crystal and preventing a drug crystalline habit from changing to a different habit.

The invention relates to making a pharmaceutical that can be made as a hydrate, more soluble or stable by forming a PG solvate of the drug.

The invention further relates to making a pharmaceutical more stable in a humid environment by making a PG solvate of the drug.

The invention further relates to making a crystalline compound from a pharmaceutical that does not readily crystallize by making a crystalline PG solvate of the drug.

The invention further relates to increasing the solubility of a crystalline pharmaceutical by making a PG solvate of the drug.

The invention further relates to methods of lowering the amount of drug solvation during wet granulation by making a PG solvate of the drug.

A particularly important aspect of the present invention is the realization that formation of propylene glycol solvates is applicable in a general way to drugs whereby the above advantages may be conferred. For example, the invention further relates to reducing the level of hygroscopicity of a pharmaceutical metal salt (crystalline, amorphous, solvate

(e.g., hydrate)) by forming a PG solvate of the salt. Surprisingly, it has been found that the invention is particularly applicable to those drugs that are in the form of metal salts, such as alkali metal or alkaline earth metal salts. This is especially the case where the metal is selected from sodium, potassium, lithium, calcium and magnesium. Such salts can be hygroscopic and it has hitherto been difficult to find a suitable general means of formulation for these drugs.

Generally, the molar ratio of propylene glycol to drug in the solvate is in the range 0.5 to 2, e.g., 0.5, 1.0, 1.5, 2.0. Depending on the nature of the drug, the ratio of propylene glycol to drug in the solvate may be approximately 0.25, 0.33, 0.5, 0.667, 0.75, 1.0, 1.5, 2.00 or 3.

The composition may further comprise a pharmaceutically-acceptable diluent, excipient or carrier and details of pharmaceutical compositions are also set out in further detail below. The solvate of the pharmaceutical composition according to the present invention is preferably in a crystalline form.

Advantageously, the powder X-ray diffraction spectrum of the composition according to the invention differs from the corresponding powder X-ray diffraction spectrum of unsolvated drug by at least one property selected from:

- (i) a loss of at least one peak;
- (ii) shifting of more than half the peaks at the 2-theta angle by at least 0.2°, 0.3°, 0.4° or 0.5°; or
- (iii) formation of at least one new peak.

It is preferred that the solvate is stable to temperatures of up to 50 degrees C under a stream of nitrogen gas in a thermogravimetric analysis apparatus.

The PXRD could be the same if there were a host-guest relationship and the PG was not completely frozen out. This would be an inclusion compound rather than a true solvate, but it may still be less hygroscopic than a hydrate, less prone to solvent loss than an

inclusion with ethanol, less prone to being filled by some toxic co-solvent if PG fits well, and less prone to polymorphism to a less soluble form due to instability caused by a vacated void in the structure. The DSC transitions are likely to occur at different temperatures and have different intensities than for the parent molecule and it's other hydrates/solvates.

In one aspect of the invention, the drug is a hygroscopic drug, including hygroscopic metal salts. A non-exhaustive list of hygroscopic drugs is set out in Table 1, along with their suppliers and routes of administration.

Table 1

Product (company)	Active ingredient	Hygroscopic	Route(s) of Administration
Solu-Medrol (P&U)	Methyl prednisolone succinate ester	X	IV
Primaxin IV and IM (Merck)	Imipenem/cilastatin	X (cilastatin)	IV/IM
Vitravene Injection (CIBA)	Fomivirsen sodium	X	IV
Baycol (Bayer)	Cerivastatin sodium	X	Oral
Synercid IV (Aventis)	Dalfopristin/Quinoprist in	X	IV
Factrel (Wyeth)	Gonadorelin HCl (decapeptide)	X	IV/SC
Clindets Pledgets (Stiefel)	Clindamycin phosphate (ester prodrug)	X	Topical
Famvir (SKB)	Famciclovir	X	Oral
Nascobal Gel (Schwarz)	Cyanocobalamin	X	
Tasmar (Roche)	Tolcapone	X	Oral
Ellence Injection (P&U)	Epirubicin HCl	X	IV

Colestid (P&U)	Colestipol HCl (anion exc.)	X	Oral
Product (company)	Active ingredient	Hygroscopic	Route(s) of Administration
Pfizerpen Injection (Pfizer)	Penicillin G potassium	X	IV
Bacitracin Injection (Paddock)	Bacitracin (peptide)	X	IV
Lescol (Novartis)	Fluvastatin sodium	X	Oral
Voltaren XR (Novartis)	Diclofenac sodium	X	Oral
Salagen (MGI)	Pilocarpine HCl	X	Oral
Urecholine injection (Merck)	Bethanechol chloride	X	IV
Syprine (Merck)	Trientine 2(HCl)	X	Oral
Singulair chewable (Merck)	Montelukast sodium	X	Oral
Mustargen injection (Merck)	Mechlorethamine HCl	X	IV
Hydrocortone phosphate injection (Merck)	Hydrocortisone phosphate ester	X	IV
Decadron phosphate injection (Merck)	Dexamethasone phosphate ester	X	IV
Gastrocrom (Medeva)	Chromolyn sodium	X	Oral
Mestinon (ICN)	Pyridostigmine bromide	X	Oral
Adipex-P (Gate)	Phentermine HCl	X	Oral
Micardis (Boehringer-Ingelh.)	Telmisartan	X	Oral
Cerubidine injection (Bedford)	Daunorubicin HCl	X	IV
Biltricide (Bayer)	Praziquantel	X	Oral
Elmiron (Alza)	Pentosan polysulfate	X	Oral

	sodium		
--	--------	--	--

In one embodiment, the formulation comprises celecoxib. Although the invention is not limited to this particular drug, celecoxib provides a suitable example of the efficacy of the invention. Further details of celecoxib are set out below. In a further embodiment, the drug comprises naproxen, further details of which are also set out below.

In another aspect of the invention, the drug has low aqueous solubility. Typically, low aqueous solubility in the present application refers to a compound having a solubility in water which is less than or equal to 10mg/ml, when measured at 37 degrees C, and preferably less than or equal to 5mg/ml or 1mg/ml. "Low aqueous solubility" can further be defined as less than or equal to 900, 800, 700, 600, 500, 400, 300, 200 150 100, 90, 80, 70, 60, 50, 40, 30, 20 micrograms/ml, or further 10, 5 or 1 micrograms/ml, or further 900, 800, 700, 600, 500, 400, 300, 200 150, 100 90, 80, 70, 60, 50, 40, 30, 20, or 10 ng/ml, or less than 10 ng/ml when measured at 37 degrees C. Aqueous solubility can also be specified as less than 500, 400, 300, 200, 150, 100, 75, 50 or 25 mg/ml. As embodiments of the present invention, solubility can be increased 2, 3, 4, 5, 7, 10, 15, 20, 25, 50, 75, 100, 200, 300, 500, 750, 1000, 5000, or 10,000 times by making a PG solvate of the neutral (crystalline or amorphous), salt, or solvate form(e.g., hydrate, ethanolate, methanolate, isopropanolate, etc.). Further aqueous solubility can be measured in simulated gastric fluid (SGF) rather than water. SGF (non-diluted) of the present invention is made by combining 1 g/L Triton X-100 and 2 g/L NaCl in water and adjusting the pH with 200mM HCl to obtain a solution with a final pH=1.7.

PG solvates of steroids are also included as embodiments of the present invention.

Steroids are an important class of drugs which have low aqueous solubility. Particularly important steroids include acetoxypregnenolone, alclometasone dipropionate, aldosterone, anagestone, norethynodrel., androsterone, betamethasone, budesonide, chlormadinone, chloroprednisone, corticosterone, cortisone, cyclosporine, desogestrel,

desoximethasone, desoxycorticosterone, dexamethasone, dichlorisone, dimethisterone, equilenin, equilin, estradiol, estriol, estrogens, estrone, ethisterone, ethynodiol di, ethynyl estradiol, fludrocortisone, fludrocortisone, flunolide, fluocinolone acetonide, fluorohydrocortisone, fluorometholone, fluoxymesterone, fluprednisolone, flurandrenolide, flurandrenolone, fluogestone, fluticasone propionate, hydrocortisone, hydroxydion, hydroxymethylprogesterone, hydroxyprogesterone, leuprolide, levonorgestrel, loteprednol etabonate, medroxyprogesterone, melengestrol, mesalamine, mestranol, methandrostenolone, methazolamide, methyl testosterone, methylandrostenediol, methylprednisolone, mometasone furoate, norelgestromin, norethandrolone, norethindrone, norethindrone, norethisterone, norgestimate, norgestrel, normethisterone, ondansetron hydrochloride, oxandrolone, oxymetholone, paramethasone, paramethasone, prednisolone, prednisolone, prednisone, pregnenolone, progesterone, prometholone, spironolactone, testosterone, testosterone enanthate, triamcinolone, triamcinolone acetonide, triamcinolone acetonide, vetamethasone disodium phosphate (for some steroids alternative names are included). Formulating steroid drugs presents a problem because of their low aqueous solubility. Embodiments of the present invention are methods of increasing the solubility of steroids by making a PG solvate. Solubility can be specified as discussed above. It is difficult to make crystals of steroids because of their planar structure. Crystallization can be facilitated by making PG solvates. Thus, crystalline PG solvates of steroids and methods of making the same are included in embodiments of the present invention. Steroids generally tend to form non-stoichiometric channel hydrates in which water molecules are trapped in channels between planar steroid regions. Thus, embodiments of the present invention include inhibiting channel formation in steroids by making a PG solvate. Metal salts of steroid drugs can be made and are another example of hygroscopic drugs. Thus, steroid PG solvates are in accordance with one aspect of the present invention. Steroid drugs, whether hygroscopic or not, surprisingly and advantageously form stoichiometric solvates with propylene glycol. Further, the dissolution rate and solubility can be increased with propylene glycol solvates. Thus, the steroid solvates have surprisingly

new properties that make them more favourable for pharmaceutical use and are easier to handle than other forms such as hydrates.

In a further aspect, the present invention provides a method for preparing a propylene glycol solvate of a drug, which method comprises:

- (a) contacting propylene glycol with a drug in solution;
- (b) crystallizing a propylene glycol solvate of the drug from the solution; and
- (c) isolating the solvate. (the drug may be, for example, a hygroscopic drug or a drug of low aqueous solubility).

In a further aspect, the present invention provides a method for decreasing the hygroscopicity of a drug, which method comprises

- (a) contacting the drug with propylene glycol in solution;
- (b) crystallizing a propylene glycol solvate of the drug from the solution; and
- (c) isolating the solvate, wherein the solvate has decreased hygroscopicity as compared to the drug.

In a further aspect, the present invention provides a method for increasing the aqueous solubility of a drug, which method comprises

- (a) contacting the drug with propylene glycol in solution;
- (b) crystallizing a propylene glycol solvate of the drug from the solution; and
- (c) isolating the solvate, wherein the solvate has increased aqueous solubility as compared to the drug.

Typically, conditions for making a solvate are the same as for preparing the corresponding non-solvated form of the drug: the solvate of neutral compound would not be pH controlled; the solvate of an acid addition salt would be prepared by including PG with the drug and the acid; and the solvate of a base addition salt would involve adding the drug, the desired base, and the PG. Different co-solvent systems, anti-solvents, or

temperature conditions may be used to encourage PG solvate formation. Seed crystals may be added if they have previously been prepared and isolated.

The step of isolating the solvate may include separating the solution phase from the solvate. Any common method of separation may be employed, including filtration and decanting. The crystalline solvate may be rinsed one or more times with an appropriate solvent following filtration or decanting. The crystalline solvate is preferably dried to remove excess solution phase. Drying may be carried out by thermal processing, vacuum, blowing a stream of gas such as air, nitrogen, argon or another inert gas, or a combination of any or all of these methods. The intention of the rinsing and drying steps is to remove impurities including residual co-solvents and excess PG, acid, or base if used.

The invention will now be described in further detail, by way of example only, with reference to the accompanying drawings.

BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 1 shows a differential scanning calorimetry trace of the sodium salt of celecoxib prepared by Example 1 between 50 degrees C and 110 degrees C.

Fig. 2 shows a thermogravimetric analysis of the sodium salt of celecoxib prepared by Example 1, which was conducted from about 30 degrees C to about 160 degrees C.

Fig. 3 shows a PXRD pattern of the sodium salt of celecoxib prepared by Example 1.

Fig. 4 shows a differential scanning calorimetry analysis of celecoxib lithium salt MO-116-49B.

Fig. 5 shows a thermogravimetric analysis of celecoxib lithium salt MO-116-49B.

Fig. 6 shows the RAMAN spectrum of celecoxib lithium salt MO-116-49B.

Fig. 7 shows the PXRD pattern of celecoxib lithium salt MO-116-49B.

Fig. 8 shows a differential scanning calorimetry analysis of celecoxib potassium salt MO-116-49A.

Fig. 9 shows a thermogravimetric analysis of celecoxib potassium salt MO-116-49A.

Fig. 10 shows the RAMAN spectrum of celecoxib potassium salt MO-116-49A.

Fig. 11 shows the PXRD pattern of celecoxib potassium salt MO-116-49A.

Fig. 12 shows a thermogravimetric analysis of a propylene glycol solvate of a celecoxib sodium salt.

Fig. 13 shows the PXRD pattern of a propylene glycol solvate of a celecoxib sodium salt.

Fig. 14 shows a thermogravimetric analysis of a propylene glycol solvate of a celecoxib potassium salt.

Fig. 15 shows the PXRD pattern of a propylene glycol solvate of a celecoxib potassium salt.

Fig. 16 shows a thermogravimetric analysis of a propylene glycol solvate of a celecoxib lithium salt.

Fig. 17 shows the thermogravimetric analysis of a propylene glycol solvate of naproxen sodium salt.

Fig. 18 shows a PXRD pattern of a propylene glycol solvate of naproxen sodium salt.

Fig. 19 shows the PXRD pattern of celecoxib sodium salt.

Fig. 20 shows the RAMAN spectrum of celecoxib sodium salt.

Fig. 21A and Fig. 21B show PXRD patterns of propylene glycol solvates of olanzapine.

Fig. 22 shows a thermogravimetric analysis of a propylene glycol solvate of olanzapine.

Fig. 23 shows a differential scanning calorimetry analysis of a propylene glycol solvate of olanzapine.

Fig. 24A and Fig. 24B show PXRD patterns of propylene glycol solvates of cortisone acetate.

Fig. 25 shows a thermogravimetric analysis of a propylene glycol solvate of cortisone acetate.

Fig. 26 shows a differential scanning calorimetry analysis of a propylene glycol solvate of cortisone acetate.

DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to propylene glycol solvate forms, preferably stoichiometric, of certain drugs, including those which are hygroscopic or have low aqueous solubility. Whilst the invention is applicable to any such drugs in general, metal salts of the non-steroidal anti-inflammatory drug celecoxib serve to illustrate the present invention by way of example. Unlike traditional non-steroidal anti-inflammatory drugs (NSAIDs), celecoxib is a selective inhibitor of cyclooxygenase II (COX-2) which causes fewer side effects when administered to a subject. The present applicants have identified new forms of celecoxib that have improved properties, particularly as oral formulations. The applicants have found that a stable, crystalline sodium salt of celecoxib can be synthesised which is significantly more soluble in water than the neutral celecoxib on the market. This sodium salt, or other metal salts can subsequently be improved according to the present invention by the production of a propylene glycol solvate thereof.

Salts of celecoxib are formed by reaction of celecoxib with an acceptable base.

Acceptable bases include, but are not limited to, metal hydroxides and alkoxides with sufficiently high pK_a 's (e.g., pK_a 's greater than about 11 to about 12).

The celecoxib salt can be characterized by differential scanning calorimetry (DSC). The sodium salt of celecoxib prepared in (Comparative) Example 1 is characterized by at least 3 overlapping endothermic transitions between 50 degrees C and 110 degrees C (Fig. 1). Conditions for DSC can be found in Example 1.

Celecoxib salts can be characterized by thermogravimetric analysis (TGA). The sodium salt of celecoxib prepared by Example 1 was characterized by TGA, and had about 3

loosely bound equivalents of water that evaporated between about 30 degrees C and about 40 degrees C, one more tightly bound equivalent of water that evaporated between about 40 degrees C and about 100 degrees C, and one very tightly bound equivalent of water that evaporated between about 140 degrees C and about 160 degrees C (Fig. 2).

Conditions for TGA can be found in Example 1.

Celecoxib salts can also be characterized by powder x-ray diffraction (PXRD). The sodium salt of celecoxib prepared by Example 1 had an intense reflection or peak at a 2-theta angle of 6.40°, and other reflections or peaks at 7.01°, 16.73°, and 20.93° (Fig. 3).

Conditions for PXRD can be found in Example 1.

Further celecoxib salts are characterized in the Examples below.

Naproxen is a further drug which may be used to illustrate the present invention.

Naproxen is a member of the ibufenac group of NSAIDs. This drug is practically insoluble in water.

An aspect of the present invention provides a pharmaceutical composition comprising a propylene glycol solvate of a drug that is less hygroscopic than the amorphorous, neutral crystalline, or salt crystalline form, and/or has greater aqueous solubility. Hygroscopicity should be assessed by dynamic vapor sorption analysis, in which 5-50 mg of the compound is suspended from a Cahn microbalance. The compound being analyzed should be placed in a non-hygroscopic pan and its weight should be measured relative to an empty pan composed of identical material and having nearly identical size, shape, and weight. Ideally, platinum pans should be used. The pans should be suspended in a chamber through which a gas, such as air or nitrogen, having a controlled and known percent relative humidity (%RH) is flowed until equilibrium criteria are met. Typical equilibrium criteria include weight changes of less than 0.01 % change over 3 minutes at constant humidity and temperature. The relative humidity should be measured for samples dried under dry nitrogen to constant weight (<0.01 % change in 3 minutes) at 40

degrees C unless doing so would de-solvate or otherwise convert the material to an amorphous compound. In one aspect, the hygroscopicity of a dried compound can be assessed by increasing the RH from 5 to 95 % in increments of 5 % RH and then decreasing the RH from 95 to 5 % in 5 % increments to generate a moisture sorption isotherm. The sample weight should be allowed to equilibrate between each change in % RH. If the compound deliquesces or becomes amorphous between above 75 % RH, but below 95 % RH, the experiment should be repeated with a fresh sample and the relative humidity range for the cycling should be narrowed to 5-75 % RH or 10-75 % RH instead of 5-95 %RH. If the sample cannot be dried prior to testing due to lack of form stability, then the sample should be studied using two complete humidity cycles of either 10-75 % RH or 5-95 % RH, and the results of the second cycle should be used if there is significant weight loss at the end of the first cycle.

Hygroscopicity can be defined using various parameters. For purposes of the present invention, a non-hygroscopic molecule should not gain or lose more than 1.0%, or more preferably, 0.5 % weight at 25 degrees C when cycled between 10 and 75 % RH (relative humidity at 25 degrees C). The non-hygroscopic molecule more preferably should not gain or lose more than 1.0%, or more preferably, 0.5 % weight when cycled between 5 and 95 %RH at 25 degrees C, or more than 0.25 % of its weight between 10 and 75 % RH. Most preferably, a non-hygroscopic molecule will not gain or lose more than 0.25 % of its weight when cycled between 5 and 95 % RH.

Alternatively, for purposes of the present invention, hygroscopicity can be defined using the parameters of Callaghan et al., *Equilibrium moisture content of pharmaceutical excipients*, in Drug Dev. Ind. Pharm., Vol. 8, pp. 335-369 (1982). Callaghan et al. classified the degree of hygroscopicity into four classes.

Class 1: Non-hygroscopic

Essentially no moisture increases occur at relative humidities below 90%.

Class 2: Slightly hygroscopic

Essentially no moisture increases occur at relative humidities below 80%.

Class 3: Moderately hygroscopic

Moisture content does not increase more than 5% after storage for 1 week at relative humidities below 60%.

Class 4: Very hygroscopic Moisture content increase may occur at relative humidities as low as 40 to 50%.

Alternatively, for purposes of the present invention, hygroscopicity can be defined using the parameters of the European Pharmacopoeia Technical Guide (1999, p. 86) which has defined hygroscopicity, based on the static method, after storage at 25 degrees C for 24 h at 80 % RH:

Slightly hygroscopic: Increase in mass is less than 2 percent m/m and equal to or greater than 0.2 percent m/m.

Hygroscopic: Increase in mass is less than 15 percent m/m and equal to or greater than 0.2 percent m/m.

Very hygroscopic: Increase in mass is equal to or greater than 15 percent m/m.

Deliquescent: Sufficient water is absorbed to form a liquid.

PG solvates of the present invention can be set forth as being in Class 1, Class 2, or Class 3, or as being Slightly hygroscopic, Hygroscopic, or Very hygroscopic. PG solvates of the present invention can also be set forth based on their ability to reduce hygroscopicity. Thus, preferred PG solvates of the present invention are less hygroscopic than the non-

PG solvated reference compound, e.g., the reference compound of a celecoxib sodium salt PG solvate is celecoxib sodium salt. Further included in the present invention are PG solvates that do not gain or lose more than 1.0% weight at 25 degrees C when cycled between 10 and 75 % RH, wherein the reference compound gains or loses more than 1.0% weight under the same conditions. Further included in the present invention are PG solvates that do not gain or lose more than 0.5% weight at 25 degrees C when cycled between 10 and 75 % RH, wherein the reference compound gains or loses more than 0.5% or more than 1.0% weight under the same conditions. Further included in the present invention are PG solvates that do not gain or lose more than 1.0% weight at 25 degrees C when cycled between 5 and 95 % RH, wherein the reference compound gains or loses more than 1.0% weight under the same conditions. Further included in the present invention are PG solvates that do not gain or lose more than 0.5% weight at 25 degrees C when cycled between 5 and 95 % RH, wherein the reference compound gains or loses more than 0.5% or more than 1.0% weight under the same conditions. Further included in the present invention are PG solvates that do not gain or lose more than 0.25% weight at 25 degrees C when cycled between 5 and 95 % RH, wherein the reference compound gains or loses more than 0.5% or more than 1.0% weight under the same conditions.

Further included in the present invention are PG solvates that have a hygroscopicity (according to Callaghan et al.) that is at least one class lower than the reference compound or at least two classes lower than the reference compound. Non-limiting examples include; a Class 1 PG solvate of a Class 2 reference compound, a Class 2 PG solvate of a Class 3 reference compound, a Class 3 PG solvate of a Class 4 reference compound, a Class 1 PG solvate of a Class 3 reference compound, a Class 1 PG solvate of a Class 4 reference compound, or a Class 2 PG solvate of a Class 4 reference compound.

Further included in the present invention are PG solvates that have a hygroscopicity (according to the European Pharmacopoeia Technical Guide) that is at least one class

lower than the reference compound or at least two classes lower than the reference compound. Non-limiting examples include; a Slightly hygroscopic PG solvate of a Hygroscopic reference compound, a Hygroscopic PG solvate of a Very Hygroscopic reference compound, a Very Hygroscopic PG solvate of a Deliquescent reference compound, a Slightly hygroscopic PG solvate of a Very Hygroscopic reference compound, a Slightly hygroscopic PG solvate of a Deliquescent reference compound, a Hygroscopic PG solvate of a Deliquescent reference compound.

In another aspect of the present invention, the dissolution profile of the API (active pharmaceutical ingredient) (e.g. celecoxib) is modulated whereby the aqueous dissolution rate or the dissolution rate in simulated gastric fluid (SGF) or in simulated intestinal fluid (SIF), or in a solvent or plurality of solvents is increased. Dissolution rate is the rate at which API solids dissolve in a dissolution medium. For APIs whose absorption rates are faster than the dissolution rates (e.g., steroids), the rate-limiting step in the absorption process is often the dissolution rate. Because of a limited residence time at the absorption site, APIs that are not dissolved before they are removed from the intestinal absorption site are considered useless. Therefore, the rate of dissolution has a major impact on the performance of APIs that are poorly soluble. Because of this factor, the dissolution rate of APIs in solid dosage forms is an important, routine, quality control parameter used in the API manufacturing process. $\text{Dissolution rate} = K S (C_s - C)$

where K is dissolution rate constant, S is the surface area, C_s is the apparent solubility, and C is the concentration of API in the dissolution media. For rapid API absorption, $C_s - C$ is approximately equal to C_s . The dissolution rate of APIs may be measured by conventional means known in the art.

The increase in the dissolution rate of a composition of the present invention, as compared to the unsolvated form, may be specified, such as by 10, 20, 30, 40, 50, 60, 70, 80, 90, or 100%, or by 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 40, 50, 75, 100, 125, 150, 175, 200, 250, 300, 350, 400, 500, 1000, 10,000, or 100,000 fold greater than the unsolvated form in the same solution. Conditions under which the dissolution rate is

measured are discussed above. The increase in dissolution may be further specified by the time the composition remains supersaturated. Examples of above embodiments include: compositions with a dissolution rate, at 37 degrees C and a pH of 7.0, that is increased at least 5 fold over the unsolvated form, compositions with a dissolution rate in SGF that is increased at least 5 fold over the unsolvated form, compositions with a dissolution rate in SIF that is increased at least 5 fold over the unsolvated form.

The present invention demonstrates that the length of time in which celecoxib or other APIs remains in solution can be increased to a surprising high degree by using a PG solvate form as discussed herein. The presence of propylene glycol allows the formation of a supersaturated solution of the API and a high concentration of API will remain in solution for an extended period of time. Celecoxib, for example, has a solubility in water of less than 1 microgram/mL and cannot be maintained as a supersaturated solution for any appreciable time. The present invention has drawn compositions that can be maintained for a period of time (e.g., 15, 30, 45, 60, mins and longer) as supersaturated solutions at concentrations 2, 3, 5, 7, 10, 20, 30, 40, 50, 60, 70, 80, 90, or 100%, or by 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 40, 50, 75, 100, 125, 150, 175, 200, 250, 300, 350, 400, 500, 1000, 10,000, or 100,000 fold greater than the solubility of the unsolvated form in the same solution (e.g., water or SGF).

The methods of the present invention can be used to make a pharmaceutical API formulation with greater solubility, dissolution, bioavailability, AUC, reduced time to T_{max} , the average time from administration to reach peak blood serum levels, higher C_{max} , the average maximum blood serum concentration of API following administration, and longer $T_{1/2}$, the average terminal half-life of API blood serum concentration following T_{max} , when compared to the unsolvated form.

AUC is the area under the plot of plasma concentration of API (not logarithm of the concentration) against time after API administration. The area is conveniently determined by the "trapezoidal rule": the data points are connected by straight line segments,

perpendiculars are erected from the abscissa to each data point, and the sum of the areas of the triangles and trapezoids so constructed is computed. When the last measured concentration (C_n , at time t_n) is not zero, the AUC from t_n to infinite time is estimated by C_n/k_{el} .

The AUC is of particular use in estimating bioavailability of drugs, and in estimating total clearance of drugs (Cl_T). Following single intravenous doses, $AUC = D/Cl_T$, where D is the dose, for single compartment systems obeying first-order elimination kinetics; alternatively, $AUC = C_0/k_{el}$, where k_{el} is the drug elimination rate constant. With routes other than the intravenous $AUC = F \cdot D/Cl_T$, where F is the bioavailability of the drug.

Thus, in a further aspect, the present invention provides a process for modulating the bioavailability of an API when administered in its normal and effective dose range, whereby the AUC is increased, the time to T_{max} is reduced, or C_{max} is increased, which process comprises the preparation of a PG solvate.

Examples of the above embodiments include: compositions with a time to T_{max} that is reduced by at least 10% as compared to the neutral free form, compositions with a time to T_{max} that is reduced by at least 20% over the free form, compositions with a time to T_{max} that is reduced by at least 40% over the free form, compositions with a time to T_{max} that is reduced by at least 50% over the free form, compositions with a T_{max} that is reduced by at least 60% over the free form, compositions with a T_{max} that is reduced by at least 70% over the free form, compositions with a T_{max} that is reduced by at least 80% over the free form, compositions with a C_{max} that is increased by at least 20% over the free form, compositions with a C_{max} that is increased by at least 30% over the free form, compositions with a C_{max} that is increased by at least 40% over the free form, compositions with a C_{max} that is increased by at least 50% over the free form, compositions with a C_{max} that is increased by at least 60% over the free form, compositions with a C_{max} that is increased by at least 70% over the free form, compositions with a C_{max} that is increased by at least 80% over the free form,

compositions with a C_{max} that is increased by at least 2 times the free form,
compositions with a C_{max} that is increased by at least 3 times the free form,
compositions with a C_{max} that is increased by at least 4 times the free form,
compositions with a C_{max} that is increased by at least 5 times the free form,
compositions with a C_{max} that is increased by at least 6 times the free form,
compositions with a C_{max} that is increased by at least 7 times the free form,
compositions with a C_{max} that is increased by at least 8 times the free form,
compositions with a C_{max} that is increased by at least 9 times the free form,
compositions with a C_{max} that is increased by at least 10 times the free form,
compositions with an AUC that is increased by at least 10% over the free form,
compositions with an AUC that is increased by at least 20% over the free form,
compositions with an AUC that is increased by at least 30% over the free form,
compositions with an AUC that is increased by at least 40% over the free form,
compositions with an AUC that is increased by at least 50% over the free form,
compositions with an AUC that is increased by at least 60% over the free form,
compositions with an AUC that is increased by at least 70% over the free form,
compositions with an AUC that is increased by at least 80% over the free form,
compositions with an AUC that is increased by at least 1 times the free form,
compositions with an AUC that is increased by at least 2 times the free form,
compositions with an AUC that is increased by at least 3 times the free form, or
compositions with an AUC that is increased by at least 4 times the free form.

The uptake of a drug by a subject can also be assessed in terms of maximum blood serum concentration and time to reach maximum blood serum concentration. Pharmaceutical compositions with a more rapid onset to therapeutic effect typically reach a higher maximum blood serum concentration (C_{max}) a shorter time after oral administration (T_{max}). Preferably, compositions of the present invention have a higher C_{max} and/or a shorter T_{max} than in the unsolvated form. The T_{max} for the compositions of the present invention occurs within about 60 minutes, 55 minutes, 50 minutes, 45 minutes, 40 minutes, 35 minutes, 30 minutes, 25 minutes, 20 minutes, 15 minutes, 10 minutes, or

within about 5 minutes of administration (e.g., oral administration). Even more preferably, the therapeutic effects of compositions of the present invention begin to occur within about 60 minutes, 55 minutes, 50 minutes, 45 minutes, 40 minutes, 35 minutes, 30 minutes, within about 25 minutes, within about 20 minutes, within about 15 minutes, within about 10 minutes, or within about 5 minutes of administration (e.g., oral administration).

Compositions of the present invention have a bioavailability greater than their respective unsolvated forms. In other embodiments, the compositions of the present invention have a bioavailability of at least 50%, 60%, 65%, 70%, 75%, 80%, 85%, 87%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%.

In a particular embodiment of the present invention, administration of celecoxib PG solvate to a subject may result in effective pain relief. Pain relief can be attained by *inter alia* reaching an appropriate blood serum concentration of a suitable analgesic. In the case of the selective COX-2 inhibitor celecoxib, about 250 ng/mL is an appropriate concentration for the relief of pain of various causes. Any standard pharmacokinetic protocol can be used to determine blood serum concentration profile in humans following oral administration of a celecoxib formulation, and thereby establish whether that formulation meets the pharmacokinetic criteria set out herein. The prior art includes many examples of pharmacokinetic studies and as such US Pat. No. 6,579,895 and WO 01/91750 are hereby included as references in their entirety.

In a further aspect the present invention provides a process for improving the dose response of an API by making a composition of the present invention. Dose response is the quantitative relationship between the magnitude of response and the dose inducing the response and may be measured by conventional means known in the art. The curve relating therapeutic effect (as the dependent variable) to dose (as the independent variable) for an API-cell system is the "dose-response curve". Typically, the dose-response curve is the measured response to an API plotted against the dose of the API

(mg/kg) given. The dose response curve can also be a curve of AUC against the dose of the API given.

The dose-response curve for many APIs (e.g. presently-marketed celecoxib (CELEBREXTM)) is nonlinear. Preferably, the dose-response curves for the PG solvate compositions of the present invention are linear or contain a larger linear region than presently-marketed celecoxib. A preferred embodiment of the present invention may incorporate a dose-response curve with a linear slope that is steeper than that of celecoxib. This would allow a faster-onset of therapeutic relief from a smaller dosage of API. An initially steep dose-response curve which gradually levels out could be employed to generate a controlled-release formulation. Also, the absorption or uptake of many APIs (e.g. presently-marketed celecoxib) depends in part on food effects, such that uptake of the API increases when taken with food, especially fatty food. Preferably, uptake of the PG solvates of the present invention exhibit a decreased dependence on food, such that the difference in uptake of the PG solvates when taken with food and when not taken with food is less than the difference in uptake of the unsolvated form.

The compositions of the present invention, including the active pharmaceutical ingredient (API) and formulations comprising the API, are suitably stable for pharmaceutical use. Preferably, the API or formulations thereof of the present invention are stable such that when stored at 30 degrees C for 2 years, less than 0.2% of any one degradant is formed. The term degradant refers herein to product(s) of a single type of chemical reaction. For example, if a hydrolysis event occurs that cleaves a molecule into two products, for the purpose of the present invention, it would be considered a single degradant. More preferably, when stored at 40 degrees C for 2 years, less than 0.2% of any one degradant is formed. Alternatively, when stored at 30 degrees C for 3 months, less than 0.2% or 0.15%, or 0.1% of any one degradant is formed, or when stored at 40 degrees C for 3 months, less than 0.2% or 0.15%, or 0.1% of any one degradant is formed. Further

alternatively, when stored at 60 degrees C for 4 weeks, less than 0.2% or 0.15%, or 0.1% of any one degradant is formed. The relative humidity (RH) may be specified as ambient (RH), 75% (RH), or as any single integer between 1 to 99%.

APIs prepared in the form of propylene glycol solvates have several important advantages over other solvates and their free form counterparts. In general, solvates are more commonly formed with water, methanol, ethanol, or other alcohols than with propylene glycol. These more common solvates are more easily removed from the crystal matrix by elevated temperatures than propylene glycol. PG solvates have an increased thermal stability over those of more traditional solvates. Also, PG solvates are generally more pharmaceutically acceptable than other common solvates, including those formed from alcohols other than ethanol. Investigations of the PG solvates of the present invention have shown fewer solvation states than hydration states. Reference compounds for PG solvates can be unsolvated free acid, unsolvated free base, zwitter ions, hydrates, or other solvates (e.g. methanol, ethanol, etc.). This decrease in form diversity associated with PG solvates can lead to more predictability and more consistent results during production and quality control. Stabilization of a desired solvate or polymorph can be achieved by causing the less desirable forms (e.g. solvates, polymorphs, hydrates) to be energetically less favorable than the desired form. In this way, PG solvates can aid in the production of pharmaceutical formulations with increased form stability.

The present invention further relates to methods of making a pharmaceutical solvate more stable at elevated temperatures (e.g. 30, 40, 50 degrees C) by producing a PG solvate of the drug. The present invention further relates to methods of making a more pharmaceutically acceptable solvate of many APIs by employing propylene glycol rather than more biologically harmful solvents (e.g. methanol). The present invention further relates to methods of reducing the number of forms (e.g. hydration states, solvation states, polymorphs, etc.) possible for a pharmaceutical solvate.

Excipients employed in pharmaceutical compositions of the present invention can be solids, semi-solids, liquids or combinations thereof. Compositions of the invention containing excipients can be prepared by any known technique of pharmacy that comprises admixing an excipient with a drug or therapeutic agent. A pharmaceutical composition of the invention contains a desired amount of API per dose unit and, if intended for oral administration, can be in the form, for example, of a tablet, a caplet, a pill, a hard or soft capsule, a lozenge, a cachet, a dispensable powder, granules, a suspension, an elixir, a dispersion, a liquid, or any other form reasonably adapted for such administration. Presently preferred are oral dosage forms that are discrete dose units each containing a predetermined amount of the drug, such as tablets or capsules.

Non-limiting examples follow of excipients that can be used to prepare pharmaceutical compositions of the invention.

Pharmaceutical compositions of the invention optionally comprise one or more pharmaceutically acceptable carriers or diluents as excipients. Suitable carriers or diluents illustratively include, but are not limited to, either individually or in combination, lactose, including anhydrous lactose and lactose monohydrate; starches, including directly compressible starch and hydrolyzed starches (e.g., CelutabTM and EmdexTM); mannitol; sorbitol; xylitol; dextrose (e.g., CereleaseTM 2000) and dextrose monohydrate; dibasic calcium phosphate dihydrate; sucrose-based diluents; confectioner's sugar; monobasic calcium sulfate monohydrate; calcium sulfate dihydrate; granular calcium lactate trihydrate; dextrates; inositol; hydrolyzed cereal solids; amylose; celluloses including microcrystalline cellulose, food grade sources of alpha- and amorphous cellulose (e.g., RexcelJ), powdered cellulose, hydroxypropylcellulose (HPC) and hydroxypropylmethylcellulose (HPMC); calcium carbonate; glycine; bentonite; block co-polymers; polyvinylpyrrolidone; and the like. Such carriers or diluents, if present, constitute in total about 5% to about 99%, preferably about 10% to about 85%, and more preferably about 20% to about 80%, of the total weight of the composition.

The carrier, carriers, diluent, or diluents selected preferably exhibit suitable flow properties and, where tablets are desired, compressibility.

Lactose, mannitol, dibasic sodium phosphate, and microcrystalline cellulose (particularly Avicel PH microcrystalline cellulose such as Avicel PH 101), either individually or in combination, are preferred diluents. These diluents are chemically compatible with celecoxib. The use of extragranular microcrystalline cellulose (that is, microcrystalline cellulose added to a granulated composition) can be used to improve hardness (for tablets) and/or disintegration time. Lactose, especially lactose monohydrate, is particularly preferred. Lactose typically provides compositions having suitable release rates of celecoxib, stability, pre-compression flowability, and/or drying properties at a relatively low diluent cost. It provides a high density substrate that aids densification during granulation (where wet granulation is employed) and therefore improves blend flow properties and tablet properties.

Pharmaceutical compositions of the invention optionally comprise one or more pharmaceutically acceptable disintegrants as excipients, particularly for tablet formulations. Suitable disintegrants include, but are not limited to, either individually or in combination, starches, including sodium starch glycolate (e.g., ExplotabTM of PenWest) and pregelatinized corn starches (e.g., NationalTM 1551 of National Starch and Chemical Company, NationalTM 1550, and ColocornTM 1500), clays (e.g., VeegumTM HV of R.T. Vanderbilt), celluloses such as purified cellulose, microcrystalline cellulose, methylcellulose, carboxymethylcellulose and sodium carboxymethylcellulose, croscarmellose sodium (e.g., Ac-Di-SolTM of FMC), alginates, crospovidone, and gums such as agar, guar, locust bean, karaya, pectin and tragacanth gums.

Disintegrants may be added at any suitable step during the preparation of the composition, particularly prior to granulation or during a lubrication step prior to compression. Such disintegrants, if present, constitute in total about 0.2% to about 30%;

preferably about 0.2% to about 10%, and more preferably about 0.2% to about 5%, of the total weight of the composition.

Croscarmellose sodium is a preferred disintegrant for tablet or capsule disintegration, and, if present, preferably constitutes about 0.2% to about 10%, more preferably about 0.2% to about 7%, and still more preferably about 0.2% to about 5%, of the total weight of the composition. Croscarmellose sodium confers superior intragranular disintegration capabilities to granulated pharmaceutical compositions of the present invention.

Pharmaceutical compositions of the invention optionally comprise one or more pharmaceutically acceptable binding agents or adhesives as excipients, particularly for tablet formulations. Such binding agents and adhesives preferably impart sufficient cohesion to the powder being tableted to allow for normal processing operations such as sizing, lubrication, compression and packaging, but still allow the tablet to disintegrate and the composition to be absorbed upon ingestion. Such binding agents may also prevent or inhibit crystallization or recrystallization of a celecoxib salt of the present invention once the salt has been dissolved in a solution. Suitable binding agents and adhesives include, but are not limited to, either individually or in combination, acacia; tragacanth; sucrose; gelatin; glucose; starches such as, but not limited to, pregelatinized starches (e.g., NationalTM 1511 and NationalTM 1500); celluloses such as, but not limited to, methylcellulose and carmellose sodium (e.g., TyloseTM); alginic acid and salts of alginic acid; magnesium aluminum silicate; PEG; guar gum; polysaccharide acids; bentonites; povidone, for example povidone K-15, K-30 and K-29/32; polymethacrylates; HPMC; hydroxypropylcellulose (e.g., KlucelTM of Aqualon); and ethylcellulose (e.g., EthocelTM of the Dow Chemical Company). Such binding agents and/or adhesives, if present, constitute in total about 0.5% to about 25%, preferably about 0.75% to about 15%, and more preferably about 1% to about 10%, of the total weight of the pharmaceutical composition.

Many of the binding agents are polymers comprising amide, ester, ether, alcohol or ketone groups and, as such, are preferably included in pharmaceutical compositions of the present invention. Polyvinylpyrrolidones such as povidone K-30 are especially preferred. Polymeric binding agents can have varying molecular weight, degrees of crosslinking, and grades of polymer. Polymeric binding agents can also be copolymers, such as block co-polymers that contain mixtures of ethylene oxide and propylene oxide units. Variation in these units' ratios in a given polymer affects properties and performance. Examples of block co-polymers with varying compositions of block units are Poloxamer 188 and Poloxamer 237 (BASF Corporation).

Pharmaceutical compositions of the invention optionally comprise one or more pharmaceutically acceptable wetting agents as excipients. Non-limiting examples of surfactants that can be used as wetting agents in pharmaceutical compositions of the invention include quaternary ammonium compounds, for example benzalkonium chloride, benzethonium chloride and cetylpyridinium chloride, dioctyl sodium sulfosuccinate, polyoxyethylene alkylphenyl ethers, for example nonoxynol 9, nonoxynol 10, and octoxynol 9, poloxamers (polyoxyethylene and polyoxypropylene block copolymers), polyoxyethylene fatty acid glycerides and oils, for example polyoxyethylene (8) caprylic/capric mono- and diglycerides (e.g., LabrasolTM of Gattefosse), polyoxyethylene (35) castor oil and polyoxyethylene (40) hydrogenated castor oil; polyoxyethylene alkyl ethers, for example polyoxyethylene (20) cetostearyl ether, polyoxyethylene fatty acid esters, for example polyoxyethylene (40) stearate, polyoxyethylene sorbitan esters, for example polysorbate 20 and polysorbate 80 (e.g., TweenTM 80 of ICI), propylene glycol fatty acid esters, for example propylene glycol laurate (e.g., LauroglycolTM of Gattefosse), sodium lauryl sulfate, fatty acids and salts thereof, for example oleic acid, sodium oleate and triethanolamine oleate, glyceryl fatty acid esters, for example glyceryl monostearate, sorbitan esters, for example sorbitan monolaurate, sorbitan monooleate, sorbitan monopalmitate and sorbitan monostearate, tyloxapol, and mixtures thereof. Such wetting agents, if present, constitute in total about

0.25% to about 15%, preferably about 0.4% to about 10%, and more preferably about 0.5% to about 5%, of the total weight of the pharmaceutical composition.

Wetting agents that are anionic surfactants are preferred. Sodium lauryl sulfate is a particularly preferred wetting agent. Sodium lauryl sulfate, if present, constitutes about 0.25% to about 7%, more preferably about 0.4% to about 4%, and still more preferably about 0.5% to about 2%, of the total weight of the pharmaceutical composition.

Pharmaceutical compositions of the invention optionally comprise one or more pharmaceutically acceptable lubricants (including anti-adherents and/or glidants) as excipients. Suitable lubricants include, but are not limited to, either individually or in combination, glyceryl behenate (e.g., CompritolTM 888 of Gattefosse); stearic acid and salts thereof, including magnesium, calcium and sodium stearates; hydrogenated vegetable oils (e.g., SterotexTM of Abitec); colloidal silica; talc; waxes; boric acid; sodium benzoate; sodium acetate; sodium fumarate; sodium chloride; DL-leucine; PEG (e.g., CarbowaxTM 4000 and CarbowaxTM 6000 of the Dow Chemical Company); sodium oleate; sodium lauryl sulfate; and magnesium lauryl sulfate. Such lubricants, if present, constitute in total about 0.1% to about 10%, preferably about 0.2% to about 8%, and more preferably about 0.25% to about 5%, of the total weight of the pharmaceutical composition.

Magnesium stearate is a preferred lubricant used, for example, to reduce friction between the equipment and granulated mixture during compression of tablet formulations.

Suitable anti-adherents include, but are not limited to, talc, cornstarch, DL-leucine, sodium lauryl sulfate and metallic stearates. Talc is a preferred anti-adherent or glidant used, for example, to reduce formulation sticking to equipment surfaces and also to reduce static in the blend. Talc, if present, constitutes about 0.1% to about 10%, more preferably about 0.25% to about 5%, and still more preferably about 0.5% to about 2%, of the total weight of the pharmaceutical composition.

Glidants can be used to promote powder flow of a solid formulation. Suitable glidants include, but are not limited to, colloidal silicon dioxide, starch, talc, tribasic calcium phosphate, powdered cellulose and magnesium trisilicate. Colloidal silicon dioxide is particularly preferred.

Other excipients such as colorants, flavors and sweeteners are known in the pharmaceutical art and can be used in pharmaceutical compositions of the present invention. Tablets can be coated, for example with an enteric coating, or uncoated. Compositions of the invention can further comprise, for example, buffering agents.

Optionally, one or more effervescent agents can be used as disintegrants and/or to enhance organoleptic properties of pharmaceutical compositions of the invention. When present in pharmaceutical compositions of the invention to promote dosage form disintegration, one or more effervescent agents are preferably present in a total amount of about 30% to about 75%, and preferably about 45% to about 70%, for example about 60%, by weight of the pharmaceutical composition.

According to a particularly preferred embodiment of the invention, an effervescent agent, present in a solid dosage form in an amount less than that effective to promote disintegration of the dosage form, provides improved dispersion of the celecoxib in an aqueous medium. Without being bound by theory, it is believed that the effervescent agent is effective to accelerate dispersion of the drug, such as celecoxib, from the dosage form in the gastrointestinal tract, thereby further enhancing absorption and rapid onset of therapeutic effect. When present in a pharmaceutical composition of the invention to promote intragastric dispersion but not to enhance disintegration, an effervescent agent is preferably present in an amount of about 1% to about 20%, more preferably about 2.5% to about 15%, and still more preferably about 5% to about 10%, by weight of the pharmaceutical composition.

An "effervescent agent" herein is an agent comprising one or more compounds which, acting together or individually, evolve a gas on contact with water. The gas evolved is generally oxygen or, most commonly, carbon dioxide. Preferred effervescent agents comprise an acid and a base that react in the presence of water to generate carbon dioxide gas. Preferably, the base comprises an alkali metal or alkaline earth metal carbonate or bicarbonate and the acid comprises an aliphatic carboxylic acid.

Non-limiting examples of suitable bases as components of effervescent agents useful in the invention include carbonate salts (e.g., calcium carbonate), bicarbonate salts (e.g., sodium bicarbonate), sesquicarbonate salts, and mixtures thereof. Calcium carbonate is a preferred base.

Non-limiting examples of suitable acids as components of effervescent agents and/or solid organic acids useful in the invention include citric acid, tartaric acid (as D-, L-, or D/L-tartaric acid), malic acid, maleic acid, fumaric acid, adipic acid, succinic acid, acid anhydrides of such acids, acid salts of such acids, and mixtures thereof. Citric acid is a preferred acid.

In a preferred embodiment of the invention, where the effervescent agent comprises an acid and a base, the weight ratio of the acid to the base is about 1:100 to about 100:1, more preferably about 1:50 to about 50:1, and still more preferably about 1:10 to about 10:1. In a further preferred embodiment of the invention, where the effervescent agent comprises an acid and a base, the ratio of the acid to the base is approximately stoichiometric.

Excipients which solubilize metal salts of drugs like celecoxib typically have both hydrophilic and hydrophobic regions, or are preferably amphiphilic or have amphiphilic regions. One type of amphiphilic or partially-amphiphilic excipient comprises an amphiphilic polymer or is an amphiphilic polymer. A specific amphiphilic polymer is a polyalkylene glycol, which is commonly comprised of ethylene glycol and/or propylene

glycol subunits. Such polyalkylene glycols can be esterified at their termini by a carboxylic acid, ester, acid anhydride or other suitable moiety. Examples of such excipients include poloxamers (symmetric block copolymers of ethylene glycol and propylene glycol; e.g., poloxamer 237), polyalkylene glycolated esters of tocopherol (including esters formed from a di- or multi-functional carboxylic acid; e.g., d-alpha-tocopherol polyethylene glycol-1000 succinate), and macroglycerides (formed by alcoholysis of an oil and esterification of a polyalkylene glycol to produce a mixture of mono-, di- and tri-glycerides and mono- and di-esters; e.g., stearyl macrogol-32 glycerides). Such pharmaceutical compositions are advantageously administered orally.

Solid dosage forms of the invention can be prepared by any suitable process, not limited to processes described herein.

An illustrative process comprises (a) a step of blending a celecoxib salt of the invention with one or more excipients to form a blend, and (b) a step of tableting or encapsulating the blend to form tablets or capsules, respectively.

In a preferred process, solid dosage forms are prepared by a process comprising (a) a step of blending a drug salt such as a celecoxib salt of the invention with one or more excipients to form a blend, (b) a step of granulating the blend to form a granulate, and (c) a step of tableting or encapsulating the blend to form tablets or capsules respectively. Step (b) can be accomplished by any dry or wet granulation technique known in the art, but is preferably a dry granulation step. A salt of the present invention is advantageously granulated to form particles of about 1 micrometer to about 100 micrometer, about 5 micrometer to about 50 micrometer, or about 10 micrometer to about 25 micrometer. One or more diluents, one or more disintegrants and one or more binding agents are preferably added, for example in the blending step, a wetting agent can optionally be added, for example in the granulating step, and one or more disintegrants are preferably added after granulating but before tableting or encapsulating. A lubricant is preferably added before tableting. Blending and granulating can be performed independently under

low or high shear. A process is preferably selected that forms a granulate that is uniform in drug content, that readily disintegrates, that flows with sufficient ease so that weight variation can be reliably controlled during capsule filling or tableting, and that is dense enough in bulk so that a batch can be processed in the selected equipment and individual doses fit into the specified capsules or tablet dies.

In an alternative embodiment, solid dosage forms are prepared by a process that includes a spray drying step, wherein a celecoxib salt is suspended with one or more excipients in one or more sprayable liquids, preferably a non-protic (e.g., non-aqueous or non-alcoholic) sprayable liquid, and then is rapidly spray dried over a current of warm air.

A granulate or spray dried powder resulting from any of the above illustrative processes can be compressed or molded to prepare tablets or encapsulated to prepare capsules. Conventional tableting and encapsulation techniques known in the art can be employed. Where coated tablets are desired, conventional coating techniques are suitable.

Excipients for tablet compositions of the invention are preferably selected to provide a disintegration time of less than about 30 minutes, preferably about 25 minutes or less, more preferably about 20 minutes or less, and still more preferably about 15 minutes or less, in a standard disintegration assay.

Celecoxib dosage forms of the invention preferably comprise celecoxib in a daily dosage amount of about 10 mg to about 1000 mg, more preferably about 25 mg to about 400 mg, and most preferably about 50 mg to about 200 mg.

In a further embodiment the PG solvate comprises an API from Table 6. For APIs in Table 6 listed as salts, solvates, hydrates, and the like, the PG solvate can either be of the form listed in Table 6 or a PG solvate of the free form, or a PG solvate of another form that is not listed. Table 6 includes the CAS number, chemical name or a PCT or patent reference (each incorporated herein in their entireties). In another embodiment, any one

or more of the APIs of Table 6 may be specifically excluded from the present invention. Any APIs currently known in the art may also be specifically excluded from the present invention. For example, azithromycin may be specifically excluded from the present invention.

EXEMPLIFICATION

Procedure for Raman Acquisition, Filtering and Binning

Acquisition

The sample was either left in the glass vial in which it was processed or an aliquot of the sample was transferred to a glass slide. The glass vial or slide was positioned in the sample chamber. The measurement was made using an Almega™ Dispersive Raman (Almega™ Dispersive Raman, Thermo-Nicolet, 5225 Verona Road, Madison, WI 53711-4495) system fitted with a 785 nm laser source. The sample was manually brought into focus using the microscope portion of the apparatus with a 10x power objective (unless otherwise noted), thus directing the laser onto the surface of the sample. The spectrum was acquired using the parameters outlined in Table 1. (Exposure times and number of exposures may vary; changes to parameters will be indicated for each acquisition.)

Filtering and Binning

Each spectrum in a set was filtered using a matched filter of feature size 25 to remove background signals, including glass contributions and sample fluorescence. This is particularly important as large background signal or fluorescence limits the ability to accurately pick and assign peak positions in the subsequent steps of the binning process. Filtered spectra were binned using the peak pick and bin algorithm with the parameters given in Table 2. The sorted cluster diagrams for each sample set and the corresponding cluster assignments for each spectral file were used to identify groups of samples with similar spectra, which was used to identify samples for secondary analyses.

Table 2. Raman Spectral acquisition parameters

<u>Parameter</u>	<u>Setting Used</u>
Exposure time (s)	2.0
Number of exposures	10
Laser source wavelength (nm)	785
Laser power (%)	100
Aperture shape	pin hole
Aperture size (um)	100
Spectral range	104-3428
Grating position	Single
Temperature at acquisition (degrees C)	24.0

Table 3. Raman Filtering and Binning Parameters

<u>Parameter</u>	<u>Setting Used</u>
<u>Filtering Parameters</u>	
Filter type	Matched
Filter size	25
<u>QC Parameters</u>	
Peak Height Threshold	1000
Region for noise test (cm ⁻¹)	0-10000
RMS noise threshold	10000
Automatically eliminate failed spectra	Yes
<u>Region of Interest</u>	
Include (cm ⁻¹)	104-3428

Exclude region I (cm ⁻¹)	
Exclude region II (cm ⁻¹)	
Exclude region III (cm ⁻¹)	
Exclude region IV (cm ⁻¹)	
<u>Peak Pick Parameters</u>	
Peak Pick Sensitivity	Variable
Peak Pick Threshold	100
<u>Peak Comparison Parameters</u>	
Peak Window (cm ⁻¹)	2
<u>Analysis Parameters</u>	
Number of clusters	Variable

Procedure for Powder X-Ray Diffraction (PXRD)

All powder x-ray diffraction patterns were obtained using the D/Max Rapid X-ray Diffractometer (D/Max Rapid, Contact Rigaku/MSC, 9009 New Trails Drive, The Woodlands, Texas, USA 77381-5209) equipped with a copper source (Cu/K_α 1.5406 Å), manual x-y stage, and 0.3 mm collimator. The sample was loaded into a 0.3 mm boron rich glass capillary tube (e.g., Charles Supper Company, 15 Tech Circle, Natick Massachusetts 01760-1024) by sectioning off one end of the tube and tapping the open, sectioned end into a bed of the powdered sample or into the sediment of a slurried precipitate. Note, precipitate can be amorphous or crystalline. The loaded capillary was mounted in a holder that was secured into the x-y stage. A diffractogram was acquired (e.g., Control software: RINT Rapid Control Software, Rigaku Rapid/XRD, version 1.0.0, © 1999 Rigaku Co.) under ambient conditions at a power setting of 46 kV at 40 mA in reflection mode, while oscillating about the omega-axis from 0 - 5 degrees at 1 degree/s and spinning about the phi-axis at 2 degrees/s. The exposure time was 15 minutes unless otherwise specified. The diffractogram obtained was integrated over 2-theta from 2–60 degrees and chi (1 segment) from 0–360 degrees at a step size of 0.02 degrees using the *cyllnt* utility in the RINT Rapid display software (Analysis software:

RINT Rapid display software, version 1.18, Rigaku/MSC.) provided by Rigaku with the instrument. The dark counts value was set to 8 as per the system calibration (System set-up and calibration by Rigaku); normalization was set to average; the omega offset was set to 180°; and no chi or phi offsets were used for the integration. The analysis software JADE XRD Pattern Processing, versions 5.0 and 6.0 ((⁸1995-2002, Materials Data, Inc. was also used.

Procedure for Differential Scanning Calorimetry (DSC)

An aliquot of the sample was weighed into an aluminum sample pan. (e.g., Pan part # 900786.091; lid part # 900779.901; TA Instruments, 109 Lukens Drive, New Castle, Delaware 19720) The sample pan was sealed either by crimping for dry samples or press fitting for wet samples (e.g., hydrated or solvated samples). The sample pan was loaded in to the apparatus (DSC: Q1000 Differential Scanning Calorimeter, TA Instruments, 109 Lukens Drive, New Castle, Delaware 19720), which is equipped with an autosampler, and a thermogram was obtained by individually heating the sample (e.g., Control software: Advantage for QW- Series, version 1.0.0.78, Thermal Advantage Release 2.0, © 2001 TA instruments – Water LLC) at a rate of 10 degrees C /min from T_{\min} (typically 20 degrees C) to T_{\max} (typically 300 degrees C) (Heating rate and temperature range may vary, changes to these parameters will be indicated for each sample) using an empty aluminum pan as a reference. Dry nitrogen (e.g., Compressed nitrogen, grade 4.8, BOC Gases, 575 Mountain Avenue, Murray Hill, New Jersey 07974-2082) was used as a sample purge gas and was set at a flow rate of 50 mL/min. Thermal transitions were viewed and analyzed using the analysis software (Analysis Software: Universal Analysis 2000 for Windows 95/95/2000/NT, version 3.1E; Build 3.1.0.40, © 1991 - 2001TA instruments – Water LLC) provided with the instrument.

Procedure for Thermogravimetric Analysis (TGA)

An aliquot of the sample was transferred into a platinum sample pan. (Pan part # 952019.906; TA Instruments, 109 Lukens Drive, New Castle, Delaware 19720) The pan was placed on the loading platform and was then automatically loaded in to the apparatus (TGA: Q500 Thermogravimetric Analyzer, TA Instruments, 109 Lukens Drive, New Castle, Delaware 19720) using the control software (Control software: Advantage for QW- Series, version 1.0.0.78, Thermal Advantage Release 2.0, © 2001 TA instruments – Water LLC). Thermograms were obtained by individually heating the sample at 10 degrees C/min from 25 degrees C to 300 degrees C (Heating rate and temperature range may vary, changes in parameters will be indicated for each sample) under flowing dry nitrogen (e.g., Compressed nitrogen, grade 4.8, BOC Gases, 575 Mountain Avenue, Murray Hill, New Jersey 07974-2082), with a sample purge flow rate of 60 mL/min and a balance purge flow rate of 40 mL/min. Thermal transitions (e.g. weight changes) were viewed and analyzed using the analysis software (Analysis Software: Universal Analysis 2000 for Windows 95/95/2000/NT, version 3.1E; Build 3.1.0.40, © 1991 - 2001TA instruments – Water LLC) provided with the instrument.

Example 1 (Comparative)

Celecoxib sodium salt from aqueous solution

To 77.3 mg of commercially-available celecoxib was added 1.0 mL distilled water, followed by 0.220 mL of 1 M NaOH (VWR). The mixture was heated with stirring to 60 degrees C, whereupon an additional 1.0 mL distilled water was added. Solid NaOH (22 mg) was added, and the solid NaOH and celecoxib dissolved. The mixture was heated again at 60 degrees C to evaporate water. About 15 mL reagent-grade ethanol was added, while the mixture was stirred and heated at 60 degrees C with air blowing over the solution. Heating continued until the solution was dry. The resulting material was analyzed by differential scanning calorimetry (DSC), thermogravimetric analysis (TGA), and powder x-ray diffraction (PXRD), the results of which are shown in Figs. 1-3. The product was found to contain about 5.5 equivalents of water per equivalent of salt.

DSC analysis of the salt sample prepared above was performed using a Q1000 Differential Scanning Calorimeter (TA Instruments, New Castle, Delaware, U.S.A.), which uses Advantage for QW-Series, version 1.0.0.78, Thermal Advantage Release 2.0 (⁸2001 TA Instruments-Water LLC). In addition, the analysis software used was Universal Analysis 2000 for Windows 95/95/2000/NT, version 3.1E;Build 3.1.0.40 (⁸2001 TA Instruments-Water LLC).

For the DSC analysis, the purge gas used was dry nitrogen, the reference material was an empty aluminum pan that was crimped, and the sample purge was 50 mL/minute.

DSC analysis of the sample was performed by placing 2.594 mg of sample in an aluminum pan with a crimped pan closure. The starting temperature was 20 degrees C with a heating rate of 10 degrees C/minute, and the ending temperature was 200 degrees C. The resulting DSC analysis is shown in Fig. 1.

TGA analysis of the salt sample prepared above was performed using a Q500 Thermogravimetric Analyzer (TA Instruments, New Castle, Delaware, U.S.A.), which uses Advantage for QW-Series, version 1.0.0.78, Thermal Advantage Release 2.0 (⁸2001 TA Instruments-Water LLC). In addition, the analysis software used was Universal Analysis 2000 for Windows 95/95/2000/NT, version 3.1E;Build 3.1.0.40 (⁸2001 TA Instruments-Water LLC).

For all of the TGA experiments, the purge gas used was dry nitrogen, the balance purge was 40 mL/minute N₂, and the sample purge was 60 mL/minute N₂.

TGA was performed on the sample by placing 2.460 mg of sample in a platinum pan. The starting temperature was 20 degrees C with a heating rate of 10 degrees C/minute, and the ending temperature was 300 degrees C. The resulting TGA analysis is shown in Fig. 2.

A powder X-ray diffraction pattern for the salt sample prepared above was performed using a D/Max Rapid, Contact (Rigaku/MSC, The Woodlands, Texas, U.S.A.), which uses as its control software RINT Rapid Control Software, Rigaku Rapid/XRD, version 1.0.0 (⁸1999 Rigaku Co.). In addition, the analysis software used were RINT Rapid display software, version 1.18 (Rigaku/MSC), and JADE XRD Pattern Processing, versions 5.0 and 6.0 (⁸1995-2002, Materials Data, Inc.).

For the PXRD analysis, the acquisition parameters were as follows: source was Cu with a K line at 1.5406 Å; x-y stage was manual; collimator size was 0.3 mm; capillary tube (Charles Supper Company, Natick, Massachusetts, U.S.A.) was 0.3 mm ID; reflection mode was used; the power to the X-ray tube was 46 kV; the current to the X-ray tube was 40 mA; the omega-axis was oscillating in a range of 0-5 degrees at a speed of 1 degree/minute; the phi-axis was spinning at an angle of 360 degrees at a speed of 2 degrees/second; 0.3 mm collimator; the collection time was 60 minutes; the temperature was room temperature; and the heater was not used. The sample was presented to the X-ray source in a boron rich glass capillary.

In addition, the analysis parameters were as follows: the integration 2-theta range was 2-60 degrees; the integration chi range was 0-360 degrees; the number of chi segments was 1; the step size used was 0.02; the integration utility was cylint; normalization was used; dark counts were 8; omega offset was 180; and chi and phi offsets were 0. All values of peaks on diffractograms are accurate to ± 0.1 degrees 2-theta.

The PXRD pattern for the compound prepared above is shown in Fig. 3. In the diffractogram of Fig. 3, the background has been removed.

Example 2 (Comparative)

Celecoxib-Lithium Salt Preparation Method: MO-116-49B

To 100 mg of commercially available Celecoxib was added 0.35 M LiOH (aq) (Lithium Hydroxide Monohydrate – Aldrich Cat#25,427-4, Lot 00331K1) solution with a

lithium:celecoxib ratio of 1.53:1 in a vial with a Teflon coated silicon rubber septum cap. The mixture was gently heated during dissolution with occasional swirling until all solids dissolved. Flowing dry nitrogen was blown over the solution for 2 days through stainless steel needles inserted into the septum cap until the solution was dry. Characterization of the product was achieved via DSC (Fig. 4), TGA (Fig. 5), Raman spectroscopy (Fig. 6) and PXRD (Fig. 7).

Unless specifically stated, all equipment and instrumentation used for analysis is the same as in Example 1.

Celecoxib-Lithium Salt Data (DSC)

1.56 mg of collected sample was placed into an aluminum DSC pan with cover. The DSC pan was sealed with crimping and placed in TA Instruments Q1000 DSC. The sealed pan was heated 10 degrees C/min to 300 degrees C with 50 mL/min nitrogen purge gas. Figure 4 is the resulting DSC analysis.

Celecoxib-Lithium Salt Data (TGA)

8.2290 mg of collected sample was placed into a platinum TGA pan. The pan was placed in TA Instruments Q500 TGA. The pan was heated 10 degrees C/min to 300 degrees C with 40 mL/min nitrogen purge gas. The results of the TGA are depicted in Fig. 5.

Celecoxib-Lithium Salt (MO-116-49A) Data (Raman)

A small quantity of collected sample was placed on a glass slide and mounted in the Thermo Nicolet Almega Dispersive Raman. The sample capture was set to 6 background scans and 12 sample collection scans. The parameters used for this analysis were:

Table 4

DATA COLLECTION INFORMATION	SPECTROMETER DESCRIPTION
Exposure time: 2.00 sec	Spectrometer: Visible Raman Microscope
Number of exposures: 12	Laser: 785 nm
Number of background exposures: 6	Laser power level: 100%
	Laser polarization: Parallel
	Grating: 360 lines/mm
	Spectrograph aperture: 100 micrometer slit
	Sample position: Microscope
	Camera temperature: -50 degrees C
	CCD rows binned: 89-150
	CCD binning: On chip
	RIM position: Mirror
	Polarization analyzer: Out
	Illuminators: Of

The results of the Raman spectroscopy are depicted in Fig. 6.

Celecoxib-Lithium Salt Data (PXRD)

A small amount of collected sample was placed in a 0.3 mm glass PXRD tube.. The tube was placed into a Rigaku D/Max Rapid PXRD and set to: Cu; 46 kV/40 mA; Collimeter: 0.3; Omega-axis oscillation, Pos(deg) 0-5, speed 1; Phi-axis spin, Pos 360, Speed 2; Collection time was equal to 15 minutes.

Example 3 (Comparative)

Celecoxib-Potassium Salt: Preparation Method MO-116-49A

100 mg of Celecoxib (Fako Ilaclari A,S,) was dissolved in a 0.35 M KOH(aq) solution (Potassium Hydroxide – Spectrum, Cat# P0180, Lot#PN0690) with a potassium:celecoxib ratio of 1.40:1 in a vial with a Teflon coated silicon rubber septum cap. The resulting solution was gently warmed during dissolution with occasional swirling until all solids dissolved. After all solids were dissolved, the solution was dried

by flowing dry nitrogen over the solution for 2 days through stainless steel needles inserted into the septum cap. Analysis of the resulting product was performed. Characterization of the product was achieved via DSC (Fig. 8,) TGA (Fig. 9), Raman spectroscopy (Fig. 10) and PXRD (Fig. 11).

Celecoxib-Potassium Salt (MO-116-49A) Data (DSC)

1.119 mg of collected sample was placed into an aluminum DSC pan with cover. The pan was sealed with crimping and placed into a TA Instruments Q1000 DSC. The DSC was heated 10 degrees C/min to 300 degrees C with 50 mL/min nitrogen purge gas. The results are depicted in the graph of Fig. 8.

Celecoxib-Potassium Salt (MO-116-49A) Data (TGA)

5.9890 mg of collected sample was placed into a platinum TGA pan. The pan was placed in TA Instruments Q500 TGA and heated 10 degrees C/min to 90 degrees C, held for 10 minutes, ramped 10 degrees C/min to 300 degrees C, and held for 10 minutes with 40 mL/min nitrogen purge gas. The results are depicted in Fig. 9.

Celecoxib-Potassium Salt (MO-116-49A) Data (Raman)

A small quantity of collected sample was placed on a glass slide and mounted in the Thermo Nicolet Almega Dispersive Raman. The sample capture was set to 6 background scans and 12 sample collections. The parameters used for this analysis were:

Table 5

DATA COLLECTION INFORMATION	SPECTROMETER DESCRIPTION
Exposure time: 2.00 sec	Spectrometer: Visible Raman Microscope
Number of exposures: 12	Laser: 785 nm
Number of background exposures: 6	Laser power level: 100%
	Laser polarization: Parallel
	Grating: 360 lines/mm
	Spectrograph aperture: 100 micrometer slit
	Sample position: Microscope
	Camera temperature: -50 degrees C
	CCD rows binned: 89-150
	CCD binning: On chip
	RIM position: Mirror
	Polarization analyzer: Out
	Illuminators: Of

The results are depicted in Fig. 10.

Celecoxib-Potassium Salt (MO-116-49A) Data (PXRD)

A small amount of collected sample was placed in a 0.3mm glass PXRD tube. The tube was placed in Rigaku D/Max Rapid PXRD set to Cu; 46kV/40mA; Collimeter:0.3; Omega-axis oscillation, Pos(deg) 0-5, speed 1; Phi-axis spin, Pos 360, Speed 2; Collection time was equal to 15 minutes. The results are depicted in Fig. 11.

Example 4

Preparation of Celecoxib-Sodium Salt PG solvate

A propylene glycol solvate of the sodium salt of celecoxib was prepared. To a solution of celecoxib (312 mg; 0.818 mmol) in Et₂O (6 mL) was added propylene glycol (0.127 ml, 1.73 mmol). To the clear solution was added NaOEt in EtOH (21%, 0.275 microL, 0.817 mmol). After 1 minute, crystals began to form. After 5 minutes, the solid had completely crystallized. The solid was collected by filtration and was washed with Et₂O

(10 mL). The off-white solid was then air-dried and collected. This was a 1:1 solvate. The solid was characterized by TGA and PXRD. The results are depicted in Fig. 12 and 13.

Example 5

Preparation of Celecoxib-Potassium Salt PG Solvate

A propylene glycol solvate of the potassium salt of celecoxib was prepared. To a solution of celecoxib (253 mg, 0.664 mmol) in Et₂O (6 mL) was added propylene glycol (0.075 ml, 1.02 mmol). To the clear solution was added KOtBu in THF (1 M, 0.66 mL, 0.66 mmol). Crystals immediately began to form. After 5 minutes, the solid had completely crystallized. The solid was collected by filtration and was washed with Et₂O (10 mL). The white solid was then air-dried and collected. This solid was a 1:1 solvate. The solid was characterized by TGA and PXRD. The results are depicted in Fig. 14 and 15.

Example 6

Preparation of Celecoxib-Lithium Salt PG Solvate

A propylene glycol solvate of lithium salt of celecoxib was prepared. To a solution of celecoxib (264 mg, 0.693 mmol) in Et₂O (8 mL) was added propylene glycol (0.075 ml, 1.02 mmol). To the clear solution was added tBu-Li in pentane (1.7 M, 0.40 mL, 0.68 mmol). A brown solid formed immediately but dissolved within one minute yielding white solid. The white solid crystallized completely after 10 minutes. The solid was collected by filtration and was washed with Et₂O (10 mL). The white solid was then air-dried and collected. The solid was a 1:1 solvate. The solid was characterized by TGA and the results are depicted in Fig. 16.

While this invention has been particularly shown and described with references to preferred embodiments thereof, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the scope of the invention encompassed by the appended claims.

Example 7

Preparation of Naproxen-Sodium Salt PG Solvate

A propylene glycol solvate of a sodium salt of Naproxen was prepared. To a solution of naproxen (mg, mmol) in Et₂O (10 mL) was added propylene glycol (ml, mmol). To the clear solution was added NaOEt in EtOH (21%, mL, mmol). The solution became slightly yellow due to NaOEt. After 1 minute, crystals begin to form. After 5 minutes, the solid had completely crystallized. The solid was collected by filtration and was washed with Et₂O (10 mL). The product was then air-dried and collected. The solvate was 2:1 naproxen Na:PG. The solid was characterised by TGA and PXRD. The results are depicted in Fig. 17 and Fig. 18.

Example 8

Preparation of Celecoxib Sodium

The free acid of celecoxib (5.027 g) was suspended in an aqueous solution of NaOH (13.181 mL, 1 M). The suspension was gently heated at 60 degrees C for 1 minute to dissolve the remaining solid. The mixture was allowed to cool to room temperature, which yielded no precipitation. Further cooling in an ice bath for 1 hour gives precipitation of the product. The resulting solution was filtered and allowed to air dry.

Characterization of the product has been achieved via TGA, DSC, PXRD, Raman spectroscopy, microscopy, and ¹H NMR spectroscopy. NMR acquisitions were performed on a Varian 300 MHz Spectrometer in (methyl sulfoxide)-d₆.

The PXRD pattern has characteristic peaks as shown in Fig. 19. An intense peak can be seen at 19.85 with other peaks at 2-theta angles including but not limited to, 3.57, 10.69, 13.69, 20.43, and 21.53. The crystal can be characterized by any one, any two, any three, any four, or all five of the peaks above, or any one or combination of 2-theta angles of Fig. 19.

Results of Raman spectroscopy can be seen in Fig. 20. Raman shift (cm^{-1}) peaks occur at positions including, but not limited to, any two, any three, any four, all five of 1617.11, 1446.20, 1373.73, 975.02 and 800.15, or any combinations 2, 3, 4, 5 or more peaks of Fig. 20.

Example 9

Preparation of Olanzapine PG solvate

Olanzapine PG solvate was prepared by dissolving 1.05 g of olanzapine form I in 8 mL of isopropylacetate and 2.0 mL of propylene glycol with heating. The hot liquid was filtered through a 0.2 micrometer nylon syringe filter. Crystallization occurred after cooling to RT. The addition of a small amount of seed crystals from a previous reaction followed by sonication for 10 seconds also facilitated crystallization. The product was isolated by suction filtration, rinsed with isopropylacetate and allowed to air dry. Product is a fine yellow powder. The crystals grow in three dimensions yielding chunks.

Another batch of olanzapine PG solvate was prepared by dissolving 16.2 mg of olanzapine form I in 0.05 ml of PG and 0.05 ml of isopropylacetate with heating. The sample was cooled to RT and a single crystal from a previous preparation was added. The sample was allowed to sit undisturbed for 2 days during which an aggregate clump of several large crystals grew. The contents of the vial were poured onto filter paper. The crystals were transferred to a filter paper, rinsed with a single drop of IPAC, and dried by dabbing with the filter paper. The rinse procedure was repeated a total of four times with fresh filter paper. Characterization of the product has been achieved via TGA, DSC, PXRD, Raman spectroscopy, and microscopy.

The PXRD pattern has characteristic peaks as shown for two sample preparations in Fig. 21A and 21B. Peaks can be seen at 2-theta angles including but not limited to 8.330, 8.949, 11.749, 14.470, 15.610, 17.950, 19.209, 19.570, 20.649, 21.410, 22.030, and 23.590 in Fig. 20A. The crystal can be characterized by any one, any two, any three, any four, any 5, any 6, any 7, any 8, any 9, any 10, any 11 (each combination included as

individual species of the present invention), or all 12 of the peaks above. In the second representative sample, peaks can be seen at 2-theta angles including but not limited to 8.390, 8.889, 13.951, 14.450, 15.550, 17.911, 19.130, 19.550, 20.610, 21.469, 22.070, and 23.310 in Fig. 21A. The crystal can be characterized by any one, any two, any three, any four, any 5, any 6, any 7, any 8, any 9, any 10, any 11 (each combination included as individual species of the present invention), or all 12 of the peaks above.

Results from TGA analysis show an 18.05% weight loss representing loss of PG (Fig. 22). Results from DSC show a peak endothermic transition at 92.63 degrees C (Fig. 23).

Example 10

Preparation of Cortisone Acetate PG Solvate

Cortisone acetate PG solvate was prepared by dissolving 9.7 mg cortisone acetate in 0.6 mL propylene glycol with heating. Needle-like crystals formed upon cooling, followed by the conversion to large, very thin, rectangular plates over a couple hours.

Another preparation of cortisone acetate PG solvate was completed by dissolving 11.9 mg cortisone acetate in 0.7 mL isopropylacetate with heating to reflux. Upon crystal formation, 0.05 mL propylene glycol was added, heated to reflux to dissolve, and crystals again formed. The resultant crystals were collected and analyzed by PXRD, TGA, and DSC.

Another preparation was completed by dissolving 65.8 mg cortisone acetate in 7.0 mL isopropylacetate and 0.05 mL propylene glycol with heating. The mixture was cooled slightly and seed crystals from a previous reaction (second preparation above) were added. Crystals were harvested after 30 minutes and analyzed by single crystal x-ray. Prior to PXRD measurement, the sample was ground, transferred to a vial, and left open to the atmosphere for 4 days.

The resultant crystals form rods, or long rectangular plates that are birefringent when viewed by plane polarized microscopy.

The PXRD of cortisone acetate PG solvate crystallized from isopropylacetate/propylene glycol solution is shown in two diffractograms in Fig. 24A and Fig. 24B. Peaks can be seen at 2-theta angles including, but not limited to, 5.3, 10.7, 14.6, 15.7, 18.5, 21.4, and 23.5 degrees. The crystal can be characterized by any one, any two, any three, any four, any five, any six, or any seven, or any combination of the peaks listed above, or other peaks present on the diffractogram not listed above.

Results from TGA analysis show a 15.9 % weight loss at temperatures up to 150 degrees C (Fig. 25). 14.9 % weight loss occurred between 70 and 150 degrees C while up to 1.2 % weight loss occurred at lower temperatures. This weight loss is representative of a cortisone acetate PG solvate with 1.0 equivalents of propylene glycol. DSC was completed in a closed, not sealed aluminium pan from room temperature to 300 degrees C at 10 degrees/minute (Fig. 26). The compound was discovered to have two endothermic transitions, one at 148 degrees C with an intensity of 146 J/g, and the second at 237 degrees C with an intensity of 77 J/g.

TABLE 6

API Gen ric Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
(-)-amlodipine	3,5-Pyridinedicarboxylic acid, 2-((2-aminoethoxy)methyl)-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-, 3-ethyl-5-methyl ester, (S)- [CAS]	103129-82-4	WO 9310779	Antihypertensive, other
(-)-halofenate	(-)-Benzenecacetic acid, 4-chloro-Alpha-[3-(trifluoromethyl)-phenoxy]-, 2-(acetylamino)ethyl ester		US 6262118	Antidiabetic
(R)-salbutamol	1,3-Benzenedimethanol, Alpha1-(((1,1-dimethylethyl)amino)methyl)-4-hydroxy-[CAS]			Formulation, modified-release, <=24hr
(R)-salbutamol	1,3-Benzenedimethanol, Alpha1-(((1,1-dimethylethyl)amino)methyl)-4-hydroxy-[CAS]	34391-04-3	US 5547994	Antiasthma
(R,R)-formoterol	Formamide, N-(2-hydroxy-5-(1-hydroxy-2-((2-(4-methoxyphenyl)-1-methylethyl)amino)ethyl)phenyl)- (R- (R*, R*))- [CAS]	67346-49-0	US 5795564	Antiasthma
(S)-doxazosin	(S)-1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(1,4-benzodioxan-2-yl carbonyl)piperazine	70918-18-2	WO 9409785	Prostate disorders
(S)-fluclofenone	Benzenepropanamide, N-methyl-Gamma-(4-(trifluoromethyl)phenoxy)- (S)			Antimigraine
(S)-oxybutynin	Benzenecacetic acid, Alpha-cyclohexyl-Alpha-hydroxy-, 4-(diethylamino)-2-butynyl ester, (S)- [CAS]	119618-22-3		Urological
1,2-Naphthoquinone		524-42-5		
17 α -Hydr xypr q sterone		68-96-2		
17-Methyltest sterone		58-18-4		
195mPt-cisplatin	Platinum-195m, diamminedichloro, (SP-4-2)-		US 6074626	Anticancer, alkylating
1 α -Hydr xych l calciferol		41294-56-8		

TABLE 6

Example f Indication
Hypertension, general
Diabetes, Type II
Asthma
Asthma
Asthma
Benign prostatic hyperplasia
Migraine
Incontinence
Cancer, liver

TABLE 6

API Gen ric Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
1-Naphthyl Salicylate		550-97-0		
1-Naphthylamine-4-sulf nic Acid		84-86-6		
1-The br mineacetic Acid		5614-56-2		
2,4,6-Tribromo-m-cresol		4619-74-3		
2,6-Diamino-2'-butyloxy-3,5'-az pyridine		617-19-6		
21-Ac toxypregnenolone		566-78-9		
2-Amino-4-pic line		695-34-1		
2-Amin thiazole		96-50-4		
2-ethoxybenzoic acid	2-Ethoxybenzoic acid		DE 5134001	Analgescic, NSAID
2-Naphthyl Benzoate		135-19-3		
2-Naphthyl Lactate		93-44-7		
2-Naphthyl Salicylate		93-43-6		
2-p-Sulfanilylanilin ethanol		613-78-5		
		80-02-4		
2-Thi uracil		141-90-2		
3',3'',5',5''-Tetrabromophenolphthalin		76-62-0		
3-Amin -4-hydroxybutyric Acid		589-44-6		
3-Br m -d-camphor		76-29-9		
3-Hydr xycamphor		10373-81-6		
3-O-Lauroylpyridoxol Diacetate		1562-13-6		
3-Pentadecylcatechol		492-89-7		
3-Quinuclidinol		1619-34-7		

TABLE 6

API Gen ric Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
4,4'-Oxydi-2-butanol		821-33-0		
4,4'-Sulfinyldianiline		119-59-5		
4-Amino-3-hydroxybutyric Acid		352-21-6		
4-Amino-3-phenylbutyric Acid		1078-21-3		
4-aminosalicylic acid	Benzolic acid, 4-amino-2-hydroxy- [CAS]	65-49-6		GI inflammatory/bowel disorders
4-Chloro-m-cresol		59-50-7		
4-Hexylresorcinol		136-77-6		
4-Salicyl ylm rpholine		3202-84-4		
5-Nitr -2'-pr p xyac tanilide		553-20-8		
5-aminolevulinic acid, DUSA	Pentanoic acid, 5-amino-4-oxo- [CAS]	106-60-5		Dermatological
5-azacitidine	1,3,5-Triazin-2(1H)-one, 4-amino-1-β-D-ribofuranosyl- [CAS]	320-67-2		Anticancer, antimetabolite
5-Bromosalicylhydroxamic Acid		5798-94-7		
5F-Df-203	2-(4-Amino-3-methylphenyl)-6-hydroxybenzothiazole			Anticancer, other
5-FU	2,4(1H,3H)-Pyrimidinedione, 5-fluoro [CAS]	51-21-8		Formulation, parenteral, targeted
5-HT3 antagonists			US 6037360	Male sexual dysfunction
6-Azauridine		54-25-1		
6-Mercapt purine		50-44-2		
8-Hydroxyquinoline		148-24-3		
9-Amin campt thecin		91421-43-1		
A-151892	N-[2-(2,2,2-Trifluoro-1-hydroxy-1-trifluoromethyl-ethyl)-naphthalen-1-yl] amide			
α1-Antitrypsin		9041-92-3		Urological

TABLE 6

Exempl of Indication
Inflammatory bowel disease
Keratosis
Myelodysplastic syndrome
Cancer, breast
Cancer, general
Premature ejaculation
Overactive bladder

TABLE 6

API Gen. ric Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
A-5021	6H-Purin-6-one, 2-amino-9-((1S,2R)-1,2-bis(hydroxymethyl)cyclopropyl)methyl)-1,9-dihydro- [CAS]	145512-85-2		Antiviral, other
Abacavir	2-Cyclopentene-1-methanol, 4-(2-amino-6-(cyclopropylamino)-9H-purin-9-yl)-, (1S-cis)-, sulfate (2:1) (salt) [CAS]	136470-78-5		
abacavir sulfate		136470-78-5 188062-50-2	EP 434450	Antiviral, anti-HIV
abaperidone hydrochloride	7-[3-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidin-1-yl]propoxy]-3-(hydroxymethyl)chromen-4-one hydrochloride			
		183849-43-6	WO 9632389	Neuroleptic
abarelix	D-Alaninamide, N-acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridinyl)-D-alanyl-L-seryl-N-methyl-L-tyrosyl-D-asparaginyl-L-leucyl-N6-(1-methylethyl)-L-lysyl-L-prolyl- [CAS]	183552-38-7	US 5843902	Anticancer, hormonal
Abciximab		143653-53-6		
Ab carnit		111841-85-1		
abelimus		169147-32-4	US 5552391	Immunosuppressant
abiraterone	Androsta-5,16-dien-3-ol, 17-(3-pyridinyl)-, acetate (ester), (3S)-, [CAS]	154229-18-2	GB 2265624	Anticancer, hormonal
α -Bisab I I		515-69-5		
ABLC	Amphotericin B [CAS]	1397-89-3 30652-87-0		Formulation, conjugate, carbohydrate
ABT-751	Benzenesulfonamide, N-[2-[(4-hydroxyphenyl)amino]-3-pyridinyl]-4-methoxy- [CAS]	141430-65-1	EP 472053	Anticancer, other
AC-5216	N-benzyl-N-ethyl-2-(7,8-dihydro-7-methyl-8-oxo-2-phenyl-9H-purin-9-yl)acetamide			Anxiolytic
Acadesine		2627-69-2		
acamprostate	1-Propanesulfonic acid, 3-(acetylamino)- [CAS]	77337-76-9	GB 2051789	Dependence treatment
Acampr sat		77337-73-6		

TABLE 6

Example of Indication
Infection, varicella zoster virus
Infection, HIV/AIDS
Schizophrenia
Cancer, prostate
Lupus erythematosus, systemic
Cancer, prostate
Infection, Candida, general
Cancer, general
Anxiety, general
Addiction, alcohol

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Acarbos	7H-Purine-7-acetic acid, 1,2,3,6-tetrahydro-1,3-dimethyl-2,6-dioxo-compd. with trans-4-[[[(2-amino-3,5-dibromophenyl)methyl]amino]cyclohexanol (1:1) [CAS]	56180-94-0		
acebrophylline		96989-76-3	DE 3425007	Antisthma
acebutolol	Butanamide, N-[3-acetyl-4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]phenyl]-, (+/-)- [CAS]	34381-88-5 37517-30-9	US 3726919	Antihypertensive, adrenergic
Acetaminide		32795-44-1		
Acetacarbamol		77-66-7		
aceclofenac	Benzeneacetic acid, 2-[(2,6-dichlorophenyl)amino]-, carboxymethyl ester [CAS]	89796-99-8	EP 119932	Anti-inflammatory
Acedapsone		77-46-3		
Acediasulfone		80-03-5		
Acefylline		652-37-9		
Aceglutamide		2490-97-3		
aceglutamide	Aluminum, pentakis[N(2-acetyl-L-glutaminato)tetrahydroxytri- [CAS]	12607-92-0	DE 2127176	Antilicer
acemetacin	1H-Indole-3-acetic acid, 1-(4-chlorobenzoyl)-5-methoxy-2-methyl-, carboxymethyl ester [CAS]	53164-05-9	US 3910952	Anti-inflammatory
Acemetacin		53164-05-9		
Acen coumar I		152-72-7		
Acetal		105-57-7		
Acetamid eug nol		305-13-5		
Acetaminoph n		103-90-2		
Acetamin sal I		118-57-0		
Acetanilid		103-84-4		
Acetarson		97-44-9		
Ac taz lamid		59-66-5		
Ac tiamine		299-89-8		
Acet h xamid		968-81-0		
Acet hydroxamic Acid		546-88-3		
Acet ph nazin		2751-68-0		

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Acetophenone		98-86-2		
Acetaminophen		128-12-1		
Acetazolamide		6277-14-1		
Acetoxolone	Olean-12-en-30-oic acid, 3B-hydroxy-11-oxo-acetate, aluminum salt [CAS]	29728-34-5 6277-14-1	US 3764818	Anticancer
Acetate		129-63-5		
Acetyl				
Sulfamethoxypyrazine		3590-05-4		
Acetylcarnitine		14992-62-2		
Acetylcholine		66-23-9		
Acetylcholine		60-31-1		
Acetylcholine		616-91-1		
Acetylcholine		149-90-6		
Acetylcholine				
Acetylcholine		13402-08-9		
Acetylcholine	Benzoic acid, 2-(acetyloxy)- [CAS]	50-78-2		Formulation, optimized, microencapsulate
Acetylsalicylic acid, Eurand		530-75-6		
Acetylsalicylic acid				
Acetylcholine		15879-93-3		
Acetylcholine	6H-Purin-6-one, 2-amino-1,9-dihydro-9-[(2-hydroxyethoxy)methyl]- [CAS]	59277-89-3		Formulation, dermal, topical
Acifran		72420-38-3		
Acipimox	Pyrazinecarboxylic acid, 5-methyl-, 4-oxide [CAS]	51037-30-0	GB 1361967	Hypolipemic/Antiatherosclerosis
Acitazanolast	Acetic acid, oxo[[9-(1H-tetrazol-5-yl)phenyl]amino]- [CAS]	114607-46-4	EP 256507	Ophthalmological
Acitretin	2,4,6,8-Nonatetraenoic acid, 9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-, (all-E)- [CAS]	55079-83-9 57576-44-0 75443-99-1	GB 1469401 US 3988315	Antipsoriasis Anticancer, antibiotic
Aciclovir		55077-30-0		
Acidatum Napadlsilate				
Acidatum		302-27-2		
Acidatum		1684-42-0		
Acidatum		8048-52-0		

TABLE 6

API Gen ric Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
AcrisorcIn		7527-91-5		
acivastine	2-Propenoic acid, 3-[6-(1-(4-methylphenyl)-3-(1-pyrrolidinyl)-1-propenyl)-2-pyridinyl], (E,E)- [CAS]	87848-99-5	EP 85959	Antipruritic/inflamm, allergic
acivastine + pseudoephedrine	Benzenemethanol, Alpha-[1-(methylamino)ethyl]-, hydrochloride, [S-(R*,R*)], mixt with 2-Propenoic acid, 3-[6-(1-(4-methylphenyl)-3-(1-pyrrolidinyl)-1-propenyl)-2-pyridinyl], (E,E)-			Antiallergic, non-asthma
actagardine derivative	3,3-dimethyl-1-propylamide HCl monocarboxamide actagardine			Peptide antibiotic
Actarfit		18699-02-0		
ACTH		9002-60-2		
Acyclovir		59277-89-3		
adapalene	2-Naphthalenecarboxylic acid, 6-(4-methoxy-3-tricyclo[3.3.1.1 ^{3,7} dec-1-ylphenyl]- [CAS]	106685-40-9	EP 199636	Antiacne
Adapalene		106685-40-9		
ADCON-L	GL 402 [CAS]	137802-74-5		Formulation, other
Ad f vir		106941-25-7		
adefovir dipivoxil	Propanoic acid, 2,2-dimethyl-, (((2-(6-amino-9H-purin-9-yl)ethoxy)methyl)phosphinylidene)bis(oxyethylene)ester- [CAS]	142340-99-6	EP 205826	Antiviral, other
Adenoscan	6-Amino-9-β-D-ribofuranosyl-9H-purine [CAS]	58-61-7		Imaging agent
Aden sine Triphosphate		56-65-5		
ADEPT, CRT		156079-88-8		Immunoconjugate, other
Adinaz lam		37115-32-5		
Adiphenine		64-95-9		
ADL-10-0101			WO 9732857	Analgesic, other
Adrafinil		63547-13-7		
Adrenalone		99-45-6		
Adr n chr m		54-06-8		

TABLE 6

Example of Indication
Rhinitis, allergic, general
Rhinitis, allergic, seasonal
Infection, general
Acne
Fibrosis, epidural
Infection, hepatitis-B virus
Diagnosis, coronary
Cancer, colorectal
Pain, general

TABLE 6

API Gen ric Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
adrogolide	Benzo(f)thieno(2,3-c)quinoline-9,10-diol, 4,5,5a,6,7,11b-hexahydro-2-propyl-, diacetate (ester), hydrochloride (5aR-trans) [CAS]	186591-11-3 171752-56-0	US 5597832 US 6103714	Dependence treatment Neuroprotective
AEOL-10150				
AET		56-10-0		
α -Ethylbenzyl Alcohol		93-54-9		
AF-2259	Benzeneacetic acid, Alpha-methyl-4-(2-methylpropyl)-, 2-methoxyphenyl ester [CAS]	68332-77-2	DE 2726435	Anti-inflammatory
Afl qual ne		56287-74-2		
AG-041R	1H-Indole-3-acetamide, 1-(2,2-diethoxyethyl)-2,3-dihydro-N-(4-methylphenyl)-3-(((4-methylphenyl)amino)carbonyl)amino)-2-oxo-, (3R)- [CAS]	199800-49-2	WO 9419322	Alimentary/Metabolic, other
AG-2037	N-(5-[2-(2-amino-4(3H)-oxo-5,6,7,8-tetrahydropyrido[2,3-d]pyrimidin-6-yl)ethyl]-4-methylthieno-2-yl) glutamic acid			Anticancer, antimetabolite
α -Glucos -1-phosphate		59-56-3		
AGN-194310	Benzoic acid, 4-((4-(4-ethylphenyl)-2,2-dimethyl-2H-1-benzothiofuran-6-yl)ethynyl) [CAS]	229961-45-9	WO 9709297	Dermatological
agomelatine	Acetamide, N-(2-(7-methoxy-1-naphthalenyl)ethyl)-, [CAS]	138112-76-2	EP 447285	Antidepressant
Ahistan		518-61-6		
AHL-157			US 5411972	Hypolipaeic/Antiatherosclerosis
AIT-034	9H-Purine-9-propanamide, 1,6-dihydro-6-oxo-N-(3-(2-oxo-1-pyrrolidinyl)propyl)- [CAS]	138117-48-3	US 5447939	Cognition enhancer
AIT-202	N-[2-(5-Hydroxy-1H-indol-3-yl)ethyl]-3-(6-oxo-6,8-dihydro-1H-purin-9-yl)propionamide		WO 9957120	Antidepressant

TABLE 6

Exempl of Indication
Addiction, cocaine
Unspecified
Inflammation, general
Unspecified
Cancer, general
Psoriasis
Sleep disorder, general
Atherosclerosis
Dementia, senile, general
Unspecified

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
AJ-9677	Acetic acid, (3-(2R)-2-(((2R)-2-(3-chlorophenyl)-2-hydroxyethyl)amino)propyl)-1H-indol-7-yl)oxy)- [CAS]	244081-42-3		Antidiabetic
AJG-049			WO 9733885	Gastroprokinetic
Ajmaline		127/4360		
Alacepril		74258-86-9		
albaconazole	4(3H)-Quinazolinone, 7-chloro-3-((1R,2R)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl)- [CAS]	187949-02-6	WO 9705131	Antitungal
albendazole	Carbamic acid, [5-(propylthio)-1H-benzimidazol-2-yl]-, methyl ester [CAS]	54029-12-8 54965-21-8	GB 1464326	Anthelmintic
Albuterol		18559-94-9		
Albuterol		830-89-7		
alclofenac	Benzeneacetic acid, 3-chloro-4-(2-propenyl)- [CAS]	22131-79-9	GB 1174535	Anti-inflammatory
Alclometason		67452-97-5		
alclometasone	Pregna-1,4-diene-3,20-dione, 7-chloro-11-hydroxy-16-methyl-17,21-bis(1-oxopropoxy)- (7Alpha,11B,16Alpha)- [CAS]	68734-13-2	US 4124707	Antipruritic/inflam, allergic
Alclometasone				
Alcuronium		23214-96-2		
Aldi xa		5579-81-7		
Aldol		107-89-1		
Aldosterone		52-39-1		
alendronate sodium	Phosphonic acid, (4-amino-1-hydroxybutylidene)bis-, monosodium salt- [CAS]	121268-17-5 129318-43-0	GB 2118042	Osteoporosis treatment
Alendronic Acid		66376-36-1		
Al xidine		22573-93-9		
alfacalcidol, Teva	9,10-Secocholesta-5,7,10(19)-triene-1,3-diol, (1Alpha,3B,5Z,7E)- [CAS]	41294-56-8		Osteoporosis treatment
Alfad i n Ac tate		23930-37-2		
Alfaxal n		23930-19-0		

TABLE 6

Exempl f Indication
Diabetes, Type II
Motility dysfunction, GI, general
Infection, Candida, general
Infection, helminth, general
Inflammation; dermal
Osteoporosis
Osteodystrophy

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Alfentanil		71195-58-9		
Alfinetase		259074-78-5		Fibrinolytic
Alfuzosin	2-Furancarboxamide, N-[3-[(4-amino-6,7-dimethoxy-2-quinazolinyl)methylamino]propyl]tetrahydro-[CAS]	81403-68-1 81403-80-7	GB 2013679	Prostate disorders
Alfuzosin, GEOMATRIX	2-Furancarboxamide, N-[3-[(4-amino-6,7-dimethoxy-2-quinazolinyl)methylamino]propyl]tetrahydro-[CAS]	81403-68-1 81403-80-7		Formulation, modified-release, other
Algeston		595-77-7		
Algestone Acetophenide		24356-94-3		
Algin		9005-38-3		
Alglucerase		143003-46-7		
Albendol		26750-81-2		
Aliskiren	(2S,4S,5S,7S)-5-Amino-N-(2-carbamoyl-2-methylpropyl)-4-hydroxy-2-isopropyl-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-8-methylnonanamide	173334-57-1		Antihypertensive, renin system
Alitretinoin		5300-03-8		
Alitretinoin, Basilea	9-cis retinoic acid			Antipruritic/inflamm, allergic
Alizapride	1H-Benzotriazole-5-carboxamide, 6-methoxy-N-[(1-(2-propenyl)-2-pyrrolidinyl)methyl]- [CAS]	59338-93-1	GB 1475234	Antiemetic
Alkannin		517-88-4		
Alkafanin		7527-94-8		
Allantoin		97-59-6		
Allobarbitol		52-43-7		
Allopurinol		315-30-0		
Allopurinol				
Allyl Isothiocyanate		57-06-7		
Allyl stiretol		432-60-0		

TABLE 6

Example of Indication
Peripheral vascular disease
Benign prostatic hyperplasia
Benign prostatic hyperplasia
Hypertension, general
Eczema, general
Nausea and vomiting, general

TABLE 6

API Gen eric Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
almagate	Magnesium, [carbonato(2- heptahydroxy(aluminum)tri-, dihydrate [CAS]	66827-12-1 72526-11-5	US 4447417	Antacid/Antiflatulent
Almagate		66827-12-1		
alminoprofen	Benzeneacetic acid, Alpha-methyl-4-[(2- methyl-2-propenyl)amino]- [CAS]	39718-89-3	US 3957850	Anaesthetic, NSAID
Alminopri n		39718-89-3		
almitrine	1,3,5-Triazine-2,4-diamine, 6-[4-bis(4- fluorophenyl)methyl]-1-piperazinyl-N,N'-di- 2-propenyl-, dimethanesulfonate [CAS]	27469-53-0 29608-49-9	GB 1256513	Respiratory
almotriptan	Pyrrolidine, 1-((3-(2-(dimethylamino)ethyl)- 1H-indol-5-yl)methyl)sulfonyl)- [CAS]	154323-57-6	WO 9402460	Antimigraine
Al -Em din		481-72-1		
Alolin		5133-19-7		
alosetron	2,3,4,5-Tetrahydro-5-methyl-2-[(5-methyl- 1H-imidazol-4-yl)methyl]-1H-pyridol[4,3- b]indol-1-one [CAS]	122852-42-0 122852-69-1 132414-02-9	EP 3068323	GI inflammatory/bowel disorders
alovudine	Thymidine, 3'-deoxy-3'-fluoro- [CAS]	25526-93-6	EP 470355	Antiviral, anti-HIV
Al xiprin		9014-67-9		
Alpha-1 protease inhibitor, Nektar			US 5780014	Formulation, inhalable, topical
Alpha-dihydroergocryptine, Poli	Ergocryptine, 9,10-dihydro- methanesulfonate (salt)- [CAS]	29261-93-6		Formulation, other
Alphaprodin		77-20-3		
Alpid m		82626-01-5		
Alpir pride		81982-32-3		
alprazolam	4H-[1,2,4]Triazolo[4,3- a][1,4]benzodiazepine, 8-chloro-1-methyl-6- phenyl-[CAS]	28981-97-7	US 3987052	Anxiolytic
alprazolam, I2R	4H-[1,2,4]Triazolo[4,3- a][1,4]benzodiazepine, 8-chloro-1-methyl-6- phenyl-[CAS]	28981-97-7		Formulation, modified-release, immediate
Alpr notol		13655-52-2		
alsactide	Alpha 1-17-Corticotropin, 1-8-alanine-17-[N- (4-aminobutyl)-L-tyrosinamide]- [CAS]	34765-98-3	US 3749704	ACTH

TABLE 6

Example of Indication
Bronchitis, chronic
Migraine
Irritable bowel syndrome
Infection, HIV/AIDS
Emphysema, alpha-1 antitrypsin deficiency
Parkinson's disease
Anxiety, general
Panic disorder
Arthritis, rheumatoid

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
ALT-711	Thiazolium, 4,5-dimethyl-3-(2-oxo-2-phenylethyl)-, bromide [CAS]	181069-80-7	WO 9622095	Symptomatic antidiabetic
Althiazid		5588-16-9		
atinicline	Pyridine, 3-ethynyl-5-((2S)-1-methyl-2-pyrrolidinyl)- [CAS]	179120-92-4	US 5594011	Antiparkinsonian
altretamine	1,3,5-Triazine-2,4,6-triamine, N,N,N',N',N'',N''-hexamethyl- [CAS]	645-05-6	US 3424752	Anticancer, alkylating
aluminium chloride hexahydrate	Aluminium chloride, hexahydrate	7446-70-0		Dermatological
Alumin n		569-58-4		
Aluminum Acetate		8006-13-1		
S lution				
Aluminum Chl rate		15477-33-5		
Aluminum		1327-41-9		
Hydroxychloride				
Aluminum Potassium Sulfat		10043-67-1		
Aluminum Sodium Sulfate		10102-71-3		
alusulf	Aluminum hydroxide sulfate (Al7(OH)17(SO4)2), dodecahydrate [CAS]	61115-28-4	DE 2510663	Urological
Alverin		150-59-4		
	Glycine, N-[(2S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl- [CAS]	156053-89-3	EP 657428	GI inflammatory/bowel disorders
alvimopan				
alvocidib	4H-1-Benzopyran-4-one, 2-(2-chlorophenyl)-5,7-dihydroxy-8-(3-hydroxy-1-methyl-4-piperidinyl)-, cis-(-) [CAS]	131740-09-5 146426-40-6		Anticancer, other
ALX-0646			WO 9506638	Antimigraine
AM-24	2,4,6-Trilodophenol	609-23-4		GI inflammatory/bowel disorders
AM-36	1-Piperazineethanol, 4-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]methyl]-Alpha-(4-chlorophenyl)- [CAS]	199467-52-2		Neuroprotective

TABLE 6

Exemplification
Hypertension, general
Parkinson's disease
Cancer, ovarian
Hyperhidrosis
Hyperphosphataemia
Ileus
Cancer, renal
Migraine
Crohn's disease
Unspecified

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
AM-477	2-Methoxyoestradiol			Antiasthma
Amantadine		768-94-5		
amantanium	1-Decanaminiun, N,N-dimethyl-N-[2- [[tricyclo[3.3.1.1 ^{3,7} dec-1-yl carbonyloxy]ethyl]-, bromide [CAS]	58158-77-3	US 4288609	Antifungal
Ambazone		539-21-9		
Amb nonlum		115-79-7		
ambriisentan	(+)-(2S)-2-[(4,6-dimethylpyrimidin-2-yl)oxy]- 3-methoxy-3,3-diphenylpropanoic acid	177036-94-1		Vasodilator, peripheral
ambroxol	Cyclohexanol, 4-[(2-amino-3,5- dibromophenyl)methylamino]-, trans- [CAS]	18683-91-5 23828-92-4	GB 1178034	COPD treatment
Ambr xol		18683-91-5		
Ambucain		119-29-9		
Ambuphylline		5634-34-4		
Ambusid		3754-19-6		
Ambutonium Bromide		115-51-5		
amcinonide	Pregna-1,4-diene-3,20-dione, 21- (acetyloxy)-16,17- [cyclopentylidenebis(oxy)]-9-fluoro-11- hydroxy-, (11B,16Alpha)- [CAS]	51022-89-6	DE 2437847	Antipsoriasis
AMD-3100	1,4,8,11-Tetraazacyclotetradecane, 1,11- (1,4-phenylenebis(methylene))bis-, octahydrochloride [CAS]	155148-31-5	US 5612478	Haematological
Amdin cillin		32887-01-7		
Amdin cillin Pivoxil		32886-97-8		
amdoxovir	1,3-Dioxolane-2-methanol, 4-(2,6-diamino- 9H-purin-9-yl)- (2R-cis)- [CAS]	145514-04-1	EP 656778	Antiviral, anti-HIV
amelubant	Carbamic acid, ((4-((3-((4-(1-(4- hydroxyphenyl)-1- methylethyl)phenoxy)methyl)phenyl)metho xy)phenyl)iminomethyl)- ethyl ester [CAS]	346735-24-8	DE 10000907	COPD treatment

TABLE 6

Example of Indication
Asthma
Infection, general
Heart failure
Bronchitis, chronic
Chemotherapy-induced injury, bone marrow, leucopenia
Infection, HIV/AIDS
Chronic obstructive pulmonary disease

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Americaine	Benzenemethanaminium, N,N-dimethyl-N-[2-[2-[4-(1,1,3,3-tetramethylbutyl)phenoxy]ethoxy]ethyl]-chloride, mixt. with ethyl 4-aminobenzoate [CAS]	129128-13-8		Formulation, inhalable, other
Amezinium		30578-37-1		
Amf nac		51579-82-9		
Amidephrine		3354-67-4		
Amidinomycin		3572-60-9		
amifostine	Ethanolol, 2-[(3-aminopropyl)amino]-, dihydrogen phosphate (ester)- [CAS]	20537-88-6 63717-27-1	EP 131500	Radio/chemoprotective
amiglumide	Pentanoic acid, 5-(dipentylamino)-4-[(2-naphthalenylcarbonyl)amino]-5-oxo- (R)- [CAS]	119363-62-1	WO 8805774	GI inflammatory/bowel disorders
amikacin		37517-28-5 39831-55-5		Formulation, optimized, microencapsulate
Amiloride		2609-46-3		
Aminacrine		90-45-9		
amineptine	Heptanoic acid, 7-[(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)amino] [CAS]	30272-08-3 57574-09-1	US 3758528	Antidepressant
Aminitr z le		140-40-9		
Amino Acid Preparations				
Aminocaproic Acid				
aminoglutethimide	2,6-Piperidinedione, 3-(4-aminophenyl)-3-ethyl- [CAS]	125-84-8 79-17-4	US 3944671	Anticancer, hormonal
Aminoguanidine				
Aminohippurate Sodium				
Amin m tradine		642-44-4		
Aminop ntamide		60-46-8		
Aminophylline		317-34-0		
aminophylline	1H-Purine-2,6-dione, 3,7-dihydro-1,3-dimethyl-, compd. with 1,2-ethanediamine (2:1) [CAS]	317-34-0		Formulation, modified-release, other
Aminopromazine		58-37-7		

TABLE 6

Exempl f Indication
Pain, general
Chemotherapy-induced injury, renal
Pancreatitis
Infection, general
Cancer, breast
Asthma

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Amin pyrine		58-15-1		
Aminoquinuride		3811-56-1		
Aminorex		2207-50-3		
amiodarone	Methanone, (2-butyl-3-benzofuranyl)(4-{2-(diethylamino)ethoxy}-3,5-difodophenyl)-[CAS]	1951-25-3 19774-82-4	US 3248401	Antiarrhythmic
Amiphenazole		490-55-1		
Amipril se		56824-20-5		
amisulpride	Benzamide, 4-amino-N-[(1-ethyl-2-pyrrolidinyl)methyl]-5-(ethylsulfonyl)-2-methoxy- [CAS]	71675-85-9	US 4401822	Neuroleptic
Amitriptyline		50-48-6		
amitriptyline+ketamine	1-Propanamine,3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N,N-dimethyl + cyclohexanone,2-(2-chlorophenyl)-2-(methylamino)			
Amitriptylin xide		4317-14-0		Formulation, fixed-dose combinations
amlexanox	5H-[1]Benzopyrano[2,3-b]pyridine-3-carboxylic acid, 2-amino-7-(1-methylethyl)-5-oxo- [CAS]	68302-57-8	US 4299963	Antiasthma
amlodipine	3,5-Pyridinedicarboxylic acid, 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-, 3-ethyl 5-methyl ester [CAS]	111470-99-6 88150-42-9 88150-47-4	EP 89167	Antianginal
Aml dipin		88150-42-9		
Amm niacum		377/9000		
Ammonium B nzoate		1863-63-4		
Ammonium Mandelate		530-31-4		
Ammonium Salicylate		528-94-9		
Amm nium Valerate		42739-38-8		
Am barbital		57-43-2		
Amocarzine		36590-19-9		
Amodiaquin		86-42-0		
amorolline	Morpholine, 4-[3-{4-(1,1-dimethylpropyl)phenyl}-2-methylpropyl]-2,6-dimethyl-, cis- [CAS]	78613-35-1 78613-38-4	EP 24334	Antifungal

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Amoscanate		26328-53-0		
amosulalol	Benzenesulfonamide, 5-[1-hydroxy-2-[(2-methoxyphenoxy)ethyl]amino]ethyl]-2-methyl-, (+/-) [CAS]	70958-86-0 85320-88-9	EP 136103	Antihypertensive, adrenergic
Am triph n		5585-64-8		
amoxapine	Dibenz[b,f][1,4]oxazepine, 2-chloro-11-(1-piperazinyl)- [CAS]	14028-44-5	GB 1192812	Antidepressant
Amoxapine		14028-44-5		
amoxicillin, Advancis	4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[amino(4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-, [2S-(2Alpha,5Alpha,6S(S*))] [CAS]	26787-78-0		Formulation, modified-release, other
amoxicillin, CSL		61336-70-7		Formulation, other
amoxicillin	4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[amino(4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-, [2S-(2Alpha,5Alpha,6S(S*))] [CAS]	26787-78-0		Formulation, other
amoxicillin+potassium clavulan		74469-00-4	GB 1508977	Formulation, fixed-dose combinations
AMPAlex	Piperidine, 1-(6-quinolalyl(carbonyl)-[CAS]	154235-89-3	US 5650409	Psychostimulant
Amphetamin		300-62-9		
Amphetaminil		17590-01-1		
amphotericin B, BDSI	Amphotericin B [CAS]	1397-89-3		Formulation, optimized, microencapsulate
amphotericin B, InterMune	Amphotericin B compd. with (3B)-cholest-en-3-yl hydrogen sulfate (1:1) [CAS]	120895-52-5	US 4822777	Formulation, optimized, liposomes
ampicillin	4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[amino(phenylacetyl)amino]-3,3-dimethyl-7-oxo-, [2S-(2Alpha,5Alpha,6S(S*))]]	69-53-4 7177-48-2		Formulation, fixed-dose combinations
Ampr xicam		99464-64-9		
Amplig n		38640-92-5		

TABLE 6

Exempl 1 Indication
Hypertension, general
Depression, general
Infection, general
Infection, general
Infection, general
Infection, respiratory tract, general
Attention deficit disorder
Infection, fungal, general
Infection, general
Infection, general

TABLE 6

API Gen ric Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
amprenavir	Carbamic acid, (3-(((4-aminophenyl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-(phenylmethyl)propyl)-, tetrahydro-3-furanyl ester, (3S-(3R*(1R*,2S**))- [CAS]	161814-49-9	US 5783701	Antiviral, anti-HIV
amifone	[3,4'-Bipyridin]-6'(1H)-one, 5-amino- [CAS]	60719-84-8	US 4004012	Cardio stimulant
amrubicin	5,12-Naphthacenedione, 9-acetyl-9-amino-7-((2-deoxy-β-D-erythro-pentopyranosyl)oxy)-7,8,9,10-tetrahydro-6,11-dihydroxy-, hydrochloride, (7S-cis)- [CAS]	75898-90-7		
amsacrine	Methanesulfonamide, N-[4-(9-acridinylamino)-3-methoxyphenyl]- [CAS]	51264-14-3		Anticancer, other
ambimatin guacil	Glycine, N-[[1-methyl-5-(4-methylbenzoyl)-1H-pyrol-2-yl]acetyl]-, 2-methoxyphenyl ester [CAS]	87344-06-7	GB 2115417	Analgesic, NSAID
Amylocaine Hydr chl rid AN-152		532-59-2		
anabolic steroids, IC Innov			WO 9718954	Anticancer, antibiotic
Anagest n			WO 9848812	Cardiovascular
Anagrelide		2740-52-5		
		68475-42-3		
anagrelide	Imidazo[2,1-b]quinazolin-2(3H)-one, 6,7-dichloro-1,5-dihydro-, monohydrochloride [CAS]	58579-51-4 68475-42-3	GB 1418822	Haematological
anastrozole	1,3-Benzenediacetonitrile, Alpha,Alpha,Alpha'-tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)- [CAS]	120511-73-1	EP 296749	Anticancer, hormonal
Anazolene		3861-73-2		
Ancitabin		31698-14-3		
Ancrod		9046-56-4		
andolast	N-4'-[5-Tetrazolyl]-phenyl-4-(5-tetrazolyl)-benzamide			
Andr is xazol		132640-22-3	EP 460083	Antiasthma
		360-66-7		

TABLE 6

Example of Indication
Infection, HIV/AIDS
Cancer, lung, non-small cell
Cancer, leukaemia, acute lymphocytic
Arthritis, rheumatoid
Cancer, prostate
Heart failure
Thrombocytosis
Cancer, breast
Asthma

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Andr stenediol	21-(Acetyloxy)-17-hydroxypregna-4,9(11)-diene-3,20-dione	521-17-5		
anecortave acetate		7753-60-8		Ophthalmological
Anethol		4180-23-8; 104-46-1 (unspecified)		
Anethole Trithione		532-11-6		
Angiogenix			US 6417205	Cardiovascular
Angiotensin		1407-47-2		
anhydrovinblastine	Vincalukoblastine, 3',4'-didehydro-4'-deoxy- [CAS]	38390-45-3	US 6011041	Anticancer, other
anidulatungin	Echinocandin B, 1-((4R,5R)-4,5-dihydroxy-N2-((4"-pentylloxy)(1,1'-4,1"-terphenyl)-4-yl)carbonyl)-L-ornithine)- [CAS]	166663-25-8	US 6384013	Antifungal
Anileridin		144-14-9		
Anirac tam		72432-10-1		
Anisindi n		117-37-3		
Anisomycin		22862-76-6		
Anisotr pin		80-50-2		
Methylbromid				
anistreplase	Anistreplase [CAS]	81669-57-0	EP 28489	Fibrinolytic
Antazoline		91-75-8		
Anthlollimin		305-97-5		
Anthralin		1143-38-0		
Anthramycin		4803-27-4		
Anthrar bin		577-33-3		
anthrax inhibitor			US 6436933	Anti-infective, other
antiangiogenic dendrimers			US 6426067	Anticancer, other
Anticort	L-Ascorbic acid, mxt with 2-(diethylamino)ethyl 4-aminobenzoate			
antidepressants, Nutrition	monohydrochloride, disodium hydrogen phosphate, potassium benzoate and zinc sulfate (1:1) [CAS]	186646-39-9	WO 9640038	Anabolic
anti-invasins, Microbia			US 5898036	Antidepressant
			US 6303302	Antifungal

TABLE 6

Example of Indication
Macular degeneration
Cardiomyopathy, ischaemic
Cancer, general
Infection, Candida, general
Infarction, myocardial
Infection, anthrax
Cancer, general
Cachexia
Depression, general
Infection, fungal, general

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Antimony Potassium Tartrate		28300-74-5		
Antimony Sodium Thi glycollat		539-54-8		
Antimony Thioglyc llamide		6533-78-4		
Antiprogesterin	19-Norpregna-4,9-dien-3-one,(acetylphenyl)-20,20,21,21,21-pentafluoro-17-hydroxy-(11B,17A)pha [CAS]	211254-73-8	DE 19706061	Anticancer, hormonal
Antipyrine		60-80-0		
Antipyrine Salicylate		520-07-0		
antithrombin III, Kabi		9000-94-6		Blood fraction
anxiolytics, Drug Discovery	Antithrombin, III [CAS]	90170-80-2		Anxiolytic
AP-521	N-Piperonyl-2-amino-1,2,3,4-tetrahydrobenzo(b)thieno(2,3-c)pyridine-3-carbamide	151227-08-6	WO 9321189	Anxiolytic
AP-5280			US 5965118	Anticancer, alkylating
Apalcillin		63469-19-2		
apaziquone	1H-indole-4,7-dione, 5-(1-aziridinyl)-3-(hydroxymethyl)-2-(3-hydroxy-1-propenyl)-1-methyl-, (E)- [CAS]	114560-48-4	WO 8706227	Anticancer, alkylating
Apazon		13539-59-8		
α-Phenylbutyramide		90-26-6		
Ap c deln		641-36-1		
apomine	Phosphoric acid, (2-(3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl)ethylidene)bis- tetrakis(1-methylethyl) ester [CAS]	126411-13-0		Anticancer, other
Ap m rphine		58-00-4		
apomorphine	4H-Dibenzo[de,g]quinoline-10,11-diol, 5,6,6a,7-tetrahydro-6-methyl-, hydrochloride			
apraclonidine	1,4-Benzenediamine, 2,6-dichloro-N1-(4,5-dihydro-1H-imidazol-2-yl)- [CAS]	314-19-2 66711-21-5 73218-79-8	US 4517199	Formulation, trans mucosal, nasal Antiglaucoma

TABLE 6

Example of Indication
Cancer, breast
Antithrombin III deficiency
Anxiety, general
Anxiety, general
Cancer, general
Cancer, breast
Cancer, prostate
Impotence
Glaucoma

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
aprepitant	3H-1,2,4-Triazol-3-one, 5-[[2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-1,2-dihydro- [CAS]	170729-80-3	US 5719147	Antiemetic
aprimidine	1,3-Propanediamine, N-(2,3-dihydro-1H-inden-2-yl)-N',N'-diethyl-N-phenyl- [CAS]	33237-74-0 37640-71-4	GB 1321424	Antiarrhythmic
Aprobarbital		77-02-1		
Apronalid		528-92-7		
Aprotinin		9087-70-1		
Aptiganel		137159-92-3		
AQ4N	9,10-Anthracenedione, 1,4-bis((2-(dimethyloxidoamino)ethyl)amino)-5,8-dihydroxy- [CAS]	136470-65-0	US 5132327	Anticancer, other
Aquavan			US 6204257	Anaesthetic, injectable
AR-116081			US 6107324	Neuroleptic
AR-A2	(R)-N-[5-methyl-8-(4-methylpiperazin-1-yl)-1,2,3,4-tetrahydro-2-naphthyl]-4-morpholinobenzamide			Anxiolytic
Arachidonic Acid		506-32-1		
aranidipine	3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-, methyl 2-oxopropyl ester- [CAS]	86780-90-7	GB 2111978	Antihypertensive, other
arbekacin	D-Streptamine, O-3-amino-3-deoxy-Alpha-D-glucopyranosyl-(1-6)-O-[2,6-diamino-2,3,4,6-tetra-deoxy-Alpha-D-erythro-hexopyranosyl-(1-4)]-N1-(4-amino-2-hydroxy-1-oxobutyl)-2-deoxy-, (S)- [CAS]	51025-85-5 75282-65-4	US 4001208	Aminoglycoside antibiotic
Arbidol	1H-Indole-3-carboxylic acid, 6-bromo-4-(((dimethylamino)methyl)-5-hydroxy-1-methyl-2-((phenylthio)methyl)-, ethylester, monohydrochloride [CAS]	131707-23-8	WO 9008135	Immunostimulant, other
arbutamine	1,2-Benzenediol, 4-[[1-hydroxy-2-[[4-(4-hydroxyphenyl)butyl]amino]ethyl]-, (R)- [CAS]	128470-16-6	WO 9220324	Diagnostic
Arcitum mab		154361-48-5		
ardeparin	Heparin [CAS]	9005-49-6		Anticoagulant

TABLE 6

Exempl of Indication
Chemotherapy-induced nausea and vomiting
Cancer, general
Anaesthesia
Unspecified
Anxiety, general
Hypertension, general
Infection, general
Infection, influenza virus
Diagnosis, coronary
Thrombosis, venous

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
arecoline, transdermal	1,2,5,6-Tetrahydro-1-methyl-3-pyridine carboxylic acid methyl ester			Formulation, transdermal, patch
argatroban	2-Piperidinecarboxylic acid, 1-[5-[(aminolinomethyl)amino]-1-oxo-2-[[[1,2,3,4-tetrahydro-3-methyl-8-quinolinyl)sulfonyl]amino]pentyl]-4-methyl- [CAS]	74863-84-8	EP 8746	Anticoagulant
Argatr ban		74863-84-6		
Arginine		74-79-3		
Ariflo®		153259-65-5		
aripiprazole	2(1H)-Quinolirone, 7-[4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butoxy]-3,4-dihydro- [CAS]	129722-12-9	EP 367141	Neuroleptic
arofylline	1H-Purine-2,6-dione, 3-(4-chlorophenyl)-3,7-dihydro-1-propyl- [CAS]	136145-07-8	EP 435811	COPD treatment
arotinolol	2-Thiophenecarboxamide, 5-[2-[[3-[(1,1-dimethylthyl)amino]-2-hydroxypropyl]thio]-4-thiazolyl]-, (±)- [CAS]	104766-23-6 68377-92-4	US 3932400	Antihypertensive, adrenergic
Arotin lol		68377-92-4		
Arsacetin		618-22-4		
arsenic trioxide	Arsenic oxide (As ₂ O ₃) [CAS]	1327-53-3		Anticancer, other
Arsphenamine		139-93-5		
Arsthin I		119-96-0		
Art ether		75887-54-6		
Arteflen		123407-36-3 (Z-form)		
Artem th r		71963-77-4		
Art misinin		63968-64-9		
artemotil	3,12-Epoxy-12H-pyranol[4,3-j]-1,2-benzodioxepin, 10-ethoxydecahydro-3,6,9-trimethyl-, [3R-(3A)pha,5aB,6B,8aB,9aAlpha,10Alpha,12B,12aR)]- [CAS]	75887-54-8		Antimalarial

TABLE 6

Example of Indication
Alzheimer's disease
Thrombosis, arterial
Schizophrenia
Chronic obstructive pulmonary disease
Hypertension, general
Cancer, leukaemia, acute myelogenous
Infection, malaria

TABLE 6

API Gen ric Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
artesunate	Butanedioic acid mono- [(3R,5aS,6R,8aS,9R,10R,12R,12aR)- decahydro-3,6,9-trimethyl-3,12-epoxy-12H- pyrano[4,3-j]-1,2-benzodioxepin-10-yl]ester	88495-63-0		Formulation, transmucosal, systemic
arizoxifene hydrochloride	Benzo(b)thiophene-6-ol, 2-(4- methoxyphenyl)-3-(4-(2-(1- piperidinyl)ethoxy)phenoxy)-, hydrochloride [CAS]	182133-27-3	WO 9609041	Anticancer, hormonal
AS-3201	Spiro(pyrrolidine-3,4'(1'H)-pyrrolo(1,2- a)pyrazine)-1',2,3,5(2'H)-tetrone, 2'-((4- bromo-2-fluorophenyl)methyl)-, (3'R)- [CAS]	147254-64-6	EP 520320	Symptomatic antidiabetic
ASA, Benzon	Benzoic acid, 2-(acetyloxy)- [CAS]	50-78-2		Formulation, modified-release, other
ASA, Mayne	Benzoic acid, 2-(acetyloxy)- [CAS]	56449-07-1		Formulation, modified-release, other
ASA, Micropump	Benzoic acid, 2-(acetyloxy)- [CAS]	50-78-2		Formulation, optimized, microencapsulate
ASA, Verex	Benzoic acid, 2-(acetyloxy)- [CAS]	50-78-2	US 4375468	Formulation, modified-release, >24hr
α-Santonin		56449-07-1		
Ascarid le		481-06-1		
Ascorbic Acid		512-85-6		
		50-81-7		
asenapine maleate	1H-Dibenz[2,3:6,7]oxepino[4,5-c]pyrrole, 5- chloro-2,3,3a,12b-tetrahydro-2-methyl-, trans-, (Z)-2-butenedioate (1:1) [CAS]	85650-56-2	WO 9523600	Neuroleptic
asimadoline	Benzenecetamide, N-[2-(3-hydroxy-1- pyrrolidinyl)-1-phenylethyl]-N-methyl-Alpha- phenyl-, [S-(R*,R*)]- [CAS]	153205-46-0	DE 4215213	GI inflammatory/bowel disorders
asoprisnil	11β-[4-(Hydroxyiminomethyl)phenyl]-17β- methoxy-17Alpha-(methoxymethyl)estra- 4,9-dien-3-one	199396-78-4	EP 0648778	Menstruation disorders
As xime Chl ride		34433-31-3		
Aspartic Acid		56-84-8		
Aspidin		584-28-1		
Aspidinol		519-40-4		
Aspirin		50-78-2		

TABLE 6

Example of Indication
Infection, malaria
Cancer, breast
Diabetic complication, general
Pain, general
Thrombosis, general
Infarction, myocardial
Arthritis, general
Psychosis, general
Irritable bowel syndrome
Endometriosis

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Aspirin, Dipyridamole				
asproxillin	Glycinamide, N-methyl-D-asparaginyl-N-(2-carboxy-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-6-yl)-D-2-(4-hydroxyphenyl)-, [2S-(2 α ,5 α ,6 β)]-[CAS]	83358-49-6	GB 1533413	Penicillin, injectable
AST-120	AST 120 [CAS]	90597-58-3		Urological
Astemizol		68844-77-9		
asulacrine	4-Acridinecarboxamide, 9-[[2-methoxy-4-[(methylsulfonyl)amino]phenyl]amino]-N,5-dimethyl- [CAS]	80841-47-0 80841-48-1	EP 39224	Anticancer, other
AT-1015	(N-[2-(4-(5H-Dibenzof[a,d]cyclohepten-5-ylidene)-piperidinylethyl)-1-formyl-4-piperidinecarboxamide monohydrochloride monohydrate			Antithrombotic
ataamestane	Androsta-1,4-diene-3,17-dione, 1-methyl-[CAS]	96301-34-7	DE 3338212	Anticancer, hormonal
atazanavir	2,5,6,10,13-Pentazetetradecanedioic acid, 3,12-bis(1,1-dimethylethyl)-8-hydroxy-4,11-dioxo-9-(phenylmethyl)-6-((4-(2-pyridinyl)phenyl)methyl)-dimethyl ester, (3S,8S,9S,12S)-, sulfate (1:1) (salt) [CAS]	229975-97-7 29122-68-7 73677-19-7		Antiviral, anti-HIV
atenolol	Benzeneacetamide, 4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]- [CAS]		GB 1285038	Antihypertensive, adrenergic
atenolol + chlorthalidone	Benzeneacetamide, 4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]-, mixt. with 2-chloro-5-(2,3-dihydro-1-hydroxy-3-oxo-1H-isoindol-1-yl)benzenesulfonamide [CAS]	73677-19-7	US 3836671	Formulation, fixed-dose combinations
atenolol + nifedipine	Benzeneacetamide, 4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]- + 4-(2-nitrophenyl)-2,6-dimethyl-3,5-dicarbomethoxy-1,4-dihydropyridine			Formulation, fixed-dose combinations
α -T rpln ol		98-55-5		
At viridin		136816-75-6		

TABLE 6

Example of Indication
Infection, respiratory tract, general
Renal failure
Cancer, general
Thrombosis, general
Cancer, breast
Infection, HIV/AIDS
Hypertension, general
Hypertension, general
Hypertension, general

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
alipamezole	1H-Imidazole, 4-(2-ethyl-2,3-dihydro-1H-inden-2-yl)- [CAS]	104054-27-5	EP 183492	Reproductive/gonadal, general
aliprimod dimaleate	2-Azaspiro[4.5]decane-2-propanamine, N,N-diethyl-8,8-dipropyl, dimaleate	130065-61-1	US 5744495	Antiarthritic, Immunological
ATL-146a			US 6232297	Imaging agent
α -Tocopherol		59-02-9		
atomoxetine	Benzenepropanamine, N-methyl-Gamma-(2-methylphenoxy)-, (R)- [CAS]	82248-69-7		
At rovastatin		83015-26-3	EP 52492	Neurological
		134523-00-5		
atorvastatin calcium	1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-8, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, calcium salt [R-(R*, R*)]-[CAS]		EP 409281	Hypolipaeic/Antiatherosclerosis
atosiban	Oxytocin, 1-(3-mercaptopropanoic acid)-2-(O-ethyl-D-tyrosine)-4-L-threonine-8-L-ornithine- [CAS]	134523-03-8		
At sibran		90779-69-4	EP 112809	Labour inhibitor
		90779-69-4		
atovaquone	1,4-Naphthalenedione, 2-[4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-, trans- [CAS]	95233-18-4	EP 123238	Antifungal
atovaquone + proguanil, GSK	1,4-Naphthalenedione, 2-[4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-, trans + N-(4-chloro-phenyl)-N-(1-methylethyl)imidodicarbonimidic diamide			Antimalarial
atracturium besilate	Isoquinolinium, 2,2'-(1,5-pentanediyldi[bis(oxy(3-oxo-3,1-propanediy)]bis[1'-[(3,4-dimethoxyphenyl)methyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl, dibenzenesulfonate [CAS]	64228-81-5	US 4179557	Muscle relaxant
atrasentan	3-Pyrolidinocarboxylic acid, 4-(1,3-benzodioxol-5-yl)-1-[2-(dibutylamino)-2-oxoethyl]-2-(4-methoxyphenyl)-, (2R,3R,4S)- [CAS]	173937-81-2	WO 9730045	Anticancer, other

TABLE 6

Example of Indication
Sexual dysfunction, female
Arthritis, rheumatoid
Unspecified
Attention deficit disorder
Hypercholesterolaemia
Labour, preterm
Infection, Pneumocystis jirovecii
Infection, malaria
Surgery adjunct
Cancer, prostate

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Atrial Natriuretic Peptide		85637-73-6		
Atrolactamid		2019-68-3		
Atrazine		51-55-8		
Augmentin XR, Glaxo		74489-00-4		Formulation, modified-release, other
auranofin	Gold, (1-thio-β-D-glucopyranose 2,3,4,6-tetraacetato-S)(triethylphosphine)-[CAS]	34031-32-8	US 3708579	Antiarthritic, other
Aurothiogluconate		12192-57-3		
avasimibe	Sulfamic acid, [[2,4,6-tris(1-methylethyl)phenyl]acetyl]-, 2,6-bis(1-methylethyl)phenyl ester [CAS]	166518-60-1	US 5491172	Hypolipemic/Antiatherosclerosis
Avbenzone		70356-09-1		
AWD-12-281	AWD 12-281 [CAS]	257892-33-4		Antiallergic, non-asthma
Azacitidine		320-67-2		
Azacyclonolone		115-46-8		
azanidazole	2-Pyrimidinamine, 4-[2-(1-methyl-5-nitro-1H-imidazol-2-yl)ethenyl]-, (E)- [CAS]	82973-76-6	US 3882105	Antibacterial, other
azapropazone	1H-Pyrazolo[1,2-a][1,2,4]benzotriazine-1,3(2H)-dione, 5-(dimethylamino)-9-methyl-2-propyl- [CAS]	13539-59-8	FR 1440629	Anti-inflammatory
Azaserine		115-02-6		
azasetron	2H-1,4-Benzoxazine-8-carboxamide, N-1-azabicyclo[2.2.2]oct-3-yl-6-chloro-3,4-dihydro-4-methyl-3-oxo-, monohydrochloride- [CAS]	123040-16-4 123040-94-8 123040-96-0	EP 313393	Antiemetic
Azaspirin		123040-69-7		
Azatadine		3964-81-6		
Azathioprine		446-86-6		
azathioprine	6-[(1-Methyl-4-nitro-1H-imidazol-5-yl)thio]-1H-purine			Formulation, oral, other
AZD-4282	glycine	446-86-6		Analgesic, other
AZD-6140	3,4-Difluorophenylcyclopropylamine			Antithrombotic
Azelaic Acid		123-99-9		

TABLE 6

Examp ^l of Indication
Infection, respiratory tract, general
Arthritis, rheumatoid
Atherosclerosis
Rhinitis, allergic, general
Infection, trichomoniasis
Nausea and vomiting, general
Transplant rejection, bone marrow
Pain, neuropathic
Thrombosis, arterial

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
azelaic acid	Nonanedioic acid [CAS]	123-99-9		Antiacne
Az lastine		58581-89-8		
	1(2H)-Phthalazinone, 4-[(4-chlorophenyl)methyl]-2-(hexahydro-1-methyl-1H-azepin-4-yl)-, monohydrochloride [CAS]	58581-89-8 79307-99-0	GB 1377231	Antiasthma
	3,5-Pyridinedicarboxylic acid, 2-amino-1,4-dihydro-6-methyl-4-(3-nitrophenyl)-, 3-[1-(diphenylmethyl)-3-azetidinyl] 5-(1-methylethylester, (+/-)) [CAS]	123524-52-7	EP 266922	Antihypertensive, other
Azidamfenicol		13838-08-9		
Azid cillin		17243-38-8		
Azimilide		149908-53-2		
Azintamid		1830-32-6		
	9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin-A	76801-85-9 83905-01-5 92395-24-9	US 4328334	Macrolide antibiotic
Azithr mycin		83905-01-5		
	9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin-A			Formulation, modified-release, other.
	4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3,3-dimethyl-7-oxo-6-[[[(2-oxo-1-imidazolidinyl)carbonyl]amino]phenyl]acetyl]amino]-, [2S-[2.alpha.,5.alpha.,6B(s*)]]-[CAS]	37091-65-9 37091-66-0	GB 1392849	Penicillin, injectable
Az s mide		27589-33-9		
	Propanoic acid, 2-[[[1-(2-amino-4-thiazolyl)-2-[(2-methyl-4-oxo-1-sulfo-3-azetidinyl)amino]-2-oxoethylidene]amino]oxy]-2-methyl-, [2S-[2Alpha,3B(Z)]]-[CAS]	104184-69-2 78110-38-0	GB 2071650	Beta-lactam antibiotic
aztreonam				
	Propanoic acid, 2-[[[1-(2-amino-4-thiazolyl)-2-[(2-methyl-4-oxo-1-sulfo-3-azetidinyl)amino]-2-oxoethylidene]amino]oxy]-2-methyl-, [2S-[2Alpha,3B(Z)]]-[CAS]	104184-69-2 78110-38-0		Formulation, inhalable, topical

TABLE 6

Example of Indication	
Acne	
Asthma	
Hypertension, general	
Infection, respiratory tract, lower	
Conjunctivitis	
Infection, general	
Infection, general	
Infection, respiratory tract, general	

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
azulene	Sodium 5-isopropyl-3,8-dimethyl-1-azulene sulfonate	6223-35-4	EP 88958	Formulation, modified-release, other
bacampicillin	4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[[aminophenyl(acyl)amino]-3,3-dimethyl-7-oxo-, 1-[(ethoxycarbonyloxy)ethyl ester, [2S-[2Alpha,5Alpha,6B(S')]]]- [CAS]	37661-08-8 50872-17-3	GB 1363506	Penicillin, oral
Bacampicillin		50972-17-3		
Bacitracin		1405-87-4		
baclofen	B-(Aminomethyl)-4-chlorobenzenepropanoic acid [CAS]	1134-47-0		Formulation, implant
Baical In		491-67-8		
baclofloxacin	3-Quinolonecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[3-(methylamino)-1-piperidinyl]-4-oxo- [CAS]	127294-70-6	EP 342675	Quinolone antibacterial
balsalazide	Benzoic acid, 5-[4-[(2-carboxyethyl)amino]carbonyl]phenyl]azo]-2-hydroxy-, (E)- [CAS]	80573-04-2	US 4412992	GI inflammatory/bowel disorders
Bambuterol		81732-65-2		
bambuterol	Carbamic acid, dimethyl-, 5-[2-[(1,1-dimethylethyl)amino]-1-hydroxyethyl]-1,3-phenylene ester, monohydrochloride [CAS]	81732-46-9	EP 43807	Antiasthma
Bamethan		3703-79-5		
Bamifyllin		2016-63-9		
Bamipin		4945-47-5		
Barbital		57-44-3		
barnidipine	3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, methyl-1-(phenylmethyl)-3-pyrrolidinyl ester, [S-(R*,R*)]-	104713-75-9 104757-53-1 71863-56-4	US 4220649	Antihypertensive, other
Barnidipin		104713-75-9		
BAS-118	N-Methyl-3-[2-(2-naphthyl)acetyl]amino]benzamide			Antibacterial, other

TABLE 6

Example 1 Indication
Inflammation, general
Infection, general
Spastic paralysis
Infection, urinary tract
Colitis, ulcerative
Asthma
Hypertension, general
Infection, Helicobacter pylori

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Basic Aluminum Carbamate Gel		1339-92-0		
Basiliximab		179045-86-4		
Batimastat		130370-60-4		
Batraxobin		9039-61-6		
Bay-41-2272	5-cyclopropyl-2-[1-(2-fluoro-benzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-(4-morpholinyl)pyrimidin-4-ylamine			Male sexual dysfunction
Bay-41-8543	2-[1-(2-Fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-(4-morpholinyl)pyrimidine-4,6-diamine			Cardiovascular
BAY-43-9006	N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea			Anticancer, other
BAY-57-1293	N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide			
bazedoxifen	TSE 424 [CAS]	198481-33-3	EP 802183	Antiviral, other
β-B nzalbutyramide		7236-47-7		Osteoporosis treatment
BBR-3464	Platinum(4+), hexaaminedichlorobis(μ -(1,6-hexanediamine-N,N'))tri- stereoisomer, tetranitrate [CAS]	172903-00-3	US 5744497	Anticancer, alkylating
BBR-3576			US 5519029	Anticancer, antibiotic
BBR-3610			US 6060616	Anticancer, alkylating
β-Caroten		7235-40-7		
BCH-1868	(-)-2-R-dihydroxyphosphinoyl-5-(S)-(guanin-9'-yl-methyl)tetrahydrofuran			Anticancer, antimetabolite
Bebeerin		477-60-1		
B clamid		501-68-8		
bclometasone	Pregna-1,4-diene-3,20-dione, 9-chloro-11 β ,17,21-trihydroxy-16 β -methyl, 17,21-dipropionate [CAS]	5534-09-8	WO 0006132	Formulation, inhalable, solution

TABLE 6

Exemplification
Sexual dysfunction, male, general
Unspecified
Cancer, liver
Infection, herpes simplex virus
Osteoporosis
Cancer, lung, non-small cell
Cancer, prostate
Cancer, general
Cancer, general
Asthma

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
beclometasone	Pregna-1,4-diene-3,20-dione, 9-chloro-11,17,21-trihydroxy-18-methyl-, (11B,16B)-[CAS]	4419-39-0		Formulation, inhalable, dry powder
Befloxaton		134564-82-2		
befunolol	Ethanol, 1-7-[2-hydroxy-3-[(1-methyl[ethy]lamino)propoxy]-2-benzofuranyl]-[CAS]	39543-79-8 39552-01-7		Antiglaucoma
Bemegride		64-65-3		
Benactyzine		302-40-9		
benazepril	1H-1-Benzazepine-1-acetic acid, 3-[[1-(ethoxycarbonyl)-3-phenylpropyl]amino]-2,3,4,5-tetrahydro-2-oxo-, [S-(R*,R*)]-[CAS]	86541-74-4 86541-75-5 86541-76-8	EP 72852	Antihypertensive, renin system
Bencyclane		2179-37-5		
bencyclane	1-Propanamine, N,N-dimethyl-3-[[1-(phenylmethyl)cycloheptyloxy]-, (E)-2-butenedioate (1:1) [CAS]	14288-84-1	WO 9829409	Vasodilator, peripheral
Bendazac		20187-55-7		
bendazac	L-Lysine, mono[[[1-(phenylmethyl)-1H-indazol-3-yl]oxy]acetate] [CAS]	81919-14-4 73-48-3	GB 2081708	Ophthalmological
Bendr flumethiazide		78718-25-9		
Benexate				
benfluorex	Ethanol, 2-[[1-methyl-2-[3-(trifluoromethyl)phenyl]ethy]amino]-, benzoate (ester) [CAS]	23602-78-0 23842-66-2	GB 1175516	Hypolipaeimic/Antiatherosclerosis
Benf tiamin		22457-89-2		
Benfur dil		3447-95-8		
Hemisuccinat				
bendipiline	3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, methyl 1-(phenylmethyl)-3-piperidinyl ester, monohydrochloride (R*,R*)-(+)-[CAS]	105979-17-7 91599-74-5	EP 63365	Antihypertensive, other
Ben rylate		5003-48-5		
Benoxaprofen		67434-14-4		
Ben xinat		99-43-4		
Benp rid I		2062-84-2		
Benpr perin		2156-27-6		

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Benserazide		322-35-0		
bentazepam	2H-[1]Benzothieno[2,3-e]-1,4-diazepin-2-one, 1,3,6,7,8,9-hexahydro-5-phenyl[CAS]	29462-18-8	DE 2005276	Anxiolytic
B ntiomid		37106-97-1		
B nt quatam		1340-69-8		
B nzalkonium Chloride		8001-54-5		
B nzar n		1477-19-6		
benzbromarone	Methanone, (3,5-dibromo-4-hydroxyphenyl)(2-ethyl-3-benzofuranyl)-[CAS]	3562-84-3	US 3012042	Antigout
Benzethonium Chloride		121-54-0		
Benzetimide		14051-33-3		
Benzil nium Bromide		1050-48-2		
Benzi dar ne		68-90-6		
benzimidazole	N-benzyl-2-nitroimidazole-1-acetamide	22994-85-0	GB 1138529	Protozoacide
B nz caine		94-09-7		
Benzocaine				
benzocaine, Vinas				
B nzocetamin	Benzolic acid, 4-amino-, ethyl ester	94-09-7		Formulation, fixed-dose combinations
B nz natate		17243-39-9		
Benz xonium Chloride		104-31-4		
		19379-90-9		
B nzoyl P r xide		94-36-0		
benzoyl peroxide	Peroxide, dibenzoyl [CAS]	94-36-0		Formulation, other
Benzoylpas		13898-58-3		
Benzphetamin		156-08-1		
Benzpip rylon		53-89-4		
Benzquinamid		63-12-7		
B nzthiazide		91-33-8		
Benztropine M sylvate		132-17-2		
Benzydamin		642-72-8		

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
benzylamine flufenamate	N-(Alpha,Alpha,Alpha-trifluoromethyl)antranilate of 1-benzyl-3-(3-dimethylamine-propoxy)-1H-imidazol			Anti-inflammatory, topical
benzylamine	1-Propanamine, N,N-dimethyl-3-[(1-phenylmethyl)-1H-imidazol-3-yl]oxy]- [CAS]	132-89-4 842-72-8		Stomatological, reproductive/gonadal, anti-inflammatory
Benzyl B nzoate		120-51-4		
Benzylhydro. chlorothiazid		1824-50-6		
Benzylm rphine		14297-87-1		
Bephenium		3818-50-6		
Hydr xynaphthoate				
Bep tastine		190786-43-7		
bepotastine	1-Piperidinebutanoic acid, 4-[(4-chlorophenyl)-2-pyridinylmethoxy]-, (S)-, monobenzenesulfonate [CAS]	190786-44-8	WO 9829409	Antiallergic, non-asthma
bepiridil	1-Pyrrolidineethanamine, 8-[(2-methylpropoxy)methyl]-N-phenyl-N-(phenylmethyl)- [CAS]	84708-54-3 74764-40-2 74764-75-3	EP 146155	Antianginal
beraprost	1H-Cyclopenta[b]benzoturan-5-butanoic acid, 2,3,3a,8b-tetrahydro-2-hydroxy-1-(3-hydroxy-4-methyl-1-octen-6-ynyl)- [CAS]			
B rapr st		88475-69-8	US 4474802	Prostaglandin
Berberin		88430-50-6		
Bergapt n		2086-83-1		
B m pr fen		484-20-8		
B sipirdin		78499-27-1		
		119257-34-0		
betahistine	2-Pyridineethanamine, N-methyl-, dihydrochloride	5579-84-0 5638-76-6		Formulation, modified-release, <=24hr
betaine	Betaine- [CAS]	107-49-7		Metabolic and enzyme disorders
betamethasone	Pregna-1,4-diene-3,20-dione, 9-fluoro-11,17,21-trihydroxy-16-methyl-, (11b,16b)- [CAS]			
Betamipron		378-44-9		Formulation, dermal, topical
Betasin		3440-28-6 3734-24-5		

TABLE 6

Exempl f Indication
Inflammation, general
Allergy, general
Angina, general
Peripheral vascular disease
Meniere's disease
Homocystinuria
Psoriasis

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
betaxolol	2-Propanol, 1-[4-(2-(cyclopropylmethoxy)ethyl)phenoxy]-3-[(1-methylethyl)amino]- [CAS]	63659-18-7 63659-19-8	US 4252884	Antihypertensive, adrenergic
B tazole		105-20-4		
Bethan ch l Chloride		590-63-6		
Bethanidine		55-73-2		
Bet xycaine		3818-62-0		
β-Eucalin		500-34-5		
bevantolol	2-Propanol, 1-[2-(3,4-dimethoxyphenyl)ethyl]amino]-3-(3-methylphenoxy)- [CAS]	42864-78-8 59170-23-9	US 3857891	Antihypertensive, adrenergic
Bev nium M thyl Sulfat		5205-82-3		
bexarotene	Benzoic acid, 4-(1-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)ethenyl)- [CAS]	153559-49-0	WO 9321146	Anticancer, other
bezafibrate	Propanoic acid, 2-[4-{2-[(4-chlorobenzoyl)amino]ethyl}phenoxy]-2-methyl- [CAS]	41859-67-0	GB 1359264	Hypolipaeic/Antiatherosclerosis
Bezitramide		15301-48-1		
BG-9928		166374-48-7		Cardiosimulant
BIA-2-024	10,11-dihydro-10-hydroxyimino-5H-dibenz[b,f]azepine-5-carboxamide	199997-15-4	WO 9745416	Antiepileptic
BIA-2-093	(S)-(-)-10-acetoxy-10,11-dihydro-5H-dibenzo[b,f]azepine-5-carboxamide- [CAS]	236395-14-5		Antiepileptic
BIA-3-202	1-(3,4-dihydroxy-5-nitrophenyl)-2-phenylethanone	274925-86-9	EP 1010688	Antiparkinsonian
Blalamic I		493-75-4		
biapenem	5H-Pyrazolo[1,2-a][1,2,4]triazol-4-ium, 6-[[2-carboxy-5-(1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-en-3-yl]thio]-6,7-dihydro-, hydroxide, inner salt, [4R-[4Alpha,5S,6S(R*)]]- [CAS]	120410-24-4	EP 289801	Beta-lactam antibiotic

TABLE 6

Examp ^l	f Indication
	Hypertension, general, glaucoma
	Hypertension, general
	Cancer, lymphoma, T-cell
	Heart failure
	Epilepsy, general
	Epilepsy, general
	Parkinson's disease
	Infection, beta-lactamase resistant

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Bibenzonium Bromide		15585-70-3		
Bibrocathol		6915-57-7		
	Propanamide, N-(4-cyano-3-(trifluoromethyl)phenyl)-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methyl-, (+/-) [CAS]			
bicalutamide		90357-08-5	EP 100172	Anticancer, hormonal
bicifadine	3-Azabicyclo[3.1.0]hexane, 1-(4-methylphenyl)-, (+/-) [CAS]	66504-75-4	DE 2740582	Analgesic, other
bicyclic monoterpene diols		71185-57-8	US 6294585	Dermatological
Bidisomide		116078-65-0		
Bietamiverin		479-81-2		
Bietanautin		6888-11-5		
Bietaspin		53-18-9		
	1-Butanamine, N-methyl-4-[2-(phenylmethyl)phenoxy]-, hydrochloride [CAS]	82232-46-6	GB 1512880	Cognition enhancer
bifemelane		90293-01-9		
Bifluranol		34633-34-6		
		60628-96-8		
bifonazole	1H-Imidazole, 1-[(1,1'-biphenyl)-4-ylphenylmethyl]- [CAS]	80829-08-5	US 4118487	Antifungal
	5-Heptenamide, 7-(3,5-dihydroxy-2-(3-hydroxy-5-phenyl-1-pentenyl)cyclopentyl)-N-ethyl (1R-1Alpha(Z)2R(1E,3S,3Alpha,5Alpha)) [CAS]			
bimatoprost	N-[2-hydroxy-3-(1-piperidinyl)propoxy]-3-pyridinecarboximidoyl chloride, (Z)-2-butanedioate (1:1)	155206-00-1	US 5688819	Prostaglandin
bimoclomol	(1,1'-Biphenyl)-3-acetic acid, 3',3'''-(1,6-hexanediyl)bis(6'-Alpha-D-mannopyranosyloxy)-, [CAS]	130493-04-8	US 5147874	Symptomatic antidiabetic
bimosiamose		187269-40-5	US 5444050	Antiasthma
Binifibrate		69047-39-8		
binodenoson	Adenosine, 2-((cyclohexylmethylene)hydrazino)- [CAS]	144348-08-3		Vasodilator, coronary
Biomad-101			US 6423744	Anticancer, other
Biotin		58-85-5		
Biperiden		514-65-8		

TABLE 6

Exempl	f Indication
	Cancer, prostate
	Pain, general
	Unspecified
	Attention deficit disorder
	Infection, fungal, general
	Glaucoma
	Neuropathy, diabetic
	Asthma
	Diagnosis, coronary
	Cancer, renal

TABLE 6

API Gen. ric Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Bircodar		15997-94-1		
	2-Piperidinecarboxylic acid, 1-(oxo(3,4,5-trimethoxyphenyl)acetyl)-4-(3-pyridinyl)-1-(3-(3-pyridinyl)propyl)butyl ester, (S)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:2) [CAS]			
bircodar dicitrate		174254-13-8		Radio/chemosensitizer
	1-Butanone, 1-(4-fluorophenyl)-4-(3,4,6,7,12,12a-hexahydropyrazino[1',2':1,6]pyrido[3,4-b]indol-2(1H)-yl)- [CAS]	42021-34-1	DE 233922	Neuroleptic
biriperone		603-50-9		
Bisacodyl		78186-34-2		
Bisantren		2667-89-2		
Bisbentiamin		52951-36-7		
Bisdequalinium Chloride				
Bismuth Aluminate		12284-76-3		
Bismuth		53897-25-9		
Butylthi laurat		52951-37-8		
Bismuth Ethyl Camph rate				
Bismuth I dosubgallate		138-58-9		
Bismuth Sodium Iodide		53778-50-0		
Bismuth Sodium Triglycollamat		5798-43-6		
Bismuth Subcarbonate		5892-10-4		
Bismuth Subgallate		22650-86-8		
Bismuth Subnitrate		1304-85-4		
Bismuth Subsalcylate		14882-18-9		
Bismuth		5175-83-7		
Tribrom phenate				
bisoprolol	2-Propanol, 1-[4-[(2-{1-methylethoxy}ethoxy)methyl]phenoxy]-3-[(1-{104344-23-2 methylethyl}amino)- [CAS]	66722-44-9	GB 1532380	Antihypertensive, adrenergic

TABLE 6

Example 1 Indication
Cancer, breast
Heart failure

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
bisoprolol + HCTZ	2-Propanol, 1-[4-[(2-(1-methylethoxy)ethoxy)methyl]phenoxy]-3-[(1-methylethoxy)amino] mixt. with 6-chloro-3,4-dihydro-2H-1,2,4-benzothiazine-7-sulfonamide 1,1-dioxide			Formulation, fixed-dose combinations
bisoprolol+trichloromethiazide	2-Propanol, 1-[4-[(2-(1-methylethoxy)ethoxy)methyl]phenoxy]-3-[(1-methylethoxy)amino] mixt. with 6-chloro-3-(dichloromethyl)-3,4-dihydro-2H-1,2,4-benzothiazine-7-sulfonamide 1,1-dioxide			Formulation, fixed-dose combinations
Bis xatin Acetate		14008-48-1		
Bithionol		97-18-7		
Bit It rol		30392-40-6		
Bit scanate		4044-65-9		
BL-3875			WO 0218378	Anti-inflammatory
bleomycin sulfate	Bleomycin sulphate (salt) [CAS]	11056-06-7 9041-93-4		Formulation, transdermal, enhanced
blonanserlin	Cycloocta[b]pyridine, 2-(4-ethyl-1-piperazinyl)-4-(4-fluorophenyl)-5,6,7,8,9,10-hexahydro- [CAS]	132810-10-7	EP 385237 EP 639577	Neuroleptic Anticancer, other
BMS-184476	cis-(+/-)-2-(Ethylthio)-5,7-dihydroxy-8-(3-hydroxy-1-methyl-4-piperidinyl)-4H-1-benzopyran-4-one		WO 9742949	Anticancer, other
BMS-387032	4-[2-(aminomethyl)-1,3-thiazol-4-yl]-2,6-di-tert-butylphenol, dihydrochloride			Neuroprotective
BN-82451	Ethanesulfonic acid, 2,2'-dithiobis-, disodium salt [CAS]	16208-51-8		Radio/chemoprotective
BNP-7787				
BO-653	5-Benzofuranol, 4,6-bis(1,1-dimethylethyl)-2,3-dihydro-2,2-dipentyl- [CAS]	157360-23-1	WO 9408930	Hypolipemic/Antiatherosclerosis
Bolandi I		19793-20-5		
Bolasterone		1605-89-6		
Bolden ne		846-48-0		

TABLE 6

Example of indication
Hypertension, general
Hypertension, general
Unspecified
Cancer, head and neck
Schizophrenia
Cancer, breast
Cancer, general
Unspecified
Chemotherapy-induced nausea and vomiting
Atherosclerosis

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
bopindolol	2-Propanol, 1-[(1,1-dimethylethyl)amino]-3-[[2-methyl-1H-indol-4-yl]oxy]-, benzoate (ester), (+/-) [CAS]	62658-63-3 92857-38-3	US 4340541	Antihypertensive, adrenergic
Bornyl Chloride		464-41-5		
Bornyl Salicylate		560-88-3		
bortezomib	Boric acid, [(1R)-3-methyl-1-[[2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]- [CAS]	179324-69-7	US 6271199	Anticancer, other
bosentan	Benzenesulfonamide, 4-(1,1-dimethylethyl)-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)[2,2'-bipyrimidin]-4-yl]- [CAS]	147536-97-8	EP 633259	Vasodilator, peripheral
BP2.94	Phenol, 2-[[[(1R)-2-(1H-imidazol-4-yl)-1-methylethyl]imino]phenylmethyl]- [CAS]	139191-80-3	WO 9117146	Respiratory
BP4.897	N-[4-[4-(2-methoxyphenyl)-1-piperazinyl]butyl]naphthalene-2-carboxamide		EP 779284	Dependence treatment
β-Propiolactone		57-57-8		
Bradykinin		140661-97-8		
Brain Natriuretic Peptide		114471-18-0		
Brall barbitol		561-86-4		
brasofensine	8-Azabicyclo[3.2.1]octane-2-carboxaldehyde, 3-(3,4-dichlorophenyl)-8-methyl-, O-methylloxime, (1R-(1Alpha,2B(E),3Alpha,5Alpha))- [CAS]	171655-91-7	WO 9528401	Antiparkinsonian
Brequinar		96187-53-0		
Br tylium Tosylate		61-75-6		
Brilliant Green		633-03-4		
brimonidine	6-Quinoxalinamine, 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)- [CAS]	59803-98-4	DE 2538620	Antiglaucoma
brinzolamide	2H-Thieno[3,2-e]-1,2-thiazine-6-sulfonamide, 4-(ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-, 1,1-dioxide, (R)- [CAS]	138890-62-7	US 5378703	Antiglaucoma

TABLE 6

Example of Indication
Hypertension, general
Cancer, myeloma
Hypertension, pulmonary
Rhinitis, general
Addiction, cocaine
Parkinson's disease
Glaucoma
Glaucoma

TABLE 6

API Gen ric Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
brivudin	Uridine, 5-(2-bromoethenyl)-2'-deoxy, (E)- [CAS]	69304-47-8		Antiviral, other
Brodin prim		56518-41-3		
Bromazepam		1812-30-2		
Br mfenac		91714-94-2		
bromfenac	Benzeneacetic acid, 2-amino-3-(4-bromobenzoyl)- [CAS]	91714-93-1 91714-94-2		Formulation, mucosal, topical
Bromhexine		3572-43-8		
Br mindion		1146-98-1		
Br misovalum		496-67-3		
Br mocrptine		25614-03-3		
Brom diphenhydramine		118-23-0		
Brom f rm		75-25-2		
Brom pride		4093-35-0		
Br m salicylchloranilide		3679-64-9		
bromperidol	1-Butanone, 4-[4-(4-bromophenyl)-4-hydroxy-1-piperidinyl]-1-(4-fluorophenyl)- [CAS]	10457-90-6	US 3438991	Neuroleptic
Brompheniramine		86-22-6		
Br par str I		479-68-5		
Bropirimin		56741-95-8		
brostallicin	4-(2-Bromoacrylamido)-N ^m -(2-guanidinoethyl)-1,1',1'',1'''-tetramethyl-N,4'-N',4''-N'',4'''-quater-[pyrrole-2-carboxamide] [CAS]			Anticancer, other
brotizolam	6H-Thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine, 2-bromo-4-(2-chlorophenyl)-9-methyl- [CAS]	57801-81-7	US 4094984	Hypnotic/Sedative
Brovincamine		57475-17-9		
Broxuridin		59-14-3		
Br xyquin lin		521-74-4		
Brucine		357-57-3		
β-Sit ster I		83-46-5		
Bucetin		1083-57-4		
Bucillamin		65002-17-7		

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Bucindolol		71119-11-4		
bucindesine	Adenosine, N-(1-oxobutyl)-, cyclic 3',5'-(hydrogen phosphate) 2'-butanoate [CAS]	362-74-3	JP 51113896	Cardio stimulant
Buciadesine		362-74-3		
Bucilizin		82-95-1		
Bucisamid		575-74-6		
Bucolom		841-73-6		
bucicaine	9-Acridinamine, N-butyl-1,2,3,4-tetrahydro-, monohydrochloride [CAS]	82696-28-0		Anaesthetic, local
Bucumolol		58409-59-9		
budesonide	Pregna-1,4-diene-3,20-dione, 16,17-[butylidenebis(oxy)]-11,21-dihydroxy-, (11B,16Alpha)- [CAS]	51333-22-3	GB 1428922	Antiasthma
budesonide + formoterol	Pregna-1,4-diene-3,20-dione, 16,17-[butylidenebis(oxy)]-11,21-dihydroxy-, (11B,16Alpha) + formamide, N-[2-hydroxy-5-[1-hydroxy-2-[[2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]phenyl]-(R*,R*)-(±)			Formulation, fixed-dose combinations
budesonide	Pregna-1,4-diene-3,20-dione, 16,17-[butylidenebis(oxy)]-11,21-dihydroxy-, (11B,16Alpha)- [CAS]	51333-22-3		Formulation, inhalable, solution
bucipine	Piperidine, 1-(1,1-dimethylethyl)-4,4-diphenyl- [CAS]	57982-78-2 63661-61-0	DE 2825322	Antiparkinsonian
Budipine		57982-78-2		
Budralazin		36798-79-5		
Bufenlode		22103-14-6		
Bufetolol		53684-49-4		
bufexamac	p-butoxyacetohydroxamic acid	2438-72-4	US 3479396	Anti-inflammatory
buftomedil	1-Butanone, 4-(1-pyrrolidinyl)-1-(2,4,6-trimethoxyphenyl)- [CAS]	35543-24-9 55837-25-7	GB 1325192	Vasodilator, peripheral
Bufit medil		55837-25-7		
Buf rmin		692-13-7		
Bufuralol		54340-62-4		
Bumadizol		3583-64-0		

TABLE 6

Example of Indication
Wound healing
Asthma
Asthma
Asthma, Crohn's disease
Parkinson's disease

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
bumetanide	Benzoic acid, 3-(aminosulfonyl)-5-(butylamino)-4-phenoxy- [CAS]	28395-03-1	US 3806534	Antihypertensive, diuretic
bunafine	1-Naphthalenecarboxamide, N-butyl-N-[2-(diethylamino)ethyl]- [CAS]	32421-46-8	DE 2009894	Antiarhythmic
Bunafine		32421-46-8		
Bunamlodyl Sodium		1923-76-8		
bunazosin	1H-1,4-Diazepine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)hexahydro-4-(1-oxobutyl)- [CAS]	52712-76-2 80755-51-7	GB 1398455	Antihypertensive, adrenergic
Bunazosin		80755-51-7		
bunitrolol	Benzonitrile, 2-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]- [CAS]	34915-68-9	US 3940489	Antihypertensive, adrenergic
Bunitrolol		34915-68-9		
Bupivacaine		2180-92-9		
bupivacaine	2-Piperidinecarboxamide, 1-butyl-N-(2,6-dimethylphenyl)- [CAS]	38396-39-3		Formulation, modified-release, >24hr
bupivacaine	2-Piperidinecarboxamide, 1-butyl-N-(2,6-dimethylphenyl)- [CAS]			Formulation, parenteral, other
Bupranolol		14556-46-8		
buprenorphine	6,14-Ethenomorphinan-7-methanol, 17-(cyclopropylmethyl)-Alpha-(1,1-dimethylethyl)-4,5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy-Alpha-methyl-, [5Alpha,7Alpha(S)]- [CAS]	52485-78-7 53152-21-9	US 3433791	Analgesic, other
bupropion	1-Propanone, 1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]-, (+/-)- [CAS]	31677-93-7 34911-55-2	US 4425363	Antidepressant
bupropion	1-Propanone, 1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]-, (+/-)- [CAS]	31677-93-7 34911-55-2		Formulation, modified-release, <=24hr
Buramat		4663-83-6		
buserelin	Luteinizing hormone-releasing factor (pig), 6-[O-(1,1-dimethylethyl)-D-serine]-9-(N-ethyl-L-prolinamide)-10-deglycinamide- [CAS]	57982-77-1 68630-75-1	GB 1523623	Releasing hormones
bupirone	8-Azaspiro[4.5]decane-7,9-dione, 8-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]- [CAS]	36505-84-7	EP 276536	Anxiolytic
busulfan	1,4-Butanediol, dimethanesulfonate [CAS]	55-98-1		Formulation, optimized, microparticles

TABLE 6

Examp ^l f Indication
Hypertension, general
Hypertension, general
Anaesthesia
Anaesthesia
Depression, general
Depression; general
Cancer, prostate
Anxiety, general
Cancer, general

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
busulfan	1,4-Butanediol, dimethanesulfonate- [CAS]	55-98-1		Formulation, parenteral, other
Butabarbital Sodium		143-81-7		
Butacain		149-16-6		
Butac tin		2109-73-1		
Butalamine		22131-35-7		
Butalbital		77-26-9		
Butallylonal		1142-70-7		
Butamben		94-25-7		
Butamben	4-Aminobenzoic acid butyl ester [CAS]	94-25-7		Formulation, modified-release, other
Butamirac		18109-80-3		
	Benzeneacetic acid, Alpha-ethyl-, 2-[2-(diethylamino)ethoxy]ethyl ester, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) [CAS]	18109-80-3 18109-81-4		Antitussive
butamirac citrate		3785-21-5		
Butanillicaine		653-03-2		
Butaperazine		55837-14-4		
Butaverin		18790-49-1		
Butaz lamide		51395-42-7		
Butedronic Acid				
butenafine	1-Naphthalenemethanamine, N-((4-(1,1-dimethylethyl)phenyl)methyl)-N-methyl- [CAS]	101827-46-7 101828-21-1	EP 164697	Antifungal
Butenafine		101828-21-1		
Butethal		77-28-1		
But thamate		14007-64-8		
But thamin		2090-89-3		
Buthallal S dium		510-90-7		
Buthiazid		2043-38-1		
Butibufen		55837-18-8		
Butidine Hydrochloride		1506-12-3		
butobendine	benzoic acid, 3,4,5-trimethoxy-, 1,2-ethanediybis[(methylimino)(2-ethyl-2,1-ethanediy)] ester, [S-(R*,R*)]- [CAS]	55769-64-7 55769-65-8	US 4021473	Antiarrhythmic
Butobendine		55769-65-8		

TABLE 6

API Gen ric Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
butoconazole	1H-Imidazole, 1-[4-(4-chlorophenyl)-2-[(2,6-dichlorophenyl)thio]butyl]-, (+/-)-[CAS]	64872-76-0 64872-77-1	GB 1567431	Antifungal
butoconazole, KV	1H-Imidazole, 1-[4-(4-chlorophenyl)-2-[(2,6-dichlorophenyl)thio]butyl]-, (+/-)-[CAS]	64872-76-0		Formulation, mucosal, topical
Butoctamid		32838-26-9		
Butofilolol		64552-17-6		
butorphanol	Morphinan-3,14-diol, 17-(cyclobutylmethyl)-, [S-(R*, R*)]-2,3-dihydroxybutanedioate (1:1) (salt) [CAS]	42408-82-2 58786-99-5	GB 1412129	Analgesic, other
Butoxycalin		3772-43-8		
Butriptylin		35941-65-2		
Butroplum Bromide		29025-14-7		
Buzeptide		3691-21-2		
BVT-5182			WO 0208178	Anorectic/Antiobesity
BXT-51072	2H-1,2-Benzoselenazine, 3,4-dihydro-4,4-dimethyl- [CAS]	173028-17-0		GI inflammatory/bowel disorders
C-1311	6H-Imidazo[4,5,1-de]acridin-6-one, 5-[[2-(diethylamino)ethyl]amino]-8-hydroxy-, 2HCl, 2H ₂ O			Anticancer, other
cabergoline	Ergoline-8-carboxamide, N-[3-(dimethylamino)propyl]-N-[[[(ethylamino)carbonyl]-6-(2-propenyl)-, (8S)-] [CAS]	81409-90-7 85329-89-1	GB 2103603	Antiprolactin
Caberg lin		81409-90-7		
Cacodylic Acid		75-60-5		
Cactinomycin		8052-16-2		
cadexomer iodine	Cadexomer iodine [CAS]	94820-09-4		Anti-Infective, other
Cadmium Salicylate		19010-79-8		
Cadralazine		64241-34-5		
Cafaminol		30924-31-3		
Caff ine		58-08-2		
caffeine citrate	1,2,3-Propanetricarboxylic acid, 2-hydroxy-mixt. with 3,7-dihydro-1,3,7-trimethyl-1H-purine-2,6-dione [CAS]	69-22-7		Respiratory

TABLE 6

Example of Indication
Infection, Candida, general
Infection, gynaecological
Obesity
Colitis, ulcerative
Cancer, general
Galactorrhoea
Ulcer, venostasis
Apnoea

TABLE 6

API Gen ric Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Calcif diol		19356-17-3		
Calcipotriene		112965-21-6		
calcipotriol	9,10-Secochola-5,7,10(19),22-tetraene-1,3,24-triol, 24-cyclopropyl-, (1Alpha,38,5Z,7E,22E)- [CAS]	112965-21-6	WO 8700834	Antipsoriasis
calcipotriol+betametasone	9,10-Secochola-5,7,10(19),22-tetraene-1,3,24-triol, 24-cyclopropyl-, (1Alpha,38,5Z,7E,22E) + Pregna-1,4-diene-3,20-dione, 9-chloro-118,17,21-trihydroxy-168-methyl, 17,21-dipropionate			Formulation, fixed-dose combinations
calcitriol	9,10-Secocholesta-5,7,10(19)-triene-1,3,25-triol, (1Alpha,38,5Z,7E)- [CAS]	32222-06-3		Antipsoriasis
Calcium 3-Aur thio-2-pranol-1-sulfonate		5743-29-3		
Calcium Acetylsalicylate		69-46-5		
Calcium		33659-28-8		
Br m lact bl nate		471-34-1		
Calcium Carb nate		299-28-5		
Calcium Gluc nate		27214-00-2		
Calcium				
Glyc r phosphate				
calcium hopantothenate	Calcium D-(+)-4-(2,4-dihydroxy-3,3-dimethylbutyramido)butyrate (hemihydrate) [CAS]	17097-76-6	EP 117260	Neurological
Calcium Iodobehenate		1319-91-1		
Calcium I dostearate		1301-16-2		
Calcium Lactat		814-80-2		
Calcium Levullinate		591-64-0		
Calcium M soxalate		21085-60-9		
Calcium N-		16649-79-9		
Carbamoylaspartate				
Calcium P lycarbophil		9003-97-8		
calcium polycarbophil, Fujisawa	Polycarbophil, calcium salt- [CAS]	126040-58-2		GI inflammatory/bowel disorders

TABLE 6

Example of Indication
Psoriasis
Psoriasis
Psoriasis
Attention deficit disorder
Irritable bowel syndrome

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Calcium Propionate		4075-81-4		
Calcium Succinate		140-99-8		
calcaret	5-methyl-2-(1-piperazinyl)-benzenesulfonic acid monohydrate	133804-44-1		Cardio stimulant
Calusterone		17021-26-0		
Camazepam		36104-80-0		
camostat	Benzeneacetic acid, 4-[[4-[(aminomino)ethyl]amino]benzoyloxy]-, 2,5,7,21,28-7 (dimethylamino)-2-oxoethyl ester, monomethanesulfonate [CAS]	59721-28-7 59721-29-8 71079-09-9	US 4021472	GI inflammatory/bowel disorders
Camphor		76-22-2		
Camphotamid		4876-45-3		
campothecin, Sonus	4-Ethyl-4-hydroxy-1H-pyrano-[3,4:6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione			Formulation, optimized, microemulsion
Cand sarian		139481-59-7		
candesartan cilexetil	1H-Benzimidazole-7-carboxylic acid, 2-ethoxy-1-[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl-, 1-[[cyclohexyloxy]carbonyloxy]ethyl ester, (+/-) [CAS]	145040-37-5 123122-55-4	EP 520423	Antihypertensive, renin system
canertinib dihydrochloride	N-[4-(3-(Chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide dihydrochloride	289499-45-2 976-71-6 56-25-7		Anticancer, other
Canr n ne				
Cantharidin	Maytansine, N2-deacetyl-N2-(3-mercaptopropyl)-, conjugated humanized C242 monoclonal antibody	139504-50-0		Immunotoxin
canzumab mertansine		154361-50-9	EP 602454	Anticancer, antimetabolite
cepecitabine	Cytidine, 5-deoxy-5-fluoro-N-[[pentyl]oxy]carbonyl- [CAS]	21434-91-3		
Cap b nlc Acid				

TABLE 6

Example of Indication
Heart failure
Pancreatitis
Cancer, general
Hypertension, general
Cancer, lung, non-small cell
Cancer, colorectal
Cancer, breast

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
capravirine	1H-imidazole-2-methanol, 5-(3,5-dichlorophenylthio)-4-(1-methylethyl)-1-(4-pyridinyl)methyl carbamate (ester) [CAS]	178979-85-8		Antiviral, anti-HIV
Capr mab .		151763-64-3		
capsaicin cream, Maruishi	N-[(4-hydroxy-3-methoxyphenyl)methyl]-8-methyl-, (E)- [CAS]	404-88-4		Formulation, dermal, topical
Captodiamine		486-17-9		
captopril	L-Proline, 1-(3-mercaptopropan-2-yl)-1-oxopropyl-, (S)- [CAS]	62571-86-2	US 4105776	Antihypertensive, renin system
captopril + HCTZ	L-Proline, 1-(3-mercaptopropan-2-yl)-1-oxopropyl-, (S)-, mlt. with 6-chloro-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide [CAS]	110075-07-5	US 4217347	Antihypertensive, renin system
Capuride		5579-13-5		
carabersat	Benzamide, N-(6-acetyl-3,4-dihydro-3-hydroxy-2,2-dimethyl-2H-1-benzopyran-4-yl)-4-fluoro, (3R-trans)- [CAS]	184653-84-7	WO 9811890	Antiepileptic
Caramiph n		77-22-5		
carazotol	2-Propanol, 1-(9H-carbazol-4-yl)-3-[(1-methylethyl)amino]- [CAS]	57775-29-8	DE 2240599	Antihypertensive, adrenergic
Carazol I		57775-29-8		
Carbachol		51-83-2		
Carbamaz pin		298-46-4		
carbamazepine, Microtol	5H-Dibenz[b,f]azepine-5-carboxamide [CAS]	298-46-4		Formulation, modified-release, other
Carbamide P r xide		124-43-6		
Carbars ne		121-59-5		
Carbaryl		63-25-2		
Carbaz chr me		13051-01-9		
Salicylat				
Carbaz chr me Sodium		51460-26-5		
Sulf nat				
carbendazim	Methyl-2-benzimidazolecarbamate			Anticancer, other
Carb nicillin		4697-36-3		
Carbenox I n		5697-56-3		

TABLE 6

Example f Indication
Infection, HIV/AIDS
Pain, post-herpetic
Hypertension, general
Epilepsy, general
Epilepsy, general
Cancer, general

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Carbetapentane	Carbonic acid disodium salt, mixt. with monosodium salt- [CAS]	77-23-6		
Carbicarb		72227-05-5		Alimentary/Metabolic, other
Carbidopa	S-Alpha Hydrazino-3,4-dihydroxy-Alpha methyl benzene propanoic acid monohydrate +3-hydroxy-L-tyrosine	28860-95-9		
carbidopa+levodopa-1,Nouvel				Formulation, fixed-dose combinations
carbidopa+levodopa-2,NeoPharma	S-Alpha Hydrazino-3,4-dihydroxy-Alpha methyl benzene propanoic acid monohydrate+3-hydroxy-L-tyrosine			Formulation, fixed-dose combinations
Carbimazole		22232-54-8		
Carbin xamine		486-16-8		
Carb cloral		541-79-7		
Carb cysteine		638-23-3		
carbocysteine lysine salt, Dom		151756-26-2	EP 546272	Cystic fibrosis treatment
Carb n T trachloride		56-23-5		
carboplatin	Platinum, diammine[1,1-cyclobutanedicarboxylato(2-)]-, (SP-4-2)-[CAS]	41575-94-4		Anticancer, alkylating
Carbopr st		35700-23-3		
carboprost trometamol	Prosta-5,13-dien-1-oic acid, 9,11,15-trihydroxy-15-methyl-, (5Z,9.alpha.,11Alpha,13E,15S)-, compd. with 2-amino-2-(hydroxymethyl)-1,3-propanediol(1:1) [CAS]	58551-69-2 74849-93-7	US 3728382	Prostaglandin
Carboquone	2,5-Cyclohexadiene-1,4-dione, 2-[2-[(aminocarbonyloxy)-1-methoxyethyl]-3,6-bis(1-aziridinyl)-6-methyl- [CAS]	24279-91-2	DE 1905224	Anticancer, antibiotic
Carb qu ne		24279-91-2		
Carbr mai		77-65-6		
Carbubarb		960-05-4		
Carbutamide		339-43-5		
Carbut rol		34866-47-2		
Carfimat		3567-38-2		

TABLE 6

Examp f Indication
Acidosis
Parkinson's disease
Parkinson's disease
Cystic fibrosis
Cancer, ovarian
Abortion

TABLE 6

API Gen ric Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
carglumic acid, Orphan Europe	N-Carbamoyl-L-glutamic acid	1188-38-1		Metabolic and enzyme disorders
Cargutocin		33605-67-3		
Carindacillin		35531-88-5		
cariporide	Benzamide, N-(aminiminomethyl)-4-(1-methylethyl)-3-(methylsulfonyl)- [CAS]	159138-80-4 159138-81-5	EP 589336	Antianginal
Cariporide		159138-80-4		
Caris prodol		78-44-4		
carimofur	1(2H)-Pyrimidin-5-carboxamide, 5-fluoro-N-hexyl-3,4-dihydro-2,4-dioxo- [CAS]	61422-45-5	US 4071519	Anticancer, antimetabolite
Carmofur		61422-45-5		
Carmoxir I		98323-83-2		
carmustine, Guilloford	Urea, N,N'-bis(2-chloroethyl)-N-nitroso- [CAS]	154-93-8		Formulation, Implant
carmustine, Sanchundang	Urea, N,N'-bis(2-chloroethyl)-N-nitroso- [CAS]	154-93-8		Formulation, Implant
carmustine, Direct Therapeutics	Urea, N,N'-bis(2-chloroethyl)-N-nitroso- [CAS]	154-93-8		Formulation, parenteral, other
Carnitine		461-06-3		
Car v rine		23465-76-1		
Car xaz ne		18464-39-6		
Carph nazin		2622-30-2		
Carpipramin		5942-95-0		
carprofen	9H-Carbazole-2-acetic acid, 6-chloro-Alpha-methyl-, (+/-)- [CAS]	53716-49-7	US 3886145	Anti-inflammatory
Carsalam		2037-95-8		
carteolol	2(1H)-Quinolone, 5-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]-3,4-dihydro-, monohydrochloride [CAS]	51781-06-7 51781-21-6	US 3910924	Antihypertensive, adrenergic
carteolol, ophthalmic	2(1H)-Quinolone, 5-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]-3,4-dihydro- [CAS]	51781-06-7 51781-21-6		Formulation, mucosal, topical
Carticaln		23964-58-1		
Carubicin		50935-04-1		
Carum nam		87638-04-8		
Carvacr I		499-75-2		

TABLE 6

API Gen ric Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
carvedilol	2-Propanol, 1-(9H-carbazol-4-yl-oxy)-3-[(2-methoxyphenoxy)ethyl]amino-[CAS]	72956-09-3	EP 4920	Antihypertensive, adrenergic
Carvon		99-49-0		
Cascarin		10118-56-6		
	Pneumocandin B0, 1-(4R,5S)-5-[(2-aminoethyl)amino]-N2-(10,12-dimethyl-1-oxotetradecyl)-4-hydroxy-L-ornithine)-5-(threo-3-hydroxy-L-ornithine)-, diacetate (salt) [CAS]	162808-62-0 179463-17-3	WO 9421677	Antifungal
Catechin		154-23-4		
cathepsin K inhibitors, Celera			WO 9613523	Osteoporosis treatment
	N-(1-benzothien-2-ylcarbonyl)-N-[2-(2-fluorophenyl)-4-oxo-1,2,3,4-tetrahydropyrimidin-5-yl]-L-leucinamide			
cathepsin K inhibitors, NAEJA				Osteoporosis treatment
	N-(1-benzothien-2-ylcarbonyl)-N-[2-(2-fluorophenyl)-4-oxo-1,2,3,4-tetrahydropyrimidin-5-yl]-L-leucinamide			
cathepsin S inhibitors, NAEJA				Asthma
CC-401			US 6342595	Immunosuppressant
CCI-779	Rapamycin 42-(3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate) [CAS]	162635-04-3		Anticancer, antibiotic
CCR5 antagonists, Euroscreen			WO 9732019	Antiviral, anti-HIV
CDC-394			US 634061	Anticancer, other
CDC-801			US 5605914	GI inflammatory/bowel disorders
CEE-03-310	1H-3-Benzazepin-7-ol, 5-(2,3-dihydro-7-benzofuran-2-yl)-2,3,4,5-tetrahydro-3-methyl-8-nitro, (5S)- [CAS]			
	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[aminophenylacetyl]amino]-3-chloro-8-oxo-, [6R-[6Alpha,7B(R*)]]- [CAS]	128022-68-4	EP 347672	Dependence treatment
cefactor		53994-73-3 70358-03-5		
Cefactor		70356-03-5	GB 1461323	Cephalosporin, oral

TABLE 6

Example of Indication
Hypertension, general
Infection, Aspergillus
Osteoporosis
Osteoporosis
Asthma
Arthritis, rheumatoid
Cancer, renal
Infection, HIV/AIDS
Cancer, myeloma
Crohn's disease
Addiction, alcohol
Infection, Haemophilus influenzae prophylaxis

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
cefadroxil	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[amino(4-hydroxyphenyl)acetyl]amino]-3-methyl-8-oxo-, [6R-[6Alpha,7B(R*)]]- [CAS]	50370-12-2	GB 1240687	Cephalexin, oral
Cefadroxil	66592-87-8			
cefalexin HCl monohydrate	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[[amino(phenylacetyl)amino]-3-methyl-8-oxo-, monohydrochloride, monohydrate, [6R-[6Alpha,7B(R*)]]- [CAS]	105879-42-3	US 4775751	Cephalexin, oral
cefalexin pivoxil	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[[amino(phenylacetyl)amino]-3-methyl-8-oxo-, (2,2-dimethyl-1-oxopropoxy)methyl ester, monohydrochloride, [6R-[6Alpha,7B(R*)]]- [CAS]	27726-31-4		Cephalexin, oral
cefalexin, Shionogi	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[[amino(phenylacetyl)amino]-3-methyl-8-oxo-, [6R-[6Alpha,7B(R*)]]- [CAS]	15686-71-2		Formulation, modified-release, other
cefamandole	7-D-mandelamido-3-[[[1-methyl-1H-tetrazol-5-yl]thio]methyl]-3-cephem-4-carboxylic acid	34444-01-4	US 3641021	Cephalexin, injectable
cefatrizine	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[amino(4-hydroxyphenyl)acetyl]amino]-8-oxo-3-[[[1H-1,2,3-triazol-4-ylthio]methyl]-, [6R-[6Alpha,7B(R*)]]- [CAS]	51627-14-6	GB 1460914	Cephalexin, oral
cefatrizine, Ausonia	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[amino(4-hydroxyphenyl)acetyl]amino]-8-oxo-3-[[[1H-1,2,3-triazol-4-ylthio]methyl]-, [6R-[6Alpha,7B(R*)]]- [CAS]	51627-14-6		Cephalexin, oral
Cefazedone		56187-47-4		
Cefazolin		25953-19-9		
Cefbuparazone		76610-84-9		

TABLE 6

Example of Indication
Infection, general
Infection, respiratory tract, upper
Infection, general
Infection, general
Infection, general
Infection, general

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
cefcapene pivoxil	7B-[(Z)-2-(2-amino-4-thiazolyl)-2-pentenylamino]-3-carbamoyloxymethyl-3-cephem-4-carboxylic acid, pivaloyloxymethyl ester HCl [CAS]	105889-45-0 105889-46-1	GB 2173194	Cephalexin, oral
Cefcapene Pivoxil		105889-45-0		
Cefcladin		105239-91-6		
cefdir	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[[(2-amino-4-thiazolyl)(hydroxymethyl)acetyl]amino]-3-ethenyl]-8-oxo-, [6R-(6Alpha,7B(Z))]- [CAS]	91832-40-5	EP 105459	Cephalexin, oral
cefditoren pivoxil	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[[(2-amino-4-thiazolyl)(methoxymethyl)acetyl]amino]-3-[(2,4-methyl-5-thiazolyl)ethenyl]-8-oxo-, (2,2-dimethyl-1-oxopropoxy)methyl ester, [6R-(3(Z),6Alpha,7B(Z))]- [CAS]	104145-95-1 104146-53-4 117467-28-4	JP 61178991	Cephalexin, oral
cefepime	Pyrolidinium, 1-[[7-[(2-amino-4-thiazolyl)(methoxymethyl)acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl-1-methyl-, hydroxide, inner salt, [6R-(6Alpha,7B(Z))]- [CAS]	107648-80-6 123171-59-5 88040-23-7	EP 531981	Cephalexin, injectable
Cefepime		88040-23-7		
Cefetamet		65052-63-3		
cefetamet pivoxil	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[[(2-amino-4-thiazolyl)(methoxymethyl)acetyl]amino]-3-methyl-8-oxo-, (2,2-dimethyl-1-oxopropoxy)methyl ester, monohydrochloride, [6R-(6Alpha,7B(Z))]- [CAS]	111696-23-2	GB 1581854	Cephalexin, oral
ceftixime	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[[(2-amino-4-thiazolyl)(carboxymethoxymethyl)acetyl]amino]-3-ethenyl]-8-oxo-, [6R-(6Alpha,7B(Z))]- [CAS]	79350-37-1	EP 30630	Cephalexin, oral

TABLE 6

Example f Indication
Infection, respiratory tract, general
Infection, dermatological
Infection, general
Infection, respiratory tract, lower
Infection, general
Infection, general

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
cefmenoxime	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[[(2-amino-4-thiazolyl)(methoxyimino)acetyl]amino]-3-[[[(1-methyl-1H-tetrazol-5-yl)thio]methyl]-8-oxo-, [6R-[6Alpha,7B(Z)]]- [CAS]	65085-01-0 75738-58-8	GB 1536281	Cephalosporin, injectable
cefmetazole	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[[(cyanomethyl)thio]acetyl]amino]-7-[[[(1-methyl-1H-tetrazol-5-yl)thio]methyl]-8-oxo-, [6R-[6Alpha,7B(Z)]]- [CAS]	56798-20-4 56796-39-5	GB 1449420	Cephalosporin, injectable
cefminox	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[[(2-amino-2-carboxyethyl)thio]acetyl]amino]-7-methoxy-3-[[[(1-methyl-1H-tetrazol-5-yl)thio]methyl]-8-oxo-, [6R-[6Alpha,7Alpha,7B(S*)]]- [CAS]	84305-41-9	EP 24879	Cephalosporin, injectable
cefodizime	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[[(2-amino-4-thiazolyl)(methoxyimino)acetyl]amino]-3-[[[(5-(carboxymethyl)-4-methyl-2-thiazolyl)thio]methyl]-8-oxo-, [6R-[6Alpha,7B(Z)]]- [CAS]	69739-16-8 86329-79-5	US 4590267	Cephalosporin, injectable
Cefonicid		61270-58-4		
cefonicid sodium	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[[(hydroxyphenylacetyl)amino]-8-oxo-3-[[[(1-sulfomethyl)-1H-tetrazol-5-yl]thio]methyl]-, disodium salt, [6R-[6Alpha,7B(R*)]]- [CAS]	61270-78-8	GB 1547473	Cephalosporin, injectable
cefoperazone	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[[(4-ethyl-2,3-dioxo-1-piperazinyl)carbonyl]amino](4-hydroxyphenyl)acetyl]amino]-3-[[[(1-methyl-1H-tetrazol-5-yl)thio]methyl]-8-oxo-, [6R-[6Alpha,7B(R*)]]- [CAS]	62883-19-0	GB 1508071	Cephalosporin, injectable
cefoperazone + sulbactam		92739-15-6	US 4234579	Antibiotic, other
Cefranid		60925-61-3		

TABLE 6

Example of Indication
Infection, ocular
Infection, general
Infection, urinary tract
Infection, respiratory tract, lower
Infection, general
Infection, general
Infection, general

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
cefoselis	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[2-amino-4-thiazolyl](methoxymino)acetyl]amino]-3-[[2,3-dihydro-2-(2-hydroxyethyl)-3-imino-1H-pyrazol-1-yl]methyl]-8-oxo-, [6R-[6Alpha,7B(2)]]	122841-12-7	EP 307804	Cephalosporin, injectable
Cefosells		122841-10-5		
Cefotaxime		63527-52-6		
cefotaxime sodium	(6R,7R)-7-[[2-amino-4-thiazolyl](methoxymino)acetyl]amino]cephalosporanic acid sodium salt	64485-93-4	GB 1580621	Cephalosporin, injectable
Cefotetan		69712-56-7		
cefotiam	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[2-amino-4-thiazolyl]acetyl]amino]-3-[[1-(2-(dimethylamino)ethyl)-1H-tetrazol-5-yl]thio]methyl]-8-oxo-, (6R-trans)- [CAS]	61622-34-2 66309-69-1	US 4080498	Cephalosporin, injectable
cefotiam hexetil	1-(cyclohexyloxy)carbonyloxyethyl 7B-[2-(2-aminothiazol-4-yl)acetamido]-3-[[1-(2-dimethylaminoethyl)-1H-tetrazol-5-yl]thio]methyl]ceph-3-em-4-carboxylate 2HCl [CAS]	95789-30-3	EP 128029	Cephalosporin, oral
Cefixitin		35607-66-0		
cefixitin sodium	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 3-(((aminocarbonyloxy)methyl)-7-methoxy-8-oxo-7-[(2-thienylacetyl]amino)-monosodium salt, (6R-cis)- [CAS]	33564-30-6	GB 1348984	Cephalosporin, oral
cefazopran	Imidazo[1,2-b]pyridazinium, 1-[[7-[(5-amino-1,2,4-thiadiazol-3-yl)(methoxymino)acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-, hydride, inner salt, [6R-[6Alpha,7B(2)]]- [CAS]	113359-04-9	EP 203271	Cephalosporin, injectable

TABLE 6

Example of Indication
Infection, general
Infection, general
Infection, general
Infection, respiratory tract, lower
Infection, general
Infection, general

TABLE 6

API Gen. ric Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
cefpirimazole	Pyridinium, 1-[[2-carboxy-7-[[[(5-carboxy-1H-imidazol-4-yl)carbonyl]amino]phenyl]acetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-4-(2-sulfoethyl)-, hydroxide, inner salt, [6R-[6Alpha,7B(R*)]]- [CAS]	84880-03-5 85287-61-2	EP 60028	Cephalosporin, injectable
Cefpimizole		84880-03-5		
cefpiramide	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[[(4-hydroxy-6-methyl-3-pyridinyl)carbonyl]amino](4-hydroxyphenyl)acetyl]amino]-3-[[[(1-methyl-1H-tetrazol-5-yl)thio]methyl]-8-oxo-, [6R-[6Alpha,7B(R*)]]- [CAS]	70797-11-4	US 4156724	Cephalosporin, injectable
cefprome	5H-1-Pyridinium, 1-[7-[(2-amino-4-thiazolyl)(methoxymino)acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-6,7-dihydro-hydroxide, inner salt, [6R-[6Alpha,7B(Z)]]- [CAS]	84957-29-9 98753-19-6	EP 64740	Cephalosporin, injectable
C fp doxim Proxetil		87239-81-4		
cefprozil	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[amino(4-hydroxyphenyl)acetyl]amino]-8-oxo-3-(1-propenyl)-, [6R-[6Alpha,7B(R*)]]- [CAS]	92665-29-7	GB 2173798	Cephalosporin, oral
C fpr zil		92665-29-7 (anhydrous); 121123-17-9 (monohydrate)		
cefroxadine	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[amino-1,4-cyclohexadien-1-yl]acetyl]amino]-3-methoxy-8-oxo-, [6R-[6Alpha,7B(R*)]]- [CAS]	51762-05-1	GB 1435111	Cephalosporin, oral

TABLE 6

Exempl f Indication
Infection, respiratory tract, general
Infection, general
Infection, respiratory tract, lower
Infection, dermatological
Infection, general

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
cefalulodin	Pyridinium, 4-(aminocarbonyl)-1-[(2-carboxy-8-oxo-7-[(phenylsulfoacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl)methyl]-, hydroxide, inner salt, [6R-[6Alpha,7B(R*)]]- [CAS]	52152-93-9 82587-73-9	GB 1387656	Cephalosporin, injectable
cefazidime	Pyridinium, 1-[[7-[(2-amino-4-thiazolyl)((1-carboxy-1-methylethoxy)imino)acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-, hydroxide, inner salt, [6R-[6Alpha,7B(Z)]]- [CAS]	72558-82-8 82547-58-8 26973-24-0	GB 2025398	Cephalosporin, injectable
C fteram				
Ceftazidol				
cefibuten	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[2-(2-amino-4-thiazolyl)-4-carboxy-1-oxo-2-butenyl]amino]-8-oxo-, [6R-[6Alpha,7B(Z)]]- [CAS]	97519-39-6	EP 136721	Cephalosporin, oral
cefizoxime	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[2-amino-4-thiazolyl](methoxyimino)acetyl]amino]-8-oxo-, [6R-[6Alpha,7B(Z)]]- [CAS]	68401-81-0 68401-82-1	GB 1600735	Cephalosporin, injectable
cefizoxime alapivoxil	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[2-[(2-amino-1-oxopropyl)amino]-4-thiazolyl](methoxyimino)acetyl]amino]-8-oxo-, (2,2-dimethyl-1-oxopropoxy)methyl ester, monohydrochloride, [6R-[6Alpha,7B(Z(S*))]]- [CAS]	113812-94-5 135767-36-1	JP 62209112	Cephalosporin, oral
ceftriaxone	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[2-amino-4-thiazolyl](methoxyimino)acetyl]amino]-8-oxo-3-[[1,2,5,6-tetrahydro-2-methyl-5,6-dioxo-1,2,4-triazin-3-yl]thio]methyl]-, [6R-[6Alpha,7B(Z)]]- [CAS]	73384-59-5 74578-69-1	GB 2022090	Cephalosporin, injectable
C furoxim		55268-75-2		

TABLE 6

Example of Indication
Infection, pseudomonal
Infection, respiratory tract, upper
Infection, respiratory tract, lower
Infection, general
Infection, general
Infection, respiratory tract, lower

TABLE 6

API Gen. rlc Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
cefuroxime axetil	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 3-[[[aminocarbonyloxy)methyl]-7-[2-furanyl(methoxyimino)acetyl]amino]-8-oxo-1-(acetoxy)ethyl ester, [8R-[6Alpha,7B(2)]]- [CAS]	15688-71-2 64544-07-6	GB 1571683	Cephalosporin, oral
	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 3-[[[aminocarbonyloxy)methyl]-7-[2-furanyl(methoxyimino)acetyl]amino]-8-oxo-1-(acetoxy)ethyl ester, [8R-[6Alpha,7B(2)]]- [CAS]	55268-75-2 56238-63-2	GB 1453049	Cephalosporin, injectable
Cefuzonam	Benzenesulfonamide, 4-(5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)- [CAS]	82219-78-1		
celecoxib	Butanoic acid, octahydro-1,7,8-trihydroxy-6-indoliziny ester, [1S-(1Alpha,6B,7Alpha,8B,8aB)]- [CAS]	169590-42-5	US 5760088	Antiarthritic, other
celgivosir	Urea, N-[3-acetyl-4-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]phenyl]-N,N-diethyl- [CAS]	121104-96-9	US 5017563	Antiviral, other
Cellulose Ethyl Hydroxyethyl Ether	9,12-Epoxy-1H-diindolol[1,2,3-fg:3',2',1'-k]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 5,16-bis[(ethylthio)methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- [CAS]	56980-83-9 57470-78-7 9004-58-4	GB 1441359	Antihypertensive, adrenergic
Centchr man	9,12-Epoxy-1H-diindolol[1,2,3-fg:3',2',1'-k]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 5,16-bis[(ethylthio)methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- [CAS]	31477-60-8		
CEP-1347	9,12-Epoxy-1H-diindolol[1,2,3-fg:3',2',1'-k]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 5,16-bis[(ethylthio)methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- [CAS]	156177-65-0	WO 9731002	Antiparkinsonian
CEP-701	9,12-Epoxy-1H-diindolol[1,2,3-fg:3',2',1'-k]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 5,16-bis[(ethylthio)methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10S,12R)- [CAS]	111358-88-4		Anticancer, antimetabolite
Cephacetrile Sodium		23239-41-0		
Cephalexin		483-17-0		
Cephalexin		15686-71-2		

TABLE 6

Exempl of Indication
Infection, respiratory tract, upper
Infection, general
Arthritis, rheumatoid
Infection, hepatitis virus, general
Angina, unstable
Parkinson's disease
Cancer, prostate

TABLE 6

API Gen. ric Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
C phaloglycin		3577-1-3		
Cephaloridine		50-59-9		
Cephalexin C		61-24-5		
Cephalexin		153-61-7		
Cephalexin Sodium		24356-60-3		
Cephadrin		38821-53-3		
Cerivastatin		145599-86-6		
Cer napril		111223-26-8		
certoparin	Heparin [CAS]	8005-49-6		Anticoagulant
Ceruletid		17650-98-5		
Cerviprost	Prosta-5,13-dien-1-ol-ic acid, 11,15-dihydroxy-9-oxo-, (5Z,11Alpha,13E,-15S)-[CAS]	363-24-6		Formulation, dermal, topical
C tikonium Chloride		122-18-9		
Cetamolol		34919-98-7		
Cethex nium Bromide		1794-74-7		
cethromycin	2H-Oxacyclotetradecino(4,3-d)oxazole-2,6,8,14(1H,7H,9H)-tetrone 4-ethyl-octahydro-3a,7,9,11,13,15-hexamethyl-11-((3-(3-quinolinyl)-2-propenyl)oxy)-10-((3,4,6-trideoxy-3-(dimethylamino)-8-D-xylo-hexapyranosyl)oxy)-(3a S,4R,7R,9R,10R,11R,13R,15R,15aR)-[CAS]	205110-48-1	EP 929563	Macrolide antibiotic
Cettedil		14176-10-4		
C tirizine		83881-51-0		
cetirizine dihydrochloride	Acetic acid, [2-(4-((4-chlorophenyl)phenyl)methyl)-1-piperazinyl]ethoxy]-, dihydrochloride [CAS]	83881-51-0 83881-52-1	EP 58146	Antiallergic, non-asthma
cetirizine+pseudoephedrine,UC B	Acetic acid, [2-(4-((4-chlorophenyl)phenyl)methyl)-1-piperazinyl]ethoxy]-, dihydrochloride, Benzenemethanol, Alpha-[1-(methylamino)ethyl]-, hydrochloride, [S-(R,R')]-	83881-52-1 90-82-4		Formulation, optimized, microencapsulate
Cetotiamine		137-76-8		

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Citramine		25394-78-9		
Cetirizine	Benzene propanoic acid, 4-[[4-(aminomethyl)cyclohexyl]carbonyloxy]-, trans-[CAS]	27724-86-5 34675-84-8	JP 48075547	Antitumor
Cetirizine		34675-84-8		
Cetirizine Bromide		57-09-0		
Cetorelix		120287-85-6		
Cytidine thymine dinucleotide		124-03-8		
Cetylpyridinium Chloride		123-03-5		
Cevimeline	Spiro[1-azabicyclo[2.2.2]octane-3,5'-[1,3]oxathiolane], 2'-methyl-, cis-[CAS]	107220-27-9 107233-08-9	EP 205247	Stomatological
CG-1521	7-phenyl-2,4,6-heptatrienylhydroxamic acid			Anticancer, other
Chaulmoigric Acid		29106-32-9		
Chenodeoxycholic Acid		474-25-9		
CHF-3381			EP 951465	Analgesic, other
Chlophedianol		791-35-5		
Chloracizine		800-22-6		
Chloral Betaine		2218-68-0		
Chloral Formamide		515-82-2		
Chloral hydrate, SSP	1,1-Ethanedithiol, 2,2,2-trichloro-[CAS]	302-17-0		Formulation, transmucosal, systemic
Chlorambucil		305-03-3		
Chloramine-B		127-52-6		
Chloramine-T		127-65-1		
Chloramine phenamide		121-30-2		
Chloramphenicol		56-75-7		
Chlorazepate		500-42-5		
Chlorbutol		522-18-9		
Chlorbutol		97-27-8		
Chlorbutol		82-93-9		
Chlorbutol		5588-20-5		
Chlorbutol		58-25-3		

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Chl rguanide		500-92-5		
Chlorhexadol		3563-58-4		
chlorhexidine, Knowell	2,4,11,13-Tetraazatetradecanedimidamide, N,N"-bis(4-chlorophenyl)-3,12-diimino- [CAS]	55-58-1		Formulation, other
chlorhexidine, Perio	2,4,11,13-Tetraazatetradecanedimidamide, N,N"-bis(4-chlorophenyl)-3,12-diimino- [CAS]	55-58-1		Formulation, modified-release, >24hr
Chl r is ndamine Chloride		69-27-2		
Chl r madin n Acetate		302-22-7		
Chl r m r drin		62-37-3		
Chl r m zanone		80-77-3		
Chlormidazol		3689-76-7		
Chlornaphazine		494-03-1		
Chloroaz din		502-98-7		
Chl r phyll		1406-65-1		
Chl r pr dnls ne		52080-57-6		
Chl r procain		3858-89-7		
Hydrochlorid				
Chloropyramin		59-32-5		
Chl r quine		54-05-7		
Chlor th n		148-65-2		
Chlor thiazid		58-94-6		
Chlorotrianis ne		569-57-3		
Chloroxine		773-76-2		
Chl r xyl nol		88-04-0		
Chloroz tocin		54749-90-5		
chlorphenamine	2-Pyridinepropanamine, Gamma-(4-chlorophenyl)-N,N-dimethyl- [CAS]	132-22-9		Formulation, modified-release, other
Chl rphen sln		104-29-0		
Chl rphenesin Carbamat		886-74-8		
Chlorpheniramine		132-22-9		

TABLE 6

API Gen ric Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Chlorphenoxamide		3576-64-5		
Chlorphen xamine		77-38-3		
Chlorphentermine		461-78-9		
Chl rproethazine		84-01-5		
Chlorproguanil		537-21-3		
chlorproguanil + dapson, GSK	4,4'-Sulfonyldianiline + 1-(3,4-Dichlorophenyl)5-Isopropylbiguanide	537-21-3 80-08-0		Antimalarial
Chl rpromazin		50-53-3		
Chlorpropamid		94-20-2		
Chl rprothix n		113-59-7		
Chl rquinald I		72-80-0		
Chl r t tracycline		57-62-5		
Chl rthaldione		77-36-1		
Chl rthenoxazin(e)		132-89-8		
Chlorz axon		95-25-0		
Ch lic Acid		81-25-4		
Choline Alfoscerate		28319-77-9		
Cholin Chloride		67-48-1		
Cholin Salicylate		2016-36-6		
choline theophyllinate, Amarin	Ethaniminium, 2-hydroxy-N,N,N-trimethyl-, salt with 3,7-dihydro-1,3-dimethyl-1H-purine-2,6-dione (1:1) [CAS]	4499-40-5		Formulation, modified-release, other
choline-L-alfoscerate	Ethaniminium, 2-[(2,3-dihydroxypropoxy)hydroxyphosphinyloxy]-N,N,N-trimethyl-, hydroxide, inner salt, (R)- [CAS]	28319-77-9	JP 55028955	Cognition enhancer
Chromocarb		4940-39-0		
Chromonar		804-10-4		
Chrys idine		532-82-1		
CHS-828	Guanidine, N-[6-(4-chlorophenoxy)hexyl]-N'-cyano-N"-4-pyridinyl- [CAS]	200484-11-3	US 5696140	Anticancer, other

TABLE 6

API Gen ric Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
CI-1031	Glycine, N-[2-[5-(aminiminomethyl)-2-hydroxyphenoxy]-6-[3-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenoxy]-3,5-difluoro-4-pyridinyl]-N-methyl- [CAS]	183305-24-0	WO 9638421	Antianginal
CI-1040	Benzamide, 2-[(2-chloro-4-iodophenyl)amino]-N-(cyclopropylmethoxy)-3,4-difluoro- [CAS]	212631-79-3	WO 9837881	Anticancer, other
cibenzoline	1H-Imidazole, 2-(2,2-diphenylcyclopropyl)-4,5-dihydro- [CAS]	53267-01-9	GB 1417174	Antiarrhythmic
ciclesonide	Pregna-1,4-diene-3,20-dione 16,17-((cyclohexylmethyl)ene)bis(oxy))-11-hydroxy-21-(2-methyl-1-oxopropoxy) (11B,16Alpha) [CAS]	126544-47-6	DE 4129535	Antiasthma
cicletarine	Furo[3,4-c]pyridin-7-ol, 3-(4-chlorophenyl)-1,3-dihydro-6-methyl-, (4r)- [CAS]	82747-56-6 89943-82-8	US 4383998	Antihypertensive, other
Cicletarin		89943-82-8		
cliconicate	3-Pyridinecarboxylic acid, 3,3,5-trimethylcyclohexyl ester, trans- [CAS]	53449-58-4	DE 1910481	Vasodilator, peripheral
Ciel nicate		53449-58-4		
Ciel pirox		29342-05-0		
ciclopirox olamine	2(1H)-Pyridinone, 6-cyclohexyl-1-hydroxy-4-methyl-, compd. with 2-aminoethanol (1:1) [CAS]	41621-49-2	US 3883545	Antifungal
Ciclosdomine		66564-16-7		
ciclosporin A, Chong Kun Dang	Cyclosporin A- [CAS]	59865-13-3		Formulation, optimized, microemulsion
cidofovir	Phosphonic acid, [[2-(4-amino-2-oxo-1(2H)-pyrimidinyl)-1-(hydroxymethyl)ethoxy]methyl]-, (S)- [CAS]	113852-37-2	EP 253412	Antiviral, other
cidofovir gel	Phosphonic acid, [[2-(4-amino-2-oxo-1(2H)-pyrimidinyl)-1-(hydroxymethyl)ethoxy]methyl]-, (S)-[CAS]			Antiviral, other
Cifenline		53267-01-9		

TABLE 6

Example of Indication
Angina, unstable
Cancer, general
Arrhythmia, general
Asthma
Cancer, lung, small cell
Infection, fungal, general
Transplant rejection, general
Infection, cytomegalovirus
Infection, herpes simplex virus

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
cilastatone	4H-Pyrido[3,2,1-ij]carbazol-11(8H)-one, 5,6,9,10-tetrahydro-10-[(2-methyl-1H-imidazol-1-yl)methyl]-, (R)- [CAS]	120635-74-7	EP 297651	GI inflammatory/bowel disorders
Cilastatin		82009-34-5		
	6H-Pyridazino[1,2-a][1,2]diazepine-1-carboxylic acid, 9-[[1-(ethoxycarbonyl)-3-phenylpropyl]amino]octahydro-10-oxo-, [1S] [1Alpha,9Alpha(R*)]- [CAS]	88768-40-5	GB 2128884	Antihypertensive, renin system
cilazapril	Cyclo(L-arginylglycyl-L-Alpha-aspartyl-D-phenylalanyl-N-methyl-L-valyl) [CAS]	188968-51-6	EP 770622	Anticancer, other
cilengitide	3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 2-methoxyethyl 3-phenyl-2-propenyl ester- [CAS]	102106-21-8	EP 161877	Antihypertensive, other
cilnidipine		132203-70-4		
Cilnidipin				
	Cis-4-cyano-4-(3-(cyclopentylloxy)-4-methoxyphenyl)cyclohexane-1-carboxylic acid	153259-65-5	US 5602157	COPD treatment
cilomilast				
cilostazol	2(1H)-Quinolone, 6-{4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy}-3,4-dihydro- [CAS]	73963-72-1	GB 2033893	Antithrombotic
Cim tidine		51481-61-9		
	3-Oxa-9-azoniatricyclo[3.3.1.0 ^{2,4}]nonane, 9-(cyclopropylmethyl)-7-(3-hydroxy-1-oxo-2-phenylpropoxy)-9-methyl-, bromide, [7(S)-(1Alpha,2B,4B,5Alpha,7B)]- [CAS]	51598-60-8	US 3853886	Antispasmodic
cimetopium bromide				
	1-naphthalenemethanamine, Alpha-methyl-N-[[3-[3-(trifluoromethyl)phenyl]propyl]- (AlphaR)-, hydrochloride	364782-34-3		Hormone
cinacalcet hydrochloride		485-71-2		
Cinch nidin		118-10-5		
Cinch nin		132-60-5		
Cinchoph n		23887-41-4		
Cin paz t		23887-46-9		
Cinepazide				

TABLE 6

Example of Indication
Irritable bowel syndrome
Hypertension, general
Cancer, lung, non-small cell
Hypertension, general
Chronic obstructive pulmonary disease
Peripheral vascular disease
Muscle spasm, general
Hyperparathyroidism

TABLE 6

API Gen ric Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
cinepazide maleate	Piperazine, 1-[2-oxo-2-(1-pyrrolidinyl)ethyl]-4-[1'-oxo-3-(3,4,5-trimethoxyphenyl)-2-propenyl]-, (Z)-2-butenedioate (1:1) [CAS]	28328-04-1	GB 1218591	Vasodilator, peripheral
Cinitaprid		66564-14-5		
Cinn tacin		20168-99-4		
Cinnamedrin		90-86-8		
Cinnarizine		298-57-7		
cinnolazepam	1H-1,4-Benzodiazepine-1-propanenitrile, 7-chloro-5-(2-fluorophenyl)-2,3-dihydro-3-hydroxy-2-oxo- [CAS]	75696-02-5	DE 2950235	Hypnotic/Sedative
cinoxacin	[1,3]Dioxolo[4,5-g]cinnoline-3-carboxylic acid, 1-ethyl-1,4-dihydro-4-oxo- [CAS]	28657-80-9	GB 1296753	Quinolone antibacterial
Cinoxate		104-28-9		
Cinr mid		58473-74-8		
Cit r nel		89672-11-7		
cipamyliline	1H-Purine-2,6-dione, 8-amino-1,3-bis(cyclopropylmethyl)-3,7-dihydro- [CAS]	132210-43-6	EP 389282	Antipruritic/inflam, allergic
cipralisant	1H-imidazole, 4-[(1R,2R)-2-(5,5-dimethyl-1-hexynyl)cyclopropyl]- [CAS]	213027-19-1	US 6008240	Psychostimulant
ciprofibrate	Propanoic acid, 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methyl- [CAS]	52214-84-3	GB 1385828	Hypolipaeic/Antiatherosclerosis
ciprofloxacin	3-Quinolonecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)- [CAS]	85721-33-1	US 4670444	Quinolone antibacterial
ciprofloxacin+fluocinolone,SAL	3-Quinolonecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)- + (6Alpha, 11B, 16Alpha)-6,9-Difluoro-11,21-dihydroxy-16,17-[(1-methylethylidene)bis-(oxy)]-pregna-1,4-diene-3,20-dione			
Ciramad I		63269-31-8		Formulation, fixed-dose combinations

TABLE 6

Example of Indication
Peripheral vascular disease
Insomnia
Infection, urinary tract
Eczema, atopic
Attention deficit disorder
Hyperlipidaemia, general
Infection, general
Otitis

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
cisapride	Benzamide, 4-amino-5-chloro-N-[1-[3-(4-fluorophenoxy)propyl]-3-methoxy-4-piperidinyl]-2-methoxy-, cis- [CAS]	81098-60-4	EP 76530	Gastroprokinetic
cisatracurium besylate	Isoquinolinium, 2,2'-(1,5-pentanediyldibis[oxy(3-oxo-3,1-propanediyl)])bis[1-[(3,4-dimethoxyphenyl)methyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-, [1R-[1'Alpha,2'Alpha(1'R,2'R)]]-, dibenzenesulfonate [CAS]	96946-42-8	US 5453510	Muscle relaxant
cisplatin	Platinum, diamminedichloro-, (SP-4-2)- [CAS]	15663-27-1	US 4177263	Anticancer, alkylating
Citalopram		59729-33-8		
citalopram hydrobromide	5-Isobenzofurancarboxitrile, 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-monohydrobromide [CAS]	59729-32-7	GB 1526331	Antidepressant
citicoline	Cytidine 5'-(trihydrogen diphosphate), P-[2-(trimethylammonio)ethyl]ester, hydroxide, inner salt [CAS]	987-78-0	JP 39008541	Cognition enhancer
Citi lone		1195-16-0		
Citric Acid		77-92-9		
Citrullin		372-75-8		
cizolirine citrate	Ethanamine, N,N-dimethyl-2-[(1-methyl-1H-pyrazol-5-yl)phenylmethoxy]-, 2-hydroxy-1,2,3-propanetricarboxylate [CAS]	142155-44-0		Urological
CJ-13610	4-(3-[4-(2-Methyl-imidazol-1-yl)-phenylsulfanyl]-phenyl)-tetrahydro-pyran-4-carboxylic acid amide			COPD treatment
CKD-602	1H-Pyran[3,4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione, 4-ethyl-4-hydroxy-11-[2-[(1-methylethylamino)ethyl]-, monohydrochloride, (4S)- [CAS]	213819-48-8	WO 9902530	Anticancer, other
cladribine	Adenosine, 2-chloro-2'-deoxy- [CAS]	4291-63-8	EP 173059	Anticancer, antimetabolite
Clanobutin		30544-61-7		

TABLE 6

Example f Indication
Surgery adjunct
Depression, general
Infarction, cerebral
Incontinence
Chronic obstructive pulmonary disease
Cancer, ovarian
Cancer, leukaemia, hairy cell

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
clarithromycin	Erythromycin, 6-O-methyl- [CAS]	81103-11-9	EP 41355	Macrolide antibiotic
<i>Clavulanate Potassium, Ticarcillin Disodium</i>				
Clavulanic Acid		58001-44-8		
Clebopride		55905-53-8		
Clemastin		15686-51-8		
Clemiz I		442-52-4		
Clenbuterol		37148-27-9		
Clentiazem		96125-53-0		
clevidipine	3,5-Pyridinedicarboxylic acid, 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-, methyl (1-oxobutoxy)methyl ester (±) [CAS]	167221-71-8	WO 9512578	Antihypertensive, other
clevudine	2,4(1H,3H)-Pyrimidinone, 1-(2-deoxy-2-fluoro-β-L-arabinofuranosyl)-5-methyl- [CAS]	163252-36-6		Antiviral, other
Cildanac		28968-07-2		
Cildinium Bromide		3485-62-9		
Clinafloxacin		105956-97-6		
Clindamycin		18323-44-9		
clindamycin + tretinoin, Yaman	L-Threo-Alpha-D-galacto-Octopyranoside, methyl 7-chloro-6,7,8-trideoxy-6-[[1-methyl-4-propyl-2-pyrrolidinyl]carbonylamino]-1-thio-, (2S-trans)- + retinoic acid			Formulation, fixed-dose combinations
clindamycin	L-Threo-Alpha-D-galacto-octopyranoside, methyl 7-chloro-6,7,8-trideoxy-6-[[1-methyl-4-propyl-2-pyrrolidinyl]carbonylamino]-1-thio-, 2-(dihydrogen phosphate), (2S-trans)-	18323-44-9 24729-96-2		Formulation, parenteral, other
Clin fibrat		30299-08-2		
Clinprost		88931-51-5		

TABLE 6

Exempl f Indication Infection, respiratory tract, lower	
Hypertension, general	
Infection, hepatitis-B virus	
Acne	
Infection, gynaecological	

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
clobazam	1H-1,5-Benzodiazepine-2,4(3H,5H)-dione, 7-chloro-1-methyl-5-phenyl- [CAS]	22316-47-8	GB 1214862	Anxiolytic
Clobenfurol		3611-72-1		
Cl ben side		29899-95-4		
Clobenzepam		1159-93-9		
Cl b nz r x		13364-32-4		
Clob nztr pln		5627-46-3		
Clobetasol		25122-41-2		
	Pregna-1,4-diene-3,20-dione, 21-chloro-9-fluoro-11,17-dihydroxy-16-methyl-, (11B,16B)- [CAS]			Formulation, dermal, topical
clobetasol, Solitec		25122-41-2		
Clobetas ne		54063-32-0		
	Pregna-1,4-diene-3,11,20-trione, 21-chloro-9-fluoro-16-methyl-17-(1-oxobutoxy)-, (16B)- [CAS]			
clobetasone butyrate		25122-57-0	GB 1259831	Antipruritic/inflamm, allergic
Clobutinol		14860-49-2		
Clocapramine		47739-98-0		
Clocinizin		298-55-5		
Cloconaz le		77175-51-0		
Clocortolone		4828-27-7		
	Phosphonic acid, (dichloromethylene)bis-, disodium salt- [CAS]	22560-50-5		Osteoporosis treatment
clodronate disodium, Ablogen				
	Phosphonic acid, (dichloromethylene)bis-, disodium salt- [CAS]	22560-50-5		Anticancer, hormonal
clodronate disodium, Leiras		10596-23-3		
Cl dr nlc Acid				
	2-chloro-9-(2-deoxy-2-fluoro-β-D-arabinofurasonyl)adenine			Anticancer, antimetabolite
clotafabine				
	3-(p-chloroanilo)-10-(p-chlorophenyl)-2,10-dihydro-2-(isopropylimino)-phenazine			Formulation, optimized, microencapsulate
clotazimine		2030-63-9		
Clofenamide		671-95-4		
Clofibrate		637-07-0		
Clofibrilic Acid		882-09-7		

TABLE 6

Example of Indication
Psoriasis
Pain, cancer
Hypercalcaemia of malignancy
Cancer, leukaemia, chronic lymphocytic
Infection, tuberculosis

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Cloflucarban		369-77-7		
Clofoctol		37693-01-9		
Cloforex		14261-75-7		
Clomacran		5310-55-4		
Clomestron		4091-75-2		
Clometacin		25803-14-9		
Clom thiaz I		533-45-9		
Clom t cillin		1926-49-4		
Cl miph n		911-45-5		
Cl mipramin		303-49-1		
Clomocycline		1181-54-0		
clonazepam	2H-1,4-Benzodiazepin-2-one, 5-(2-chlorophenyl)-1,3-dihydro-7-nitro- [CAS]	1622-61-3	US 4316897	Antiepileptic
clonidine, Alza	1H-Imidazo[2-amine, N-(2,6-dichlorophenyl)-4,5-dihydro- [CAS]	4205-90-7	US 4060084	Formulation, transdermal, patch
Cl nitazen		3861-76-5		
Clonitrat		2612-33-1		
Cl nixin		17737-65-4		
Clopamide		636-54-4		
Clopenthixol		982-24-1		
Cloperastine		3703-76-2		
Cl pid grel		113665-84-2		
clopidogrel hydrogen sulfate	Thieno[3,2-c]pyridine-5(4H)-acetic acid, Alpha-(2-chlorophenyl)-6,7-dihydro-, methyl ester, (S)-, sulfate (1:1) [CAS]	120202-48-4 90055-48-4	EP 99802	Antithrombotic
Clopirac		42779-82-8		
Clopr dn I		5251-34-3		
cloranolol	2-Propanol, 1-(2,5-dichlorophenoxy)-3-[[1,1-dimethylethyl]amino]- [CAS]	39563-28-5 54247-25-5	US 4310549	Antihypertensive, adrenergic
Cl ran I I		39563-28-5		
Cl raz pic Acid		23887-31-2		
Cl r x I n		2127-1-7		
cloricromene	Acetic acid, [[2-chloro-3-{2-(diethylamino)ethyl}-4-methyl-2-oxo-2H-1-benzopyran-7-yl]oxy]-, ethyl ester [CAS]	69208-94-0	US 4349566	Vasodilator, coronary

TABLE 6

API Gen ric Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Clorindione		1146-99-2		
Clorprenalin		3811-25-4		
Clorterin		10389-73-8		
Clospirazine		24527-27-3		
Cl steb I		1093-58-9		
Clothiapin		2058-52-8		
clotiazepam	2H-Thieno[2,3-e]-1,4-diazepin-2-one, 5-(2-chlorophenyl)-7-ethyl-1,3-dihydro-1-methyl- [CAS]	33671-46-4	US 3849405	Anxiolytic
clotrimazole	1-[(2-chlorophenyl)diphenylmethyl]-1H-imidazole	23593-75-1	US 3705172	Antifungal
clotrimazole + betamethasone	Pregna-1,4-diene-3,20-dione, 9-fluoro-11-hydroxy-16-methyl-17,21-bis(1-oxopropoxy)-, (11B,16B)-, mixt. with 1-[(2-chlorophenyl)diphenylmethyl]-1H-imidazole [CAS]	92522-91-3		Formulation, fixed-dose combinations
clotrimazole, Bentley	1-[(2-chlorophenyl)diphenylmethyl]-1H-imidazole	61-72-3		Formulation, dermal, topical
Cloxacinil				
cloxazolam	Oxazolo[3,2-d][1,4]benzodiazepin-6(5H)-one, 10-chloro-11b-(2-chlorophenyl)-2,3,7,11b-tetrahydro- [CAS]	24166-13-0	US 3772371	Anxiolytic
Cloxaz lam		24166-13-0		
Cloxtetosterone		53608-96-1		
Cloxyquin		130-16-5		
clozapine	5H-Dibenzo[b,e][1,4]diazepine, 8-chloro-11-(4-methyl-1-piperazinyl)- [CAS]	5786-21-0	US 3539573	Neuroleptic
CMI-392	Trans-2-[3-methoxy-4-(2-p-chlorophenylthio)ethoxy-5-(N'-methyl-N'-hydroxyureidyl)methylphenyl]-5-(3,4,5-trimethoxyphenyl)tetrahydrofuran	193739-23-0	US 5648486	Antipsoriasis
CMT-3	2-Naphthacene-carboxamide, 1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4aS,5aR,12aS)- [CAS]	15866-90-7	US 5837696	Anticancer, other

TABLE 6

API Gen ric Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
CNI-1493	Decanediamide, N,N'-bis[3,5-bis[1-[(aminoliminomethyl)hydrazono]ethyl]phenyl]-, tetrahydrochloride [CAS]	164301-51-3	US 5750573	Anti-inflammatory
CNS-5161	N'-[2-chloro-5-(methylthio)phenyl]-N-methyl-N-[3-(methylthio)phenyl]guanidine [CAS]	160754-76-7	WO 9427591	Analgesic, other
Cobamamide		13870-90-1		
C caethylen		529-38-4		
Cocaine		50-36-2		
C d ine		76-57-3		
Codein Ph sphate		52-28-8		
CoFactor	5,10 methylene - tetrahydrofolate			Anticancer, antimetabolite
Colchicine		64-86-8		
colesvelam	1-Hexanaminium, N,N,N-trimethyl-6-(2-propenylamino)-, polymer with (chloromethyl)oxirane, 2-propen-1-amine and N-2-propenyl-1-decanamine, hydrochloride [CAS]	182815-44-7	US 5607669	Hypolipaeic/Antiatherosclerosis
colestilan	1H-Imidazole, 2-methyl-, polymer with (chloromethyl)oxirane [CAS]	85522-45-5	JP 59155421	Hypolipaeic/Antiatherosclerosis
C I stip I		26658-42-4		
colforsin daropate	6-(3-dimethylaminopropionyl)forskolin-[CAS]	138605-00-2	EP 222413	Cardio stimulant
colfoscaril	3,5,9-Trioxo-4-phosphapentacosan-1-aminium, 4-hydroxy-N,N,N-trimethyl-10-oxo-7-[(1-oxohexadecyl)oxyl-, hydroxide, inner salt, 4-oxide, (R)- [CAS]	83-89-8 99732-49-7	US 4826821	Lung Surfactant
Collagraft		138331-02-9		Formulation, implant
C I cynthin		1398-78-3		
C Ip rm n		1247-71-8		
coluracetam	1-Pyrrolidineacetamide, 2-oxo-N-(5,6,7,8-tetrahydro-2,3-dimethylfuro[2,3-b]quinolin-4-yl)- [CAS]			Cognition enhancer
combreatastin A-4 produg	disodium combretastatin-A-4-3-O-phosphate	135463-81-9	EP 427636	Anticancer, other

TABLE 6

Example of Indication
Psoriasis
Pain, neuropathic
Cancer, colorectal
Hyperlipidaemia, general
Hypercholesterolaemia
Heart failure
Respiratory distress syndrome, infant
Regeneration, bone
Alzheimer's disease
Cancer, thyroid

TABLE 6

API G n r ic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
compound B, Pharmacor	[1,1'-Biphenyl]-2-carboxamide, N-[4-[(4,5-dihydro-2-methylimidazo[4,5-d][1-benzazepin-8(1H)-yl]carbonyl]phenyl]-, monohydrochloride [CAS]		US 6362165	Antiviral, anti-HIV
conivaptin hydrochloride	Hyaluronic acid [CAS]	168628-94-6	WO 9503305	GI inflammatory/bowel disorders
Connetivina		9004-61-9		Vulnery
Convallatoxin		508-75-8		
Coparaffinate		8001-60-3		
Corticoreslin Ovine Triflutate				
C r ic st r n		50-22-6		
Cortisone		53-06-5		
Cortivaz I		1110-40-3		
Cosyntropin		16960-16-0		
C tarnin		82-54-2		
Cotinlin		486-56-6		
co-trimazine	Benzenesulfonamide, 4-amino-N-2-pyrimidinyl-, mixt. with 5-[(3,4,5-trimethoxyphenyl)methyl]-2,4-pyrimidinediamine [CAS]	39474-58-3		Trimethoprim and analogues
C umetar I		4366-18-1		
CP-248	1H-Indene-3-acetamide, 5-fluoro-2-methyl-N-(phenylmethyl)-1-[(3,4,5-trimethoxyphenyl)methylene], (1Z)- [CAS]	200808-37-8	WO 9747303	Anticancer, other
CP-461			US 5948779	Anticancer, other
CPC-211	Acetic acid, dichloro-, sodium salt [CAS]	2156-56-1		Neuroprotective
CPI-1189	CPI 1189 [CAS]	210475-67-5	WO 9631462	Cognition enhancer
CRA-0450			WO 0202549	Anxiolytic
creatinal-O-phosphate	Guanidine, N-methyl-N-[2-(phosphonoxy)ethyl]- [CAS]	6903-79-3		Antianginal
CRL-5861	Oxirane, methyl-, polymer with oxirane, block [CAS]	106392-12-5	US 4837014	Antisking

TABLE 6

Example f Indication
Infection, HIV/AIDS
Hyponatraemia
Infection, urinary tract
Barrett's oesophagus
Cancer, prostate
Acidosis, lactic
Dementia, AIDS-related
Unspecified
Anaemia, sickle cell

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
crobenafine	(2R,6S)-3-[2(S)-Benzoyloxypropyl]-6,11,11-trimethyl-1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocin-10-ol			
croconazole	1H-Imidazole, 1-[1-[2-[(3-chlorophenyl)methoxy]phenyl]ethenyl]-[CAS]		WO 9914199	Neuroprotective
cromoglicic acid, Transphyto	4H-1-Benzopyran-2-carboxylic acid, 5,5'-[[2-hydroxy-1,3-propanediyl]bis(oxo)]bis(4-oxo- [CAS]	77175-51-0	DE 3021467	Antifungal
Cr m lyn		53736-52-0		Formulation, mucosal, topical
		16110-51-3		
cromolyn sodium, Durect	4H-1-Benzopyran-2-carboxylic acid, 5,5'-[[2-hydroxy-1,3-propanediyl]bis(oxo)]bis(4-oxo-, disodium salt [CAS]			Formulation, modified-release, other
cromolyn sodium, Emisphere	4H-1-Benzopyran-2-carboxylic acid, 5,5'-[[2-hydroxy-1,3-propanediyl]bis(oxo)]bis(4-oxo-, disodium salt [CAS]			Formulation, oral, other
cromolyn sodium, Premaire	4H-1-Benzopyran-2-carboxylic acid, 5,5'-[[2-hydroxy-1,3-propanediyl]bis(oxo)]bis(4-oxo-, disodium salt [CAS]	15826-37-6		Formulation, inhalable, solution
Cr propamid		633-47-6		
Cr tamit n		483-63-6		
Crotethamide		6168-76-9		
Crystacide			US 4557935	Formulation, dermal, topical
CS-502			EP 799823	Analgesic, other
CS-758	4-[(1E,3E)-4-(trans-5-[(1R,2R)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]thio)-1,3-dioxan-2-yl]-1,3-butadienyl]-3-fluorobenzonitrile			Antifungal

TABLE 6

Example of Indication
Ischaemia, cerebral
Infection, fungal, general
Conjunctivitis
Asthma
Asthma
Asthma
Infection, dermatological
Pain, general
Infection, fungal, general

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
CS-834	1-Azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, 6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-3-[[[(3R)-5-oxo-3-pyrrolidinylthio], (2,2-dimethyl-1-oxopropoxy)methyl ester, (4R,5S,6S)- [CAS]	157542-49-9	EP 599512	Beta-lactam antibiotic
CT-052923	[(2H-benzof[d]1,3-dioxalan-5-methyl)amino][4-(6,7-dimethoxyquinazolin-4-yl)pyrrolidinyl]methane-1-thione			Cardiovascular
CT-32228	N-(4-bromophenyl)-6-(5-chloro-2-methylphenyl)-1-[1,3,5]triazine-2,4-diamine			Anticancer, other
Cupric Citrate		866-82-0		
Cuproxoline		13007-93-7		
CVT-2584	Ethanol, 2,2-[[6-[[[(4-methoxyphenyl)methyl]amino]-9-(1-methylethyl)-9H-purin-2-yl]imino]bis-[CAS]	199986-75-9	WO 9805335	Cardiovascular
CX-659S	[(S)-6-amino-5-(6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxamido)-3-methyl-1-phenyl-2,4-(1H,3H)-pyrimidinone			
Cyacetacid		140-87-4		Dermatological
Cyamemazin		3546-03-0		
Cyanidin Chloride		528-58-5		
CYC400			WO 00172745	Anticancer, other
Cyclacillin		3485-14-1		
Cyclandelat		456-59-7		
Cyclazocine		3572-80-3		
Cyclexanone		15301-52-7		
Cyclexedin		532-52-5		
cyclidrol, Corvi	3-Cyclohexene-1-methanol, 5-hydroxy-Alpha,Alpha,4-trimethyl- [CAS]	498-71-5		COPD treatment, Respiratory
cyclin D1 Inhibitors, Topo			US 6033843	Anticancer, hormonal

TABLE 6

Examp ^l of Indication
Infection, general
Restenosis
Cancer, general
Restenosis
Eczema, general
Cancer, general
Bronchitis, chronic
Cancer, breast

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Cyclizine		82-92-8		
Cyclobarbital		52-31-3		
Cyclobenzazone		31431-43-3		
cyclobenzaprine, Alza	1-Propanamine, 3-(5H-dibenzo[a,d]cyclohepten-5-ylidene)-N,N-dimethyl-[CAS]	303-53-7		Formulation, modified-release, other
cyclobenzaprine, IZPR	3-(5H-Dibenzo[a,d]cyclohepten-5-ylidene)-N,N-dimethyl-1-propamide			Formulation, modified-release, immediate
cyclobenzaprine, Vela	1-Propanamine, 3-(5H-dibenzo[a,d]cyclohepten-5-ylidene)-N,N-dimethyl-[CAS]	303-53-7		Formulation, oral, other
Cycl butyrol		512-16-3		
Cycl cumarol		518-20-7		
Cyclodrin		52109-93-0		
Cyclofenil		2624-43-3		
Cycl guanil		516-21-2		
Cycl methycaine		139-62-8		
Cyclonium iodide		6577-41-9		
Cycl pentamine		102-45-4		
Cyclopentthiazide		742-20-1		
Cyclopentobarbital		76-68-6		
Cyclop nt late		512-15-2		
cyclophosphamide, Pro-Pharm	N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine-2-oxide monohydrate	50-18-0 6055-19-2		Formulation, parenteral, targeted
cyclopropralamine, FOAM-SYS	2(1H)-Pyridinone, 6-cyclohexyl-1-hydroxy-4-methyl-, compd with 2-aminoethanol(1:1) [CAS]	41821-49-2		Formulation, transdermal, other
Cycloserin		68-41-7		
Cycl thiazide		2259-96-3		
Cycloval ne		579-23-7		
Cymarin		508-77-0		

TABLE 6

API Generl Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
cymsetine	Carbamic acid, [4-(1-methylethyl)phenyl]-, (3a,8aF)-1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethylpyrrolo[2,3-b]indol-5-yl ester [CAS]	145209-39-8	WO 9902154	Cognition enhancer
Cynarin(e)		30964-13-7		
CYP26 inhibitors, derm			US 6063606	Dermatological
Cyproheptadine		129-03-3		
cyproterone	(18,28)-6-Chloro-1,2-dihydro-17-hydroxy-3H-cyclopropa[1,2]pregna-1,4,6-triene-3,20-dione [CAS]	2098-66-0		Radio/chemoprotective
Cysteamine		60-23-1		
cystic fibrosis ther, BI	[[4-[[3-[[4-[1-(4-hydroxyphenyl)-1-methyl-ethyl]phenoxy]methyl]phenyl]methoxy]-phenyl]iminomethyl]-, ethyl ester			Cystic fibrosis treatment
cytarabine octoflate	2(1H)-Pyrimidinone, 4-amino-1-[5-O-[(hydroxy(octadecyloxy)phosphoryl]-β-D-arabino furanosyl]-, monosodium salt [CAS]	65093-40-5	EP 239015	Anticancer, antimetabolite
cytarabine, DepoFoam	2(1H)-Pyrimidinone, 4-amino-1-β-D-arabino furanosyl- [CAS]	147-94-4		Formulation, modified-release, other
D-24851	N-(Pyridin-4-yl)-(1-(4-chlorobenzyl)-indol-3-yl)-glyoxy(amide)			Anticancer, other
D-4418	8-Methoxyquinoline-5-[N-(2,5-dichloropyridin-3-yl)]carboxamide			Antiasthma
DA-5018	Benzeneacetamide, 4-(2-aminoethoxy)-N-(3-(3,4-dimethylphenyl)propyl)-3-methoxy-, monohydrochloride [CAS]	174661-97-3	US 5242944	Analgesic, other
DA-6034			US 6025387	GI inflammatory/bowel disorders
DA-7867			KR 9957803	Antibacterial, other
DA-7911			KR 56034	Antiarthritic, other

TABLE 6

Example of Indication
Alzheimer's disease
Unspecified
Chemotherapy-induced injury, general
Cystic fibrosis
Myelodysplastic syndrome
Cancer, brain
Cancer, general
Asthma
Pain, musculoskeletal
Crohn's disease
Infection, general
Arthritis, rheumatoid

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
DA-8159	3-(1-Methyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo-[4,3-d]pyrimidin-5-yl)-N-[2-(1-methylpyrrolidin-2-yl)ethyl]-4-propoxybenzenesulfonamide		KR 353014	Male sexual dysfunction
Dacarbazine		4342-3-4		
Dacizumab		152923-56-3		
Dactin mycin		50-76-0		
dalbavancin	5,31-Dichloro-38-de(methoxycarbonyl)-7-demethyl-19-deoxy-58-O-[2-deoxy-2-(10-methylundecanamido)-8-D-glucopyranuronyl]-38-[N-(3-(dimethylamino)propyl]carbamoyl]-42-O-Alpha-D-mannopyranosyl-N15-methylristomycin A aglycone	171500-79-1		Peptide antibiotic
Dalt pristin		112362-50-2		
daltopristin + quinupristin	Virginiamycin M1, 26-[(2-(diethylamino)ethyl)sulfonyl]-26,27-dihydro-, (26R,27S)-, mixt with 4-(4-(dimethylamino)-N-methyl-L-phenylalanine)-5-(5-[(1-azabicyclo(2.2.2)oct-3-ylthio)methyl]-4-oxo-L-2-piperidinecarboxylic acid) virginiamycin S1- [CAS]	126602-89-9	EP 248703	Antibiotic, other
dalteparin sodium	Heparin-, sodium salt [CAS]	9041-08-1	US 4303651	Anticoagulant
Dalt ban		79094-20-5		
delta-Amin I vulinic Acid		106-60-5		
danaparoid sodium			EP 66908	Anticoagulant
danazol	Pregna-2,4-dien-20-yno[2,3-d]isoxazol-17-ol, (17Alpha)- [CAS]	17230-88-5	GB 905844	Menstruation disorders
Danthron		117-10-2		
Dantr lene		7261-97-4		
dapiprazole, ophthalmic	1,2,4-Triazolo[4,3-a]pyridine, 5,6,7,8-tetrahydro-3-[2-[4-(2-methylphenyl)-1-piperazinyl]ethyl]- [CAS]	72822-12-9 72822-13-0	US 4252721	Ophthalmological

TABLE 6

Exempl of Indication
Sexual dysfunction, male, general
Infection, dermatological
Infection, respiratory tract, general
Thromboprophylaxis
Thrombosis, venous
Glaucoma

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
dapiirine	4-[4-(2,4,6-trimethylphenyl)amino]pyrimidin-2-yl]amino]benzonitrile	244767-67-7		Antiviral, anti-HIV
dapoxetine	(+)-(S)-N,N-dimethyl-Alpha-[2-(1-naphthyl-oxy)ethyl]benzylamine HCl	119356-77-3	EP 288188	Male sexual dysfunction
dapsone	4,4'-Sulfonyldianiline	80-08-0		Formulation, dermal, topical
daptomycin	Daptomycin [CAS]	103060-83-3	EP 178152	Peptide antibiotic
<i>Darbepoetin Alfa</i>				
darifenacin	3-Pyrrolidineacetamide, 1-[2-(2,3-dihydro-5-benzofuran)ethyl]-Alpha,Alpha-diphenyl-, (S)- [CAS]	133099-04-4	EP 388054	Urological
daunorubicin	5,12-Naphthacenedione, 8-acetyl-10-[(3-amino-2,3,6-trideoxy-Alpha-L-xylo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8S-cis)- [CAS]	20830-81-3	US 5441745	Formulation, optimized, liposomes
DAX, SciClone	3-diallyl-8-cyclohexylxanthine			Cystic fibrosis treatment
DB-67	7-tert-Butyldimethylsilyl-10-hydroxycamptothecin			Anticancer, other
d-Camphocarboxylic Acid		18530-30-8		
DCF-987	Dextran		US 5514665	Formulation, other
DDT		50-29-3		
Deamin oxytocin		113-78-0		
Deanol		108-01-0		
Debris quin		1131-64-2		
Decam thonium		541-22-0		
Br mid				
Decimemide		14817-09-5		
dectabine	1,3,5-Triazin-2(1H)-one, 4-amino-1-(2-deoxy-β-D-erythro-pentofuranosyl)-[CAS]	23339-46-0 2353-33-5		Anticancer, antimetabolite
declopramide	Benzamide, 4-amino-3-chloro-N-(2-(diethylamino)ethyl)- [CAS]	891-60-1	WO 9732582	Anticancer, other

TABLE 6

Example of Indication
Infection, HIV/AIDS
Premature ejaculation
Acne
Infection, dermatological
Overactive bladder
Cancer, sarcoma, Kaposi's
Cystic fibrosis
Cancer, general
Cystic fibrosis
Myelodysplastic syndrome
Cancer, colorectal

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Deferiprone		30652-11-0		
Deferoxamine		70-51-9		
deflazacort	5H-Pregna-1,4-dieno[17,16-dioxazole-3,20-dione, 21-(acetyloxy)-11-hydroxy-2-methyl-, (11B, 16B)- [CAS]	14484-47-0 74712-90-6	GB 1077393	Hormone
Deflazacort		14484-47-0		
D fosfamide		3733-81-1		
degarelix	N-acetyl-3-(naphthalen-2-yl)-D-alanyl-4-chloro-D-phenylalanyl-3-(pyridin-3-yl)-D-alanyl-L-seryl-4-[[[(4S)-2,6-dioxohexahydropyrimidin-4-yl]carbonyl]amino]-L-phenylalanyl-4-[(carbamoyl)amino]-D-phenylalanyl-L-leucyl-N6-(1-methylethyl)-L-lysyl-L-protyl-D-alaninamide	214766-78-6		Anticancer, hormonal
dehydroascorbic acid, Progenics	L-threo-2,3-Hexodiulosonic acid gamma-lactone	490-83-5		Cognition enhancer
D hydroch lic Acid		81-23-2		
Dehydr emetine		4914-30-1		
delapril	Glycine, N-(2,3-dihydro-1H-inden-2-yl)-N-[(N-1-(ethoxycarbonyl)-3-phenylpropyl)-L-alanyl]-, (S)- [CAS]	83435-66-9 83435-67-0	EP 51391	Antihypertensive, renin system
delapril+manidipine, Chiesi	Glycine, N-(2,3-dihydro-1H-inden-2-yl)-N-[(N-1-(ethoxycarbonyl)-3-phenylpropyl)-L-alanyl]-, (S)-3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 2-[4-(diphenylmethyl)-1-piperazinyl]ethyl methyl ester [CAS]		FR 2733911	Formulation, fixed-dose combinations
delavirdine	Piperazine, 1-[3-[(1-methylethyl)amino]-2-pyridinyl]-4-[5-[(methylsulfonyl)amino]-1H-indol-2-yl]carbonyl]- [CAS]	136817-59-9	WO 9109849	Antiviral, anti-HIV
Delavirdine Mesylate				
D Imadin n Acetate		13698-49-2		
Delm pin I		79874-76-3		

TABLE 6

Example of Indication
Asthma
Cancer, prostate
Alzheimer's disease
Hypertension, general
Hypertension, general
Infection, HIV/AIDS

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
delorazepam	2H-1,4-Benzodiazepin-2-one, 7-chloro-5-(2-chlorophenyl)-1,3-dihydro- [CAS]	2894-87-9	CH 408029	Anxiolytic
delucemine hydrochloride	3,3-Bis-(m-fluorophenyl)-N-methylpropylamine hydrochloride- [CAS]	186485-99-8		Neuroprotective
D manyl Phosphate		6909-62-2		
Demecarium Bromide		56-94-0		
demeclocycline, Elan	2-Naphthacene-carboxamide, 7-chloro-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-1,11-dioxo-, [4S-(4Alpha,4aAlpha,5aAlpha,6B,12aAlpha)]- [CAS]	127-33-3		Formulation, modified-release, <=24hr
D mecolcine		477-30-5		
Demeg st n		10116-22-0		
Demexiptilin		24701-51-7		
denavaine hydrochloride	Benzeneacetic acid, Alpha-(2-ethylbutoxy)-Alpha-phenyl-, 2-(dimethylamino)ethyl ester, hydrochloride [CAS]	3321-06-0	DE 4133785	Analgesic, NSAID
D nileukin Diftitox		173146-27-5		
D n pamine		71771-90-9		
Denopterin		22006-84-4		
De xycholic Acid		83-44-3		
De xycortic sterone		64-85-7		
De xyc rtic st rone Acetate		56-47-3		
De xydihydr streptomycin		26086-49-7		
Deoxyepinephrine		501-15-5		
Depreotid		161982-62-3		
depsipeptide	L-Valine, N-[(9S,4E)-3-hydroxy-7-mercapto-1-oxo-4-heptenyl]-D-valyl-D-cysteinyl-(2Z)-2-amino-2-butenoyl-, (4-1)-lactone, cyclic (1-2)-disulfide [CAS]			
Deptropin		128517-07-7	EP 352846	Anticancer, antibiotic
D qualinium Chloride		604-51-3		
		522-51-0		

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
deslazine	Benzoic acid, 2-hydroxy-5-[[4-{3-(4-(2-methyl-1H-imidazo[4,5-c]pyridin-1-yl)methyl}-1-piperidinyl)-3-oxo-1-phenyl-1-propenyl]phenylazo] (Z) [CAS]	188913-57-7 188913-58-8	US 5747477	Anti-inflammatory
Desipidin		131-01-1		
desferrioxamine mesylate	Butanediamide, N'-(5-[[4-[[5-(acetylhydroxyamino)pentyl]amino]-1,4-dioxobutyl]hydroxyamino]pentyl)-N-(5-aminopentyl)-N-hydroxy- [CAS]	70-51-9		Antidote
Desfluran		57041-67-5		
Desipramine		50-47-5		
D slan side		17598-65-1		
desloratadine	5H-Benzo(5,6)cyclohepta(1,2-b)pyridine, 8-chloro-6,11-dihydro-11-(4-piperidinylidene)- [CAS]	100843-71-8	US 5595997	Antiallergic, non-asthma
deslorelin	Luteinizing hormone-releasing factor (pig), 8-D-typtophan-9-(N-ethyl-L-prolinamide)-10-deglycinamide- [CAS]	57773-65-6	US 4034082	Releasing hormones
desmopressin	Vasopressin, 1-(3-mercaptopropanoic acid)-8-D-arginine- [CAS]	16878-58-6	DE 2948345	Hormone
desmopressin, COLUMBIA	Vasopressin, 1-(3-mercaptopropanoic acid)-8-D-arginine- [CAS]			Formulation, transdermal, other
Desogestrel		54024-22-5		
desogestrel + estradiol, Akzo	Estra-1,3,5(10)-triene-3,17-diol (17 β)-, mixt. with (17 α)-13-ethyl-11-methylene-18,19-dinorpregn-4-en-20-yn-17-ol [CAS]	122364-17-4		Menopausal disorders
desogestrel, Akzo Nobel	18,19-Dinorpregn-4-en-20-yn-17-ol, 13-ethyl-11-methylene-, (17 α)- [CAS]	54024-55-5		Formulation, oral, other
desogestrel+ethinylestrad (1)	18,19-Dinorpregn-4-en-20-yn-17-ol, 13-ethyl-11-methylene-, (17 α)- [CAS]	54024-22-5 71138-35-7	US 3927046	Formulation, oral, other
desogestrel+ethinylestrad (2)	19-Norpregna-1,3,5(10)-trien-20-yn-3,17-diol, (17 α)-, mixt. with (17 α)-13-ethyl-11-methylene-18,19-dinorpregn-4-en-20-yn-17-ol- [CAS]	71138-35-7		Formulation, modified-release, multi
Desomorphine		427-00-9		
D s nide		638-94-8		
Desoxim tasone		382-67-2		

TABLE 6

Example 1 Indication
Colitis, ulcerative
Poisoning, metal
Rhinitis, allergic, perennial
Cancer, prostate
Enuresis
Unspecified
Hormone replacement therapy
Contraceptive, female
Contraceptive, female

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Detaxtran		9015-73-0		
Devacade			WO 9308176	Analgescic, other
D xamethason		50-02-2		
dexamethasone sodium phosphate	Pregna-1,4-diene-3,20-dione, 9-fluoro-11,17-dihydroxy-16-methyl-21-(phosphonoxy)-, disodium salt, (11B,16Alpha)- [CAS]	2392-39-4 312-93-6		Formulation, mucosal, topical
dexamethasone, Oculex	Pregna-1,4-diene-3,20-dione, 9-fluoro-11,17,21-trihydroxy-16-methyl-, (11B,16Alpha)- [CAS]	50-02-2		Formulation, other
dexanabinol	6H-Dibenzof[d]pyran-9-methanol, 3-(1,1-dimethylheptyl)-6a,7,10,10a-tetrahydro-1-hydroxy-6,6-dimethyl-, (6aS-trans)- [CAS]	112924-45-5	EP 427518	Neuroprotective
dexecadotril	Glycine, N-[2-(acetylthio)methyl]-1-oxo-3-phenylpropyl-, phenylmethyl ester, (R)- [CAS]	112573-72-5	EP 318377	Alimentary/Metabolic, other
dexelaroxan	1H-Imidazole, 2-(2-ethyl-2,3-dihydro-2-benzofuranyl)-4,5-dihydro- [CAS]	89197-00-2 89197-32-0	EP 71368	Cognition enhancer
Dex timid		21888-98-2		
dexibuprofen	Benzeneacetic acid, Alpha-methyl-4-(2-methylpropyl)-, (AlphaS)- [CAS]	51146-56-6		Analgescic, NSAID
dextetopofen, Menarini	Benzeneacetic acid, 3-benzoyl-Alpha-methyl-, (S)- [CAS]	22161-81-5		Anti-inflammatory
dextoxiglumide	Pentanoic acid, 4-[(3,4-dichlorobenzoyl)amino]-5-[(3-methoxypropyl)pentylamino]-5-oxo-, (R)- [CAS]	119817-90-2	EP 0344184	GI inflammatory/bowel disorders
dexmedetomidine	1H-Imidazole, 4-[1-(2,3-dimethylphenyl)ethyl]-, (R)- [CAS]	113775-47-6 86347-15-1	EP 187471	Hypnotic/Sedative
D xmedet midline		113775-47-6		
dexmethylphenidate HCl, Celgene	2-Piperidineacetic acid, Alpha-phenyl-, methyl ester, hydrochloride, (AlphaR,2R)-	19262-68-1		Psychostimulant
Dexpanthen I		81-13-0		
dexrazoxane	2,6-Piperazinedione, 4,4'-(1-methyl-1,2-ethanediy)bis-, (S)- [CAS]	24584-09-6	DE 1910283	Radio/chemoprotective
Dextran-1	Dextran [CAS]	9004-54-0		Plasma substitute

TABLE 6

Exempl of Indication
Pain, general
Inflammation, ocular
Inflammation, ocular
Head trauma
Unspecified
Alzheimer's disease
Pain, general
Inflammation, general
Irritable bowel syndrome
Anaesthesia
Attention deficit disorder
Chemotherapy-induced injury, general

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
D xtran m r		56087-11-7		
D xtroamph tamline		51-64-9		
dextromethorphan HBr, Penmkine	Morphinan, 3-methoxy-17-methyl-, (9Alpha,13Alpha,14Alpha)-, hydrobromide, monohydrate	6700-34-1	US 4221788	Formulation, oral, other
dextromethorphan, InSys	Morphinan, 3-methoxy-17-methyl-, (9Alpha,13Alpha,14Alpha)- [CAS]	125-71-3		Formulation, fixed-dose combinations
Dextromoramide		357-56-2		
dextropropoxyphene, Benzon	Benzeneethanol, Alpha-[2-(dimethylamino)-1-methylethyl]-Alpha-phenyl-, propanoate (ester), [S-(R*,S*)]- [CAS]	469-62-5		Formulation, modified-release, other
D z cin		53648-55-8		
DF-1012	N-Tropyl 7-azaindol-3-ylcarboxamide	163220-65-3	WO 9504742	Respiratory
DFA-IV	di-D-fructofuranose 2,6':6,2' dianhydride			
d-F nch n		4695-62-9	US 5700832	Antianaemic
D-Glucuron lactone		32449-92-6		
Diab II	Diab II	309956-85-2	US 6153632	Antidiabetic
diacerein	2-Anthracenecarboxylic acid, 4,5-bis(acetyloxy)-9,10-dihydro-8,10-dioxo-[CAS]	13739-02-1	US 4244968	Antiarthritic, other
Diampromide		552-25-0		
Diamthaz le		136-96-9		
Dihydrochloride		5964-62-5		
Diathym sulfone		737-31-5		
Diatrizoate S dium				
diazepam emulsion, Pharmacia	2H-1,4-Benzodiazepin-2-one, 7-chloro-1,3-dihydro-1-methyl-5-phenyl- [CAS]	439-14-5		Formulation, parenteral, other
diazepam, Dumex-Alpha	2H-1,4-Benzodiazepin-2-one, 7-chloro-1,3-dihydro-1-methyl-5-phenyl- [CAS]	439-14-5		Formulation, transmucosal, systemic
diazepam, Elan	2H-1,4-Benzodiazepin-2-one, 7-chloro-1,3-dihydro-1-methyl-5-phenyl- [CAS]	439-14-5		Formulation, transmucosal, systemic
Diaziqu n		57998-68-2		
Diazoxide		364-98-7		

TABLE 6

Example of Indication
Cough
Emotional lability
Pain, general
Respiratory disease, general
Anaemia, aplastic
Diabetes, Type II
Arthritis, rheumatoid
Anxiety, general
Anxiety, general
Epilepsy, general

TABLE 6

API Gen ric Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Dib kacin	D-Streptamine, O-3-amino-3-deoxy-Alpha-D-glucopyranosyl-(1-6)-O-[2,6-diamino-2,3,4,6-tetra-deoxy-Alpha-D-erythro-hexopyranosyl-(1-4)]-2-deoxy-, sulfate (salt)[CAS]	34493-98-6		
dibekacin sulfate		34493-98-6 58580-55-5	GB 1349302	Aminoglycoside antibiotic
Dibenz pin		4498-32-2		
Dibrom propamidine		496-00-4		
Dibucaine Hydrochloride		61-12-1		
Dichloralphenazone		480-30-8		
Dichl ramline T		473-34-7		
Dichloris n		7008-26-6		
Dichlorobenzyl Alcohol		1777-82-8		
Dichl r phen		97-23-4		
Dichlorophenarsine		536-29-8		
Hydrochl rid				
Dichl rphenamide		120-97-8		
diclofenac + HA, SkyePharma	Hyaluronic acid + benzenecarboxylic acid, 2-[(2,6-dichlorophenyl)amino]- [CAS]			Formulation, transdermal, systemic
diclofenac gel, SkyePharma	Benzenecarboxylic acid, 2-[(2,6-dichlorophenyl)amino]- [CAS]	15307-86-5		Formulation, mucosal, topical
diclofenac once-daily, SSP	Benzenecarboxylic acid, 2-[(2,6-dichlorophenyl)amino]-, monosodium salt [CAS]	15307-79-6 15307-86-5		Formulation, modified-release, <=24hr
diclofenac potassium	Benzenecarboxylic acid, 2-[(2,6-dichlorophenyl)amino]-, monopotassium salt- [CAS]	15307-81-0		Anti-inflammatory
Dicloxacillin		3116-76-5		
Dicumarol		66-76-2		
Dicyclomine		77-19-0		
didanosine	Inosine, 2',3'-dideoxy- [CAS]	69655-05-6	US 4861759	Antiviral, anti-HIV
Dide xyaden sine		4097-22-7		
diox	Benzamide, N,3,4-trihydroxy- [CAS]	69839-83-4	US 4263322	Anticancer, antimetabolite
Dien str l		84-17-3		

TABLE 6

Example of Indication
Infección, general
Keratosis
Pain, general
Pain, general
Pain, general
Infection, HIV/AIDS
Cancer, general

TABLE 6

API G neric Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
dienogest	19-Norpregna-4,9-diene-21-nitrile, 17-hydroxy-3-oxo-, (17Alpha)- [CAS]	65928-58-7	GB 1524917	Menstruation disorders
dienogest+estradiol, sequentia	19-Norpregna-4,9-diene-21-nitrile, 17-hydroxy-3-oxo-, (17Alpha) + Estra-1,3,5(10)-triene-3,17-diol(17B)			Formulation, fixed-dose combinations
Diethadione		702-54-5		
DI thazin		60-91-3		
Diethylbromoacetamide		511-70-6		
DI thylcarbamazine		90-89-1		
diethylpropion, Biovail	1-Propanone, 2-(diethylamino)-1-phenyl- [CAS]	90-84-6		Formulation, modified-release, <=24hr
DI thylstilbestr I		56-53-1		
Difemerine		80387-96-8		
Dif namizol		20170-20-1		
Dif n xin		28782-42-5		
Difenpiramid		51484-40-3		
diflomotecan	(5R)-5-Ethyl-9,10-difluoro-1,4,5,13-tetrahydro-5-hydroxy-3H,15H-oxepino[3',4':6,indolizino[1,2-b]quinoline-3,15-dione			Anticancer, other
Difloras n		220997-97-7		
		2557-49-5		
diflorasone diacetate	Pregna-1,4-diene-3,20-dione, 17,21-bis(acetyloxy)-6,9-difluoro-11-hydroxy-16-methyl-, (6Alpha,11B,16B)- [CAS]	33564-31-7	US 3980778	Antipsoriasis
Difloxacin		98106-17-3		
Difluc rtol n		6/9/2607		
diflunisal	2',4'-difluoro-4-hydroxy[1,1'-biphenyl]-3-carboxylic acid	23674-86-4	GB 1175212	Analgesic, NSAID
Diflunisal		22494-42-4		
Difluprednate		23674-86-4		
Digitalin		752-61-4		
Digitoxin		71-63-6		
Dig xin		20830-75-5		

TABLE 6

Example of Indication
Endometriosis
Contraceptive, female
Obesity
Cancer, general
Pain, post-operative

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
digoxin, Beiersdorf	Card-20(22)-enolide, 3-[(O-2,6-dideoxy-β-D-ribo-hexopyranosyl-(1-4)-O-2,6-dideoxy-β-D-ribo-hexopyranosyl-(1-4)-2,6-dideoxy-β-D-ribo-hexopyranosyl)oxy]-12,14-dihydroxy-, (38,58,128)- [CAS]	20830-75-5	US 4088750	Formulation, oral, enteric-coated
Dihexyverine		561-77-3		
Dihydralazin		484-23-1		
Dihydrocod in		125-28-0		
Dihydrocodeinone Enol		466-90-0		
Acetate				
dihydroergocryptine, Pol	Ergocryptine, dihydro- [CAS]	25447-66-9		Formulation, other
	Ergotaman-3',6',18-trione, 9,10-dihydro-12'-hydroxy-2'-methyl-5'-(phenylmethyl)-, (5'Alpha,10Alpha)- [CAS]			
dihydroergotamine SR, Ethypha		511-12-6	6495535	Formulation, modified-release, other
	Ergotaman-3',6',18-trione, 9,10-dihydro-12'-hydroxy-2'-methyl-5'-(phenylmethyl)-, (5'Alpha,10Alpha)- [CAS]			
dihydroergotamine, bioMarieux		511-12-6		Formulation, modified-release, other
	Ergotaman-3',6',18-trione, 9,10-dihydro-12'-hydroxy-2'-methyl-5'-(phenylmethyl)-, (5'Alpha,10Alpha)- [CAS]			
dihydroergotamine, Tempo		511-12-6		Formulation, inhalable, solution
Dihydrom rphine		509-60-4		
Dihydr str pt mycin		128-46-1		
Dihydrotachysterol		67-96-9		
Dihydr xyaluminum		13682-92-3		
Amin acetat				
Dihydr xyaluminum		539-68-4		
S dium Carbonate				
Disopromin		5966-41-6		
Dis propyl Paraoxon		3254-66-8		
Dis propylamine		660-27-5		
Dichlor acetat				

TABLE 6

Exemplification	Indication
Heart failure	
Depression, general	
Migraine	
Migraine	
Migraine	

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
diltazep	Benzoic acid, 3,4,5-trimethoxy-, (tetrahydro-1H-1,4-diazepine-1,4(5H)-diyl)di-3,1-propanediyl ester [CAS]	35898-87-4	JP 51095086	Vasodilator, coronary
Dileval I		75659-07-3		
Dil xanid		579-38-4		
diloxanide furoate	2-Furancarboxylic acid, 4-[(dichloroacetyl)methylamino]phenyl ester [CAS]	3736-81-0		Amoebicide
diltiazem	1,5-Benzothiazepin-4(5H)-one, 3-(acetyloxy)-5-[2-(dimethylamino)ethyl]-2,3-dihydro-2-(4-methoxyphenyl)-, (2S-cis)- [CAS]	33286-22-5 42399-41-7	US 4721619 US 5529791 EP 322277	Antianginal
Diltiaz m		42399-41-7		
Diltiazem Hydrochloride				
Diltiazem Hydrochloride				
diltiazem once-daily, Bago	1,5-Benzothiazepin-4(5H)-one, 3-(acetyloxy)-5-[2-(dimethylamino)ethyl]-2,3-dihydro-2-(4-methoxyphenyl)-, (2S-cis)- [CAS]	42399-41-7		Formulation, modified-release, <=24hr
diltiazem once-daily, Biov	1,5-Benzothiazepin-4(5H)-one, 3-(acetyloxy)-5-[2-(dimethylamino)ethyl]-2,3-dihydro-2-(4-methoxyphenyl)-, (2S-cis)- [CAS]	33286-22-5 42399-41-7	US 5529791	Formulation, modified-release, <=24hr
diltiazem once-daily, Elan	1,5-Benzothiazepin-4(5H)-one, 3-(acetyloxy)-5-[2-(dimethylamino)ethyl]-2,3-dihydro-2-(4-methoxyphenyl)-, (2S-cis)- [CAS]	42399-41-7		Formulation, modified-release, <=24hr
diltiazem once-daily, Biovail-2	1,5-Benzothiazepin-4(5H)-one, 3-(acetyloxy)-5-[2-(dimethylamino)ethyl]-2,3-dihydro-2-(4-methoxyphenyl)-, (2S-cis)- [CAS]			Formulation, modified-release, <=24hr
diltiazem SR, Ethypharm	1,5-Benzothiazepin-4(5H)-one, 3-(acetyloxy)-5-[2-(dimethylamino)ethyl]-2,3-dihydro-2-(4-methoxyphenyl)-, (2S-cis)- [CAS]	33286-22-5 42399-41-7		Formulation, modified-release, other

TABLE 6

Exempl of Indication
Angina, general
Hypertension, general
Angina, general
Hypertension, general
Hypertension, general

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
diltiazem twice-daily, Elan	(1,5-Benzothiazepin-4(5H)-one, 3-(acetyloxy)-5-[2-(dimethylamino)ethyl]-2,3-dihydro-2-(4-methoxyphenyl)-, (2S-cis) [CAS]	42399-41-7		Formulation, modified-release, <=24hr
diltiazem, Alza	1,5-Benzothiazepin-4(5H)-one, 3-(acetyloxy)-5-[2-(dimethylamino)ethyl]-2,3-dihydro-2-(4-methoxyphenyl)-, (2S-cis) [CAS]	42399-41-7		Formulation, modified-release, <=24hr
diltiazem, Amarin	1,5-Benzothiazepin-4(5H)-one, 3-(acetyloxy)-5-[2-(dimethylamino)ethyl]-2,3-dihydro-2-(4-methoxyphenyl)-, (2S-cis) [CAS]	42399-41-7		Formulation, modified-release, <=24hr
diltiazem, Andrx, PPDS	1,5-Benzothiazepin-4(5H)-one, 3-(acetyloxy)-5-[2-(dimethylamino)ethyl]-2,3-dihydro-2-(4-methoxyphenyl)-, (2S-cis) [CAS]	42399-41-7		Formulation, modified-release, other
diltiazem, Andrx, SMHS	1,5-Benzothiazepin-4(5H)-one, 3-(acetyloxy)-5-[2-(dimethylamino)ethyl]-2,3-dihydro-2-(4-methoxyphenyl)-, (2S-cis) [CAS]	42398-41-7		Formulation, oral, solubility-enhanced
diltiazem, Difutab	1,5-Benzothiazepin-4(5H)-one, 3-(acetyloxy)-5-[2-(dimethylamino)ethyl]-2,3-dihydro-2-(4-methoxyphenyl)-, (2S-cis) [CAS]	42399-41-7		Formulation, modified-release, <=24hr
diltiazem, Douglas	1,5-Benzothiazepin-4(5H)-one, 3-(acetyloxy)-5-[2-(dimethylamino)ethyl]-2,3-dihydro-2-(4-methoxyphenyl)-, (2S-cis) [CAS]	33286-22-5 42399-41-7		Formulation, modified-release, other
diltiazem, Dov Pharmaceutical	1,5-Benzothiazepin-4(5H)-one, 3-(acetyloxy)-5-[2-(dimethylamino)ethyl]-2,3-dihydro-2-(4-methoxyphenyl)-, (2S-cis) [CAS]	33286-22-5 42399-41-7		Formulation, modified-release, multi
diltiazem, GEOMATRIX	(1,5-Benzothiazepin-4(5H)-one, 3-(acetyloxy)-5-[2-(dimethylamino)ethyl]-2,3-dihydro-2-(4-methoxyphenyl)-, (2S-cis) [CAS]	42399-41-7		Formulation, modified-release, multi

TABLE 6

Example of Indication
Angina, general
Hypertension, general
Angina, general
Angina, general
Angina, general
Angina, general
Angina, general
Angina, general
Angina, general
Hypertension, general

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
diltiazem, once-daily, Mundipharma	1,5-Benzothiazepin-4(5H)-one, 3-(acetyloxy)-5-[2-(dimethylamino)ethyl]-2,3-dihydro-2-(4-methoxyphenyl)-1,5-benzothiazepin-4(5H)-one, (2S-cis)- [CAS]	42399-41-7		Formulation, modified-release, <=24hr
diltiazem, once-daily, Synthe	1,5-Benzothiazepin-4(5H)-one, 3-(acetyloxy)-5-[2-(dimethylamino)ethyl]-2,3-dihydro-2-(4-methoxyphenyl)-, (2S-cis)- [CAS]	42399-41-7	EP 322277	Formulation, modified-release, <=24hr
diltiazem, SURECAPS	1,5-Benzothiazepin-4(5H)-one, 3-(acetyloxy)-5-[2-(dimethylamino)ethyl]-2,3-dihydro-2-(4-methoxyphenyl)-, (2S-cis)- [CAS]	42399-41-7		Formulation, modified-release, <=24hr
Dimecrotic Acid		7706-67-4		
Dimeflin		1165-48-6		
Dim m rfan		36309-01-0		
Dimenhydrinate		523-87-5		
Dimen xadol		509-78-4		
Dimepheptanol		545-90-4		
Dimercapr I		59-52-9		
Dim tacrine		4757-55-5		
Dim thadi n		695-53-4		
Dimethazan		519-30-2		
Dimethind ne		5636-83-9		
Dimethis quin		86-80-6		
Dimethisterone		79-64-1		
Dim thocaine		94-15-5		
Dimethoxanat		477-93-0		
Dimethyl Sulfoxide		67-68-5		
Dim thylthiambutene		524-84-5		
Dimetofrin		22950-29-4		
Dim rpholamine		119-48-2		
dinoprostone, Controlled Ther	Prosta-5,13-dien-1-olc acid, 11,15-dihydroxy-9-oxo-, (5Z,11Alpha,13E,15S)- [CAS]	363-24-6		Formulation, modified-release, <=24hr
diosmectite	Smecta- [CAS]	110070-78-5	FR 2770778	Antidiarrhoeal

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
diocimin	4H-1-Benzopyran-4-one, 7-[[6-O-(6-deoxy- Alpha-L-mannopyranosyl)-beta-D- glucopyranosyloxy]-5-hydroxy-2-(3- hydroxy-4-methoxyphenyl)- [CAS]	520-27-4	DE 2602314	Vasoprotective, systemic
Diosmin		520-27-4		
DI xadr I		6495-46-1		
Dioxaphetyl Butyrate		467-86-7		
DI xethedrin		497-75-6		
Dioxybenz n		131-53-3		
Diph manli		62-97-5		
Methylsulfate				
Diphenadione		82-66-6		
Diphencypr n		886-38-4		
Diphenhydramine		58-73-1		
Diphenid I		972-02-1		
Diphen xylate		915-30-0		
Diphenylpyraline		147-20-6		
Diphetarson		515-76-4		
Diphtheria & Tetanus Toxoids And Acellular Pertussis Vaccine Adsorbed				
Dipipan n		467-83-4		
dipivefrin	Propanoic acid, 2,2-dimethyl-, 4-{1-hydroxy- 2-(methylamino)ethyl}-1,2-phenylene ester, (+)- [CAS]	52385-63-6	US 3809714	Antiglaucoma
Dipiv frin		52365-63-6		
Dipyridamol		58-32-2		
Dipyrrocetyl		486-79-3		
Dipyr ne		5907-38-0		
diquafosol tetrasodium	Uridine 5'-(pentahydrogen tetraphosphate)- 5'-ester with uridine, tetrasodium salt [CAS]	211427-08-6		Ophthalmological

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
dithromycin	Erythromycin, 9-deoxy-11-deoxy-9,11-[imino]-2-(2-methoxyethoxy)ethylidene]oxyl-, [9S(R)]- [CAS]	62013-04-1	DE 2515075	Macrolide antibiotic
Dirithromycin		62013-04-1		
disodium pamidronate	Phosphonic acid, (3-amino-1-hydroxypropylidene)bis-, disodium salt [CAS]	57248-88-1	EP 177443	Osteoporosis treatment
disodium pamidronate, Gador	Phosphonic acid, (3-amino-1-hydroxypropylidene)bis-, disodium salt [CAS]	57248-88-1	AR 200473	Formulation, oral, enteric-coated
Disofenin		65717-97-7		
Disopyramid		9/5/3737		
disopyramide SR, Ethypharm	2-Pyridineacetamide, Alpha-[2-bis(1-methyl(ethyl)amino)ethyl]-Alpha-phenyl- [CAS]	3737-09-5		Formulation, modified-release, other
disopyramide, AstraZeneca	2-Pyridineacetamide, Alpha-[2-bis(1-methyl(ethyl)amino)ethyl]-Alpha-phenyl- [CAS]	3737-09-5		Formulation, modified-release, <=24hr
disopyramide, Bloval	2-Pyridineacetamide, Alpha-[2-bis(1-methyl(ethyl)amino)ethyl]-Alpha-phenyl- [CAS]	3737-09-5		Formulation, modified-release, <=24hr
Distigmine Bromide		15876-67-2		
Disulfamide		671-88-5		
Disulfiram		97-77-8		
<i>Disulfiram</i>				
Ditazol		18471-20-0		
Dithiazanin Iodide		514-73-8		
dithranol, Bioglan	9(10H)-Anthracenone, 1,8-dihydroxy- [CAS]	1143-38-0		Formulation, dermal, topical
Diltioarb Sodium		148-18-5		
Dixanth gen		502-55-6		
Dixyrazin		2470-73-7		
DJ-927			WO 01027115	Anticancer, other

TABLE 6

Exemplification
Tonsillitis
Hypercalcaemia of malignancy
Paget's disease
Arrhythmia, general
Arrhythmia, general
Arrhythmia, general
Psoriasis
Cancer, general

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
DK-507k	(-)-7-(7S)-7-Amino-5-azaspiro[2,4]heptan-5-yl]-6-fluoro-1-[(1R,2S)-2-fluoro-1-cyclopropyl]-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid hydrochloride monohydrate			Quinolone antibacterial
DL-Lactic Acid		598-82-3		
DMDC	Cytidine, 2'-deoxy-2'-methylene-, monohydrochloride [CAS]	113648-25-2	WO 8807049	Anticancer, antimetabolite
DMXAA	5,6-dimethylxanthenone-4-acetic acid			Anticancer, other
DNA Stealth Nucleosides, Koron			US 6132776	Antiviral, anti-HIV
Dob silate Calcium		20123-80-2		
dobutamine	1,2-Benzenediol, 4-[2-[3-(4-hydroxyphenyl)-1-methylpropyl]amino]ethyl-, (+)- [CAS]	34368-04-2 49745-95-1	US 3987200	Cardio stimulant
D butamin		34368-04-2		
D carpamin		74639-40-0		
docetaxel	(2R,3S)-N-Carboxy-3-phenylisoserine, N-tert-butyl ester, 13-ester with 5B,20-epoxy-1,2Alpha,4,7B,10B,13Alpha-hexahydroxytax-11-en-9-one 4-acetate 2-benzoate- [CAS]	114977-28-5 148408-66-6 114977-28-5	EP 253738	Anticancer, other
Docetaxel				
docetaxel formulation, Aventis	(2R,3S)-N-Carboxy-3-phenylisoserine, N-tert-butyl ester, 13-ester with 5B,20-epoxy-1,2Alpha,4,7B,10B,13Alpha-hexahydroxytax-11-en-9-one 4-acetate 2-benzoate [CAS]	114977-28-5 148408-66-6		Formulation, other
docosahexaenoic acid, Martek			EP 707487	Hypolipaeamic/Antiatherosclerosis
docosanol	1-Docosanol [CAS]	661-19-8	EP 469064	Antiviral, other
docusate			US 4752617	Formulation, dermal, topical
D cusate Calcium		128-49-4		
D cusate Sodium		577-11-7		

TABLE 6

Exempl of Indication
Infection, general
Cancer, general
Cancer, lung, general
Infection, HIV/AIDS
Cancer, breast
Cancer, general
Hypertipidaemia, general
Infection, herpes simplex virus
Infection, herpes simplex virus prophylaxis

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
dofetilide	Methanesulfonamide, N-[4-[2-[methoxy-2-((methanesulfonyl)amino)phenoxy]ethyl]aminophenyl]- [CAS]	115256-11-6	EP 245997	Antiarrhythmic
Dofetilid		115256-11-6		
<i>Dofetilide</i>				
Dolas tron		115956-12-2		
dolasetron mesilate	1H-Indole-3-carboxylic acid, octahydro-3-oxo-2,6-methano-2H-quinolizin-8-yl ester, (2Alpha,6Alpha,8Alpha,9Alpha)-, monomethanesulfonate- [CAS]	115956-13-3	EP 266730	Antiemetic
<i>Dolasetron Mesylate</i>				
<i>Dolasetron Mesylate</i>				
Domiodol		61869-07-6		
Domiphen Bromide		538-71-6		
D mitr ban		112966-96-8		
domperidone	2H-Benzimidazol-2-one, 5-chloro-1-[1-[3-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)propyl]-4-piperidinyl]-1,3-dihydro- [CAS]	57808-66-9	US 4065772	Antiemetic
Domperid n		57808-66-9		
D nep zil		120014-06-4		
donepezil hydrochloride	1H-Inden-1-one, 2,3-dihydro-5,6-dimethoxy-2-((1-(phenylmethyl)-4-piperidinyl)methyl)-, hydrochloride- [CAS]	120011-70-3 120014-06-4	EP 296560	Cognition enhancer
donitriptan mesylate	Piperazine, 1-((3-(2-aminoethyl)-1H-Indol-5-yl)oxy)acetyl)-4-(4-cyanophenyl)- [CAS]	170912-52-4		Antimigraine
D pamin		51-61-6		
Dop xamine		86197-47-9		
doramipimod	urea, N-[3-((1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl)-N'-[4-[2-(4-morpholinyl)ethoxy]-1-naphthalenyl]-	285983-48-4		Antiarthritic, Immunological

TABLE 6

Exempl of Indication
Fibrillation, atrial
Chemotherapy-induced nausea and vomiting
Alzheimer's disease
Migraine
Arthritis, rheumatoid

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
dorantidazole	(±)-1,2,4-Butanetriol, 3-[(2-nitro-1H-imidazol-1-yl)methoxy]- [CAS]	137339-64-1	WO 9414778	Radio/chemosensitizer
doripenem	(1R,5S,6S)-2-[(3S,5S)-5-(sulfamoylaminoethyl)pyrrolidin-3-yl]thio-6-[(1R)-1-hydroxyethyl]-1-methylcarbapenem-3-carboxylic acid	148016-81-3	EP 528678	Beta-lactam antibiotic
dorzolamide	4H-Thieno(2,3-b)thiopyran-2-sulfonamide, 4-(ethylamino)-5,6-dihydro-6-methyl-, 7,7-dioxide (4S-trans)- [CAS]	120279-96-1	EP 296879	Antiglaucoma
D rz lamide		120279-96-1		
dorzolamide + timolol	4H-Thieno(2,3-b)thiopyran-2-sulfonamide, 4-(ethylamino)-5,6-dihydro-6-methyl-, 7,7-dioxide (4S-trans) + ethyl 2-propanol, 1-[[[1,1-dimethylamino]-3-[[4-(4-morpholinyl)-1,2,5-thiadiazol-3-yl]oxy]-, (S), (Z)-2-butenedioate (1:1) (salt) [CAS]	120279-96-1 26839-75-8 26921-17-5		Formulation, fixed-dose combinations
dosmalfate	Aluminium, (μ7-7-[(6-O-(6-deoxy-2,3,4-tri-O-sulfo-Alpha-L-mannosylpyranosyl)-2,3,4-tri-O-sulfo-8-D-glucopyranosyl)oxy)-5-hydroxy-2-(4-methoxy-3-(sulfooxy)phenyl)-4H-1-benzopyran-4-onato(7-))tetradeca-μ-hydroxyphenylcosahydroxytetradeca- [CAS]	122312-55-4		Antitumor
dosulepine	1-Propanamine, 3-dibenzo[b,e]thiepin-11(6H)-ylidene-N,N-dimethyl- [CAS]	113-53-1		Antidepressant
D tarizine		84625-59-2		
D thiepin		113-53-1		
D xacurium Chloride		106819-53-8		
Doxapram		309-29-5		
doxazosin	Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-[(2,3-dihydro-1,4-benzodioxin-2-yl)carbonyl]- [CAS]	74191-85-8	GB 2007656	Antihypertensive, adrenergic
Doxazosin		74191-85-8		

TABLE 6

Example f Indication
Surgery adjunct
Infection, urinary tract
Glaucoma
Glaucoma
Ulcer, gastric
Hypertension, general

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
doxazosin-GITS	Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-[(2,3-dihydro-1,4-benzodioxin-2-yl)carbonyl]- [CAS]	74191-85-8		Formulation, modified-release, <=24hr
Dox fazepam		40762-15-0		
Dox nitoin		3254-93-1		
D x pin		1668-19-5		
doxepin, GenDerm	1-Propanamine, 3-dibenz[b,e]oxepin-11(6H)-ylidene-N,N-dimethyl-	1668-19-5		Formulation, dermal, topical
doxercalciferol	9,10-secoergosta-5,7,10(19),22-tetraene-1,3-diol (1Alpha, 3B, 5Z, 7E, 22E) [CAS]	54573-75-0	US 5104854	Hormone
Doxercalciferol		54573-75-0		
doxifluridine	Uridine, 5'-deoxy-5-fluoro- [CAS]	3094-09-5	US 4071680	Anticancer, antimetabolite
Doxifluridine		9/5/3094		
doxofylline	1H-Purine-2,6-dione, 7-(1,3-dioxolan-2-ylmethyl)-3,7-dihydro-1,3-dimethyl- [CAS]	69975-86-6	US 4187308	Antiasthma
Doxofylline		69975-86-6		
Doxorubicin		23214-92-8		
doxorubicin citrate, TLC	5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-Alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S-cis)- [CAS]	23214-92-8	EP 191824	Formulation, optimized, liposomes
doxorubicin Extra	5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-Alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S-cis)-[CAS]	23214-92-8		Formulation, parenteral, other
Doxorubicin Hydrochloride				
Doxorubicin Hydrochloride				

TABLE 6

Exemplar Indication
Hypertension, general
Pruritus
Hyperparathyroidism
Cancer, colorectal
Asthma
Cancer, breast
Cancer, general

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
doxorubicin, Advertec	5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-Alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S)-cis- [CAS]	23214-92-8		Formulation, optimized, nanoparticles
doxorubicin, BioAlliance	5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-Alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S)-cis- [CAS]	23214-92-8		Formulation, optimized, nanoparticles
doxorubicin, FeRx doxorubicin, inhaled	5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-Alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S)-cis- [CAS]	23214-92-8 23214-92-8		Formulation, parenteral, targeted Formulation, inhalable, solution
doxorubicin, Mitsubishi	5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-Alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S)-cis- [CAS]			Formulation, optimized, liposomes
doxorubicin, NeoPharm	5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-Alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S)-cis- [CAS]	23214-92-8		Formulation, optimized, liposomes
doxorubicin, Nippon Kayaku	5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-Alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S)-cis- [CAS]			Formulation, optimized, nanoparticles

TABLE 6

Example of Indication
Cancer, brain
Cancer, liver
Cancer, liver
Cancer, lung, non-small cell
Cancer, stomach
Cancer, prostate
Cancer, general

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
doxorubicin, Pro-Pharm	5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-Alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S-cis)- [CAS]	23214-92-8		Formulation, parenteral, targeted
doxorubicin, Regulon	5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-Alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S-cis)- [CAS]	23214-92-8		Formulation, optimized, liposomes
doxorubicin, SIRTex	5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-Alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S-cis)- [CAS]	23214-92-8		Formulation, optimized, microencapsulate
doxorubicin, Stealth	5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-Alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S)-cis- [CAS]	23214-92-8	US 5213804	Formulation, optimized, liposomes
doxorubicin, Supratek	5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-Alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S-cis)- [CAS]	23214-92-8		Formulation, other
doxorubicin, Targesome	5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-Alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S-cis)- [CAS]			Formulation, optimized, liposomes

TABLE 6

Example of Indication
Cancer, general
Cancer, general
Cancer, liver
Cancer, sarcoma, Kaposi's
Cancer, oesophageal
Cancer, general

TABLE 6

API Gen ric Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Doxycycline		17086-28-1 (monohydrate); 564-25-0 (anhydrous)		
doxycycline, Arix	2-Naphthacene-carboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-[4S-(4Alpha,4aAlpha,5Alpha,5aAlpha,6Alpha,12aAlpha)]- [CAS]	564-25-0		Formulation, modified-release, immediate
doxycycline, CollaGenex	2-Naphthacene-carboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-[4S-(4Alpha,4aAlpha,5Alpha,5aAlpha,6Alpha,12aAlpha)]- [CAS]	564-25-0		Formulation, oral, other
Doxylamine	N,N-Dimethyl-2-[1-phenyl-1-(2-pyridinyl)ethoxy]ethanamine	469-21-6		
doxylamine, I2R	B-D-2',3'-didehydro-2',3'-dideoxy-5-fluorocytidine			Formulation, transmucosal, systemic
DPC-817				Antiviral, anti-HIV
DPI-3280			US 5681830	Analgesic, other
DQ-113	5-Amino-7-[(3S,4R)-(1-aminocyclopropyl)-3-fluoropyrrolidin-1-yl]-1-[(1R,2S)-2-fluoro-1-cyclopropyl]-1,4-dihydro-8-methyl-4-oxo-3-quinolinecarboxylic acid			Quinolone antibacterial
Dr f nin		1679-76-1		
Droloxif ne		82413-20-5		
Dr m triz le		2440-22-4		
Drom stanolone		58-19-5		
dronabinol, Pars	6H-Dibenzo[b,d]pyran-1-ol, 6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-, (6aR-trans)- [CAS]	1972-08-3		Antiemetic

TABLE 6

Example of Indication
Periodontitis
Periodontitis
Rhinitis, allergic, general
Infection, HIV/AIDS
Pain, general
Infection, general
Chemotherapy-induced nausea and vomiting

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
dronedarone hydrochloride	2-n-Butyl 3-[4-(3-di-n-butylamino-propoxy)benzoyl]5-methylsulfonamidobenzofuran hydrochloride			Antiarrhythmic
Dr peridol		548-73-2		
Dropr nilamin		57653-27-7		
Dropropizin		17692-31-8		
Drospirenon		67392-87-4		
Drotav rin		14009-24-6		
Drotebanol		3/2/3176		
droxycam	2H,5H-1,3-Oxazino[5,6-c][1,2]benzothiazine-2,4(3H)-dione, 5-methyl-3-(2-pyridinyl)-, 8,6-dioxide [CAS]	90101-16-9	EP 99770	Anti-inflammatory
Droxycam		90101-16-9		
droxidopa	L-Tyrosine, β ,3-dihydroxy-, threo- [CAS]	23651-95-8	EP 128684	Antiparkinsonian
Dr xid pa		23651-95-8		
DU-125530	1,2-Benzisothiazol-3(2H)-one, 2-[4-[4-(7-chloro-2,3-dihydro-1,4-benzodioxin-5-yl)-1-piperazinyl]butyl]-, 1,1-dioxide [CAS]	161611-99-0	EP 633260	Anxiolytic
Duloxetine		116539-59-4		
duloxetine hydrochloride	2-Thiophenepropanamine, N-methyl-Gamma-(1-naphthalenyloxy)-, hydrochloride, (S)- [CAS]	136434-34-9	US 5362886	Antidepressant
duramycin, MoliChem			WO 9428726	Formulation, inhalable, solution
Durapatite		1306-06-5		
dutasteride	4-Azaandrost-1-ene-17-carboxamide, N-(2,5-bis(trifluoromethyl)phenyl)-3-oxo-, (5 α), 17 β - [CAS]	164656-23-9	US 5565467	Prostate disorders
Dutasteride		164656-23-9		
DW-1141	N,N-dilisopropyl-4-[4-(3-aminobenzodisoxazol-6-yloxy)butoxy]-3-methoxybenzamide			Osteoporosis treatment

TABLE 6

Example of Indication
Arrhythmia, general
Inflammation, general
Parkinson's disease
Anxiety, general
Depression, general
Cystic fibrosis
Benign prostatic hyperplasia
Osteoporosis

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
DW-286a	(R)-(-)-7-((4-aminomethyl-4-methyl-3-(Z)-methoxyimino)pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro[1,8]naphthyridine-3-carboxylic acid			Quinolone antibacterial
DW-471			US 5922871	Antiviral, other
DX-9065a	2-Naphthalenepropanoic acid, 7-(aminominoethyl)-Alpha-[4-[[1-(1-iminoethyl)-3-pyrrolidinyl]oxy]phenyl]-, monohydrochloride, pentahydrate, [S-(R*, R*)]- [CAS]	155204-81-2		Antithrombotic
DY-9760e	1H-Indazole, 3-[2-[4-(3-chloro-2-methylphenyl)-1-piperazinyl]ethyl]-1-(1H-imidazol-4-ylmethyl)-5,6-dimethoxy- [CAS]	160522-00-9	US 5681954	Neuroprotective
Dycl nline		586-60-7		
Dydr gest r ne		152-62-5		
Dymanthine		124-28-7		
Dyphylline		479-18-5		
E-1010	1-Azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, 6-[(1R)-1-hydroxyethyl]-3-[[[(3S,5S)-5-[(R)-hydroxy(3R)-3-pyrrolidinylmethyl]-3-pyrrolidinyl]thio]-4-methyl-7-oxo-, monohydrochloride, (4R,5S,6S)- [CAS]	186319-97-1		Beta-lactam antibiotic
E-2101	N-Ethyl-(1-[1-(2-fluorophenethyl)]piperidin-4-yl)-1H-indol-6-yl)acetamide			Muscle relaxant
E2F antagonists, TopoTarget			WO 9608943	Anticancer, other
E-3620	Benzamide, 4-amino-5-chloro-N-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-2-[(1-methyl-2-butyloxy)]-, monohydrochloride, [3(S)-endo]- [CAS]	151213-86-4	EP 554794	Antacid/Antiflatulent

TABLE 6

Example of Indication
Infection, general
Infection, hepatitis-B virus
Thrombosis, general
Ischaemia, cerebral
Infection, general
Muscle spasm, general
Cancer, general
Dyspepsia

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
E-5564	Alpha-D-Glucopyranose, 3-O-decyl-2-deoxy-6-O-(2-deoxy-3-O-((3R)-3-methoxydecyl)-6-O-methyl-2-(((11Z)-1-oxo-11-octadecenyl)amino)-4-O-phosphono-8-D-glucopyranosyl)-2-((1,3-dioxotetradecyl)amino)- 1-(dihydrogen phosphate), tetrasodium salt [CAS]	185954-98-7	EP 536969	Septic shock treatment
E-5842	Pyridine, 4-(4-fluorophenyl)-1,2,3,6-tetrahydro-1-(4-(1H-1,2,4-triazol-1-yl)butyl)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) [CAS]	220120-14-9		Neuroleptic
E-6259	1-(4-Aminosulfonylphenyl)-5-(2,4-difluorophenyl)-4,5-dihydro-3-trifluoromethyl-1H-pyrazole			Antiarthritic, other
EAA-90	[2-(8,9-Dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)-ethyl]phosphonic acid			Analgesic, other
e-Acetamidocaprolic Acid		57-08-9		
e-Aminocaprolic Acid		60-32-2		
ebastine	1-Butanone, 1-(4-(1,1-dimethylethyl)phenyl)-4-(4-(diphenylmethoxy)-1-piperidinyl)- [CAS]	90728-43-4	EP 134124	Antiallergic, non-asthma
Ebastin		90729-43-4		
eberconazole	1H-Imidazole, 1-(2,4-dichloro-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)- [CAS]	128326-82-9 130104-32-4	ES 2012297	Antifungal
ebrotidine	Benzenesulfonamide, N-[[2-[[2-((aminiminomethyl)amino)-4-thiazolyl]methyl]thio]ethyl]amino[methylene]-4-bromo- [CAS]	100981-43-9	EP 159012	Antilucer
ebiselen	1,2-Benziselenazol-3(2H)-one, 2-phenyl- [CAS]	60940-34-3	EP 44971	Neuroprotective
Eburnam nin		474-00-0		
Ecabaprid		104775-36-2		

TABLE 6

Example of Indication
Sepsis
Schizophrenia
Unspecified
Pain, neuropathic
Rhinitis, allergic, seasonal
Infection, dermatological
Ulcer, duodenal
Haemorrhage, subarachnoid

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
ecabet	1-Phenanthrenecarboxylic acid, 1,2,3,4,4a,9,10,10a-octahydro-1,4a-dimethyl-7-(1-methylethyl)-6-sulfo-, [1R-(1Alpha,4aB,10aAlpha)]- [CAS]	33159-27-2 86408-72-2	DE 3239172	Anticancer
ecadotil	Glycine, N-[2-[(acetylthio)methyl]-1-oxo-3-phenylpropyl]-, phenylmethyl ester, (S)- [CAS]	112573-73-6	EP 318377	Antihypertensive, other
Ecgnidine		484-93-5		
Ecgnin		481-37-8		
Ech thiophat iodide		513-10-0		
Econazole		27220-47-9		
ecopipam	5H-Benzodiazepine[2,1-b]azepin-12-ol, 11-chloro-5,6a,7,8,9,13b-hexahydro-7-methyl-, (6aS-trans)- [CAS]	112108-01-7	EP 230270	Anorectic/Antiobesity
ecraprost	Prosta-8,13-dien-1-ol, 11,15-dihydroxy-9-(1-oxobutoxy)-, butyl ester, (11Alpha,13E,15S)- [CAS]	136892-64-3	EP 423697	Vasodilator, peripheral
Ectylurea		95-04-5		
ED-71	9,10-Secocholesta-5,7,10(19)-triene-1,3,25-triol, 2-(3-hydroxypropoxy)-, (1Alpha,2B,3B,5Z,7E)- [CAS]	104121-92-8	EP 184206	Osteoporosis treatment
edaravone	3H-Pyrazol-3-one, 2,4-dihydro-5-methyl-2-phenyl- [CAS]	89-25-8	JP 62108814	Neuroprotective
Edatrexate		80576-83-6		
Edetat Calcium		62-33-9		
Dis dium				
Ed tate Disodium		139-33-3		
Edetat Sodium		64-02-8		
Edetate Tris dium		150-38-9		
edonantan	Butanamide, N-[2'-[4,5-dimethyl-3-isoxazoyl]amino]sulfonyl]-4-(2-oxazoyl)[1,1'-biphenyl]-2-yl[methyl]-N,3,3-trimethyl-, monohydrate			Cardio stimulant
		210891-04-6		

TABLE 6

Exempl of indication
Ulcer, gastric
Hypertension, general
Obesity
Peripheral vascular disease
Osteoporosis
Infarction, cerebral
Heart failure

TABLE 6

API Gen. ric Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
edotreotide	[N-[2-(4,7-Bis((carboxy-kappaO)methyl)-10-(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl-kappaN4,kappaN10)acetyl]-D-phenylalanyl-L-cysteiny-L-tyrosyl-D-tryptophyl-L-lysyl-L-threonyl-L-cysteiny-L-threoninol cyclic (2-7)-disulfidato(3-yl)]trium	204318-14-9	US 6183721	Anticancer, hormonal
edoxudine	Uridine, 2'-deoxy-5-ethyl- [CAS]	15176-29-1	GB 1170565	Antiviral, other
Edr c I mab		156586-89-9		
Edr ph nium		116-38-1		
Efalith	Butanedioic acid, lithium salt [CAS]	16090-09-8		Antipruritic/inflam, allergic
efaproxiral sodium	Propanoic acid, 2-[4-{2-[(3,5-dimethylphenyl)amino]-2-oxoethyl}phenoxy]-2-methyl- [CAS]	131179-95-8	US 5705521	Radio/chemosensitizer
efavirenz	2H-3,1-Benzoxazin-2-one, 6-chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-, (S)- [CAS]	154598-52-4	WO 9403440	Antiviral, anti-HIV
eflaticizine	[2-[4-[Bis(p-fluorophenyl)methyl]-1-piperazinyl]ethoxy]acetic acid	150758-35-7	GB 2311940	Antiallergic, non-asthma
Eflornithin		67037-37-0		
eflornithine	DL-Ornithine, 2-(difluoromethyl)- [CAS]	70052-12-9	US 4413141	Protozoacide, dermal, topical
Efl xat		119-41-5		
eflucimibe	Benzeneacetamide, Alpha-(dodecylthio)-N-(4-hydroxy-2,3,5-trimethylphenyl)- (S)- [CAS]	202340-45-2		Hypolipaeic/Antiatherosclerosis
efonidipine	3-pyridinecarboxylic acid, 5-(5,5-dimethyl-1,3,2-dioxaphosphorinan-2-yl)-1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 2-(phenyl(phenylmethyl)amino)ethyl ester, P-oxide [CAS]	111011-53-1 111011-63-3 111011-76-8	EP 230944	Antihypertensive, other
EGIS-7229	5-Chloro-4-[3-[N-[2-(3,4-dimethoxyphenyl)ethyl]-N-methylamino]propylamino]-3(2H)-pyridazinone fumarate [CAS].	150800-12-7 190339-92-7	DE 4243381	Antiarrhythmic

TABLE 6

Example 1 Indication
Cancer, lung, small cell
Infection, herpes virus, general
Eczema, seborrhoic
Cancer, brain
Infection, HIV/AIDS
Allergy, general
Infection, trypanosomiasis, African, Hirsutism
Hyperlipidaemia, general
Hypertension, general
Arrhythmia, general

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
eglumegad	Bicyclo[3.1.0]hexane-2,6-dicarboxylic acid, 2-amino-, (1S,2S,5R,6S)- [CAS]	176199-48-7 209216-09-1		Anxiolytic
egualen	1-Azulenecarboxylic acid, 3-ethyl-7-(1-methylethyl)-	97683-31-3 99287-30-6	EP 147915	Anticancer
Eicosapentaenoic Acid		10417-94-4		
elarfiban	3-Pyridinepropanoic acid, B-(((3R)-1-(1-oxo-3-(4-piperidinyl)propyl)-3-piperidinyl)carbonylamino)-, (8S)- [CAS]	198958-88-2	WO 9741102	Antithrombotic
Elcatenin		60731-46-6		
Elidolisin		69-25-0		
elotriptan	1H-Indole, 3-((1-methyl-2-pyrrolidinyl)methyl)-5-(2-(phenylsulfonyl)ethyl)- (R)- [CAS]	143322-58-1	US 5607851	Antimigraine
Elgodipin		119413-55-7		
Ellagic Acid		476-66-4		
Elipitinium		58337-35-2		
Eltoprazin		98224-03-4		
elvucitabine	B-L-2,3'-Didehydro-2',3'-dideoxy-5-fluorocytidine	161765-84-2		Antiviral, other
elzasonan	(2Z)-4-(3,4-dichlorophenyl)-2-[2-(4-methylpiperazin-1-yl)benzylidene]thiomorpholin-3-one monohydrochloride- [CAS]	220322-05-4 361343-20-6		Antidepressant
Emb lin		550-24-3		
Embramine		3565-72-8		
emedastine	1H-Benzimidazole, 1-(2-ethoxyethyl)-2-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)-, (E)-2-butenedioate (1:2) [CAS]	87233-61-2 87233-62-3	EP 79545	Antiallergic; non-asthma
Enepronium Bromide		3614-30-0		
Emtine		483-18-1		
Emit fur		110690-43-2		
EMM-210525	17Alpha-Acetoxy-6Alpha-methyl-19-nor-18,28-dihydrocyclopropa[1,2]pregn-4-ene-3,20-dione+Estra-1,3,5(10)-triene-3,17-diol(17B)			Formulation, fixed-dose combinations

TABLE 6

Exempl f Indication
Anxiety, general
Ulcer, gastric
Thrombosis, general
Migraine
Infection, hepatitis-B virus
Depression, general
Rhinitis, allergic, general
Hormone replacement therapy

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Emodin		518-82-1		
emorifazone	3-(2H)-Pyridazinone, 4-ethoxy-2-methyl-5-(4-morpholinyl)- [CAS]	38957-41-4	JP 7224030	Anti-inflammatory
EMR-62203			WO 9806722	Male sexual dysfunction
emtricitabine	2-(1H)-Pyrimidinone, 4-amino-5-fluoro-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-, (2R,4S)- [CAS]			
Emylcamat		143491-57-0	WO 9214743	Antiviral, anti-HIV
		78-28-4		
enalapril	L-Proline, 1-[N-(1-(ethoxycarbonyl)-3-phenylpropyl)-L-alanyl]-, (S)-, (Z)-2-butenedioate [CAS]	76095-16-4	US 4374829	Antihypertensive, renin system
Enalaprilat		76420-72-9		
Enallypropymal		1861-21-8		
Encainide		66778-36-7		
Enciprazine		68576-86-3		
Endralazin		39715-02-1		
enfenamic acid	Benzoic acid, 2-[(2-phenylethyl)amino]- [CAS]	23049-93-6	IN 103066	Anti-inflammatory
enflurane	Ethane, 2-chloro-1-(difluoromethoxy)-1,1,2-trifluoro- [CAS]	13838-16-9	US 3469011	Anaesthetic, inhalation
Enilic nazole		35554-44-0		
Eniluracil		59989-18-3		
ENMD-0995	S-3-amino-phthalidoglutarimide		US 5712291	Anticancer, other
Enocitabine		55726-47-1		
Enol-3-IPA	1H-Indole-3-propanoic acid, Alpha-oxo- [CAS]	392-12-1	EP 106813	Hypnotic/Sedative
enoxacin	1,8-Naphthyridine-3-carboxylic acid, 1-ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)- [CAS]	74011-58-8	US 4359578	Quinolone antibacterial
enoxaparin sodium	Heparin, sodium salt- [CAS]	9005-49-6		
enoximone	2H-Imidazol-2-one, 1,3-dihydro-4-methyl-5-(4-(methylthio)benzoyl)- [CAS]	9041-08-1	EP 40144	Antithrombotic
Enox 1 ne		77671-31-9	EP 59948	Cardio stimulant
		471-53-4		

TABLE 6

Exempl f Indication
Impotence
Infection, HIV/AIDS
Anaesthesia
Cancer, myeloma
Insomnia
Infection, general
Thrombosis, venous
Heart failure

TABLE 6

API Gen. Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
enprostil	4,5-Heptadienoic acid, 7-[3-hydroxy-2-(3-hydroxy-4-phenoxy-1-butenyl)-5-oxocyclopentyl]-, methyl ester, [1Alpha,2B(1E,3R'),3Alpha]- [CAS]	73121-56-9	GB 2025431	Prostaglandin
enrasentan	1H-Indene-2-carboxylic acid, 1-(1,3-benzodioxol-5-yl)-2,3-dihydro-3-(2-(2-hydroxyethoxy)-4-methoxyphenyl)-5-propoxy-, (1S-(1'Alpha,2B,3Alpha))- [CAS]	167256-08-8	US 5817693	Antihypertensive, other
entacapone	2-Propenamide, 2-cyano-3-(4,5-dihydroxy-3-nitrophenyl)-N,N-diethyl- [CAS]	130929-57-6	EP 426468	Antiparkinsonian
entecavir	6H-Purin-6-one, 2-amino-1,9-dihydro-9-((1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl)- [CAS]	142217-69-4	EP 481754	Antiviral, other
Enviomycin	3-Thiazolidineacetic acid, 5-(2-methyl-3-phenyl-2-propenyldene)-4-oxo-2-thioxo-, (E,E)- [CAS]	33103-22-9		
epalrestat	L-lysine-cis-5,8,11,14,17-eicosapentanoate with L-lysine-cis-4,7,10,13,16,19-doahexanoate	82159-09-9	EP 47109	Symptomatic antidiabetic
Epavir	L-ascorbic acid 2-[3,4-dihydro-2,5,7,8-tetramethyl-2-(4,8,12-trimethyltridecyl)-2H-1-benzopyran-6-yl]-hydrogen phosphate/potassium- [CAS]	127061-56-7	EP 127471	Neuroprotective
eperisone	1-Propanone, 1-(4-ethylphenyl)-2-methyl-3-(1-piperidinyl)- [CAS]	64840-90-0	US 3995047	Muscle relaxant
epervudine, Biogal	Uridine, 2'-deoxy-5-(1-methylethyl)- [CAS]	60136-25-6	DE 2918260	Antiviral, other
Ephedrin		299-42-3		
Epicillin		26774-90-3		
Epimestrol		7004-98-0		
ephastine, oral, BI	1H-Dibenz[c,f]imidazo[1,5-a]azepin-3-amine, 9,13b-dihydro- [CAS]	80012-43-7	DE 3008944	Antiasthma
epinephrine	(R)-4-[1-hydroxy-2-(methylamino)-ethyl]-1,2-benzenediol	51-43-4		Formulation, inhalable, dry powder

TABLE 6

Example 1 Indication
Ulcer, duodenal
Hypertension, pulmonary
Parkinson's disease
Infection, hepatitis-B virus
Neuropathy, diabetic
Infection, herpes simplex virus
Infarction, cerebral
Spastic paralysis
Infection, herpes simplex virus
Asthma
Anaphylaxis

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Epirizole		18694-40-1		
eprubicin	5,12-Naphthacenedione, 10-((3-amino-2,3,6-trideoxy-Alpha-L-arabino-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S-cis)- [CAS]	56390-09-1 56420-45-2	GB 1457632	Anticancer, antibiotic
Epitostanol		2363-58-8		
epiprenone	Pregn-4-ene-7,21-dicarboxylic acid, 9,11-epoxy-17-hydroxy-3-oxo-Gamma-lactone, methyl ester (7Alpha,11Alpha,17Alpha)-[CAS]	107724-20-9	EP 122232	Antihypertensive, diuretic
epilivanserlin	1-Propanone, 1-(2-fluorophenyl)-3-(4-hydroxyphenyl)-, O-(2-(dimethylamino)ethyl)oxime, (Z)-, (E)-2-butenedioate (2:1) (salt) [CAS]	130580-02-8	EP 373998	Anxiolytic
epoprostenol	Prosta-5,13-dien-1-ol acid, 6,9-epoxy-11,15-dihydroxy-, (5Z,9Alpha,11Alpha,13E,15S)-[CAS]	35121-78-9 61849-14-7	DE 2720999	Prostaglandin
Epostan		80471-63-2		
Eprazinone		10402-90-1		
Epristerid		119169-78-7		
eprosartan	3-[2-Butyl-1-(4-carboxybenzyl)-1H-imidazol-5-yl]-2-(2-thienylmethyl)-2-(E)-propenoic acid	133040-01-4 32665-36-4	EP 403159	Antihypertensive, renin system
Eprozin I				
eptapirone	4-methyl-2-[4-(4-(pyrimidin-2-yl)-piperazino)-butyl]-2H,4H-1,2,4-triazin-3,5-dione	179756-85-5		Antidepressant
eptaplatin	Platinum, [(4R,5R)-2-(1-methylethyl)-1,3-dioxolane-4,5-dimethanamine-kappaN4,kappaN5][propanedioato(2-)-kappaO1,kappaO3]-, (SP-4-2)- [CAS]	146865-77-2	WO 9216539	Anticancer, alkylating
Eptastigmin		101246-68-8		
eptazocine	1,6-Methano-1H-4-benzazonin-10-ol, 2,3,4,5,6,7-hexahydro-1,4-dimethyl-, (1S)-[CAS]	72522-13-5	US 4082744	Analgesic, other
Eptifibatide		188627-80-7		

TABLE 6

Example f Indication
Hypertension, general
Schizophrenia
Hypertension, pulmonary
Hypertension, general
Depression, general
Cancer, lung, small cell

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Equilenin		517-09-9		
Equilin		474-86-2		
ERA-923	ERA 923 [CAS]	352233-89-7	EP 802183	Female contraceptive
erdosteine	Acetic acid, [(2-oxo-2-[(tetrahydro-2-oxo-3-thienyl)amino]ethylthio)- [CAS]	84611-23-4	EP 61386	Respiratory
Erg c mln		564-36-3		
Ergocorninine		564-37-4		
Ergol id Mesylates		8067-24-1		
Ergonovine		60-79-7		
Ergost rol		57-87-4		
ergotamine tartrate, TEMPO	(5'Alpha)-12'-Hydroxy-2'methyl-(phenyl)methylergotaman-3',6', 18-trione	113-15-5		Formulation, inhalable, systemic
Eritadenine		23918-98-1		
erlotinib	4-Quinazolinamine, N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-, monohydrochloride [CAS]	183319-69-9	WO 9830347	Anticancer, other
Ertapen m		153832-46-3		
ertapenem sodium	1-Azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, 3-[[[(3S,5S)-5-[[[(3-carboxyphenyl)amino]carbonyl]-3-pyrrolidinylthio]-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-, monosodium salt, (4R,5S,6S)- [CAS]	153773-82-1	WO 9315078	Beta-lactam antibiotic
Erythrityl Tetranitrate		7297-25-8		
Erythrocentaurin		50276-98-7		
erythromycin acistrate	Erythromycin, 2'-acetate, octadecanoate (salt) [CAS]	96128-89-1	US 4589326	Macrolide antibiotic
Erythr mycin Acistrate		96128-89-1		
Erythr mycin Estolate		3521-62-8		
Erythromycin		23067-13-2		
Glucosept nat				
Erythromycin		3847-29-8		
Lact bl nate				
Erythromycin		134-36-1		
Pr pionat				

TABLE 6

Example of Indication
Contraceptive, female
Respiratory disease, general
Migraine
Cancer, lung, non-small cell
Infection, GI tract
Infection, general

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Erythromycin Stearate		643-22-1		
erythromycin stearate	Erythromycin, 2'-propanoate, compd. with N-acetyl-L-cysteine (1:1) [CAS]	84252-03-9	EP 57489	Macrolide antibiotic
erythromycin	Erythromycin [CAS]	114-07-8		Formulation, dermal, topical
Erythr phlein		36150-73-9		
Esapraz I		64204-55-3		
escitalopram oxalate	5-Isobenzofurancarboxonitrile, 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-, (S)- [CAS]	128196-01-0	EP 347066	Antidepressant
Esculin		531-75-9		
Eseridin		25573-43-7		
esmolol	Benzenepropanoic acid, 4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]-, methyl ester, (+/-)- [CAS]	81147-92-4	US 4387103	Antihypertensive, adrenergic
esomeprazole magnesium	Magnesium, bis (5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl)-1H-benzimidazolato	161973-10-0	US 5877192	Antispasmodic
estazolam	4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-6-phenyl- [CAS]	29975-16-4	US 3987052	Hypnotic/Sedative
estradiol	Androst-4-en-3-one, 17-hydroxy-, (17β)- [CAS]	58-22-0	US 5460820	Formulation, transdermal, patch
estradiol	Estra-1,3,5(10)-triene-3,17-diol (17β)- [CAS]	50-28-2	EP 430491	Formulation, transdermal, systemic
Estramustine		2998-57-4		
estramustine phosphate	Estra-1,3,5(10)-triene-3,17-diol (17β)-, 3-[bis(2-chloroethyl)carbamate] 17-(dihydrogen phosphate) [CAS]	2998-57-4 4891-15-0 52205-73-9		
Estriol		50-27-1		Anticancer, alkylating
estrogen			WO 9924041	Menopausal disorders
Estron		53-16-7		
eszopiclone	1-Piperazinecarboxylic acid, 4-methyl- 6-(5-chloro-2-pyridinyl)-6,7-dihydro-7-oxo-5H-pyrrolo(3,4-b)pyrazin-5-yl ester (S)- [CAS]	138729-47-2	US 5786357	Hypnotic/Sedative

TABLE 6

Example f indication
Infection, respiratory tract, lower
Acne
Depression, general
Tachycardia, supraventricular
Gastro-oesophageal reflux
Sexual dysfunction, female
Menopausal symptoms, general
Cancer, prostate
Menopausal symptoms, general
Insomnia

TABLE 6

API Gen ric Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Etafedrine		7681-79-0		
Etaf none		90-54-0		
Etamiphyllin		314-35-2		
Etanerc pt		185243-69-0		
Etanidaz le		22668-01-5		
Etaqual ne		7432-25-9		
Eterobarb		27511-99-5		
Ethacridine		442-16-0		
Ethacrynic Acid		58-54-8		
Ethadi n		520-77-4		
Ethambutol		74-55-5		
Ethamivan		304-84-7		
Ethamsylate		2624-44-4		
Ethanolamin		141-43-5		
Ethav rine		486-47-5		
Ethchl ryyn l		113-18-8		
Ethenzamide		938-73-8		
Ethiazide		1824-58-4		
Ethinamat		126-52-3		
Ethinyl Estradiol		57-63-6		
ethinyl estradiol sulfonate	19-Norpregna-1,3,5(10)-trien-20-yne-3,17-diol, 3-(2-propanesulfonate), (17Alpha)-[CAS]	28913-23-7	DE 1949095	Formulation, modified-release, >24hr
Ethionamid		536-33-4		
Ethist rone		434-03-7		
Eth heptazine		77-15-6		
Ethopropazin		522-00-9		
Ethosuximide		77-67-8		
Ethotoin		86-35-1		
Eth xz lamid		452-35-7		
Ethyb nztropine		524-83-4		
Ethyl Alcohol		64-17-5		
Ethyl Biscoumacetate		548-00-5		
Ethyl Chloride		75-00-3		
Ethyl Dibunat		5560-69-0		

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Ethyl Ether		60-29-7		
ethyl icosapentate	5,8,11,14,17-Eicosapentaenoic acid, ethyl ester, (all-Z)- [CAS]	86227-47-6	JP 61043143	Antithrombotic
ethyl loflazepate	1H-1,4-Benzodiazepine-3-carboxylic acid, 7-chloro-5-(2-fluorophenyl)-2,3-dihydro-2-oxo-, ethyl ester [CAS]	29177-84-2	US 3657223	Anxiolytic
Ethyl loflazepate		29177-84-2		
Ethylamin		75-04-7		
Ethylene		74-85-1		
Ethyl str nol		965-90-2		
Ethyliden Dic umarol		1821-16-5		
Ethylmethythiambutene		441-61-2		
Ethylm rphin		76-58-4		
Ethylm r pin phrine		536-24-3		
Ethyn diol		1231-93-2		
ethynylcytidine	Uridine, 3'-C-ethynyl- [CAS]	180300-49-6	WO 9618636	Anticancer, antimetabolite
Etid caln		36637-18-0		
etidronate disodium	Phosphonic acid, (1-hydroxyethylidene)bis-, disodium salt- [CAS]	2809-21-4 7414-83-7	US 4137309	Osteoporosis treatment
Etidr nic Acid		2809-21-4		
Etifelmin		341-00-4		
etifoxine	4H-3,1-Benzoxazin-2-amine, 6-chloro-N-ethyl-4-methyl-4-phenyl- [CAS]	21715-48-8	US 3725404	Anxiolytic
Ettil frin		709-55-7		
etilvodopa	L-Tyrosine, 3-hydroxy-, ethyl ester [CAS]	37178-37-3	US 5354885	Antiparkinsonian
etiprednol dicloacetate	androsta-1,4-diene-17-carboxylic acid, 17-[[dichloroacetyl]oxy]-11-hydroxy-3-oxo-, ethyl ester, (11 β ,17 α)	199331-40-3		GI inflammatory/bowel disorders
Etiroxate		17365-01-4		
Etizolam		40054-69-1		
etodolac	Pyranol[3,4-b]indole-1-acetic acid, 1,8-diethyl-1,3,4,9-tetrahydro- [CAS]	41340-25-4	US 3939178	Antiarthritic, other
Et dr xizine		17692-34-1		

TABLE 6

Example of Indication
Peripheral vascular disease
Anxiety, general
Cancer, general
Osteoporosis
Parkinson's disease
Crohn's disease
Arthritis, osteo

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
etofenamate	Benzoic acid, 2-[(3-(trifluoromethyl)phenyl)amino]-, 2-(2-hydroxyethoxy)ethyl ester [CAS]	30544-47-9	GB 1285400	Anti-inflammatory, topical
etofibrate	3-Pyridinecarboxylic acid, 2-[2-(4-chlorophenoxy)-2-methyl-1-oxopropoxy]ethyl ester [CAS]	31637-97-5	US 3723446	Hypolipaeic/Antiatherosclerosis
Etofyllin		519-37-9		
etofylline dlofibrate	Propanoic acid, 2-(4-chlorophenoxy)-2-methyl-, 2-(1,2,3,6-tetrahydro-1,3-dimethyl-2,6-dioxo-7H-purin-7-yl)ethyl ester [CAS]	54504-70-0	DE 2308826	Hypolipaeic/Antiatherosclerosis
Et fyllin Nic tinate		13425-39-3		
Etoglucid		1954-28-5		
Etomidate		33125-97-2		
Etomidololn		21590-92-1		
Etonitazene		911-65-9		
etonogestrel	18,19-Dinopregn-4-en-20-yn-3-one, 13-ethyl-17-hydroxy-11-methylene, (17Alpha)-[CAS]	54048-10-1		Formulation, implant
Etoperid n		52942-31-1		
etoposide	Furo[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-6(5aH)-one, 9-[(4,6-O-ethylidene-8-D-glucopyranosyl)oxy]-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)-, [5R-[5Alpha,5aB,8aAlpha,9B(R')]]- [CAS]	33419-42-0	GB 1205966	Anticancer, other
etoposide phosphate	Furo[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-6(5aH)-one, 5-[3,5-dimethoxy-4-(phosphonoxy)phenyl]-9-[(4,6-O-ethylidene-8-D-glucopyranosyl)oxy]-5,8,8a,9-tetrahydro-, [5R-[5Alpha,5aB,8aAlpha,9B(R')]]- [CAS]	117091-64-2	EP 302473	Anticancer, other
etoricoxib	2,3-Bipyridine, 5-chloro-6-methyl-3-(4-methylsulfonyl)phenyl [CAS]	202409-33-4	WO 9803484	Antiarthritic, other
Et xadrol		28189-85-7		
Et z lin		73-09-6		
etretnate	2,4,6,8-Nonatetraenoic acid, 9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-, ethyl ester, (all-E)- [CAS]	54350-48-0	US 4215215	Antipsoriasis

TABLE 6

Examp! f Indication
Inflammation, general
Contraceptive, female
Cancer, testicular
Cancer, testicular
Arthritis, osteo

TABLE 6

API Gen ric Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Etryptamine		2235-90-7		
Etymemazin		523-54-6		
Eucatropine		100-91-4		
Eugen I		97-53-0		
EUK-134	Manganese, chloro[[2,2'-(1,2-ethanediybis((nitro-kappaN)methylidene))bis(6-methoxyphenolato-kappaO)]], (SP-5-13)-[CAS]	81065-76-1	US 6046188	Cardiovascular
EUK-189			US 6046188	Radio/chemoprotective
Evan's Blu		314-13-6		
everolimus	Rapamycin, 42-O-(2-hydroxyethyl)- [CAS]	159351-69-6	WO 9409010	Immunosuppressant
exalamide	Benzamide, 2-(hexyloxy)- [CAS]	53370-90-4	GB 726786	Antifungal
Exalamide		53370-90-4		
Exametazime		105613-48-7		
exatecan mesylate	10H,13H-Benzof[de]pyrano[3',4':6,7]indolizino[1,2-b]quinoline-10,13-dione, 1-amino-9-ethyl-5-fluoro-1,2,3,9,12,15-hexahydro-9-hydroxy-4-methyl-, (1S,9S)-, monomethanesulfonate (salt) [CAS]	171335-80-1		Anticancer, other
exemestane	Androsta-1,4-diene-3,17-dione, 6-methylene- [CAS]	107868-30-4	DE 3622841	Anticancer, hormonal
Exifone		52479-85-3		
exisulind	1H-Indene-3-acetic acid 5-fluoro-2-methyl-1-((4-(methylsulfonyl)phenyl)methylene)-, (Z)- [CAS]	59973-80-7		Anticancer, other
Ex surf®		99732-49-7		
ezetimibe	2-Azetidinone, 1-(4-fluorophenyl)-3-((3S)-3-(4-fluorophenyl)-3-hydroxypropyl)-4-(4-hydroxyphenyl)-, (3R,4S)- [CAS]	163222-33-1	US 5846966	Hypolipemic/Antiatherosclerosis
Ez timibe		163222-33-1		
Fact r IX		9001-28-9		
Factor VIII		9001-27-8		

TABLE 6

Example f Indication
Unspecified
Chemotherapy-induced injury, general
Transplant rejection, general
Infection, fungal, general
Cancer, pancreatic
Cancer, breast
Polyp
Hypercholesterolaemia

TABLE 6

API Gen eric Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Fact r XIII		9013-56-3		
fadolmidine	1H-Inden-5-ol, 2,3-dihydro-3-(1H-imidazol-4-ylmethyl)-, monohydrochloride [CAS]	188353-32-0	WO 9712874	Analgescic, other
Fadr zol		102676-47-1		
falecalcitriol	9,10-Secocholesta-5,7,10(19)-triene-1,3,25-triol, 26,26,27,27-hexafluoro-, (1Alpha,38,52,7E)- [CAS]	83805-11-2	JP 03099022	Osteoporosis treatment
famciclovir	1,3-Propanediol, 2-[2-(2-amino-9H-purin-9-yl)ethyl], diacetate (ester)- [CAS]	104227-87-4	JP 61083388	Antiviral, other
famotidine	Propanimidamide, 3-[[[2-[(aminiminomethyl)amino]-4-thiazolyl]methylthio]-N-(aminosulfonyl)- [CAS]			
fampridine	4-pyridinamine	76824-35-6	US 4283408	Antitumor
fandofloxacin hydrochloride	3-Quinolonecarboxylic acid, 6-fluoro-1-(5-fluoro-2-pyridinyl)-1,4-dihydro-7-(4-methyl-1-piperazinyl)-4-oxo, monohydrochloride [CAS]	504-24-5		Neuroprotective
Fant far ne		164150-85-0 164150-99-6 114432-13-2	US 5496947	Quinolone antibacterial
faropenem daloxate	(5R,6S)-6-[1(R)-Hydroxyethyl]-2-[2(R)-tetrahydrofuryl]-2-penam-3-carboxylic acid-5-methyl-2-oxo-1,3-dioxol-4-ylmethyl ester			Beta-lactam antibiotic
faropenem sodium	4-Thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, 6-(1-hydroxyethyl)-7-oxo-3-(tetrahydro-2-furanyl)-, monosodium salt, [5R-[3(R*),5Alpha,6Alpha(R*)]]-[CAS]	122547-49-3	EP 410727	Beta-lactam antibiotic
fascidolril	L-Alanine, N-[(2S)-3-(acetylthio)-2-(1,3-benzodioxol-5-ylmethyl)-1-oxopropyl]-, phenylmethyl ester [CAS]	135038-57-2	EP 419327	Antihypertensive, renin system
fascidil	1H-1,4-Diazepine, hexahydro-1-(5-isoquinolinesulfonyl)- [CAS]	103745-39-7 105628-07-7	EP 187371	Neuroprotective
Fazadinium Bromide		49564-56-9		
febarbamate	2,4,6-(1H,3H,5H)-Pyrimidinetrione, 1-[2-[(aminocarbonyloxy)-3-butoxypropyl]-5-ethyl-5-phenyl]- [CAS]			
Febuprol		13246-02-1 3102-00-9	US 3075983	Psychostimulant

TABLE 6

Example of Indication
Pain, general
Hyperparathyroidism
Infection, gynaecological
Ulcer, duodenal
Spinal cord injury
Infection, urinary tract
Infection, general
Infection, ocular
Hypertension, general
Vasospasm, general

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
febuxostat	5-Thiazolecarboxylic acid, 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methyl- [CAS]	144060-53-7	WO 9209279	Antigout
Fedotozin	1,3-Propanediol, 2-phenyl-, dicarbamate [CAS]	123618-00-8		
felbamate	[1,1'-Biphenyl]-4-acetic acid [CAS]	25451-15-4	US 4868327	Antiepileptic
felbinac	3,5-Pyridinedicarboxylic acid, 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-, ethyl methyl ester [CAS]	5728-52-9	EP 127840	Anti-inflammatory, topical
felodipine		72509-76-3	US 4264611	Antihypertensive, other
Felypr ssin		56-59-7		
Femoxetin		59859-58-4		
Fenb nicllin		1926-48-3		
fenbuten	[1,1'-Biphenyl]-4-butanolic acid, Gamma-oxo- [CAS]	36330-85-5	US 3784701	Anti-inflammatory
F nbutrazate		4378-36-3		
Fencamfamine		1209-98-9		
Fencamin		28947-50-4		
Fenclozic Acid		17969-20-9		
Fendiline		13042-18-7		
Fend sal		53597-27-6		
F nethyliline		3736081		
Fenfluramin		458-24-2		
Fenipent l		583-03-9		
fenofibrate, Pan Medica	Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester [CAS]	26129-32-8		Formulation, modified-release, <=24hr
fenoldopam	1H-3-Benzazepine-7,8-diol, 6-chloro-2,3,4,5-tetrahydro-1-(4-hydroxyphenyl)- [CAS]	67227-56-9		
Fen pr f n		67227-57-0	EP 22330	Antihypertensive, other
F noter l		31879-05-7		
		13392-18-2		
fenoverine	10H-Phenothiazine, 10-[[4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl]acetyl]-[CAS]	37561-27-6	FR 2092639	Antispasmodic
Fen xaz lin		4846-91-7		
Fenoxedil		54063-40-0		

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Fenozolon		15302-16-6		
Fenpentadiol		15687-18-0		
F npiprane		3540-95-2		
Fenpiverinium Bromide		125-60-0		
F npr p rex		15686-61-0		
F nquizone		20287-37-0		
fenretinide	Retinamide, N-(4-hydroxyphenyl)- [CAS]	65646-66-6	BE 847942	Anticancer, other
Fenspirid		5053066		
F ntanyl		437-38-7		
fentany citrate	Propanamide, N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]- [CAS]	437-38-7		Formulation, transmucosal, systemic
Fentiazac		18046-21-4		
Fenticlor		97-24-5		
fenticonazole	1H-Imidazole, 1-[2-(2,4-dichlorophenyl)-2-[[4-(phenylthio)phenyl]methoxy]ethyl]- [CAS]	72479-26-6 73151-29-8	US 4221803	Antifungal
Fent nium Br mide		5868064		
fepradinol	Benzenemethanol, Alpha-[(2-hydroxy-1,1-dimethylethyl)amino]methyl-, (+)- [CAS]	96981-91-6 67704-50-1		Anti-inflammatory, topical
Fepradin I		63075-47-8		
F praz n		30748-29-9		
Ferric Sodium Edetate		15708-41-5		
ferrioxamine B			WO 9426263	Septic shock treatment
Ferr chollinate		1336-80-7		
Ferr us Gluc nate		299-29-6		
ferumoxitol	Polyglucose sorbitol carboxymethyl ether-coated non-stoichiometric magnetite			Imaging agent
fesoterodine	2-[(1R)-3-bis(1-methylethyl)amino)-1-phenylpropyl]-4-(hydroxymethyl)Phenyl ester, (2E)-2-butenedioate (1:1) (Salt) - [CAS]	266930-03-8		Urological

TABLE 6

Example of Indication
Cancer, breast
Anaesthesia, adjunct
Infection, gynaecological
Respiratory distress syndrome, adult
Diagnosis, cancer
Incontinence

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
F. xofenadin		83799-24-0		
	Benzeneacetic acid, 4-[1-hydroxy-4-(4-hydroxydiphenylmethyl)-1-piperidinyl]butyl]-Alpha, Alpha-dimethyl-, hydrochloride [CAS]			
lexofenadine HCl		153439-40-8	US 5375693	Antiallergic, non-asthma
	Benzeneacetic acid, 4-[1-hydroxy-4-(4-hydroxydiphenylmethyl)-1-piperidinyl]butyl]-Alpha, Alpha-dimethyl-, hydrochloride [CAS]	138452-21-8		
lexofenadine		153439-40-8		Formulation, modified-release, <=24hr
Fibrostat			CA 2132416	Vulnary
	Spiro(4H-1-benzopyran-4,4'-imidazolidine)-2-carboxamide, 6-fluoro-2,3-dihydro-2',5'-dioxo-, (2S-cis)-, [CAS]			
fidarestat		136087-85-9	EP 418634	Symptomatic antidiabetic
	8-Phenyl-3-[4-[(3aR,9bR)-1,3a,4,9b-tetrahydro-9-methoxy[1]benzopyrano[3,4-c]pyrrol-2(3H)-yl]butyl]pyrazino[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione	208893-54-8		Prostate disorders
fiduxosin				
	4-Azaandrosta-1-ene-17-carboxamide, N-(1,1-dimethylethyl)-3-oxo-, (5Alpha, 17B)-[CAS]			
finasteride		98319-26-7	EP 155096	Prostate disorders
	Benzonitrile, 4-(3-(4-fluorophenyl)-2-hydroxy-1-(1H-1,2,4-triazol-1-yl)-propyl)-[CAS]	160146-16-7	EP 476944	Urological
Fipexide		34161-24-5		
	N-(4-Acetyl-1-piperazinyl)-4-fluorobenzamide monohydrate- [CAS]	133920-70-4	WO 9101979	Cognition enhancer
FK-960		146426-40-6		
Flavopiridol				
	4H-1-Benzopyran-8-carboxylic acid, 3-methyl-4-oxo-2-phenyl-, 2-(1-piperidinylethyl ester [CAS]	15301-69-6		
flavozate		3717-88-2	US 2921070	Urological
Flav xat		15301-69-6		
FI calinide		54143-55-4		
	Benzamide, N-(2-piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)-, monoacetate [CAS]	54143-55-4		
flecainide acetate, CR		54143-56-5		Formulation, modified-release, <=24hr

TABLE 6

Examp f Indication
Rhinitis, allergic, seasonal
Rhinitis, allergic, seasonal Wound healing
Neuropathy, diabetic
Benign prostatic hyperplasia
Benign prostatic hyperplasia
Urinary retention
Alzheimer's disease
Fibrillation, atrial

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
fleroxacin	3-Quinolonecarboxylic acid, 6,8-difluoro-1-(2-fluoroethyl)-1,4-dihydro-7-(4-methyl-1-piperazinyl)-4-oxo- [CAS]	79860-53-0 79860-72-3	US 4398029	Quinolone antibacterial
FliesInoxan	2H-Benzimidazol-2-one, 1,3-dihydro-1-(2-(4-(3-(trifluoromethyl)phenyl)-1-piperazinyl)ethyl)- [CAS]	98206-10-1		
flibansefin	Benzoic acid, 2-[(8-(trifluoromethyl)-4-quinolinyl)amino]-, 2,3-dihydroxypropyl ester [CAS]	167833-07-5		Reproductive/gonadal, general
fluctatenine		23779-99-9	US 3644368	Analgesic, NSAID
flomoxel	5-Oxa-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[[(difluoromethyl)thio]acetyl]amino]-3-[[[1-(2-hydroxyethyl)-1H-tetrazol-5-yl]thio]methyl]-7-methoxy-8-oxo-, (6R-cis)- [CAS]	92823-03-5 99665-00-6	EP 128536	Cephalosporin, injectable
Fl mox f		99665-00-6		
Fl pr pi n		2295-58-1		
Fl rantyron		519-95-9		
Flosequinan		76568-02-0		
Fl xacillin		5250-39-5		
Fl xuridine		50-91-9		
Fluacizine		30223-48-4		
Fluanis ne		1480-19-9		
fluasterone	Androst-5-en-17-one, 16-fluoro-, (16Alpha)- [CAS]	112859-71-9	EP 246650	Cardiovascular
fluazacort	5H-Pregna-1,4-dieno[17,16-d]oxazole-3,20-dione, 21-(acetyloxy)-9-fluoro-11-hydroxy-2'-methyl-, (11B,16B)- [CAS]	19888-56-3	US 3461119	Antipruritic/inflam, non-allergic
Fluclor nide		3693-39-8		
flucloxacillin, CSL		1847-24-1 34214-51-2		Formulation, other
fluconazole	1H-1,2,4-Triazole-1-ethanol, Alpha-(2,4-difluorophenyl)-Alpha-(1H-1,2,4-triazol-1-ylmethyl)- [CAS]	86386-73-4	EP 96569	Antifungal
Flucyt sin		2022-85-7		
Fludarabin		21679-14-1		

TABLE 6

Exemplification
Infection, general
Sexual dysfunction, female
Infection, general
Keratosis
Infection, general
Infection, dermatological

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
fludarabine phosphate	8H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-β-D-arabinofuranosyl)- [CAS]	75607-67-9	US 4357324	Anticancer, antimetabolite
Flude xygluc se F ₁₈		105851-17-0		
Fludiaz pam		3900-31-0		
Fludr cortisone		127-31-1		
Fluf namic Acid		530-78-9		
Fluindione		957-56-2		
flumazenil	4H-Imidazo[1,5-a][1,4]benzodiazepine-3-carboxylic acid, 8-fluoro-5,6-dihydro-5-methyl-6-oxo-, ethyl ester [CAS]			
Flumecinol		78755-81-4	EP 27214	Neurological
Flumequin		56430-99-0		
Flumethasone		42835-25-6		
Flumethazid		2135-17-3		
		148-56-1		
flunarizine	Piperazine, 1-[bis(4-fluorophenyl)methyl]-4-(3-phenyl-2-propenyl)-(E)- [CAS]	30484-77-6 52468-60-7	GB 1268710	Antimigraine
flunarizine	Piperazine, 1-[bis(4-fluorophenyl)methyl]-4-(3-phenyl-2-propenyl)-(E)- [CAS]	27848-84-6 52468-60-7		Formulation, fixed-dose combinations
flunisolide	Pregna-1,4-diene-3,20-dione, 6-fluoro-11,21-dihydroxy-16,17-(1-methylethylidene)bis(oxy)-, (6Alpha,11β,16Alpha)- [CAS]	3385-03-3	US 3124571	Asthma
flunitrazepam	2H-1,4-Benzodiazepin-2-one, 5-(2-fluorophenyl)-1,3-dihydro-1-methyl-7-nitro- [CAS]	1622-82-4		
Flunoxapron		66934-18-7	US 3116203	Hypnotic/Sedative
Flu cinnamyl Acetonide		67-73-2		
Flu cinnamyl		356-12-7		
Flu cinnamyl Butyl		41767-29-7		
Flu cinnamyl		152-97-6		
Fluorocin		2321075		
Fluorescein Sodium				

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Flurson		2924-67-6		
Fluorometholone		426-13-1		
Fluor salan		4776061		
fluorouracil, microcapsule	2,4-(1H,3H)-Pyrimidinone, 5-fluoro- [CAS]	51-21-8		Formulation, transdermal, enhanced
fluoxetine	Benzenepropanamine, N-methyl-Gamma-[4-(trifluoromethyl)phenoxy]-, (+/-)- [CAS]	54910-89-3 56296-78-7	US 4314081	Antidepressant
Fluoxymesterone		76-43-7		
Flupentixol		2709-56-0		
Fluprenolone Acetate		2119-75-7		
Fluphenazine		69-23-8		
flupirtine	Carbamic acid, [2-amino-6-[(4-fluorophenyl)methyl]amino]-3-pyridinyl-, ethyl ester [CAS]	33400-45-2 56995-20-1 75507-68-5	US 4481205	Analgesic, other
Fluprednolone Acetate		1255-35-2		
Fluprednisolone		53-34-9		
Fluproquazone		40507-23-1		
Flurandrenolide		1524-88-5		
Flurazepam		17617-23-1		
flurbiprofen	[1,1'-Biphenyl]-4-acetic acid, 2-fluoro-Alpha-methyl- [CAS]	5104-49-4	US 3793457	Anti-inflammatory
flurbiprofen transdermal, Lead	[(1,1'-Biphenyl)-4-acetic acid, 2-fluoro-Alpha-methyl- [CAS]	5104-49-4		Formulation, transdermal, patch
flurithromycin ethylsuccinate	Erythromycin, 8-fluoro-mono(ethyl butanedioate) (ester)- [CAS]	82730-23-2	EP 56291	Macrolide antibiotic
Flurogestone Acetate		2529-45-5		
Flurothyl		333-36-8		
Flur x n		406-90-6		
Fluspirilone		1841-19-6		
flutamide	Propanamide, 2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]- [CAS]	13311-84-7	US 4329384	Anticancer, hormonal
flutazepam	Oxazol[3,2-d][1,4]benzodiazepin-6(5H)-one, 10-chloro-11b-(2-fluorophenyl)-2,3,7,11b-tetrahydro-7-(2-hydroxyethyl)- [CAS]	27060-91-9	US 3905956	Anxiolytic

TABLE 6

Example of Indication
Keratosis
Depression, general
Pain, post-operative
Pain, general
Infection, respiratory tract, lower

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Fluticasone Propionate		80474-14-2		
	Androsta-1,4-diene-17-carbothioic acid, 6,9-difluoro-11,17-dihydroxy-16-methyl-3-oxo-, S-(fluoromethyl) ester, (6Alpha,11B,16Alpha,17Alpha)- [CAS]	80474-14-2 90566-53-3		Formulation, inhalable, solution
flutoprazepam	2H-1,4-Benzodiazepin-2-one, 7-chloro-1-(cyclopropylmethyl)-5-(2-fluorophenyl)-1,3-dihydro- [CAS]	25967-29-7	GB 1253368	Anxiolytic
flutrimazole	1H-Imidazole, 1-((2-fluorophenyl)(4-fluorophenyl)phenyl)methyl- [CAS]	119006-77-8 63516-07-4	EP 352352	Antifungal
Flutrimazole Br mide				
fluvastatin	6-Heptenoic acid, 7-[3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl]-3,5-dihydroxy-, monosodium salt, [R*,S*(E)]-(+)- [CAS]	93957-55-2 93957-54-1	EP 114027	Hypolipaeic/Antiatherosclerosis
Fluvastatin				
fluvoxamine	1-Pentanone, 5-methoxy-1-(4-(trifluoromethyl)phenyl)-O-(2-aminoethyl)oxime, (E)- [CAS]	54739-18-3 61718-82-9	GB 1535226	Antidepressant
fluvoxamine	1-Pentanone, 5-methoxy-1-(4-(trifluoromethyl)phenyl)-O-(2-aminoethyl)oxime, (E)- [CAS]			Formulation, modified-release, other
F llic Acid		59-30-3		
F llinic Acid		58-05-9		
F m piz l		7554-65-6		
forminoben	Benzamide, N-[3-chloro-2-[[methyl(2-(4-morpholinyl)-2-oxoethyl)amino]methyl]phenyl]- [CAS]	18053-31-1 24600-36-0	US 3661903	Respiratory stimulant
Fornivirsen		144245-52-3		
F m cain		17692-39-6		
Fonazine		7456-24-8		
Fondaparinux		114870-03-0		

TABLE 6

Exempl of Indication
Asthma
Psychosis, general
Infection, dermatological
Hypercholesterolaemia
Depression, general
Obsessive-compulsive disorder
Eczema, general

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
fondaparinux sodium	Alpha-D-Glucopyranoside, methyl O-2-deoxy-6-O-sulfo-2-(sulfoamino)-Alpha-D-glucopyranosyl-(1-4)-O-8-D-glucopyranuronosyl-(1-4)-O-2-deoxy-3,6-di-O-sulfo-2-(sulfoamino)-Alpha-D-glucopyranosyl-(1-4)-O-2-O-sulfo-Alpha-L-idopyranuronosyl-(1-4)-2-deoxy-2-(sulfoamino)-,6-(hydrogen sulfate) [CAS]	104993-28-4 2454117		Anticoagulant
Formbiline				
formestane	Androst-4-ene-3,17-dione, 4-hydroxy- [CAS]	566-48-3	EP 348953	Anticancer, hormonal
Formic acid		2825-60-7		
formoterol	Formamide, N-[2-hydroxy-5-[1-hydroxy-2-[[2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]phenyl]-, (R*,R*)-(+)- [CAS]	43229-80-7 73573-87-2	GB 1415256	Antiasthma
formoterol	Formamide, N-[2-hydroxy-5-[1-hydroxy-2-[[2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]phenyl]-, (R*,R*)-(+)- [CAS]	43229-80-7 73573-87-2		Formulation, inhalable, dry powder
fosamprenavir calcium	Carbamic acid, ((1S,2R)-3-(((4-aminophenyl)sulfonyl)(2-methylpropyl)amino)-1-(phenylmethyl)-2-(phosphonoxy)propyl)- C-(3S)-tetrahydro-3-furanyl ester, calcium salt (1:1) [CAS]	226700-81-8		Antiviral, anti-HIV
foscarnet	Phosphinecarboxylic acid, dihydroxy-, oxide, trisodium salt [CAS]	34156-56-4 4428-95-9 63585-09-1	US 4839445	Antiviral, other
Fosfostriol		522-40-7		
fosfluconazole	2,4-difluoro-Alpha,Alpha-bis(1H-1,2,4-triazol-1-ylmethyl)benzyl alcohol, dihydrogen phosphate (ester)	194798-83-9		Antifungal
fosfomycin	Phosphonic acid, (3-methoxyisopropyl)-, (2R-cis)- [CAS]	23155-02-4 26016-98-8	GB 1223923	Antibiotic, other
Fosfomycin		23155-02-4		

TABLE 6

Example of Indication
Thrombosis, venous
Cancer, breast
Asthma
Asthma
Infection, HIV/AIDS
Infection, cytomegalovirus
Infection, fungal, general
Infection, general

TABLE 6

API Gen ric Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
fosfomycin trometamol	Phosphonic acid, (3-methyloxytrany)-, (2R-cis)-, compd. with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1)- [CAS]	78964-85-9	EP 27597	Antibiotic, other
Fosf sal		6064-83-1		
	L-Proline, 4-cyclohexyl-1-[[[2-methyl-1-(1-oxopropoxy)propoxy]-(4-phenylbutyl)phosphiny]acetyl]-, (2Alpha,4B)- [CAS]	88889-14-9 98048-97-6	EP 63896	Antihypertensive, renin system
fosinopril	2,4-Imidazolidinedione, 5,5-diphenyl-3-[(phosphonooxy)methyl]- [CAS]	92134-98-0 93390-81-9	US 4260769	Antiepileptic
fosphenytoin	Phosphonic acid, [1-[[[2-chloroethyl]nitrosoamino]carbonyl]amino]ethyl]-, diethyl ester [CAS]	92118-27-9	EP 117959	Anticancer, alkylating
fosmustine		105560-14-9		
Fr pen m				
frivatriptan	1H-Carbazole-6-carboxamide, 2,3,4,9-tetrahydro-3-(methylamino)-, (R)- [CAS]	158747-02-5	WO 9922730	Antimigraine
Fructose		57-48-7		
Fructose-1,6-diphosphate		488-69-7		
FTC	2(1H)-Pyrimidinone, 4-amino-5-fluoro-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)- (4R)			Antiviral, anti-HIV
FTY-720	1,3-Propanediol, 2-amino-2-(2-(4-octylphenyl)ethyl)-, hydrochloride [CAS]	162359-56-0	WO 9408943	Immunosuppressant
fudosteine	Alanine, 3-((3-hydroxypropyl)thio)- [CAS]	13189-98-5	US 5047428	Antitussive
fulvestrant	Estra-1,3,5(10)-triene-3,17-diol, 7-[9-[(4,4,5,5,5-pentafluorophenyl)sulfinyl]nonyl]-, (7Alpha,17B)- [CAS]	129453-61-8	EP 346014	Anticancer, hormonal
	2,4,6,8-Decatetraenedioic acid, mono[5-methoxy-4-[2-methyl-3-(3-methyl-2-butenyl)oxiranyl]-1-oxaspiro[2.5]oct-6-yl] ester, [3R-]			
fumagilline	[3Alpha,4Alpha(2R*,3R*),5B,6B(4E)]- [CAS]	23110-15-8		Protozoacide
Fumagillin		23110-15-8		

TABLE 6

Example of Indication
Infection, urinary tract
Hypertension, general
Epilepsy, generalized, tonic-clonic
Cancer, melanoma
Migraine
Infection, HIV/AIDS
Transplant rejection, general
Cough
Cancer, breast
Infection, GI tract

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Furaltad n		139-91-3		
Furazabol		1239-29-8		
Furaz lidon		67-45-8		
Furazolium Chloride		5118-17-2		
Furonazid		3460-67-1		
furosemide	Benzoic acid, 5-(aminosulfonyl)-4-chloro-2-[(2-furanylmethyl)amino]- [CAS]	54-31-9		Formulation, modified-release, other
Fursultiamine		804-30-8		
Furtrethonium		7618-86-2		
Fusidic Acid		6/3/6990		
G1, YM BioSciences	1-(5-bromofur-2-yl)-2-bromo-2-nitroethene			Antifungal
G25			WO 9804252	Antimalarial
GABA-A Alpha5 inverse agonist, Mer			WO 0206285	Cognition enhancer
gabapentin	Cyclohexanecarboxylic acid, 1-(aminomethyl)- [CAS]	60142-96-3	US 4152326	Antiepileptic
gabexate	Benzoic acid, 4-[[6-[(aminiminomethyl)amino]-1-oxohexyloxy]-ethyl ester, monomethanesulfonate [CAS]	39492-01-8 56974-61-9	US 3751447	GI inflammatory/bowel disorders
gaboxadol	Isosaxazol[5,4-c]pyridin-3(2H)-one, 4,5,6,7-tetrahydro- [CAS]	64603-91-4	CA 1125288	Hypnotic/Sedative
Gadobenat		127000-20-8		
Dimeglumin		138071-82-6		
Gadobutrol		131410-48-5		
Gad diamid		80529-93-7		
Gadopentetic Acid		120066-54-8		
Gad t rid l		131069-91-5		
Gadoversetamide		135326-11-3		
Gadoxetic Acid	(4aS,6R,8aS)-6-Hydroxy-3-methoxy-11-methyl-5,6,9,10,11,12-hexahydro-4aH-benzofuro[3a,3,2-e,f][2]benzazepine			Formulation, modified-release, other
galantamine				
Galanthamin		357-70-0		

TABLE 6

[illegible]

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
galarubicin hydrochloride	8-Alanine, 2-[4-[(2,6-dideoxy-2-fluoro-Alpha-L-falopyranosyl)oxy]-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-2-naphthacenyl]-2-oxoethyl ester, hydrochloride, (2S-cis) [CAS]	140637-82-7 140637-86-1	EP 424899	Anticancer, antibiotic
Gallamine Tri thiodide		65-29-2		
Galllic Acid		149-91-7		
gallium maltolate	4H-Pyran-4-one, 3-hydroxy-2-methyl-, gallium complex			Anticancer, other
gallium nitrate	Nitric acid, gallium salt [CAS]	13494-90-1	US 4529593	Osteoporosis treatment
gallopamil	Benzeneacetonitrile, Alpha-[3-[(2-(3,4-dimethoxyphenyl)ethyl)(methylamino)propyl]-3,4,5-trimethoxy-Alpha-(1-methylethyl)-[CAS]	16662-47-8	GB 1367677	Antianginal
Gall pamil		16662-47-8		
γ-Aminobutyric Acid		56-12-2		
Ganax Ion		38398-32-2		
ganciclovir	6H-Purin-6-one, 2-amino-1,9-dihydro-9-[[2-hydroxy-1-(hydroxymethyl)ethoxy]methyl]-[CAS]	107910-75-8 82410-32-0	EP 49072	Antiviral, other
ganirelix	[N-Ac-D-Nal,D-pCl-Phe,D-Pal,D-hArg(Et)2,hArg(Et)2,D-Ala]GnRH- [CAS]	124904-83-4	EP 312052	Releasing hormones
ganstigmine hydrochloride	Carbamic acid, (2-ethylphenyl)-, (3aS,8aS)-1,2,3,3a,8a-hexahydro-1,3a,8-trimethylpyrrolo[2,3-b]indol-5-yl ester, hydrochloride			
		223585-99-7	EP 1023297	Cognition enhancer
gantofiban	1-Piperazineacetic acid, 4-[[[5R)-3-[4-[imino[(methoxycarbonyl)amino]methyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-, ethylester [CAS]	183547-57-1	EP 741133	Antithrombotic

TABLE 6

Exempl of Indication
Cancer, breast
Cancer, myeloma
Hypercalcaemia of malignancy
Angina, general
Infection, cytomegalovirus
Infertility, female
Alzheimer's disease
Thrombosis, general

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
garenoxacin	3-Quinolonecarboxylic acid, 1-cyclopropyl-8-(difluoromethoxy)-7-((1R)-2,3-dihydro-1-methyl-1H-isolindol-5-yl)-1,4-dihydro-4-oxo-1-monomethanesulfonate [CAS]	223652-82-2		Quinolone antibacterial
garnocestim	5-73-macrophage inflammatory protein 2Alpha (human gene gro2)- [CAS]	246861-96-1		Radio/chemoprotective
gatifloxacin	3-Quinolonecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(3-methyl-1-piperazinyl)-4-oxo-, (+/-)- [CAS]	112811-59-3	EP 230295	Quinolone antibacterial
Gatifloxacin		112811-59-3		
Gefarnat		51-77-4		
gefitinib	4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy) [CAS]	184475-35-2	WO 9633980	Anticancer, other
gemcabene calcium	calcium 6,6'-oxybis(2,2-dimethylhexanoate)	209789-08-2		Hypolipemic/Antiatherosclerosis
Gemcitabin		95058-81-4		
gemcitabine hydrochloride	Cytidine, 2'-deoxy-2', 2'-difluoro-, monohydrochloride [CAS]	122111-03-9		
		95058-81-4	GB 2136425	Anticancer, antimetabolite
gemeprost	Prosta-2,13-dien-1-ol-ic acid, 11,15-dihydroxy-16,16-dimethyl-9-oxo-, methyl ester, (2E,11Alpha,13E,15E)- [CAS]	64318-79-2		Prostaglandin
G m pr st		64318-79-2		
gemfibrozil	Pentanoic acid, 5-(2,5-dimethylphenoxy)-2,2-dimethyl- [CAS]	25812-30-0	US 3674836	Hypolipemic/Antiatherosclerosis
Gemfibr zil		25812-30-0		
gemifloxacin	1,8-Naphthyridine-3-carboxylic acid, 7-(3-(aminomethyl)-4-(methoxymino)-1-pyrrolidinyl)-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo- [CAS]	175463-14-6	US 5869670	Quinolone antibacterial
gentamicin	Gentamicin [CAS]	1403-66-3		Formulation, implant
G ntian Viol t		548-62-9		
G ntiopticin		20831-76-9		

TABLE 6

Examl of Indication
Infection, respiratory tract, lower
Chemotherapy-induced injury, bone marrow, neutropenia
Infection, respiratory tract, general
Cancer, lung, non-small cell
Hyperlipidaemia, general
Cancer, pancreatic
Hyperlipidaemia, general
Infection, respiratory tract, general
Infection, general

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
G ntisic Acid		490-79-9		
G pefrin		18840-47-6		
geprone-ER	2,6-Piperidinedione, 4,4-dimethyl-1-(4-(4-(2-pyrimidinyl)-1-piperazinyl)butyl)- [CAS]			Formulation, modified-release, other
gestodene	18,19-Dinorepregna-4,15-dien-20-yn-3-one, 13-ethyl-17-hydroxy-, (17Alpha)- [CAS]	109852-02-0 60282-87-3	GB 1569135	Formulation, fixed-dose combinations
gestodene + ethinyllest, Scheri	18,19-Dinorepregna-4,15-dien-20-yn-3-one, 13-ethyl-17-hydroxy-, (17Alpha) mixt with 19-Norepregna-1,3,5(10)-trien-20-yn-13,17-diol (17Alpha)			Formulation, modified-release, >24hr
Gestonor n Caproate		1253-28-7		
Gestrin n		16320-04-0		
γ-Hydroxybutyrate		591-81-1		
gimatecan	(4S)-11-{(E)-[(1,1-dimethylethoxy)imino]methyl}-4-ethyl-4-hydroxy-1-12-dihydro-14H-pyran[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H)-dione	292618-32-7		Anticancer, other
Giractide		24870-04-0		
Gitoxin		4562-36-1		
GL-406349	N,N-Bis[2-[N-(2-(N2,N5-dimethyl-DL-lysylamino)-ethyl]carbonyl]1H-indol-6-yl]-1H-indole-2,5-dicarboxamide			Antifungal
Glafl nin		3820-67-5		
Glatramer		28704-27-0		
glatramer acetate	L-Glutamic acid, polymer with L-alanine, L-lysine and L-tyrosine, acetate (salt) [CAS]	147245-92-9	WO 5800808	Multiple sclerosis treatment
Gilbormurid		26944-48-9		
gliclazide	Benzenesulfonamide, N-[[[hexahydrocyclopenta[c]pyrrol-2(1H)-yl]amino]carbonyl]-4-methyl- [CAS]	21187-98-4	GB 1153982	Antidiabetic

TABLE 6

Example of Indication
Depression, general
Contraceptive, female
Contraceptive, female
Cancer, brain
Infection, fungal, general
Multiple sclerosis, relapsing- remitting
Diabetes, Type II

TABLE 6

API Gen ric Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Gliclazid	1H-Pyrrole-1-carboxamide, 3-ethyl-2,5-dihydro-4-methyl-N-[2-[4-[[[4-methylcyclohexyl]amino]carbonyl]amino]sulfonyl]phenyl]ethyl]-2-oxo- [CAS]	21187-98-4		
glimepiride		93479-97-1	WO 9303724	Antidiabetic
γ -Linolenic Acid		506-26-3		
glipizide	Pyrazinecarboxamide, N-[2-[4-[[[(cyclohexylamino)carbonyl]amino]sulfonyl]phenyl]ethyl]-5-methyl- [CAS]	29094-61-9	US 3669968	Antidiabetic
gliquidone	Benzenesulfonamide, N-[(cyclohexylamino)carbonyl]-4-[2-(3,4-dihydro-7-methoxy-4,4-dimethyl-1,3-dioxo-2(1H)-isoquinolinyl)ethyl]- [CAS]	33342-05-1	GB 1277847	Antidiabetic
glisclamide	3-Isosazolecarboxamide, N-[2-[4-[[[(cyclohexylamino)carbonyl]amino]sulfonyl]phenyl]ethyl]-5-methyl- [CAS]	24477-37-0		Antidiabetic
Gils xepid		25046-79-1		
Glucametacin		52443-21-7		
Glucophage nlc Acid		87-74-1		
Gluc nlc Acid		526-95-4		
Gluc samlin		3416-24-8		
glucosamine sulfate	D-Glucose, 2-amino-2-deoxy-, sulfate (salt) [CAS]	28031-19-4	DE 1953689	Antiarthritic, other
Gluc sulfon S dlum		554-18-7		
glufostamide	3-D-Glucopyranose, 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate)- [CAS]	132682-98-5	DE 3835772	Anticancer, alkylating
Glutamic Acid		56-86-0		
Glutaraldehyd		111-30-8		
Glutethimide		77-21-4		
Glyburid		10238-21-8		
Glybuthiazol()		535-65-9		
Glybuzole		1492-02-0		
Glyc rol		56-81-5		
Glycocyamine		352-97-6		
Glycol Salicylat		87-28-5		

TABLE 6

Example 1 Indication
Diabetes, Type II
Diabetes, general
Diabetes, general
Arthritis, osteo
Cancer, general

TABLE 6

API Gen ric Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Glyconlazide		3691-74-5		
Glyc pyr late		596-51-0		
Glyhexamide		451-71-8		
Glymidine		339-44-6		
Glypinamide		1228-19-9		
GMDP	N-acetylglucosaminyl-N-acetylmuramyl dipeptide			Anti-infective, other
G id S dium Thiomalate		12244-57-4		
Gold Sodium Thiosulfate		10233-88-2		
goserelin	Luteinizing hormone-releasing factor (pig), 6-[O-(1,1-dimethylethyl)-D-serine]-10-deglychamide-, 2-(aminocarbonyl)hydrazide [CAS]	65807-02-5	US 4100274	Releasing hormones
Goserelin Acetate				
GPI-1485	L-Proline, 1-(3,3-dimethyl-1,2-dioxopentyl)-, 3-(3-pyridinyl)propyl ester [CAS]	188452-09-5		Antiparkinsonian
GPI-5693	2-(Phosphonomethyl)pentanedioic acid		US 5672592	Analgesic, other
Graftskin				
granisetron	1H-Indazole-3-carboxamide, 1-methyl-N-(9-methyl-9-azabicyclo[3.3.1]non-3-yl), endo-[CAS]	107007-99-8 109889-09-0	EP 200444	Antiemetic
Gr pafli xacin		119914-60-2		
griseofulvin	Spiro[benzofuran-2(3H),1'-[2(cyclohexane)-3,4'-dione, 7-chloro-2',4,6-trimethoxy-6'methyl-, (1'S-trans)- [CAS]	128-07-8		Formulation, dermal, topical
Guaiaac I		90-05-1		
Guaiaapat		852-42-6		
Guaiazul n		489-84-9		
Guaif n sin		93-14-1		
gualmesal	4H-1,3-Benzodioxin-4-one, 2-(2-methoxyphenoxy)-2-methyl- [CAS]	81674-79-5	GB 2098201	Anti-inflammatory

TABLE 6

Exemplification of Indication
Infection, general
Cancer, prostate
Parkinson's disease
Pain, neuropathic
Chemotherapy-induced nausea and vomiting
Infection, dermatological

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Guamecycline		16545-11-2		
Guanabenz		5051-62-7		
Guanadrel		40580-59-4		
Guan thidin		55-65-2		
Guanfacine		29110-47-2		
Guanoxabenz		24047-25-4		
Guan xan		2165-19-7		
gugulipid	Pregna-4,17(20)-diene-3,16-dione [CAS]	95975-55-6	EP 447706	Hypolipaeic/Antiatherosclerosis
Gusp rimus		104317-84-2		
GW-280430A	(Z)-2-Chlorofumaric acid 1-[3-{[6,7-dimethoxy-2(S)-methyl-1(R)-(3,4,5-trimethoxybenzyl)-1,2,3,4-tetrahydroisoquinolinium-2-yl]propyl}]			Muscle relaxant
GW-320659	[2S,3S,5R]-2-[3,5-difluorophenyl]-3,5-dimethyl-2-morpholinol			Anorectic/Antiobesity
GYKI-16084	(+)-R-2-[3-[N-(2-Benzo[1,4]dioxanylmethyl)amino]-1-propyl]-3(2H)-pyridazinone hydrochloride		US 6194411	Prostate disorders
Hachimycin		1394-02-1		
Halazepam		23092-17-3		
Halcinonide		3093-35-4		
halobetasol propionate	Pregna-1,4-diene-3,20-dione, 21-chloro-6,9-difluoro-11-hydroxy-16-methyl-17-(1-oxopropoxy)-, (6Alpha,11B,16B) [CAS]	66852-54-8	US 4619921	Antipsoriasis
halofantline	9-Phenanthrenemethanol, 1,3-dichloro-Alpha-[2-(dibutylamino)ethyl]-6-(trifluoromethyl)- [CAS]	36167-63-2 69756-53-2	EP 138374	Antimalarial
halometasone	Pregna-1,4-diene-3,20-dione, 2-chloro-6,9-difluoro-11,17,21-trihydroxy-16-methyl-, (6Alpha,11B,16Alpha)- [CAS]	50829-82-8	US 4076737	Antipruritic/inflamm, allergic
Halop ridol		52-86-8		

TABLE 6

Exempl of Indication
Anaesthesia, adjunct
Obesity
Benign prostatic hyperplasia
Psoriasis
Infection, malaria

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Haloperidol Decanoate				
Halopredon Acetate		57781-14-3		
Haloproglin		777-11-7		
Halopropan		679-84-5		
Halothane		151-67-7		
Haloxazolam		59128-97-1		
harkoseride	2(R)-Acetamido-N-benzyl-3-methoxypropionamide		WO 9733861	Antiepileptic
HE-2000	16Alpha-Bromo-3B-hydroxy-5Alpha-androstane-17-one			Antiviral, anti-HIV
Healos			WO 9714376	Musculoskeletal
Hemat p rphyrin		14459-29-1		
Hepr nicate		7237-81-2		
Heptabarbital		509-86-4		
H ptamin I		372-66-7		
H tacillin		3511-16-8		
Hetastarch		9004-62-0		
H xachlor phene		70-30-4		
Hexadimethrin Bromide		28728-55-4		
Hexafluorenum Bromid		317-52-2		
Hexamethonium		60-26-4		
H xamidin		3811-75-4		
H xapr pymate		358-52-1		
Hexedine		5980-31-4		
Hex str I		84-16-2		
H x str I Bis(β - diethylaminoethyl ether)		2691-45-4		
H xethal Sodium		144-00-3		

TABLE 6

API Gen. ri Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
H xetidin		141-94-6		
Hex barbital		56-29-1		
H xobendine		54-03-5		
Hexocyclium Methyl Sulfate		115-63-9		
Hex pr nalin		3215-70-1		
Hextend	Hextend [CAS]	235746-51-7	US 5407428	Plasma substitute
Hexylcalne		532-76-3		
Hydr chl rid				
HF-0299	11b-hydroxy androstenedione			Osteoporosis treatment
	Benzeneacetic acid, 4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]-, 2-tricyclo[3.3.1.1 ^{3,7}]dec-1-ylethyl ester, (2Z)-2-butenedioate (1:1) (salt) [CAS]			
HGP-2		121009-31-2		Antiglaucoma
	8-Azoniabicyclo[3.2.1]octane, 3-(3-ethoxy-1,3-dioxo-2-phenylpropoxy)-8,8-dimethyl-, (3-endo)-, methyl sulfate [CAS]	113932-41-5		Antiepileptic
HGP-8A		120250-44-4		Vasoprotective, systemic
hidrosmin	Hydrosmin- [CAS]	51-45-6		
Histamin	histamine dihydrochloride		EP 0493468	Anticancer, immunological
Histapyr din		493-80-1		
	Luteinizing hormone-releasing factor (pig), 6-[1-(phenylmethyl)-D-histidine]-8-(N-ethyl-L-prolinamide)-10-deglycinamide- [CAS]	76712-82-8	EP 217659	Releasing hormones
histrelin				
HM-101	HM 101 [CAS]	217311-70-1		Osteoporosis treatment
	(E)-4-[2-(p-methoxybenzenesulfonamide)-phenyl]ethenylpyridine-1-oxide			
HMN-214				
Homatr pine		87-00-3		Anticancer, other
Homocamfin		535-86-4		
H m chlorcyclizine		848-53-3		
Hopantenic Acid		18679-90-8		

TABLE 6

Example of Indication
Surgery adjunct
Osteoporosis
Glaucoma
Epilepsy, general
Cancer, melanoma
Precocious puberty
Osteoporosis
Cancer, general

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
HP-228	Glycinamide, N-acetyl-L-norleucyl-L-glutamyl-L-histidyl-D-phenylalanyl-L-arginyl-D-tryptophyl- [CAS]	172617-89-9	EP 759770	Analgasic, other
Hyaluronic acid	Hyaluronic acid [CAS]	102518-79-6		Formulation, other
Hyaluronic acid	Hyaluronic acid [CAS]	9004-61-9		
Hyaluronic acid	Hyaluronic acid [CAS]	3105-97-3		
Hyaluronic acid	Hyaluronic acid [CAS]	459-67-6		
Hyaluronic acid	Hyaluronic acid [CAS]	86-54-4		
Hyaluronic acid	Hyaluronic acid [CAS]	118-08-1		
Hyaluronic acid	Hyaluronic acid [CAS]	6592-85-4		
Hyaluronic acid	Hyaluronic acid [CAS]	58-93-5		
Hyaluronic acid	Hyaluronic acid [CAS]	125-29-1		
Hyaluronic acid	Morphinan-6-one, 4,5-epoxy-3-hydroxy-17-methyl-, (5Alpha)- [CAS]	466-99-9		Formulation, modified-release, other
Hyaluronic acid	Hyaluronic acid [CAS]	76-47-1		
Hyaluronic acid	Hyaluronic acid [CAS]	50-23-7		
hydrocortisone aceponate	Pregn-4-ene-3,20-dione, 21-(acetyloxy)-11-hydroxy-17-(1-oxopropoxy)-, (11B)- [CAS]	74050-20-7	DE 2826257	Dermatological
hydrocortisone butyrate propionate	Pregn-4-ene-3,20-dione, 11-hydroxy-17-(1-oxobutoxy)-21-(1-oxopropoxy)-, (11B)- [CAS]	72590-77-3	DE 2910899	Antipruritic/inflam, allergic
hydrocortisone-17-butyrate	Pregn-4-ene-3,20-dione, 11,21-dihydroxy-17-(1-oxobutoxy)-, (11B)- [CAS]	13609-67-1		Formulation, optimized, microemulsion
Hydroflumethiazide		135-09-1		
hydromorphone	Morphinan-6-one, 4,5-epoxy-3-hydroxy-17-methyl-, (5Alpha)-, mixt with acetamide, N-(4-hydroxyphenyl)-, mixt with morphinan-6-one, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-, (5Alpha)-	103-90-2 16590-41-3 466-99-9		Formulation, fixed-dose combinations
Hydroquinone		1435-55-8		
Hydroquinone		522-66-7		
Hydroquinone		123-31-9		

TABLE 6

Example of Indication
Pain, post-operative
Restenosis
Pain, general
Unspecified
Eczema, atopic
Pain, general

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Hydroxocobalamin		13422-51-0		
Hydroxyamphetamine		1518-86-1		
Hydroxychloroquine		118-42-3		
Hydroxydihydroquinoline		53-10-1		
Hydroxyphenanthridine		468-56-4		
Hydroxyphenanthrene		50-19-1		
Hydroxypropyl Cellulose		9004-64-2		
Hydroxyethylamine		495-99-8		
Hydroxyethylamine		490-98-2		
Hydroxyethylamine		68-88-2		
Hylan G-F 20				
Hymecromone		90-33-5		
Hydroxyethylamine sulfate	benzeneacetic acid, Alpha(hydroxymethyl)-, 8-methyl-8-azabicyclo [3.2.1]oct-3-yl ester, [3(S)-endo], sulfate (2:1), dihydrate	101-31-5		Formulation, oral, orally-disintegrating
hypericin	Phenanthro[1,10,9,8-opq]perylene-7,14-dione, 1,3,4,6,8,13-hexahydroxy-10,11-dimethyl- [CAS]	548-04-9		Anticancer, other
IACFT		180468-34-2		
Ibandronic acid	Phosphonic acid, [1-hydroxy-3-(methylpentylamino)propylidene] bis- [CAS]	114084-78-5	EP 252504	Osteoporosis treatment
Ibopamine	Propanoic acid, 2-methyl-, 4-[2-(methylamino)ethyl]-1,2-phenylene ester- [CAS]	66195-31-1	GB 1551661	Cardio stimulant
Ibopamine	Propanoic acid, 2-methyl-, 4-[2-(methylamino)ethyl]-1,2-phenylene ester- [CAS]	66195-31-1		Formulation, mucosal, topical
Ibritum mab Tiuxetan		206181-63-7		
Ibuprofen	Phosphonic acid, [(4-[(4-bromo-2-cyanophenyl)amino]carbonyl]phenyl)methyl]-, diethyl ester [CAS]	133208-93-2	EP 402033	Hypolipemic/Antiatherosclerosis

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Ibudilast	1-Propanone, 2-methyl-1-[2-(1-methyl(ethyl)pyrazol-5-yl)pyridin-3-yl]- [CAS]	50847-11-5	EP 215438	Antiasthma
Ibuprofen	Benzeneacetic acid, Alpha-methyl-4-(2-methylpropyl)-, 2-pyridinylmethyl ester [CAS]	1553-60-2		
Ibuprofen piconol	Benzeneacetic acid, Alpha-methyl-4-(2-methylpropyl)- [CAS]	64622-45-3	DE 2658610	Antipruritic/inflamm, non-allergic
Ibuprofen	Benzeneacetic acid, Alpha-methyl-4-(2-methylpropyl)- [CAS]	15687-27-1		Formulation, modified-release, other
Ibuprofen xam		53648-05-8		
Ibutilide		122647-31-8		
Ibutilide fumarate	Methanesulfonamide, N-[4-{4-(ethylheptylamino)-1-hydroxybutyl}phenyl]-, (+)-, (E)-2-butenedioate (2:1) (salt) [CAS]	122647-31-8 122647-32-9	JP 60239458	Antiarrhythmic
ICA-17043			US 6288122	Antiskinning
Icodextrin, CAPD, ML Labs	Dextrin- [CAS]	9004-53-9		Urological
Icarubicin	5,12-Naphthacenedione, 9-acetyl-7-[(3-amino-2,3,6-trideoxy-Alpha-L-lyxohexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-, (7S-cis)- [CAS]	58957-92-9 86189-66-4	US 4471052	Anticancer, antibiotic
Idaz xan		79944-58-4		
IdB-1016	2-(2,3-dihydro-2-(4-hydroxy-3-methoxyphenyl)-3-(hydroxymethyl)-1,4-benzodioxin-6-yl)-2,3-dihydro-3,5,7-trihydroxy-4H-1-benzopyran-4-one phosphatidylcholine complex	134489-06-2	EP 209038	Anticancer, hormonal
Idenone	2,5-Cyclohexadiene-1,4-dione, 2-(10-hydroxydecyl)-5,6-dimethoxy-3-methyl- [CAS]	58186-27-9	EP 58057	Neuroprotective

TABLE 6

Example of Indication
Asthma
Eczema, contact
Inflammation, general
Fibrillation, atrial
Anaemia, sickle cell
Renal failure
Cancer, leukaemia, acute lymphocytic
Cancer, ovarian
Ischaemia, cerebral

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
IDN-5109	4-Hexenoic acid, 3-[[[(1,1-dimethylethoxy)carbonyl]amino]-2-hydroxy-5-methyl-, (3aS,4R,7R,8aS,9S,10aR,12aS,12bR,13S,13aS)-7,12a-bis(acetoxy)-13-(benzoyloxy)-3a,4,7,8,8a,9,10,10a,12,12a,12b,13-dodecahydro-9-hydroxy-5,8a,14,14-tetramethyl-2,8-dioxo-6,13a-methanocyclodeca [1,2-d] dioxyl-4-yl ester, 2R,3S] [CAS]	186348-05-0	US 5284591	Anticancer, other
Id xif n		116057-75-1		
Idraparinux sodium	Alpha-D-Glucopyranoside, methyl O-2,3,4-tri-O-methyl-6-O-sulfo-Alpha-D-glucopyranosyl-(1-4)-O-2,3-di-O-methyl-8-D-glucopyranuronosyl-(1-4)-O-2,3,6-tri-O-sulfo-Alpha-D-glucopyranosyl-(1-4)-O-2,3-di-O-methyl-Alpha-L-idopyranuronosyl-(1-4)-, tris(hydrogen sulfate) nonasodium salt [CAS]	149920-56-9	AU 698456	Antithrombotic
Idrocilamide	2-Propenamide, N-(2-hydroxyethyl)-3-phenyl- [CAS]	6981-48-2	US 3659014	Anti-inflammatory, topical
Ifenpr dil	(7)-2-(4-benzyl piperidino)-1-p-hydroxyphenylpropanol tartrate	23210-56-2		
Ifenprodil tartrate		23210-58-4	US 3509164	Neuroprotective
Ifosfamide	2H-1,3,2-Oxazaphosphorin-2-amine, N,3-bis(2-chloroethyl)tetrahydro-2-oxide [CAS]	3778-73-2	US 3732340	Anticancer, alkylating
Iguratimod	N-[3-(Formylamino)-4-oxo-6-phenoxy-4H-chromen-7-yl] methanesulfonamide	123663-49-0	DE 3834204	Antiarthritic, other
Ilaprazole	1H-Benzimidazole, 2-(((4-methoxy-3-methyl-2-pyridinyl) methyl)sulfinyl)-5-(1H-pyrrol-1-yl)- [CAS]	172152-36-2	US 5703097	Antilucer

TABLE 6

Example f Indication
Cancer, colorectal
Thrombosis, venous
Cancer, lung, general
Arthritis, rheumatoid
Ulcer, GI, general

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
tiomastat	Butanediamide, N4-hydroxy-N1-(1-(1H-indol-3-ylmethyl)-2-(methylamino)-2-oxoethyl)-2-(2-methylpropyl)-, (S-(R*, S*))-[CAS]	142880-36-2	US 5892112	COPD treatment
tioperidone	Ethanone, 1-[4-{3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy}-3-methoxyphenyl]- [CAS]	133454-47-4	US 5776963	Neuroleptic
tioprost trometamol	Pentanoic acid, 5-(hexahydro-5-hydroxy-4-(3-hydroxy-4-methyl-1-octen-6-ynyl)-2(1H)-pentalenyldene)- [CAS]	78919-13-8	DE 3417638	Prostaglandin
tiLX23-7553	1Alpha,25-Hydroxy-16-yne vitamin D3			Anticancer, other
tiatinib	4-((Methyl-1-piperazinyl)methyl)-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-phenyl]benzamide methanesulfonate	152459-95-5	US 5521184	Anticancer, other
tiimidapril	4-Imidazolidinecarboxylic acid, 3-[2-[[1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1-methyl-2-oxo-, [4S-[3(R*(R')),4R*]]- [CAS]	89371-37-9 89396-94-1	EP 95163	Antihypertensive, renin system
tiimidapril hydrochloride, Ark	4-Imidazolidinecarboxylic acid, 3-[2-[[1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1-methyl-2-oxo-, [4S-[3(R*(R')),4R*]], monohydrochloride			Musculoskeletal
tiimidazole salicylate	Benzoic acid, 2-hydroxy-, compd. with 1H-imidazole (1:1) [CAS]	36364-49-5	US 4329340	Anti-inflammatory
tiimipenem	1-Azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, 6-(1-hydroxyethyl)-3-[2-[[[iminomethyl]amino]ethylthio]-7-oxo-, [5R-[5Alpha,6Alpha(R*)]]- [CAS]	64221-86-9 74431-23-5 81129-83-1	GB 1570980	Beta-lactam antibiotic
tiimipramin		50-49-7		
tiimipramin N-Oxide		6829-98-7		
tiimiquimod	1H-Imidazo[4,5-c]quinolin-4-amine, 1-(2-methylpropyl)- [CAS]	99011-02-6	EP 145340	Antiviral, other

TABLE 6

Example of Indication
Emphysema, smoking-related
Schizophrenia
Peripheral vascular disease
Cancer, general
Cancer, leukaemia, chronic myelogenous
Hypertension, general
Cachexia
Pain, general
Infection, general
Infection, human papilloma virus

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Imolamline		318-23-0		
Impitapide	Benzeneacetamide, Alpha-cyclopentyl-4-((2,4-dimethyl-9H-pyrido(2,3-b)indol-9-yl)methyl)-N-((1R)-2-hydroxy-1-phenylethyl)- (AlphaS)- [CAS]	177469-98-4	EP 705831	Hypolipaeamic/Antiatherosclerosis
Improsulfan		13425-98-4		
Inap rison		99323-21-4		
Incadronate disodium	Phosphonic acid, [[cycloheptylamino)methylene]bis-, disodium salt [CAS]	138330-18-4		Musculoskeletal
Incadr nlc Acid		124351-85-5		
Indalpine		63758-79-2		
Indanazoline		40507-78-6		
Indapamide	4-chloro-N-(2-methylindolin-1-yl)-3-sulfamoylbenzamide	26807-65-8	GB 1203681	Antihypertensive, diuretic
Indecalnitide		74517-78-5		
Indeloxazine	Morpholine, 2-[(1H-inden-7-yloxy)methyl]- [CAS]	60929-23-9 65043-22-3	JP 52083773	Cognition enhancer
Indeloxazin Hydrochloride		65043-22-3		
Indenolol	2-Propanol, 1-[1H-inden-4-(or 7)-yloxy]-3-[(1-methylethyl)amino]- [CAS]	30190-87-5 60607-68-3 68906-98-7	GB 1280343	Antihypertensive, adrenergic
Indinavir		150378-17-9		
Indinavir sulfate	D-erythro-Pentonamide, 2,3,5-trideoxy-N-(2,3-dihydro-2-hydroxy-1H-inden-1-yl)-5-(2-(((1,1-dimethylethyl)amino)carbonyl)-4-(3-pyridinylmethyl)-1-piperazinyl)-2-(phenylmethyl), [1S-(1'Alpha(R'),2'Alpha)]-, sulfate (1:1) (salt) [CAS]	150378-17-9 157810-81-6	EP 0541168	Antiviral, anti-HIV
Indiplon	Acetamide, N-methyl-N-(3-(2-(thienylcarbonyl)pyrazolo(1,5-a) pyrimidin-7-yl)phenyl)- [CAS]	325715-02-4	US 6399621	Hypnotic/Sedative

TABLE 6

Example of Indication
Atherosclerosis
Hypercalcaemia of malignancy
Hypertension, general
Alzheimer's disease
Infection, HIV/AIDS
Insomnia

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Indiseton	1H-Indazole-3-carboxamide, N-(3,9-dimethyl-3,9-diazabicyclo(3.3.1)non-7-yl)-, diendo- [CAS]	160472-97-9		Antiemetic
Indisulam	1,4-Benzenedisulfonamide, N-(3-chloro-1H-indol-7-yl)- [CAS]	165668-41-7		Anticancer, other
Indobufen		63610-08-2		
Indocyanin Green		3599-32-4		
Indometacin	1H-Indole-3-acetic acid, 1-(4-chlorobenzoyl)-5-methoxy-2-methyl- [CAS]	53-86-1		Formulation, modified-release, other
Indoprofen		31842-01-0		
Indoramin	Benzamide, N-[1-(2-(1H-indol-3-yl)ethyl)-4-piperidinyl]- [CAS]	26844-12-2 38821-52-2	GB 1218570	Antihypertensive, adrenergic
Inducterm			US 5993810	Labour inducer
Infliximab		170277-31-3		
In sin Pranobex		36703-88-5		
Inosit I		87-89-8		
In sitol Niacinate		6556112		
I benguane		80663-95-2		
Iobenzamic Acid		3115057		
Iobitridol		136949-58-1		
Iocarmic Acid		10397-75-8		
Iocetamic Acid		16034-77-8		
Iodamide		440-58-4		
Iodine, Symbolon	Iodine [CAS]	7553-56-2		Formulation, oral, other
Iodipamid		606-17-7		
Iodixanol		92339-11-2		
I d alphi nic Acid		577-91-3		
Iodochlorhydroxyquin	5-Chloro-7-iodo-8-quinolinol	130-26-7		Cognition enhancer
Iod f rm		75-47-8		
I dopyracet		300-37-8		
Iod pyrr le		87-58-1		
I d quin I		83-73-8		
I f tamin 1231		75917-92-9		

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
loglycamic Acid		2618-25-9		
l h xol		66108-95-0		
lomeglamic Acid		25827-76-3		
lomeprol		78649-41-9		
l pamidol		60166-93-0		
lopanoic Acid		96-83-3		
l pent l		89797-00-2		
l phenylat		99-79-6		
lophenoxic Acid		96-84-4		
l pr mid		73334-07-3		
lopr nic Acid		41473-08-9		
l pydol		5579-92-0		
l pyd n		5579-93-1		
l thalamic Acid		2276-90-6		
lotr lan		79770-24-4		
l v rs l		87771-40-2		
loxaglic Acid		59017-64-0		
loxilan		107793-72-6		
lP-751	(3R,4R)-(delta6)-THC-DMH-11-oic acid		WO 9401429	Analgesic, other
lpidacrine		62732-44-9		
	Stigmastan-15-one, 22,29-epoxy-3,4,6,7,29-pentahydroxy-, (3Alpha,4B,5Alpha,6Alpha,7B,14B,22S)-[CAS]			
lPL-576092		137571-30-3	US 6046185	Antialsthna
lpodat		5587-89-3		
lpratropium Bromide		22254-24-6		
lpratropium bromide		66985-17-9		Formulation, inhalable, solution
lpratropium, AeroDose	(endo,syn)-(+)-3-(3-Hydroxy-1-oxo-2-phenylpropoxy)-8-methyl-8-(1-methylethyl)-8-azorlabicyclo[3.2.1]octane			Formulation, inhalable, topical

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
iprazochrome	Hydrazinecarboxamide, 2-[(1,2,3,6-tetrahydro-3-hydroxy-1-(1-methylethyl)-6-oxo-5H-indol-5-ylidene)- [CAS]	7248-21-7		Haemostatic
ipriflavone	4H-1-Benzopyran-4-one, 7-[(1-methylethoxy)-3-phenyl- [CAS]	35212-22-7	EP 214647	Osteoporosis treatment
iprindole		5560-72-5		
iproclizid		3544-35-2		
iproniazid		54-92-2		
ipsapirone		95847-70-4		
irbesartan	2-n-butyl-4-spirocyclopentane-1-[(2-tetrazol-5-yl)biphenyl-4-yl)methyl]-2-imidazolin-5-one	138402-11-6	WO 9114679	Antihypertensive, renin system
IRFI-042	Butanedioic acid, mono[2-[2-(acetylthio)ethyl]-2,3-dihydro-4,8,7-trimethyl-5-benzofuranyl] ester, (+/-) [CAS]	134867-62-2	US 5114966	Cardiovascular
IRFI-165	N-Cyclopentyl-1-methylimidazo[1,2-a]quinoxalin-4-amine	191349-26-5	EP 865442	Antidepressant
Iridomyrmecin		485-43-8		
irindalone	-Imidazolidinone, 1-[2-[4-[3-(4-fluorophenyl)-2,3-dihydro-1H-inden-1-yl]-1-piperazinyl]ethyl]-, (1R-trans)- [CAS]	104113-57-7 96478-43-2	EP 183349	Antidepressant
Irinotecan		97682-44-5		
irofulven	Spiro[cyclopropane-1,5'-[5H]inden]-7'(6H)-one, 6'-hydroxy-2',4',6'-trimethyl-, (R)- [CAS]	125392-76-9	US 5563176	Anticancer, other
Iron Sorbitex		1338-16-5		
irsogladine	1,3,5-Triazine-2,4-diamine, 6-(2,5-dichlorophenyl)- [CAS]	57381-26-7 57381-28-9 57381-33-6	US 4657907	Antihypertensive, diuretic
IS-741	Cyclohexanecarboxamide, N-[2-[(ethylsulfonyl)amino]-5-(trifluoromethyl)-3-pyridinyl]- [CAS]	141283-87-6	EP 465913	GI Inflammatory/bowel disorders
isaglitazone	2,4-Thiazolidinedione, 5-[[6-[(2-fluorophenyl)methoxy]-2-naphthalenyl]methyl]-[CAS]	161600-01-7	US 5594016	Antidiabetic

TABLE 6

Example of Indication
Osteoporosis
Hypertension, general
Atherosclerosis
Depression, general
Depression, general
Cancer, prostate
Hypertension, general
Pancreatitis
Diabetes, Type II

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
ISAtx-247			NZ 502362	Immunosuppressant
Isbogr 1		89667-40-3		
Isopamcin	D-Streptamine, O-6-amino-6-deoxy-Alpha-D-glucopyranosyl-(1-4)-O-[3-deoxy-4-C-methyl-3-(methylamino)-B-L-arabinopyranosyl-(1-6)]-N1-(3-amino-2-hydroxy-1-oxopropyl)-2-deoxy-, (S)- [CAS]	58152-01-5 58152-03-7	US 4029882	Aminoglycoside antibiotic
Isoaminil		77-51-0		
Isobutyl p-Aminob nzoate		94-14-4		
Isocarboxazid		59-63-2		
Isocorazole	1-[2-(2,6-dichlorobenzoyloxy)-2-(2,4-dichlorophenyl)ethyl]	24168-98-5	GB 1244530	Antifungal
Isoc nazol		27523-40-6		
Isoetharine		530-08-5		
Isoloxethpin	1-Piperazineethanol, 4-[3-fluoro-10,11-dihydro-8-(1-methylethyl)dibenzolb, [thiepin-10-yl]- [CAS]	106819-39-0 106819-41-4 70931-18-9	GB 2010843	Neuroleptic
Isolurane	Ethane, 2-chloro-2-(difluoromethoxy)-1,1,1-trifluoro- [CAS]	26675-46-7	US 3535388	Anaesthetic, Inhalation
Is flur phat		55-91-4		
Isoladol		530-34-7		
Isomethadone		466-40-0		
Is meth ptene		503-01-5		
Is niazid		54-85-3		
Isonixin		57021-61-1		
Isopr methazine		303-14-0		
Is propamide iodide		71-81-8		
Isopr pyl Alcohol		67-63-0		
Isopropyl unoprostone	5-Heptenoic acid, 7-(3,5-dihydroxy-2-(3-oxododecyl)cyclopentyl)-, 1-methylethylester, (1R-(1Alpha(Z), 2B,3Alpha,5Alpha))- [CAS]	120373-24-2	EP 289349	Prostaglandin
Isoproter nol		7683-59-2		

TABLE 6

Example 1 Indication
Transplant rejection, general
Infection, dermatological
Infection, fungal, general
Anaesthesia
Glaucoma

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Isosorbide	D-Glucitol, 1,4:3,6-dianhydro-, dinitrate [CAS]	652-67-5		
Isosorbide dinitrate	D-Glucitol, 1,4:3,6-dianhydro-, 5-nitrate [CAS]	87-33-2		Formulation, modified-release, other
Isosorbide mononitrate		16051-77-7		Formulation, modified-release, other
Isotriphenyl		482-15-5		
Isotretinoin	Retinoic acid, 13-cis- [CAS]	4759-48-2	US 4843096	Antiacne
Isovaleryl Di thylamide		533-32-4		
Is x pac		55453-87-7		
Isoxicam		34552-84-6		
Is xsuprin		395-28-8		
Isradipine	3,5-Pyridinedicarboxylic acid, 4-(4-benzofurazanyl)-1,4-dihydro-2,8-dimethyl-, methyl 1-methylethyl ester [CAS]	75695-93-1	GB 2037766	Antihypertensive, other
Israpafant	6H-Thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine, 4-(2-chlorophenyl)-6,9-dimethyl-2-[2-(4-(2-methylpropyl)phenyl)ethyl]-[CAS]	117279-73-9	EP 268242	Antiasthma
ISV-403			US 5447926	Formulation, mucosal, topical
Itas tron		123258-84-4		
ITF-282	ITF 282 [CAS]	93615-44-2	GB 2115821	Antianaemic
Itopride	Benzamide, N-[4-[2-(dimethylamino)ethoxy]phenyl]methyl]-3,4-dimethoxy-, monohydrochloride [CAS]	122892-31-3	EP 306827	Gastroprokinetic
Itraconazole	3H-1,2,4-Triazol-3-one, 4-[4-[4-[2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-yl)methyl]-1,3-dioxolan-4-yl]methoxy]phenyl]-1-piperazinylphenyl]-2,4-dihydro-2-(1-methylpropyl)- [CAS]	84625-61-6	EP 6711	Antifungal
ltramim T sylate		13445-63-1		

TABLE 6

Example of Indication
Angina, general
Angina, general
Acne
Hypertension, general
Asthma
Conjunctivitis
Anaemia, general
Gastritis
Infection, fungal, general

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
litiglumide	1-Naphthalenepropanoic acid, 8-[2-[2-(8-azaspiro[4.5]dec-8-ylcarbonyl)-4,6-dimethylphenylamino]-2-oxoethyl]-, (9R)-[CAS]	201605-51-8	WO 9800404	Anxiolytic
litrelax	D-Alaninamide N-acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridinyl)-D-alanyl-L-seryl-N6-(3-pyridinylcarbonyl)-L-lysyl-N6-(3-pyridinylcarbonyl)-D-lysyl-L-leucyl-N6-(1-methylethyl)-L-lysyl-L-prolyl- [CAS]	112568-12-4	WO 8901944	Fertility enhancer
lvabradine hydrochloride	7,8-dimethoxy-3-(3-[(1S)/(4,5-dimethoxybenzocyclobutan-1-yl)methyl]methylamino)propyl)-1,3,4,5-tetrahydro-2H-benzazepin-2-one hydrochloride			Antianginal
lixabepilone	17-Oxa-4-azabicyclo(14.1.0)heptadecane-5,9-dione, 7,11-dihydroxy-8,8,10,12,16-pentamethyl-3-(1-methyl-2-(2-methyl-4-thiazolyl)ethenyl, (1R,3S,7S,10R,11S,12S,16R) [CAS]	219989-84-1		Anticancer, other
J-104132	5H-Cyclopenta[b]pyridine-8-carboxylic acid, 5-(1,3-benzodioxol-5-yl)-2-butyl-7-[2[(2S)-2-carboxypropyl]-4-methoxyphenyl]-6,7-dihydro-, (5S,6R,7R)- [CAS]	198279-45-7	WO 9737665	Antihypertensive, other
J-107088	5H-Indolo(2,3-a)pyrrolo(3,4-c)carbazole-5,7(6H)-dione, 12-B-D-glucopyranosyl-12,13-dihydro-2,10-dihydroxy-6-(2-hydroxy-1-(hydroxymethyl)ethyl)amino-[CAS]	174402-32-5		Anticancer, other
J-113397	1-[(3R,4R)-1-Cyclooctylmethyl-3-hydroxymethyl]-4-piperidyl-3-ethyl-1,3-dihydro-2H-benzimidazole-2-one			Analgesic, other
Janex-1	Phenol, 4-[(6,7-dimethoxy-4-quinazolinyl)amino]-[CAS]	202475-60-3		Anticancer, other

TABLE 6

Example of Indication
Anxiety, general
Infertility, female
Angina, general
Cancer, breast
Heart failure
Cancer, bladder
Pain, general
Cancer, leukaemia, general

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
fosamycin	Leucomycin V, 3-acetate 4B-(3-methylbutanoate) [CAS]	16846-24-5	JP 41021759	Macrolide antibiotic
JTV-519	1,4-Benzothiazepine, 2,3,4,5-tetrahydro-7-methoxy-4-[1'-oxo-3-[4-(phenylmethyl)-1-piperidinyl]propyl]- [CAS]	145903-06-6	WO 9212148	Cardiovascular
K-777			US 6287840	Protozoacide
Kainic Acid		487-79-6		
Kalimate	Kalimate- [CAS]	92354-70-6		Urological
Kallidin		342-10-9		
KB-130015	Acetic acid (2,8-dichloro-4-[(2-methyl-3-benzofuran-2-yl)methyl]phenox)- [CAS]	147030-48-6		Antiarrhythmic
KCB-328	Methanesulfonamide, N-[3-amino-4-[2-[(2-(3,4-dimethoxyphenyl)ethyl]methylamino]ethoxy]phenyl]-, monohydrochloride [CAS]	177596-55-3	WO 9604231	Antiarrhythmic
K buzone		853-34-9		
ketamine	2-(2-Chlorophenyl)-2-(methylamino)-cyclohexanone hydrochloride	6740-88-1		Formulation, transmucosal, nasal
ketanserim	2,4(1H,3H)-Quinazolin-2-one, 3-[2-[4-(4-fluorobenzoyl)-1-piperidinyl]ethyl]-[CAS]	74050-98-9 83846-83-7	EP 13612	Antihypertensive, other
ketazolam	4H-[1,3]Oxazino[3,2-d][1,4]benzodiazepine-4,7(6H)-dione, 11-chloro-8,12b-dihydro-2,8-dimethyl-12b-phenyl- [CAS]	27223-35-4	GB 1222284	Anxiolytic
K th xal		27762-78-3		
K t bemid n		469-79-4		
ketoconazole	Piperazine, 1-acetyl-4-[4-[(2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl)methoxy]phenyl]-, cis- [CAS]	65277-42-1	US 4335125	Antifungal
ketoprofen lysine salt	DL-Lysine, mono(3-benzoyl-Alpha-methylbenzeneacetate) [CAS]	173011-11-5	EP 502502	Formulation, transdermal, systemic
ketorolac	1H-Pyrrolizine-1-carboxylic acid, 5-benzoyl-2,3-dihydro-, (+/-)- [CAS]	74103-07-4	EP 53021	Analgesic, NSAID

TABLE 6

Exempl of Indication
Infection, general
Infarction, myocardial
Infection, trypanosomiasis, American
Arrhythmia, general
Arrhythmia, general
Pain, post-operative
Hypertension, general
Infection, fungal, general
Pain, general

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
<i>Ketorolac Tromethamine</i>				
Ketotifen		34580-13-7		
ketotifen fumarate	10H-Benzol[4,5]cyclohepta[1,2-b]thiophen-10-one, 4,9-dihydro-4-(1-methyl-4-piperidinylidene)-, (E)-2-butenedioate (1:1)-[CAS]	34580-14-8		Formulation, modified-release, ≤24hr
ketotifen hydrogen fumarate	10-H-Benzol[4,5]cyclohepta[1,2-b]thiophen-10-one, 4,9-dihydro-4-(1-methyl-4-piperidinylidene)-, (E)-2-butenedioate (1:1)-[CAS]	34580-13-7 34580-14-8	GB 1355539	Antiasthma
Khellin		82-02-0		
khellin		9001-29-0		Dermatological
	4-Thiazolidinecarboxamide, N-(1,1-dimethylethyl)-3-[2-hydroxy-3-[[2-[[[5-isoquinolinol(oxo)acetyl]amino]-3-(methylthio)-1-oxopropyl]amino]-1-oxo-4-phenylbutyl]-, [4R-[3[2S',3S'(R')],4R']]-[CAS]	147318-81-8	US 5644028	Antiviral, anti-HIV
KNI-272	(R,R)-2-(2,4-Difluorophenyl)-3-(4-methylepipiperidin-1-yl)-1-(1,2,4-triazol-1-yl)-2-butanol			Antifungal
KP-103			US 6110961	Antidepressant
KP-157			WO 9919305	Cognition enhancer
KP-544				
	L-glycero-β-L-manno-Heptopyranosylamine, 4-deoxy-4-[[[[(2E,4E)-1-oxo-2,4-tetradecadienyl]amino]acetyl]amino]-N-1H-purin-6-yl-[CAS]			Anticancer, antibiotic
KRN-5500		151276-95-8	WO 9015811	
	Alpha-D-Glucopyranoside, β-D-fructofuranosyl, mixt. with 1-ethenyl-2-pyrrolidinone homopolymer compd. with iodine [CAS]			Formulation, dermal, topical
KT-136		121602-88-8		

TABLE 6

Example of Indication
Asthma
Asthma
Photodamage
Infection, HIV/AIDS
Infection, general
Depression, general
Unspecified
Cancer, colorectal
Ulcer, decubitus

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
KUL-7211	(-)-2-[(2S)-1,2,3,4-tetrahydro-2-[(1R)-2-hydroxy-2-(4-hydroxyphenyl)ethyl]amino]naphthalen-7-yloxy]-N,N-dimethylacetamide hydrochloride monohydrate			Urological
KW-2170	6H-Pyrazolo[4,5,1-de]acridin-8-one-5-[(3-aminopropyl)amino]-7,10-dihydroxy-2-[(2-hydroxyethyl)amino]methyl-, dihydrochloride [CAS]	207862-44-0		Anticancer, alkylating
KW-6002	1H-Purine-2,6-dione, 8-(2-(3,4-dimethoxyphenyl)ethyl)-1,3-diethyl-3,7-dihydro-7-methyl- (E)- [CAS]	155270-99-8		Antiparkinsonian
KW-7158	3,3,3-Trifluoro-2-hydroxy-2-methyl-N-(10-oxo-4,10-dihydrothieno[3,2-C][1]benzothiepin-9-yl)propanamide 5,5 dioxide			
L-365260	Urea, N-(2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-(3-methylphenyl)-, (R)- [CAS]	118101-09-0	EP 284256	Anticancer, other
L-5-hydroxytryptophan	L-Tryptophan, 5-hydroxy- [CAS]	4350-09-8		Metabolic and enzyme disorders
L-745337	Methanesulfonamide, N-[6-(2,4-difluorophenyl)thio]-2,3-dihydro-1-oxo-1H-inden-5-yl]- [CAS]	158205-05-1	WO 9413635	Analgesic, NSAID
L-758298	Phosphonic acid, [3-[(2R,3S)-2-((1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy)-3-(4-fluorophenyl)-4-morpholinyl)methyl]-2,5-dihydro-5-oxo-1H-1,2,4-triazol-1-yl]- [CAS]	172673-20-0	WO 9523798	Antiemetic
L-826141			WO 9722585	Antiasthma
labetalol	5-[1-hydroxy-2-[(1-methyl-3-phenylpropyl)amino]ethyl]salicylamide HCl	32780-64-6 36894-69-6	US 4012444	Antihypertensive, adrenergic
lacidipine	3,5-Pyridinedicarboxylic acid, 4-[2-[3-(1,1-dimethylethoxy)-3-oxo-1-propenyl]phenyl]-1,4-dihydro-2,6-dimethyl-, diethyl ester, (E)- [CAS]	103890-78-4	GB 2164336	Antihypertensive, other

TABLE 6

Example of Indication
Urinary calculus
Cancer, lung, non-small cell
Parkinson's disease
Incontinence
Cancer, general
Unspecified
Pain, general
Chemotherapy-induced nausea and vomiting
Unspecified
Hypertension, general

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
<i>Lactic Acid</i>				
lactitol	D-Glucitol, 4-O-β-D-galactopyranosyl- [CAS]	585-86-4		Hepatoprotective
Lactit I		585-86-4		
Lactulose		4618-18-2		
lafutidine	Acetamide, 2-[(2-furanyl(methyl)sulfinyl)-N- [4-[(1-piperidinyl(methyl)-2-pyridinyl]oxy]- 2-butenyl]-, (Z)- [CAS]	118288-08-7	EP 282077	Antilulcer
Lafutidine		118288-08-7; 169899-19-8		
Lamifiban		144412-49-7		
lamivudine	2(1H)-Pyrimidinone, 4-amino-1-[2- (hydroxymethyl)-1,3-oxathiolan-5-yl], (2R- cis)- [CAS]	134678-17-4	EP 513917	Antiviral, anti-HIV
lamotrigine	1,2,4-Triazine-3,5-diamine, 6-(2,3- dichlorophenyl)- [CAS]	84057-84-1	EP 21121	Antiepileptic
landiolol	Benzene propanoic acid, 4-[2-hydroxy-3-[[2- [(4-morpholinylcarbonyl)amino]ethyl]amino]pro- poxyl-, (2,2-dimethyl-1,3-dioxolan-4- yl)methyl ester, [S-(R*,R*)]- HCL			
landiolol	(S)-Alpha-phenyl-2-pyridine ethanamine dihydrochloride	133242-30-5	EP 397031	Antiarrhythmic
lanicemine		153322-05-5		Neurological
laniquidar	Methyl 6,11-dihydro-11'-[1'-[2-[4-(2- quinolylmethoxy)phenyl]ethyl]-4- piperidinylidene]-5H-imidazo[2,1- b][3]benzazepine-3-carboxylate	197509-46-9	WO 9734897	Radio/chemosensitizer
lanconazole	1H-Imidazole-1-acetonitrile, Alpha-[4-(2- chlorophenyl)-1,3-dithiolan-2-ylidene]-, (E)- (+)- [CAS]	101530-10-3	US 4738976	Antifungal
Lanot plase		171870-23-8		
Lanreotid		108736-35-2		
lansoprazole	1H-Benzimidazole, 2-[[[3-methyl-4-(2,2,2- trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]- [CAS]	103577-45-3	EP 174726	Antilulcer

TABLE 6

Example 1 Indication
Infection, neurological
Ulcer, gastric
Infection, HIV/AIDS
Epilepsy, partial (focal, local)
Tachycardia, general
Unspecified
Cancer, general
Infection, fungal, general
Ulcer, duodenal

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
lanthanum carbonate	Carbonic acid, lanthanum(3+) salt (3:2)[CAS]	587-26-8	US 5968976	Urological
lapatinib ditosylate	4-Quinazolinamine, N-[3-chloro-4-[(3-fluorobenzyl)methoxy phenyl]-6-[5-[[2-(methylsulfonyl)ethyl]amino]methyl]furan-2-yl] bis (4-methylbenzenesulfonate) monohydrate			
laquinimod		388082-78-8 248281-84-7		Anticancer, other Multiple sclerosis treatment
lasofoxiene	2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-(4-(2-(1-pyrrolidinyl)ethoxy)phenyl) (5R-cis)-, (S-(R*, R*))-2,3-dihydroxybutanedioate [CAS]	190791-29-8	WO 9718434	Menopausal disorders
latamoxef	5-Oxa-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[carboxy(4-hydroxyphenyl)acetyl]amino]-7-methoxy-3-[[[(1-methyl-1H-tetrazol-5-yl)thio]methyl]-8-oxo- [CAS]	64952-97-2 64953-12-4	GB 1547351	Beta-lactam antibiotic
latanoprost	5-Heptenoic acid, 7-(3,5-dihydroxy-2-(3-hydroxy-5-phenylpentyl)cyclopentyl)-, 1-methylethyl ester, (1R-(1Alpha(Z),2B(R*),3Alpha,5Alpha))- [CAS]	130209-82-4	WO 9002553	Prostaglandin
Lauroguadin		135-43-3		
Laur linium Acetate		146-37-2		
Lawson		83-72-7		
LAX-111	1-(Z,Z,Z,Z-icos-5,8,11,14,17-pentaenoyloxy)-3-(Z,Z,Z,Z-icos-5,8,11,14,17-pentaenoyloxy)-propane			Neuroleptic
Lazabemide		103878-84-8		
LB-30057	Benzenecarboximidic acid, 4-[(2S)-3-(cyclopentylmethylamino)-2-[(2-naphthalenylsulfonyl)amino]-3-oxopropyl]-, hydrazide [CAS]		WO 9749873	Antithrombotic

TABLE 6

Examp ^l of Indication
Hyperphosphataemia
Cancer, breast
Multiple sclerosis, general
Hormone replacement therapy
Infection, general
Glaucoma
Schizophrenia
Thrombosis, venous

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
L-Cystine, Inositol, Methionine, Sodium Propionate, Urea				
Lefetamine		7262-75-1		
leflunomide	4-Isoxazolecarboxamide, 5-methyl-N-[4-(trifluoromethyl)phenyl]- [CAS]	75706-12-6	EP 13376	Antiarthritic, immunological
leflunomide	4-Isoxazolecarboxamide, 5-methyl-N-[4-(trifluoromethyl)phenyl]- [CAS]	104981-93-3 75706-12-6	US 5610173	Anticancer, other
Leleopyrr I		5633-16-9		
	4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[(aminophenylacetyl)amino]-3,3-dimethyl-7-oxo-, (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester, [2S-][2Alpha,5Alpha,6S(S*)]- [CAS]	80734-02-7 86273-18-9	EP 61206	Penicillin, oral
lenampicillin		37339-90-5		Anticancer, immunological
lentiman, Ajinomoto	Lentiman [CAS]			
Lepirudin				
	3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 2-[(3,3-diphenylpropyl)methylamino]-1,1-dimethylethyl methyl ester, hydrochloride [CAS]	100427-26-7 132866-11-6	US 4705797	Antihypertensive, other
lercanidipine				
lerisetron	1H-Benzimidazole, 1-(phenylmethyl)-2-(1-piperazinyl)- [CAS]	143257-98-1	US 5256665	Antiemetic
L s pitr n		132449-46-8		
leleprinin	Benzoic acid, 4-[(3-(1,6-dihydro-6-oxo-9H-purin-9-yl)-1-oxopropyl)amino]-, monopotassium salt [CAS]	138117-50-7	US 6338963	Antiparkinsonian
leleosteine	4-Thiazolidinecarboxylic acid, 2-[2-(ethoxy-2-oxoethyl)thio]ethyl- [CAS]	53943-88-7	US 4032534	COPD treatment
leletozole	Benzonitrile, 4,4'-(1H-1,2,4-triazol-1-yl)methylene)bis- [CAS]	112809-51-5	EP 236940	Anticancer, hormonal
Leucocyanidin		480-17-1		
Leupr lide		53714-56-0		

TABLE 6

Exempl of Indication
Arthritis, rheumatoid
Cancer, ovarian
Infection, general
Cancer, stomach
Hypertension, general
Nausea and vomiting, general
Parkinson's disease
Bronchitis, chronic
Cancer, breast

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
leuprolide acetate	Luteinizing hormone-releasing factor (p/g), 6-D-leucine-9-(N-ethyl-L-prolinamide)-10-deglycinamide-, monoacetate (salt) [CAS]	53714-56-0 74381-53-6		Formulation, implant
leuporelin	Luteinizing hormone-releasing factor (p/g), 6-D-leucine-9-(N-ethyl-L-prolinamide)-10-deglycinamide- [CAS]	53714-56-0		Formulation, implant
Levallorphan		152-02-3		
levamisole	Imidazo[2,1-b]thiazole, 2,3,5,6-tetrahydro-6-phenyl-, (S)- [CAS]	14769-73-4 16595-80-5	US 4584305	Anthelmintic
Levamisole		14769-73-4		
Levromakalim		94535-50-9		
levetiracetam	1-Pyrrolidineacetamide, Alpha-ethyl-2-oxo-, (S)- [CAS]	102767-28-2	EP 162036	Antiepileptic
levobetaxolol	2-Propanol, 1-(4-(2-(cyclopropylmethoxy)ethyl)phenoxy)-3-((1-methylethyl)amino) hydrochloride [CAS]	116209-55-3		Formulation, mucosal, topical
levobunolol	1-(2H)-Naphthalenone, 5-[3-(1,1-dimethylethylamino)-2-hydroxypropoxy]-3,4-dihydro-, (S)- [CAS]	27912-14-7 47141-42-4	US 3641152	Formulation, mucosal, topical
levobupivacaine	2-Piperidinecarboxamide, 1-butyl-N-(2,6-dimethylphenyl)-, (S)- [CAS]	27262-47-1	WO 9510276	Anaesthetic, injectable
levocabastine	4-Piperidinecarboxylic acid, 1-[4-cyano-4-(4-fluorophenyl)cyclohexyl]-3-methyl-4-phenyl-, [3S-(1(cis),3Alpha,4R)]- [CAS]	78449-98-2 79516-68-0 79547-78-7	US 4369184	Antiallergic, non-asthma
levocetirizine	Acetic acid, (2-(4-(4-chlorophenyl)phenylmethyl)-1-piperazinyl)ethoxy-, (R)- [CAS]	130018-77-8	WO 9406429	Antiallergic, non-asthma
Levodopa		59-92-7		
levodropropizine	1,2-Propanediol, 3-(4-phenyl-1-piperazinyl)-, (S)- [CAS]	99291-25-5	EP 147847	Antitussive
levofloxacin	7H-Pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid, 9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-, (S)- [CAS]	100986-85-4 138199-71-0	EP 206283	Quinolone antibacterial

TABLE 6

Exempl f Indication
Cancer, prostate
Cancer, prostate
Infection, helminth, general
Epilepsy, general
Glaucoma
Glaucoma
Anaesthesia
Rhinitis, allergic, general
Allergy, general
Cough
Infection, respiratory tract, lower

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
L vom thadyl Acetate		1477-40-3		
levomoprolol	2-Propanol, 1-(2-methoxyphenoxy)-3-[(1-methylethyl)amino]-, (S)- [CAS]	27058-84-0 5741-22-0 77184-20-6	EP 15418	Antihypertensive, adrenergic
levonorgestrel, Leiras	18,19-Dinorgestrel-4-en-20-yn-3-one, 13-ethyl-17-hydroxy-, (17 α)- [CAS]	797-63-7		Formulation, implant
L v phacet perane		24558-01-8		
L vopropoxyphene		2338-37-6		
L v rphan I		77-07-6		
levosimendan	Propanedinitrile, [[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]hydrazono]-, (R)- [CAS]	131741-08-7 141505-33-1	EP 383449	Cardio stimulant
Levosimendan		141505-33-1		
levosulpiride	Benzamide, 5-(aminosulfonyl)-N-[(1-ethyl-2-pyrrolidinyl)methyl]-2-methoxy-, (S)- [CAS]	23672-07-3	GB 2014990	Antiemetic
Levothyroxine Sodium				
levovirin	1- β -L-ribofuranosyl-1,2,4-triazole-3-carboxamide			Antiviral, other
lexipafant	L-Leucine, N-methyl-N-[[4-[(2-methyl-1H-imidazo[4,5-c]pyridin-1-yl)methyl]phenyl]sulfonyl]-, ethyl ester- [CAS]	139133-26-9	WO 9203423	Neurological
LF-15-0185			WO 9624579	Immunosuppressant
LF-16-0887	2-Pyrrolidinecarboxamide, N-[3-[(4-aminolinomethyl)benzoyl]amino]propyl]-1-[[2,4-dichloro-3-[(2,4-dimethyl-8-quinolinyl)oxy]methyl]phenyl]sulfonyl]-, (2S) [CAS]	209733-45-9	FR 2756562	Neuroprotective
LGD-1550	2,4,6-Octatrienolic acid, 7-(3,5-bis(1,1-dimethylethyl)phenyl)-3-methyl-, (2E,4E,6E) [CAS]	178600-20-9		Anticancer, other

TABLE 6

Example of Indication
Contraceptive, female
Heart failure
Dyspepsia
Infection, hepatitis-C virus
Dementia, AIDS-related
Lupus erythematosus, general
Head trauma
Cancer, cervical

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
LH		9002-67-9		
LH-RH		9034-40-6		
liarazole	1H-Benzimidazole, 5-[(3-chlorophenyl)-1H-imidazol-1-ylmethyl]- [CAS]	115575-11-6		Formulation, other
licofelone	1H-Pyrrolizine-5-acetic acid, 6-(4-chlorophenyl)-2,3-dihydro-2,2-dimethyl-7-phenyl- [CAS]	156897-08-2		Antiarthritic, other
Licostinel		153504-81-5		
lidacronate	Phosphonic acid, [1-amino-3-(dimethylamino)propylidene]bis- [CAS]	63132-38-7	WO 9702827	Urological
Lidamide		66871-56-5		
lidocaine	Acetamide, 2-(diethylamino)-N-(2,6-dimethylphenyl)- [CAS]	137-58-6		Formulation, transdermal, patch
Lid fenin		59160-29-1		
Lidoflazine		3416-26-0		
limaprost	Prosta-2,13-dien-1-olc acid, 11,15-dihydroxy-17,20-dimethyl-9-oxo-, (2E,11Alpha,13E,15S,17S)-, [CAS]	74397-12-9	GB 2041368	Prostaglandin
Line mycin		154-21-2		
Lindan		58-89-9		
linezolid	Acetamide, N-[(3-(3-fluoro-4-(4-morpholinyl)phenyl)-2-oxo-5-oxazolidinyl)methyl]-, (S)- [CAS]	165800-08-3	WO 9507271	Antibiotic, other
Lin l ic Acid		60-33-3		
Lin lenic Acid		463-40-1		
Liothyr nin		6893023		
Lipas		9001-62-1		
Lipo-dexamethasone palmitate	Pregna-1,4-diene-3,20-dione, 9-fluoro-11,17-dihydroxy-16-methyl-21-[(1-oxohexadecyl)oxy]-, (11B,16Alpha)- [CAS]	14898-38-6		Formulation, optimized, microemulsion
lipo-flurbiprofen	[1,1'-Biphenyl]-4-acetic acid, 2-fluoro-Alpha-methyl-, 1-(acetyloxy)ethyl ester [CAS]	91503-79-6	JP 60208910	Formulation, optimized, microemulsion
Lipogel HA			EP 525655	Formulation, optimized, liposomes
LiquiVent	perfluorooctylbromide	423-55-2	US 5437272	Lung Surfactant

TABLE 6

Example f Indication
Psoriasis
Arthritis, osteo
Unspecified
Pain, post-herpetic
Buerger's syndrome
Infection, dermatological
Arthritis, rheumatoid
Pain, cancer
Unspecified
Respiratory distress syndrome, adult

TABLE 6

API Gen ric Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
litranafate	Carbamothioic acid, (6-methoxy-2-pyridinyl)methyl-, O-(5,6,7,8-tetrahydro-2-naphthalenyl) ester [CAS]	88678-31-3	GB 2124617	Antifungal
lisinopril	L-Proline, 1-(N2-(1-carboxy-3-phenylpropyl)-L-tyl)-, (S)- [CAS]	76547-98-3 83915-83-7	EP 12401	Antihypertensive, renin system
LLs fylin		100324-81-0		
Lisuride		18016-80-3		
lisuride hydrogen maleate	Urea, N-[(8Alpha)-9,10-didehydro-6-methylergolin-8-yl]-N,N-diethyl-, (Z)-2-butenedicate (1:1) [CAS]	19875-60-6 305-13-5		Antiprolactin
Lithium Citrat		919-16-4		
lithium	Carbonic acid, dilithium salt [CAS]	554-13-2		Formulation, modified-release, <=24hr
livaptan	Benzamide, N-[3-chloro-4-(5H-pyrrolo[2,1-c][1,4]benzodiazepin-10(11H)-ylcarbonyl)phenyl]-5-fluoro-2-methyl- [CAS]	168079-32-1	US 5736540	Cardiovascular
LJP-1082			US 6207160	Immunosuppressant
LLUAlpha	S-2,7,8-Trimethyl-6-(beta-carboxyethyl)-6-hydroxychroman			Antihypertensive, other
LMP-160			US 5643893	Antiasthma
LMP-420			US 5643893	Antiartritic, other
lobaplatin	Platinum, (1,2-cyclobutanedimethanamine-N,N')[2-hydroxypropanoato(2-)-O1,O2]-, [SP-4-3(S),(trans)]- [CAS]			
Lobelin		135558-11-1	DE 4115559	Anticancer, alkylating
L b nzarit		90-69-7		
L doxamide		63329-53-3		
		53882-12-5		
lodoxamide tromethamine	2,2'-(2-chloro-5-cyano-1,3-phenylene)dilimino)bis(2-oxoacetate):2-amino-2-(hydroxymethyl)-1,3-propanediol (1:2)			
Lofentanil		63610-09-3	US 4439445	Antiasthma
		61380-40-3		

TABLE 6

Examp! f Indication
Infection, dermatological
Hypertension, general
Acromegaly
Depression, bipolar
Heart failure
Thrombosis, venous
Hypertension, general
Asthma
Arthritis, rheumatoid
Cancer, lung, small cell
Asthma

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
lofepramine	Ethanone, 1-(4-chlorophenyl)-2-[[3-(10,11-dihydro-5H-dibenz[b,f]azepin-5-yl)propyl]methylamino]- [CAS]	23047-25-8 26786-32-3	GB 1177525	Antidepressant
lofexidine	1H-Imidazole, 2-[1-(2,6-dichlorophenoxy)ethyl]-4,5-dihydro- [CAS]	31036-90-3	GB 1181356	Antihypertensive, adrenergic
L flucarban		790-69-2		
	3-Quinolincarboxylic acid, 1-ethyl-6,8-difluoro-1,4-dihydro-7-(3-methyl-1-piperazinyl)-4-oxo- [CAS]	98079-51-7 98079-52-8		
lomeloxacin			EP 140116	Quinolone antibacterial
Lomerizine		101477-55-8		
	Piperazine, 1-[bis(4-fluorophenyl)methyl]-4-[(2,3,4-trimethoxyphenyl)methyl]-, dihydrochloride- [CAS]	101477-54-7	EP 159566	Antimigraine
lormetazine hydrochloride		10226-54-7	DE 2207860	Neurological
lormetazine	7-(5-oxohexyl)theophylline			
lomustine	Urea, N-(2-chloroethyl)-N'-cyclohexyl-N-nitroso- [CAS]	13010-47-4	JP 48075526	Anticancer, alkylating
L mustine		13010-47-4		
	1-Piperidinecarboxamide, 4-[2-[4-[(1R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-piperidinyl]-2-oxoethyl]- [CAS]	193275-84-2	US 5874442	Anticancer, other
lonafarnib		91431-42-4		
Lonapalen		53808-88-1		
Lonaz lac				
lonidamine	1H-Indazole-3-carboxylic acid, 1-(2,4-dichlorophenyl)methyl- [CAS]	50264-69-2	DE 2310031	Radio/chemosensitizer
loperamide	4-(p-chlorophenyl)-4-hydroxy-N,N-dimethyl-Alpha,Alpha-diphenyl-1-piperidine butyramide HCl	34552-83-5 53179-11-6	US 3714159	Antidiarrhoeal
	1-Piperidinebutanamide, 4-(4-chlorophenyl)-4-hydroxy-N,N-dimethyl-Alpha,Alpha-diphenyl-, 1-oxide, trans- [CAS]			
loperamide oxide	4-(p-Chlorophenyl)-4-hydroxy-N,N-dimethyl-Alpha,Alpha-diphenyl-1-piperidinebutyramide HCl	108900-12-3	EP 219898	Antidiarrhoeal
loperamide		34552-83-5 53179-11-6		Formulation, dermal, topical

TABLE 6

Exempl f Indication
Hypertension, general
Infection, respiratory tract, lower
Migraine
Cancer, lung, non-small cell
Cancer, breast
Diarrhoea, general
Diarrhoea, general
Pain, general

TABLE 6

Example. 1 Indication
Infection, HIV/AIDS
Infection, respiratory tract, lower
Rhinitis, allergic, general
Epilepsy, general
Insomnia

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
lomoxicam	2H-Thieno[2,3-e]-1,2-thiazine-3-carboxamide, 6-chloro-4-hydroxy-2-methyl-N-2-pyridinyl-, 1,1-dioxide- [CAS]	70374-39-9	EP 313935	Analgesic, NSAID
L. sartan		114798-26-4		
losartan potassium	1H-Imidazole-5-methanol, 2-butyl-4-chloro-1-[[2'-(1H-tetrazol-5-yl)]1,1'-biphenyl]-4-yl[methyl]-, monopotassium salt [CAS]	124750-99-8	EP 253310	Antihypertensive, renin system
loteprednol etabonate	Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyloxy)-11-hydroxy-3-oxo-, chloromethyl ester, (11b,17Alpha)- [CAS]	82034-46-8	GB 2079755	Anti-inflammatory, topical
L. trafiban		171049-14-2		
Lovastatin		75330-75-5		
Loxapin		10/2/1977		
loxiglumide	Pentanoic acid, 4-[(3,4-dichlorobenzoyl)amino]-5-[(3-methoxypropyl)pentylamino]-5-oxo-, (±)- [CAS]	107097-80-3	WO 8703869	GI inflammatory/bowel disorders
loxoprofen	Benzeneacetic acid, Alpha-methyl-4-[(2-oxocyclopentyl)methyl]- [CAS]	68767-14-8 80382-23-6 87828-36-2	EP 55588	Antiarthritic, other
Lu-35-138	1-[3]2-[5-chloro-1-(4-fluorophenyl)-3-1H-indolyl]ethyl[methylamino]propyl-2-imidazolidinone hydrochloride		WO 9516684	Neuroleptic
Lubeluz le		144665-07-6		
lubiprostone	(-)-7-[(2R,4aR,5R,7aR)-2-(1,1-difluoropentyl)-2-hydroxy-6-oxooctahydrocyclopenta[b]pyran-5-yl]heptanoic acid	136790-76-6		Laxative
lucanthone	Thioxanthene-9-one, 1-[(2-(diethylamino)ethyl)amino-4-methyl- [CAS]	479-50-5		Radio/chemosensitizer
Lucanthone Hydr chloride		548-57-2		
Lumefantrine		82186-77-4		

TABLE 6

Examp ^l of Indication
Pain, post-operative
Hypertension, general
Uveitis
Pancreatitis
Arthritis, rheumatoid
Psychosis, general
Constipation
Cancer, brain

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
lumiracoxib	Benzeneacetic acid, 2-[(2-chloro-6-(fluorophenyl)amino)-5-methyl- [CAS]	220991-20-8		Analgescic, NSAID
lutetecan hydrochloride, OSI	11H-1,4-Dioxino[2,3-g]pyrano[3',4':6,7]indolizino[1,2-b]quinoline-9,12[8H,14H]-dione, 8-ethyl-2,3-dihydro-8-hydroxy-15-[[4-methyl-1-piperazinyl]methyl], dihydrochloride, [S]- [CAS]	155773-58-3		Formulation, optimized, liposomes
lutetium texaphyrin	Lutetium, bis(acetato-O)[9,10-diethyl-20,21-bis-[2-(2-methoxyethoxy)ethoxy]ethoxy]-4,15-dimethyl-8,11-imino-3,6:16,13-dinitrilo-1,18-benzodiazacycloicosine-5,14-dipropionato-N1,N18,N23,N24,N25]-, (PB-7-11-233'2'4)- [CAS]	156438-90-7	WO 9906411	Radio/chemosensitizer
LV-216	Zinc[2-(2,6-dichloroanilino)phenyl]acetate			Anti-inflammatory
LX-104	Hexadecanamide, N-[4-[2-[2-[2-[O-(N-acetyl-Alpha-neuraminosyl)-(2-3)-O-8-D-galactopyranosyl-(1-4)-O-(6-deoxy-Alpha-L-galactopyranosyl-(1-3))-8-D-glucopyranosyl]oxy]ethoxy]ethoxy]ethoxymethyl]phenyl]-2-tetradecyl- [CAS]	158792-45-1		Cognition enhancer
LY-156735	B-methyl-6-chloromelatonin		EP 655243	Hypnotic/Sedative
LY-293111	Benzoic acid, 2-[3-{3-[(5-ethyl-4'-fluoro-2-hydroxy[1,1'-biphenyl]-4-yl)oxy]propoxy]-2-propylphenoxy]- [CAS]	161172-51-6		Anticancer, other
LY-293558	3-Isoquinolinecarboxylic acid, decahydro-6-[2-(1H-tetrazol-5-yl)ethyl]-, [3S-(3Alpha,4aAlpha,6B,8aAlpha)]- [CAS]	154652-83-2		Analgescic, other
LY-355703	1,4-Dioxo-8,11-diazacyclohexadec-13-ene-2,5,9,12-tetrone, 10-[(3-chloro-4-methoxyphenyl)methyl]-6,6-dimethyl-3-(2-methylpropyl)-16-[(1S)-1-(2S,3R)-3-phenylloxiranyl]ethyl]-, (3S,10R,13E,16S)- [CAS]	18256-67-7	WO 9707798	Anticancer, other
Lyapolat S dium		25053-27-4		

TABLE 6

Example of Indication
Pain, general
Cancer, ovarian
Atherosclerosis
Arthritis, rheumatoid
Dementia, senile, general
Sleep disorder, general
Cancer, melanoma
Pain, neuropathic
Cancer, lung, non-small cell

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Lym cyclin		992-21-2		
Lynestrenol		52-76-6		
Lypressin		50-57-7		
Lysine Acetylsalicylate		62952-06-1		
lysine salicylate	L-Lysine, 2-hydroxybenzoate [CAS]	59535-08-9	WO 9824331	Anaesthetic, NSAID
lysophospholipids, Atargin			WO 9843093	Diagnostic
M-40403	Dichloro[(4aR,13aR,17aR,21aR)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-icosahydro-1,7-nitro-7H-dibenzo[b,h] [1,4,7,10]tetraazacycloheptadecine-kappaN5,kappaN13,kappaN18,kappaN21,kappaN22]manganese		US 6180620	Anticancer, other
mabuprofen	Benzeneacetamide, N-(2-hydroxyethyl)-Alpha-methyl-4-(2-methylpropyl)-, (+)-[CAS]	82821-47-4	DE 3121595	Anti-inflammatory
Mabuter I		56341-08-3		
Macrophage Colony-Stimulating Factor		81627-83-0		
MADU		840-50-6		
Mafenid		138-39-6		
mafenide acetate	Benzenesulfonamide, 4-(aminomethyl)-monoacetate [CAS]	13009-99-9		Vulnery
mafosamide	Ethanesulfonic acid, 2-[[2-bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorin-4-ylthio]-, P-oxide, cis-(+)- [CAS]	88859-04-5 98845-64-8	EP 393575	Anticancer, alkylating
magaldrate	Aluminum magnesium hydroxide sulfate (Al5Mg10(OH)31(SO4)2), hydrate [CAS]	74978-16-8	US 2923660	Antacid/Antiflatulent
magaldrate, FDS	Aluminum magnesium hydroxide sulfate, hydrate [CAS]	74978-16-8		Formulation, modified-release, other
Magenta I		632-99-5		
Magnesium Acetylsalicylate		132-49-0		

TABLE 6

Example of Indication
Diagnosis, cancer
Unspecified
Burns
Cancer, renal
Gastro-oesophageal reflux

TABLE 6

API Gen ric Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Magnesium Carbonate Hydroxide		39409-82-0		
magnesium chloride, Glenfair	Magnesium chloride (MgCl ₂) [CAS]	7786-30-3		Formulation, oral, enteric-coated
Magnesium Citrate		3344-18-1		
magnesium gluconate, Sopar	D-Gluconic acid, magnesium salt (2:1) [CAS]	3632-91-5		Formulation, other
Magnesium Lactate		18917-93-6		
Magnesium Salicylate		18917-89-0		
Malathion		121-75-5		
Malotilast		59937-28-9		
Mandelic Acid		90-64-2		
Mandelic Acid Isoamyl Ester		5421045		
Mangafodipir		118248-94-5 (free acid); 155319-91-8 (hexahydrogen)		
manidipine	3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 2-[(4-(diphenylmethyl)-1-piperazinyl)ethyl methyl ester] [CAS]	89228-50-6 89226-75-5	EP 94159	Antihypertensive, other
Mannomustine		551-74-6		
mannose-6-phosphate, BTG	mannose-6-phosphate			Vulnerary
Maprotilin		10262-69-8		
maribavir	1H-Benzimidazol-2-amine, 5,6-dichloro-N-(1-methylethyl)-1-β-L-ribofuranosyl- [CAS]	176161-24-3		Antiviral, other
marimastat	N-[2,2-Dimethyl-1(S)-(N-methylcarbamoyl)propyl]-N,3(S)-dihydroxy-2(R)-isobutylsuccinamide	154039-60-8	WO 9402447	Anticancer, other

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
maxacalcitol	1,3-Cyclohexanediol, 4-methylene-5-(2-(octahydro-1-(1-(3-hydroxy-3-methylbutoxy)ethyl)-7a-methyl-4H-inden-4-ylidene)ethylidene)-, (1S-(1Alpha(R*),3aB,4E(1S*,3R*,5Z),7aAlpha))- [CAS]	103909-75-7	US 4891364	Hormone
mazindol	3H-Imidazo[2,1-a]isindol-5-ol, 5-(4-chlorophenyl)-2,5-dihydro- [CAS]	22232-71-9	US 3763178	Anorectic/Antiobesity
Mazipr d ne		13085-08-0		
MC-5723			US 6043259	Cardiovascular
MCC-478	(2-amino-6-(4-methoxyphenylthio)-9-[2-(phosphonomethoxy)ethyl]purine bis(2,2,2-trifluoroethyl) ester)			Antiviral, other
MCH-154	3(2H)-Pyridazinone, 4,5-dihydro-6-[4-(4-pyridinylamino)phenyl]-, monohydrochloride [CAS]	98326-32-0 98326-33-1	EP 145019	Cardio stimulant
m-Cr syl Acetate		122-46-3		
MDAM	Gamma-Methylene-10-deazaaminopterin			Anticancer, antimetabolite
MDI-101			US 4885311	Antiacne
MDI-403		403849-94-5	US 4677120	Antiacne
MDL-100907	4-Piperidinemethanol, Alpha-(2,3-dimethoxyphenyl)-1-(2-(4-fluorophenyl)ethyl)-, (R)- [CAS]	139290-65-6		Hypnotic/Sedative
mebendazole	methyl-5-benzoylbenzimidazole-2-carbamate	31431-39-7	GB 1307306	Anthelmintic
mebeverine	Benzoic acid, 3,4-dimethoxy-, 4-[ethyl(2-(4-methoxyphenyl)-1-methyl(ethylamino)butyl) ester [CAS]	3625-06-7		Antispasmodic
Mebhydrolin		524-81-2		
Mebrofenin		78266-06-5		
Mebutamate		64-55-1		
mecamylamine HCl, Targacept	Bicyclo(2.2.1)heptan-2-amine, N,2,3,3-tetramethyl- [CAS]	60-40-2		Neurological
Mechlorethamine		51-75-2		

TABLE 6

Example of Indication
Hyperparathyroidism
Obesity
Unspecified
Infection, hepatitis-B virus
Heart failure
Cancer, general
Acne
Acne
Sleep disorder, general
Irritable bowel syndrome
Unspecified

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Mechl r thamine Oxide Hydrochl ride		302-70-5		
meclizine	4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[(hexahydro-1H-azepin-1-yl)methylene]amino]-3,3-dimethyl-7-oxo-, [2S-(2Apha,5Apha,6beta.)]- [CAS]	32887-01-7 32887-03-9	GB 1293590	Penicillin, injectable
Mecizine		569-65-3		
Meclocycline		2013-58-3		
meclufenamate	Benzoic acid, 2-[(2,6-dichloro-3-methylphenyl)amino], monosodium salt [CAS]	6385-02-0 644-62-2		Antiarthritic, other
Meclofenamic Acid		644-62-2		
Meclofen xat		51-68-3		
Mecloqualon		340-57-8		
Mecyst ine		18598-63-5		
Hydr chlorid				
Medazepam		12/6/2898		
medifoxamine	Ethanamine, N,N-dimethyl-2,2-diphenoxy- [CAS]	32359-34-5	FR M5498	Antidepressant
Medrog st n		977-79-7		
Medr nic Acid		1984-15-2		
Medroxypr gesterone		520-85-4		
medroxyprogesterone acetate	Pregn-4-ene-3,20-dione, 17-(acetoxy)-6-methyl-, (6Alpha)	71-58-9		Formulation, fixed-dose combinations
Medrys n		2668-66-8		
M fenamic Acid		61-68-7		
Mefen r x		17243-57-1		
Mefexamid		1227-61-8		
metloquine		51773-92-3 53230-10-7 69191-18-0	GB 1594282	Antimalarial
Mefl quin	4-Quinolinemethanol, Alpha-2-piperidinyl-2,8-bis(trifluoromethyl)-, (R*,S*)-(+)-[CAS]	51773-92-3		
Hydr chl rid				
Mefruside		7195-27-9		

TABLE 6

Example f Indication
Infection, general
Arthritis, osteo
Contraceptive, female

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Megestrol Acetate		595-33-5		
Meglumine Acetrizoate		22154-43-4		
M glumine Diatrizoate		131-49-7		
meglutol	2-hydroxy-2-methyl-1,3-propanedicarboxylic acid	503-49-1	US 3629449	Hypolipaeic/Antiatherosclerosis
melagatran	Glycine, N-[(1R)-2-[(2S)-2-[[[4-(aminiminomethyl)phenyl]methyl]amino]carboxyl]-1-azetidinyl]-1-cyclohexyl-2-oxoethyl]- [CAS]	159776-70-2	WO 9616671	Antithrombotic
melanocortin-4 agonist	N-[(3R)-1,2,3,4-Tetrahydroisoquinolinium-3-ylcarboxyl]-[(1R)-1-(4-chlorobenzyl)-2-[4-cyclohexyl-4-(1H-1,2,4-triazol-1-yl)methyl]piperidin-1-yl]-2-oxoethylamine(1)			Anorectic/Antiobesity
Melars pr i		494-79-1		
Mel ng str l		5633-18-1		
melevodopa	Alanine, 3-(3,4-dihydroxyphenyl)-methyl ester [CAS]	7101-51-1	EP 252290	Antiparkinsonian
Melinamid		14417-88-0		
Melitrac n		5118-29-6		
meloxicam	2H-1,2-Benzothiazine-3-carboxamide, 4-hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-, 1,1-dioxide- [CAS]	71125-38-7	US 4233299	Antiarthritic, other
melperone	1-Butanone, 1-(4-fluorophenyl)-4-(4-methyl-1-piperidinyl)- [CAS]	1622-79-3 3575-80-2	BE 651144	Neuroleptic
M lphalan		148-82-3		
Melphalan Hydrochloride				
meludine	Benzenemethanol, 2-chloro-Alpha-(((1,1-dimethylethyl)amino)methyl)-4-hydroxy-, (R)-, (R',R'')-2,3-dihydroxybutanedioate (1:1) (salt) [CAS]	134865-37-5	EP 420120	Labour Inhibitor
M mantin		19982-08-2		

TABLE 6

Example of Indication
Hyperlipidaemia, general
Thrombosis, general
Obesity
Parkinson's disease
Arthritis, rheumatoid
Labour, preterm

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
mefenamine hydrochloride	Tricyclo[3.3.1.1 ^{3,7}]decan-1-amine, 3,5-dimethyl, hydrochloride [CAS]	41100-52-1	EP 392059	Cognition enhancer
MEN-10700	Acetamide, 2-[[[(5R,6S)-6-[(1R)-1-hydroxyethyl]-2-methyl-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-en-3-yl]methyl]methylamino]- [CAS]	195874-55-6	WO 9408803	Beta-lactam antibiotic
MEN-10755	5,12-Naphthacenedione, 7-[[4-O-(3-amino-2,3,6-trideoxy-Alpha-L-lyxo-hexopyranosyl)-2,6-dideoxy-Alpha-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-9-(hydroxyacetyl)-, hydrochloride, (7S,9S)- [CAS]	169317-77-5	WO 9509173	Anticancer, antibiotic
Menadiol		481-85-6		
Menadiol		58-27-5		
Menadiol		573-01-3		
Menbutone		3562-99-0		
Menthol	7-Alpha-Methyl-19-nortestosterone	71628-96-1		
Menthol		89-78-1		Formulation, transdermal, systemic
menthol	Cyclohexanol, 5-methyl-2-(1-methylethyl)- [CAS]	1490-04-6		Formulation, dermal, topical
Menthyl Valerate		89-47-4		
Meobentine		46464-11-3		
Mefenamine		77-75-8		
Mefenamine	Patridin, methyl ester [CAS]	11121-32-7	US 3780173	Antifungal
Mefenamine		11121-32-7		
Mefenamine		60-89-9		
Mefenamine Bromide		76-90-4		
Meperidine		57-42-1		
Mephedrone		59-47-2		
Mephedrone		70-07-5		
Mephedrone		100-92-5		
Mephedrone		50-12-4		
Mephedrone		115-38-8		

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Mepindolol		23694-81-7		
Mepitostane		21362-69-6		
Mepivacaine	N-(2,6-Dimethylphenyl)-1-methyl-2-piperidinecarboxamide	96-88-8		Formulation, modified-release, >24hr
Mepixanox		17854-59-0		
Meprednisone		1247-42-3		
Meprobamate		57-53-4		
Meprosicillin	Bufa-4,20,22-trienolide, 3-[(6-deoxy-4-O-methyl-Alpha-L-mannopyranosyl)oxy]-14-hydroxy-, (3B)- [CAS]	33396-37-1	DE 1910207	Cardio stimulant
Mepazolin	Phenol, 3-(3-ethylhexahydro-1-methyl-1H-azepin-3-yl)- [CAS]	54340-58-8 59263-76-2	GB 1285025	Analgesic, other
Megilazine	10H-Phenothiazine, 10-(1-azabicyclo[2.2.2]oct-3-ylmethyl)- [CAS]	29216-28-2	GB 1250534	Antiallergic, non-asthma
Meralein Sodium		4386-35-0		
Merallurid		8069-64-5		
Merbrin		129-16-8		
Mercaptopurine Sodium		21259-76-7		
Mercuriyllic Acid		86-36-2		
Mercuric Chloride, Ammoniated		10124-48-8		
Mercuric Oleate		1191-80-6		
Mercuric Oxycyanide		1335-31-5		
Merimepodin	Carbamic acid, ((3-(((3-methoxy-4-(5-oxazolyl)phenyl)amino)carbonyl)amino)phenyl)methyl-, (3S)-tetrahydro-3-furanyl ester [CAS]	198821-22-6	US 5807876	Antiviral, other

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
meropenem	1-Azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, 3-[[5-[(dimethylamino)carbonyl]-3-pyrrolidinyl]thio]-6-(1-hydroxyethyl)-4-methyl-7-oxo-, [4R-[3(3S*,5S*),4Alpha,5B,6B(R*)]]- [CAS]	96036-03-2	EP 126587	Beta-lactam antibiotic
Mersalyl		492-18-2		
M salamine		89-57-6		
mesalazine				
Mesna	Benzoic acid, 5-amino-2-hydroxy- [CAS]	89-57-6	WO 5541170	Formulation, oral, other
M s ridazin		19767-45-4		
Mesoridazine Besylate		5588-33-0		
M stan lon				
Mest r l ne		521-11-9		
M stranol		1424-00-6		
M sulf n		72-33-3		
Metaciaz pam		135-58-0		
M tampicillin		84031-17-4		
M tapramin		6489-97-0		
M taprot ren l		21730-16-5		
Metaproterenol Sulfate		586-06-1		
Metaraminol				
Metazocin		54-49-9		
metergoline		3734-52-9		
metformin		17692-51-2		
Methacholine	Carbamic acid, [[(88)-1,6-dimethylergolin-8-yl]methyl]-, phenylmethyl ester [CAS]	21631-37-8	GB 1401935	Antiprolactin
Methacycline	Imidodicarbonimidic diamide, N,N-dimethyl- [CAS]	2706-42-5		Formulation, modified-release, <=24hr
Methad ne		657-24-9		
M thafurylen		62-51-1		
		914-00-1		
		76-99-3		
		531-06-6		

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Methamphetamine		537-46-2		
Methandriol		521-10-8		
Methandrostenolone		72-63-9		
Methanethiol		53-46-3		
Methapyrilene		91-80-5		
Methaqualon		72-44-6		
Metharbital		50-11-3		
Methaz lamid		554-57-4		
Methdilazine		1982-37-2		
Methenamin		100-97-0		
Methenol n		153-00-4		
Methestrol		130-73-4		
Methetoin		5696-06-0		
Methicillin		132-92-3		
Methimazole		60-56-0		
Methidol		126-31-8		
Methinilic Acid		503-40-2		
Methinine		63-68-3		
Methisazon		1910-68-5		
Methitural		467-43-6		
Methixen		2/2/4969		
Meth carbam I		532-03-6		
Methohexital		22151-68-4		
Methotrexate	L-Glutamic acid, N-[4-[[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]-[CAS]	59-05-2	US 2512572	Anticancer, antimetabolite
Methotrexate Sodium				
Meth trimetrazine		60-99-1		
Meth xamine		390-28-3		
Meth xsal n		298-81-7		
Meth xyflurane		76-38-0		
Methoxyphenamine		93-30-1		

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Methoxypropazine		61-01-8		
Methscopolamine		155-41-9		
Methscopolamine Nitrate				
M thsuximide		77-41-8		
Methyclothiazide		135-07-9		
M thyl Blue		28983-56-4		
M thyl Nicotinate		93-60-7		
M thyl Propyl Ether		557-17-5		
M thyl Salicylate		119-36-8		
Methyl tert-Butyl Ether		1634-04-4		
M thylb nzethonium Chlorid		25155-18-4		
Methylcobalamin		13422-55-4		
methyl dopa	L-Tyrosine, 3-hydroxy-Alpha-methyl- [CAS]	555-30-6		Formulation, modified-release, <=24hr
Methyl n Blu		61-73-4		
Methylergon vine		113-42-8		
M thylh xaneamine		105-41-9		
methylphenidate	2-Piperidineacetic acid, Alpha-phenyl-, methyl ester [CAS]	113-45-1 298-59-9		Formulation, modified-release, multi
M thylpr dnis lone		83-43-2		
methylprednisolone aceponate	Pregna-1,4-diene-3,20-dione, 21-(acetyloxy)-11-hydroxy-8-methyl-17-(1-oxopropoxy)-, (6Alpha,11B)- [CAS]	86401-95-8	EP 72547	Antipruritic/inflam, allergic
methylprednisolone suleptanate	Pregna-1,4-diene-3,20-dione, 11,17-dihydroxy-6-methyl-21-[[8-[methyl(2-sulfoethyl)amino]-1,8-dioxoctyl]oxy]-, monosodium salt, (6Alpha,11B)- [CAS]	90350-40-6	JP 59137500	Antiasthma
M thythlouracil		56-04-2		
Methyltri n l ne		965-93-5		
Methylpryl n		125-64-4		
Methysergide		361-37-5		
M tiazinic Acid		13993-65-2		

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
metiprandiol	Phenol, 4-[2-hydroxy-3-[(1-methylethylamino)propoxy]-2,3,6-trimethyl-1-acetate [CAS]	22664-55-7	GB 1206148	Antihypertensive, adrenergic
metoclopramide	Benzanide, 4-amino-5-chloro-N-[2-(diethylamino)ethyl]-2-methoxy- [CAS]	364-62-5		Formulation, modified-release, <=24hr
M t curin l dide		7601-55-0		
M tof nazat		388-51-2		
metolazone	6-Quinazolinonesulfonamide, 7-chloro-1,2,3,4-tetrahydro-2-methyl-3-(2-methylphenyl)-4-oxo- [CAS]	17560-51-9	US 4517179	Antihypertensive, diuretic
Metopimazine		14008-44-7		
Metopon		143-52-2		
M toprolol		37350-58-6		
metoprolol	2-Propanol, 1-[4-(2-methoxyethyl)phenoxy]-3-[(1-methylethylamino)-, (+)-] [CAS]	51384-51-1 56392-17-7		Formulation, modified-release, other
Metralindole		54188-38-4		
M trizamide		31112-62-6		
M triz ic Acid		1949-45-7		
M tr n S		13946-02-6		
Metyrap n		54-36-4		
Metyr sin		672-87-7		
Mexaz lam		31868-18-5		
Mex non		1641-17-4		
Mexiletin		31828-71-4		
mezlocillin	4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3,3-dimethyl-6-[[[3-(methylsulfonyl)-2-oxo-1-imidazolidinyl]carbonyl]amino]phenylacetyl] 42057-22-7 amino]-7-oxo-, [2S-[2Alpha,5Alpha,6(S*)]] [CAS]	51481-65-3 72539-76-5	GB 1301861	Penicillin, injectable
MFH-244	Benzenecarboximide acid, 3,4,5-trihydroxy-, ethyl ester, hydrochloride	95933-76-9	US 4623659	Cardiovascular
mianserin	Dibenzof[c,f]pyrazino[1,2-a]azepine, 1,2,3,4,10,14b-hexahydro-2-methyl- [CAS]	21535-47-7 24219-97-4	GB 1173783	Antidepressant

TABLE 6

Exempl	Indication
Gastro-oesophageal reflux	
Hypertension, general	
Infection, general	
Reperfusion injury	
Depression, general	

TABLE 6

API Gen. Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Mibefradil		116644-53-2		
Mib. platin		103775-75-3		
Micafungin		235114-32-6		
miconeazole	1H-Imidazole, 1-(2,4-dichlorophenyl)-2-[2,4-dichlorophenyl]methoxy[ethyl]	22916-47-8		Formulation, modified-release, other
Micronomicin		52093-21-7		
midaxityline	1H-Purine-2,6-dione, 8-(1-aminocyclopentyl)-3,7-dihydro-1,3-dipropyl- [CAS]	151159-23-8	US 5378844	Cardiovascular
midazolam	4H-Imidazo[1,5-a][1,4]benzodiazepine, 8-chloro-6-(2-fluorophenyl)-1-methyl- [CAS]	59467-70-8 59467-94-6	US 4280957	Anaesthetic, injectable
midecamycin	Leucomycin V, 3,4B-dipropanoate [CAS]	35457-80-8	US 3761588	Macrolide antibiotic
midecamycin acetate	Leucomycin V, 3B,9-diacetate 3,4B-dipropanoate [CAS]	55881-07-7	JP 49124087	Macrolide antibiotic
midestelne	2-Thiophenecarboxylic acid, S-(1-methyl-2-oxo-2-[(tetrahydro-2-oxo-3-thienyl)amino]ethyl) ester [CAS]	94149-41-4	EP 120534	COPD treatment
midodrine	Acetamide, 2-amino-N-[2-(2,5-dimethoxyphenyl)-2-hydroxyethyl]- [CAS]	42318-56-0 42794-76-3	EP 164571	Urological
midostaurin	Benzamide, N-(2,3,10,11,12,13-hexahydro-10-methoxy-9-methyl-1-oxo-9,13-epoxy-1H,9H-dindolo[1,2,3-gh:3',2',1'-lm]pyrrolo[3,4-j][1,7]benzodiazonin-11-yl)-N-methyl-, (9Alpha,10B,11B,13Alpha)- [CAS]	120885-11-2	EP 296110	Anticancer, other
mifepristone	Estra-4,9-dien-3-one, 11-(4-(dimethylamino)phenyl)-17-hydroxy-17-(1-propynyl)-, (11B,17B)- [CAS]	84371-65-3	EP 57115	Abortifacient
Mif. pristone		84371-65-3		
milgijitol	3,4,5-Piperidinetriol, 1-(2-hydroxyethyl)-2-(hydroxymethyl)-, [2R-(2Alpha,3B,4Alpha,5B)]- [CAS]	72432-03-2	EP 55431	Antidiabetic

TABLE 6

Example of Indication
Infection, Candida, general
Unspecified
Infection, general
Infection, general
Emphysema, general
Incontinence
Cancer, leukaemia, acute myelogenous
Abortion
Diabetes, Type I

TABLE 6

API Gen. Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
nioglutat	3,4,5-Piperidinetriol, 1-butyl-2-(hydroxymethyl)-(2R-(2Alpha, 3a, 4Alpha, 5b)) [CAS]	72599-27-0	DE 2758025	Metabolic and enzyme disorders
mildronate	Hydrazinium, 2-(2-carboxylethyl)-1,1-trimethyl-, inner salt- [CAS]	76144-81-5	WO 8001068	Cardio stimulant
milnacipran	Cyclopropanecarboxamide, 2-(aminomethyl)-N,N-diethyl-1-phenyl-, cis-(+)-[CAS]	101152-94-7 92623-85-3	US 4478836	Antidepressant
Miloxacin		37065-29-5		
milrinone	(3,4'-Bipyridine)-5-carbonitrile, 1,6-dihydro-2-methyl-6-oxo- [CAS]	78415-72-2	US 4313951	Cardio stimulant
	Ethanaminium, 2-[[[hexadecyloxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, hydroxide, inner salt [CAS]	53949-20-5 58066-85-6	EP 225608	Anticancer, other
miltefosine	4-Morpholineethanamine, N-(4-methyl-6-phenyl-3-pyridazinyl)- [CAS]	25905-77-5 25953-17-7	GB 1345880	Antidepressant
minocycline	2-Naphthacene carboxamide, 4,7-bis(dimethylamino)-1,4,4a,5,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, [4S-(4Alpha,4aAlpha,5a.alpha.,12aAlpha)]-[CAS]	10118-90-8		Formulation, optimized, microparticles
minodronic acid	Phosphonic acid, (1-hydroxy-2-imidazo[1,2-a]pyridin-3-ylethylidene)bis-, [CAS]	180064-98-4	EP 354808	Anticancer, other
minoxidil	2,4-Pyrimidinediamine, 6-(1-piperidinyl)-, 3-oxide [CAS]	38304-91-5	US 4139619	Vasodilator, peripheral
Miokamycin		55881-07-7		
mirzapine	Pyrazino[2,1-e]pyrido[2,3-c][2]benzazepine, 1,2,3,4,10,14b-hexahydro-2-methyl-[CAS]	85650-52-8	GB 1543171	Antidepressant
Mirtazapine		61337-67-5		
misoprostol	Prost-13-en-1-olc acid, 11,16-dihydroxy-16-methyl-9-oxo-, methyl ester, (11Alpha,13E)-(+)- [CAS]	59122-46-2 59122-48-4	US 4301146	Prostaglandin

TABLE 6

Example f Indication
Gaucher's disease
Heart failure
Depression, general
Heart failure
Cancer, skin, general
Depression, general
Infection, oral
Cancer, myeloma
Hypertension, general
Depression, general
Ulcer, gastric

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
mitomycin	Erythromycin, 8,9-didehydro-N-demethyl-9-deoxy-6,11-dideoxy-6,9-epoxy-12-O-methyl-N-(1-methylethyl)-11-oxo-, (2E)-2-butenedioate (2:1) [CAS]	154802-96-7	WO 9324509	Gastropokinetic
mitiglinide	Calcium (2S)-2-benzyl-3-(cis-hexahydro-2-isoindolylcarbonyl)propionate, dihydrate- [CAS]	145525-41-3	EP 507534	Antidiabetic
Mitobronitrol		488-41-5		
Mitoguanine		459-86-9		
mitolactol	Galactitol, 1,6-dibromo-1,6-dideoxy- [CAS]	10318-26-0	US 3993781	Anticancer, alkylating
mitomycin	Azolino[2',3':3,4]pyrrolo[1,2-a]indole-4,7-dione, 6-amino-8-[[[(aminocarbonyloxy)methyl]-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5-methyl-, [1aS-(1aAlpha,8B,8aAlpha,8bAlpha)]- [CAS]	50-07-7		Formulation, parenteral, other
Mitotane		53-19-0		
mitoxantrone	9,10-Anthracenedione, 1,4-dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]ethyl]amino]- [CAS]	65271-80-9 70476-82-3	US 4187249	Anticancer, other
mitoxantrone	9,10-Anthracenedione, 1,4-dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]ethyl]amino]- [CAS]	65271-80-9 70476-82-9		Formulation, optimized, liposomes
MIV-210	(3'-Fluoro-2'-3'-dideoxy guanosine)			Antiviral, other
mivacurium	Isoquinolinium, 2,2'-[(1,8-dioxo-4-octene-1,8-diyl)bis(oxy-3,1-propanediyl)]bis[1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-, dichloride, [R-[R', R'-(E)]]- [CAS]	106861-44-3	EP 181055	Muscle relaxant
Mivazerol		125472-02-8		
mizolastine	4-(1H)-Pyrimidinone, 2-[[1-(4-(fluorophenyl)methyl)-1H-benzimidazol-2-yl]-4-piperidinyl]methylamino]- [CAS]	108612-45-9	EP 217700	Antiallergic, non-asthma
Mizoribine		50924-49-7		

TABLE 6

Example of Indication
Gastro-oesophageal reflux
Diabetes, Type II
Cancer, cervical
Cancer, stomach
Cancer, breast
Cancer, general
Infection, hepatitis-B virus
Anaesthesia, adjunct
Rhinitis, allergic, general

TABLE 6

API Gen. ric Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
MKC-733	(R)-N-(3-quinuclidinyl)-7-oxo-4,7-dihydrothieno[3,2-b]pyridine-6-carboxamide hydrochloride	194093-42-0	JP 09216888	Gastroprokinetic
MLN-519	6-Oxa-2-azabicyclo[3.2.0]heptane-3,7-dione, 1-[(1S)-1-hydroxy-2-methylpropyl]-4-propyl-, (1R,4R,5S)- [CAS]	211866-70-5	WO 9915183	Neuroprotective
MLN-576	4-Methoxy-benzo[a]phenazine-11-carboxylic acid (2-(dimethylamino)-1-(R)-methyl-ethyl)-amide			Anticancer, other
moclobemide	Benzamide, 4-chloro-N-[2-(4-morpholinyl)ethyl]- [CAS]	71320-77-9	EP 326023	Antidepressant
modafinil	Acetamide, 2-[(diphenylmethyl)sulfinyl]- [CAS]	68693-11-8	DE 2809625	Psychostimulant
moexipril	3-Isoquinolinecarboxylic acid, 2-[2-[1-(ethoxycarbonyl)-3-phenylpropylamino]-1-oxopropyl]-1,2,3,4-tetrahydro-6,7-dimethoxy- (3S-(2(R*(R*),3R*)))- [CAS]	103775-10-6 103775-14-0	US 4344949	Antihypertensive, renin system
M faroten		125533-88-2		
M febutaz n		2210-63-1		
Mofegiline		119386-96-8		
mofezolac	5-Isoxazoleacetic acid, 3,4-bis(4-methoxyphenyl)- [CAS]	78967-07-4	EP 26928	Analgesic, NSAID
MOL-6131	N-[4-(aminomethyl)benzyl]-8(S)-1-[4-[2-(4-aminophenyl)-acetamido]butyl]piperidin-4-yl]-2-(naphthalen-1-ylmethyl)-1,3-dioxo-2,3,5,8-tetrahydro-1H-[1,2,4]triazolo[1,2-a]pyridazine-5(R)-carboxamide			Antisthma
Molind n		7416-34-4		
Molindone Hydrochloride				
molisdomine	Sydnone imine, N'(ethoxycarbonyl)-3-(4-morpholinyl)- [CAS]	25717-80-0	US 3769283	Vasodilator, coronary

TABLE 6

Example of Indication
Gastro-oesophageal reflux
Ischaemia, cerebral
Cancer, general
Depression, general
Narcolepsy
Hypertension, general
Pain, post-operative
Asthma

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
monetasone	Pregna-1,4-diene-3,20-dione, 9,21-dichloro-11,17-dihydroxy-16-methyl-, (11B,16Alpha)- [CAS]	105102-22-5 83919-23-7	EP 57401	Antipruritic/inflamm, allergic
Monat pil		103377-41-9		
M n b nzone		103-16-2		
monolaurin	Dodecanoic acid, monoester with 1,2,3-propanetriol [CAS]	27215-38-9	US 4885282	Dermatological
Montelukast		158966-92-8		
montelukast sodium	Cyclopropaneacetic acid, 1-[[[1-[9-[2-(7-Chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]imino]methyl]-, mono sodium salt, [R-(E)]- [CAS]	151767-02-1		Antiasthma
Monteplax		122007-85-6		
M peron		1050-79-9		
M pidamol		13665-88-8		
Moprolol		5741-22-0		
moracizine	Carbamic acid, [10-[3-(4-morpholinyl)-1-oxopropyl]-10H-phenothiazin-2-yl]-, ethyl ester [CAS]	29560-58-5 31883-05-3	US 3864487	Antiarrhythmic
Morazon		8536-18-1		
Moricizin		31883-05-3		
M r xydin		3731-59-7		
Morphazinamide		952-54-5		
M rphin		57-27-2		
morphine sulfate	Morphinan-3,6-diol, 7,8-didehydro-4,5-epoxy-17-methyl- (5Alpha,6Alpha)-, sulfate	64-31-3		Formulation, modified-release, immediate
morphine, Takeda	Morphinan-3,6-diol, 7,8-didehydro-4,5-epoxy-17-methyl- (5Alpha,6Alpha)-, hydrochloride, trihydrate- [CAS]	57-27-2 6055-08-7		Formulation, parenteral, other
morphine-6-glucuronide, UFC	morphine-6-glucuronide			Formulation, inhalable, systemic
mosapramine	Spiro[imidazo[1,2-a]pyridine-3(2H),4'-piperidin]-2-one, 1'-[3-(3-chloro-10,11-dihydro-5H-dibenz[b,f]azepin-5-yl)propyl]hexahydro-, (4')- [CAS]	89419-40-9 98043-60-8	US 4337260	Neuroleptic

TABLE 6

Example of Indication
Psoriasis
Ichthyosis
Asthma
Tachycardia, ventricular
Pain, general
Pain, cancer
Pain, general

TABLE 6

API Gen ric Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
mosapride	Benzamide, 4-amino-5-chloro-2-ethoxy-N-((4-((4-fluorophenyl)methyl)-2-morpholinyl)methyl)- [CAS]	112885-41-3 112885-42-4	EP 243959	GI inflammatory/bowel disorders
motexafin gadolinium	Gadolinium, bis(acetato-kappaO)(9,10-diehy-20,21-bis(2-(2-methoxyethoxy)ethoxy)-4,15-dimethyl-8,11-imino-3,16,16,13-dinitro-1,18-benzodiazacycloheptosine-5,14-dipropionato-kappaN1, kappaN18, kappaN23, kappaN24, kappaN25), (PB-7-11-233'2'4) [CAS]	246252-08-2		Radio/chemosensitizer
M tr tinid		56281-36-8		
M v itipril		85856-54-8		
Moxalactam		64952-97-2		
Moxastin		3572-74-5		
Moxaverin		10539-19-2		
M x str l		34816-55-2		
moxifloxacin	3-Quinolonecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(octahydro-6H-pyrrolo(3,4-b)pyridin-6-yl)-4-oxo-, hydrochloride (4aS-cis)- [CAS]	188828-86-8	DE 19546249	Quinolone antibacterial
Moxifi xacin		151096-09-2		
M xisylt		54-32-0		
moxisylyte hydrochloride	Phenol, 4-[2-(dimethylamino)ethoxy]-2-methyl-5-(1-methylethyl)-, acetate (ester), hydrochloride [CAS]	964-52-3		Male sexual dysfunction
moxonidine	5-Pyrimidinamine, 4-chloro-N(4,5-dihydro-1H-imidazo[2-y]-6-methoxy-2-methyl-[CAS]	75438-57-2	DE 2849537	Antihypertensive, other
M-PGA	(-)-(-)-2-Methyl-2-(1-oxo-2,3-dihydro-1H-isoindol-2-yl)pentanedioic acid		US 5712281	Anticancer, other
MPI-5010	Platinum diamminedichloro-, (SP-4-2) + (R)-4-[1-hydroxy-2-(methylamino)-ethyl]-1,2-benzenediol		US 6224883	Formulation, parenteral, other

TABLE 6

Example of Indication
Gastritis
Cancer, brain
Infection, respiratory tract, general
Impotence
Hypertension, general
Cancer, general
Cancer, head and neck

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
MPI-5020	2,4-(1H,3H)-Pyrimidinedione, 5-fluoro- [CAS]	51-21-8	US 5750146	Formulation, parenteral, other
MPL, Corba		198076-81-2		Immunostimulant, other
MRS-1754			US 6060481	Asthma
MS-209	1-Piperazineethanol, 4-(diphenylacetyl)- Alpha-[(5-quinolinyloxy)methyl]-, (2E)-2- butenediolate(2:3) (salt) [CAS]	156681-49-3		Radio/chemosensitizer
MS-275	N-(2-Aminophenyl)-4-[N-(pyridin-3-yl)- methoxycarbonyl]aminomethylbenzamide			
MS-325		201688-00-8		Anticancer, antimetabolite
MS-377			EP 839805	Neuroleptic
Mupiricin		12650-69-0		
Muscarin		300-54-9		
Muzilimine		55294-15-0		
MX-1013			US 6133591	Hepatoprotective
	4-Hexenoic acid, 6-(1,3-dihydro-4-hydroxy- 6-methoxy-7-methyl-3-oxo-5- isobenzofuranyl)-4-methyl-, 2-(4- morpholinyl)ethyl ester, (E)- [CAS]	116680-01-4 128794-94-5	WO 9119498	Immunosuppressant
Mycophenolic Acid		24280-93-1		
	4-hexanoic acid, 6-(1,3-dihydro-4-hydroxy- 6-methoxy-7-methyl-3-oxo-5- isobenzofuranyl)-4-methyl-, monosodium salt, (4E)-			
mycophenolic acid sodium		37415-82-6		Formulation, oral, enteric-coated
Myrphlin		467-18-5		
N- (Hydroxymethyl)nicotina mide		3569-99-1		
N,N,N',N'- Tetraethylphthalimide		83-81-8		
Nz-F rmylsulfisomidine		795-13-1		

TABLE 6

Example f Indication
Cancer, breast
Vaccine adjunct
Asthma
Cancer, breast
Cancer, lung, general
Schizophrenia
Unspecified
Transplant rejection, general
Transplant rejection, general

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
N-β-D-Glucosylsulfanilamide		53274-53-6		
N-Sulfanilylsulfanilamide		547-52-4		
Nabilon		51022-71-0		
nabumetone	2-Butanone, 4-(6-methoxy-2-naphthalenyl)- [CAS]	42924-53-8	GB 1476721	Anti-inflammatory
N-acetylcysteine	L-Cysteine, N-acetyl- [CAS]	616-91-1		Anticancer, other
N-Acetylmethionine		65-82-7		
nadifloxacin	1H,5H-Benzol[1]quinoxaline-2-carboxylic acid, 9-fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidinyl)-5-methyl-1-oxo-, (+)- [CAS]	124858-35-1	US 4399134	Quinolone antibacterial
nadolol	2,3-Naphthalenediol, 5-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]-1,2,3,4-tetrahydro- [CAS]	42200-33-9	US 4346106	Antihypertensive, adrenergic
Nadoxolol		54063-51-3		
nafamostat	Benzoic acid, 4-[(aminoliminomethyl)amino]-6-(aminoliminomethyl)-2-naphthalenyl ester- [CAS]	80251-32-7 81525-10-2 82956-11-4	EP 450232	GI inflammatory/bowel disorders
nafarelin	Luteinizing hormone-releasing factor (p/g), 6-[3-(2-naphthalenyl)-D-alanine]-[CAS]	76932-56-4 86220-42-0	EP 21234	Releasing hormones
Nafacillin		147-52-4		
Nafronyl		31329-57-4		
naftidrofuryl	2-Furanpropanoic acid, tetrahydro-Alpha-(1-naphthalenylmethyl)-, 2-(diethylamino)ethyl ester	31329-57-4		Formulation, modified-release, other
naftifine	1-Naphthalenemethanamine, N-methyl-N-(3-phenyl-2-propenyl)-, (E)- [CAS]	65472-88-0 66473-14-5	US 4282251	Antifungal
naftopidil	1-Piperazineethanol, 4-(2-methoxyphenyl)-Alpha-[(1-naphthalenyl)oxy]methyl- [CAS]	57149-07-2	US 3997666	Antihypertensive, adrenergic

TABLE 6

Exempl f Indication
Arthritis, osteo.
Cancer, general
Acne
Pancreatitis
Endometriosis
Unspecified
Infection, dermatological
Hypertension, general

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
nalbuphine	Morphinan-3,6,14-triol, 17-(cyclobutylmethyl)-4,5-epoxy-, (5 α)-[CAS]	20594-83-6 23277-43-2	US 3393197	Analgescic, other
Nalidixic Acid		389-08-2		
nalmefene	Morphinan-3,14-diol, 17-(cyclopropylmethyl)-4,5-epoxy-6-methylene-, (5 α)-[CAS]	55098-26-9	JP 56167687	Dependence treatment
Nalorphine		62-67-9		
Naloxon		465-65-6		
naloxone	Morphinan-6-one, 17-allyl-4,5 α -epoxy-3,14-dihydroxy-, hydrochloride [CAS]	357-08-4		Septic shock treatment
naltrexone	Morphinan-6-one, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-, (5 α)-[CAS]	16590-41-3 16676-29-2	US 3332950	Dependence treatment
NAMI	Imidazolium trans(imidazole)(dimethylsulfoxide)tetrachlororuthenate (II)			Anticancer, other
naminidil	Guanidine, N-cyano-N'-(4-cyanophenyl)-N''-[(1R)-1,2,2-trimethylpropyl]-[CAS]	220841-11-2		Dermatological
Nandrolone		434-22-0		
Naphazoline		835-31-4		
Naphazoline Hydrochloride				
Naphthalene		91-20-3		
naproxen betahate	Methanaminium, 1-carboxy-N, N, N-trimethyl-, salt with (R)-6-methoxy- α -methyl-2-naphthaleneacetic acid (1:1), sodium salt [CAS]	104124-26-7	US 4672077	Antiarthritic, other
naproxen sodium	2-Naphthaleneacetic acid, 6-methoxy- α -methyl-, sodium salt, (S)- [CAS]	26159-34-2	GB 1211134	Analgescic, NSAID
naproxen sodium	2-Naphthaleneacetic acid, 6-methoxy- α -methyl-, sodium salt, (S)- [CAS]	26159-34-2		Formulation, modified-release, other
naproxen	2-Naphthaleneacetic acid, 6-methoxy- α -methyl-, (S)- [CAS]	22204-53-1		Formulation, modified-release, multi

TABLE 6

Example f Indication
Pain, general
Poisoning, drug
Addiction, narcotic/opiate
Cancer, general
Alopecia, general
Arthritis, rheumatoid
Arthritis, general
Pain, general

TABLE 6

API Gen. Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
naratriptan	1H-Indole-5-ethanesulfonamide, N-methyl-3-(1-methyl-4-piperidinyl)- [CAS]	121679-13-8	EP 303507	Antimigraine
Naratriptan Hydrochloride				
Narc in		131-28-2		
Narcobarbital		125-55-3		
Natamycin		7681-93-8		
nateglinide	D-phenylalanine, N-[(4-{1-methylethyl}cyclohexyl)carbonyl]-, trans- [CAS]	105816-04-4	EP 198222	Antidiabetic
N-Butyldoxynojirimycin		72599-27-0		
N-Butylscopolammonium Bromide		149-64-4		
NC-503			US 5843562	Anti-inflammatory
NC-531			US 5843562	Cognition enhancer
NCX-1000			WO 0051604	Hepatoprotective
NCX-4016	Benzoic acid, 2-(acetoxy)-, 2-((nitrooxy)methyl)phenyl ester [CAS]	175033-38-0	WO 9716405	Symptomatic antidiabetic
NCX-456	Benzoic acid, 5-amino-2-hydroxy-, 4-(nitrooxy)butyl ester [CAS]	256499-26-0		GI inflammatory/bowel disorders
NCX-950	Alpha'-[[(1,1-dimethylethyl)amino]methyl]-4-hydroxy-1,3-benzenedimethanol nitrate			
n-D cosanol		661-19-8		Antiasthma
NE-100	Benzenesethanamine, 4-methoxy-3-(2-phenylethoxy)-N,N-dipropyl-, hydrochloride [CAS]	149409-57-4	WO 9307113	Neuroleptic
Nealbarbital		561-83-1		
neбивол	2H-1-Benzopyran-2-methanol, Alpha,Alpha'-[iminobis(methylene)]bis(6-fluoro-3,4-dihydro)-, (2R',R''(S'))-(1+)- [CAS]	118457-14-0	EP 145067	Antihypertensive, adrenergic

TABLE 6

Example of Indication
Migraine
Diabetes, Type II
Amyloidosis
Alzheimer's disease
Cirrhosis, hepatic
Insulin-related metabolic syndrome
Inflammatory bowel disease
Asthma
Schizophrenia
Hypertension, general

TABLE 6

API Gen ric Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Nebivolol		99200-09-6		
nebostinel	N1-(4,4-Dimethylcyclohexyl)-L-isoglutamine	163000-63-3	EP 0688312	Cognition enhancer
Nebracetam		97205-34-0		
nedaplatin	Platinum, diammine[hydroxyacetato(2-), O1, O2], (SP-4-3)- [CAS]	95734-82-0	EP 216362	Anticancer, alkylating
nedocromil	4H-Pyranol[3,2-g]quinoline-2,8-dicarboxylic acid, 9-ethyl-6,9-dihydro-4,6-dioxo-10-propyl- [CAS]	69049-73-6 69049-74-7	EP 555718	Antiasthma
nedocromil sodium, Allergan	4H-Pyranol[3,2-g]quinoline-2,8-dicarboxylic acid, 9-ethyl-6,9-dihydro-4,6-dioxo-10-propyl- [CAS]	69049-73-6 69049-74-7		Ophthalmological
Nefazodone		83366-66-9		
nelazodone hydrochloride	3H-1,2,4-Triazol-3-one, 2-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-5-ethyl-2,4-dihydro-4-(2-phenoxylethyl)-, monohydrochloride [CAS]	82752-89-6 83366-66-9	US 4338317	Antidepressant
nefiracetam	1-Pyrrolidineacetamide, N-(2,6-dimethylphenyl)-2-oxo- [CAS]	77191-36-7	US 4341790	Cognition enhancer
netopam	1H-2,5-Benzoxazocine, 3,4,5,6-tetrahydro-5-methyl-1-phenyl- [CAS]	13889-70-0 23327-57-3	US 3487153	Analgesic, NSAID
Negamycin		33404-78-3		
Nelfinavir		159989-64-7		
nelfinavir mesylate	3-Isoquinolinecarboxamide, N-(1,1-dimethylethyl)decahydro-2-(2-hydroxy-3-((3-hydroxy-2-methylbenzoyl)amino)-4-(phenylthio)butyl)-, (3S-2(2S*,3S*)3Alpha,4aβ,8aβ))-, monomethanesulfonate (salt)- [CAS]	159989-65-8		Antiviral, anti-HIV
Nem napride		75272-39-8		
Ne stigmine		59-99-4		
nepadutant	Cyclo[3-amino-L-alanyl-L-leucyl-N-(2-(acetylamino)-2-deoxy-β-D-glucopyranosyl)-L-asparaginyl-L-Alpha-aspartyl-L-tryptophyl-L-phenylalanyl], (4-1)-lactam [CAS]	183747-35-5	WO 9628467	Antiasthma
neramexane	1,3,3,5,5-pentamethylcyclohexylamine	202807-80-5 219810-59-0		Dependence treatment

TABLE 6

Exempl of Indication
Unspecified
Rhinitis, allergic, general
Ocular disorder, general
Depression, general
Dementia, senile, general
Infection, HIV/AIDS
Asthma
Addiction, alcohol

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
neridronic acid	Phosphonic acid, (6-amino-1-hydroxyhexylidene)bis- [CAS]	79776-41-9		Musculoskeletal
Nerifolin		466-07-9		
N-Ethylamphetamine		457-87-4		
neticonazole	1H-Imidazole, 1-[2-(methylthio)-1-[2-(pentyloxy)phenyl]ethenyl]-, monohydrochloride, (E)- [CAS]	130773-02-3	EP 445540	Antifungal
N iticonaz I		130726-68-0		
	D-Streptamine, O-3-deoxy-4-C-methyl-3-(methylamino)-β-L-arabinopyranosyl-(1-6)-O-[2,6-diamino-2,3,4,6-tetra-deoxy-Alpha-D-glycero-hex-4-enopyranosyl-(1-4)]-2-deoxy-N1-ethyl- [CAS]	56391-56-1 56391-57-2	GB 1473733	Aminoglycoside antibiotic
netilmicin	6H-Dipyrrolo[3,2-b:2',3'-e][1,4]diazepin-6-one, 11-cyclopropyl-5,11-dihydro-4-methyl- [CAS]	128618-40-2	EP 429987	Antiviral, anti-HIV
nevirapine			WO 9635689	Anxiolytic
NGD-98-2		51-12-7		
Nialamid		27367-90-4		
Niaprazine		3099-52-3		
Nicametate	3-Pyridinecarboxamide, N,N'-(1-methyl-1,2-ethanediy)bis- [CAS]	79455-30-4	EP 29602	Neuroprotective
nicaraven				
	3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, methyl 2-[methyl(phenylmethyl)amino]ethyl ester [CAS]	54527-84-3 55985-32-5	US 3985758	Neuroprotective
nicardipine				
	3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, methyl 2-[methyl(phenylmethyl)amino]ethyl ester [CAS]	54527-84-3 55985-32-5		Formulation, modified-release, other
nicardipine				
	Ergoline-8-methanol, 10-methoxy-1,6-dimethyl-, (8b)-, 5-bromo-3-pyridinecarboxylate(ester)	27848-84-6		Formulation, modified-release, other
nicergoline				
Nic ritr I		5868053		

TABLE 6

Example of Indication
Osteogenesis imperfecta
Infection, Candida, general
Infection, general
Infection, HIV/AIDS
Anxiety, general
Haemorrhage, subarachnoid
Hypertension, general
Unspecified
Unspecified

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Niclosamide		50-65-7		
Nic cl nate		10571-59-2		
Nicotifurans		15351-13-0		
Nicom I		27959-26-8		
Nic morphine		639-48-5		
nicorandil	3-Pyridinecarboxamide, N-(2-nitrooxy)ethyl- [CAS]	65141-46-0	US 4792564	Vasodilator, coronary
Nic tinamide		98-92-0		
nicotine	Pyridine, 3-(1-methyl-2-pyrrolidinyl)-, (S)- [CAS]	54-11-5		Formulation, inhalable, other
Nic tinic Acid		59-67-6		
Nicotinic Acid Benzyl Ester		94-44-0		
Nicotinyl Alcohol		100-55-0		
nifedipine	4-(2-nitrophenyl)-2,6-dimethyl-3,5-dicarbomethoxy-1,4-dihydropyridine	21829-25-4	GB 1173862	Vasodilator, coronary
nifekalanit hydrochloride	2,4-(1H,3H)-Pyrimidinedione, 6-[[2-(2-hydroxyethyl)]3-(4-nitrophenyl)propylamino]ethylamino]-1,3-dimethyl-, monohydrochloride- [CAS]	130636-43-0 130656-51-8	EP 369627	Antiarrhythmic
Nifenalol		7413-36-7		
Niflumic Acid		4394-00-7		
Nifuratel		4936-47-4		
Nifurfoline		3363-58-4		
Nifur xazide		965-52-6		
Nifur xim		6236051		
Nifurpirin I		13411-16-0		
Nifurprazin		1614-20-6		
Nifurtimox		23256-30-6		
Nifurt in I		1088-92-2		
nifurzide	2-Thiophene carboxylic acid, 5-nitro-, [3-(5-nitro-2-furyl)-2-propenylidene]hydrazide [CAS]	39978-42-2	US 3847911	Antidiarrhoeal

TABLE 6

Example of Indication
Hypertension, general
Addiction, nicotine
Hypertension, general
Arrhythmia, general
Infection, GI tract

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
NIK-254	Gentamicin, sulfate (salt) [CAS]	1405-41-0		Formulation, other
Nikethamid		59-26-7		
niltamide	2,4-Imidazolidinedione, 5,5-dimethyl-3-(4-nitro-3-(trifluoromethyl)phenyl)-[CAS]	63612-50-0	US 4472382	Anticancer, hormonal
nilvadipine	3,5-Pyridinedicarboxylic acid, 2-cyano-1,4-dihydro-6-methyl-4-(3-nitrophenyl)-, 3-methyl 5-(1-methylethyl) ester [CAS]	75530-68-6	US 4338322	Antihypertensive, other
nimesulide	Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)- [CAS]	51803-78-2	US 3940597	Anti-inflammatory
Nimetazepam		2011-67-8		
nimodipine	3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 2-methoxyethyl 1-methylethyl ester [CAS]	66085-59-4	EP 533014	Neuroprotective
Nimorazole		6506-37-2		
ninostine	Urea, N'-[(4-amino-2-methyl-5-pyrimidinyl)methyl]-N-(2-chloroethyl)-N-nitroso-[CAS]	103745-00-2 42471-28-3 55661-38-6	GB 1374344	Anticancer, alkylating
Ninopterin		2179-16-0		
NIP-142	N-[4(S)-(Cyclopropylamino)-3-(R)-hydroxy-2,2-dimethyl-7-nitro-3,4-dihydro-2H-1-benzopyran-6-yl]-4-methoxybenzeneacetamide		WO 9804542	Antiarrhythmic
NIP-531	N'-[3,5-Bis(trifluoromethyl)benzyl]-N-[3-[[1-(4-fluorobenzyl)benzimidazol-2-yl]-amino]propyl-N-methylurea hydrochloride			Antipruritic/inflam, allergic
niperotide	N-[2-[[5-[(dimethylamino)methyl]furfuryl]thio]ethyl]-2-nitro-N'-piperonyl-1,1-ethenediamine	84845-75-0	GB 2104071	Antitumor
nipradilol, ophthalmic	2H-1-Benzopyran-3-ol, 3,4-dihydro-8-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]-, 3-nitrate [CAS]	81486-22-8 86247-86-1	EP 42299	Formulation, mucosal, topical
Niridaz I		61-57-4		

TABLE 6

Example 1	Indication
infection, general	
Cancer, prostate	
Hypertension, general	
Pain, general	
Cancer, brain	
Fibrillation, atrial	
Eczema, atopic	
Ulcer, GI, general	
Glaucoma	

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
nisoldipine	3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-, methyl 2-methylpropyl ester- [CAS]	63675-72-9	GB 1516793	Antihypertensive, other
nitazoxanide	Benzamide, 2-(acetyloxy)-N-(5-nitro-2-thiazolyl)- [CAS]	55981-09-4	US 5387598	Protozoacide
nitisone	1,3-Cyclohexanedione, 2-[2-nitro-4-(trifluoromethyl)benzoyl]- [CAS]	104206-65-7	EP 186118	Metabolic and enzyme disorders
nitracrine	1,3-Propanediamine, N,N-dimethyl-N'-(1-nitro-9-acridinyl)- [CAS]	4533-39-5 6514-85-8	FR 1458183	Anticancer, other
Nitraz pam		146-22-5		
nitrendipine	3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, ethyl methyl ester- [CAS]	39562-70-4	GB 1358951	Antihypertensive, other
nitrofuribuprofen	(1,1'-Biphenyl)-4-acetic acid, 2-fluoro-Alpha-methyl-, 4-(nitrooxy)butyl ester [CAS]	158836-71-6	EP 670825	Urological
Nitr furant in		67-20-9		
Nitrofuraz ne		59-87-0		
nitroglycerin	1,2,3-Propanetriol, trinitrate [CAS]	55-63-0		Formulation, transdermal, patch
Nitromersol		133-58-4		
nitronaproxen	2-Naphthaleneacetic acid, 6-methoxy-Alpha-methyl 4-(nitrooxy)butyl ester (AlphaS)- [CAS]	163133-43-5	WO 9509831	Analgesic, NSAID
nitroxazepine	Dibenz[b,f][1,4]oxazepin-11(10H)-one, 10-[3-(dimethylamino)propyl]-2-nitro-, monohydrochloride [CAS]	16398-39-3	NL 6608671	Antidepressant
Nitroxoline		4008-48-4		
nitazidine	1,1-Ethenediamine, N-[2-[(2-[(dimethylamino)methyl]-4-thiazolyl)methyl]thio]ethyl]-N'-methyl-2-nitro [CAS]	76983-41-2	EP 48618	Antituber
Niz fen n		54533-85-6		
NM-3	3-(2-methylcarboxymethyl)-6-methoxy-8-hydroxy-isocoumarin		JP 08176138	Anticancer, other

TABLE 6

Example of Indication
Hypertension, general
Infection, GI tract
Cirrhosis, hepatic
Cancer, ovarian
Hypertension, general
Incontinence
Angina, general
Pain, post-operative
Ulcer, duodenal
Cancer, general

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
NM-702	4-Bromo-5-(3-pyridylpropoxy)-3-(2H)pyridazinone hydrochloride			Antithrombotic
N-Methyl phedrine		552-79-4		
N-Methylepinephrine		554-99-4		
N-Methylglucamine		6284-40-8		
NN-414	6-chloro-3-(1-methylcyclopropylamino)-4H-thieno[3,2-e][1,2,4]thiadiazine-1,1-dioxide			Antidiabetic
NNC-05-1869	(R)-1-(3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-3-piperidine carboxylic acid			Symptomatic antidiabetic
Nogalamycin		1404-15-5		
Nolair xed		147149-76-6		
nolatrexed dihydrochloride	4(1H)-Quinazolinone, 2-amino-6-methyl-5-(4-pyridinylthio)-, dihydrochloride [CAS]	152946-68-4	WO 9320055	Anticancer, antimetabolite
nolomirole	Propanoic acid, 2-methyl-, 5,6,7,8-tetrahydro-8-(methylamino)-1,2-naphthalenediyl ester, hydrochloride, (+)- [CAS]	138531-51-8	WO 9529147	Cardio stimulant
nolpitanium	1-Azoniabicyclo[2.2.2]octane, 1-[2-[3-(3,4-dichlorophenyl)-1-[[3-(1-methylethoxy)phenyl]acetyl]-3-piperidinyl]ethyl]-4-phenyl-, chloride, (S)- [CAS]	153050-21-6	EP 591040	GI inflammatory/bowel disorders
nomegestrol	18-Norpregna-4,6-diene-3,20-dione, 17-(acetyloxy)-6-methyl- [CAS]	58652-20-3	DE 2522533	Menstruation disorders
Nomifensine		24526-64-5		
Noprysulfamide		576-97-6		
Norbol th ne		1235-15-0		
Nordazepam		1088-11-5		

TABLE 6

Exempl of Indication
Peripheral vascular disease
Diabetes, Type II
Neuropathy, diabetic
Cancer, liver
Heart failure
Inflammatory bowel disease
Menstrual disorder, general

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
N rdefrin		6539-57-7 (unspecified); 74812-63-8 (R*,S*)-(±)- form		
Nordihydroguaiaretic Acid		27686-84-6 (meso-form); 500-38-9 (unspecified)		
Norelgestromin, Ethinyl Estradiol				
N r plinephrin		51-41-2		
N r thandrolone		52-78-8		
N r thindron		68-22-4		
Norethynodrel		68-23-5		
N rfenefrin		536-21-0		
norfloxacin	3-Quinolonecarboxylic acid, 1-ethyl-6-fluoro- 1,4-dihydro-4-oxo-7-(1'-piperazinyl)- [CAS]	68077-27-0 70459-96-7	US 4146719	Quinolone antibacterial
Norgestron		13563-60-5		
Norg stimat		35189-28-7		
Norgestrel		6533-00-2		
Norgestrienon		848-21-5		
N rlev rphan I		1531-12-0		
N rmethadone		467-85-6		
Normethandrone		514-61-4		
Norm rphin		466-97-7		
N rph nazon		89-25-8		
Norpipanon		561-48-8		
Norpseudoeph drine		492-39-7		
Nortriptylin		72-69-5		
Norvinisteron		6795-60-4		
N scapine		128-62-1		
N v mbichin		1936-40-9		

TABLE 6

API Gen ric Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Novobiocin		303-81-1		
N xiptilin		3362-45-6		
N xythiolin		15599-39-0		
NS-1209	Butanoic acid, 2-[[[5-[4-((dimethylamino)sulfonyl]phenyl)-1,2,6,7,8,9-hexahydro-8-methyl-2-oxo-3H-pyrrolo[3,2-h]isoquinolin-3-ylidene]amino]oxy]-3-hydroxy- [CAS]	254751-28-5	WO 9426747	Antiepileptic
NS-1231	5-(4-chlorophenyl)-6,7,8,9-tetrahydro-1H-pyrrolo-(3,2-h)naphthalene-2,3-dione-3-oxime			
NS-126			US 5063222	Neuroprotective Antiallergic, non-asthma
NS-220	2-Methyl-5-[4-[5-methyl-2-(4-methylphenyl)-4-oxazoly]butyl]-1,3-dioxane-1,2-carboxylic acid			Hypolipemic/Antiatherosclerosis
NS-2330	NS 2330 [CAS]	402856-42-2		Cognition enhancer
NS5A Inhibitors, Questcor			US 6030785	Antiviral, other
NS-7	Pyrimidine, 4-(4-fluorophenyl)-2-methyl-6-[[[5-(1-piperidinyl)pentyl]oxy]-, monohydrochloride [CAS]	178429-67-9	WO 9607641	Neuroprotective
NS-8	2-Amino-5-(2-fluorophenyl)-4-methyl-1H-pyrrole-3-carbonitrile			Urological
NSC-330507	17-Allylaminogeldanamycin			Anticancer, antibiotic
NSC-619534	2-chloroethyl phenyl selenone			Anticancer, alkylating
NSC-697726	2,5-diazinidinyl-3-[hydroxymethyl]6-methyl-1,4-benzoquinone			Anticancer, antibiotic
N-Sulfanilyl-3,4-xylamide		120-34-3		
NU-6027	2,4-Pyrimidinediazine, 6-(cyclohexylmethoxy)-5-nitroso- [CAS]	220036-08-8		Anticancer, other
NV-07	2,4,6-(1H,3H,5H)-Pyrimidinetrione, 5-ethyl-5-sec-pentyl-, 2-oxime [CAS]	53745-16-7	US 6455032	Antipruritic/inflamm, non-allergic

TABLE 6

Exemplification of Indication
Epilepsy, general
Ischaemia, cerebral
Rhinitis, allergic, general
Atherosclerosis
Alzheimer's disease
Infection, hepatitis-C virus
Ischaemia, cerebral
Incontinence
Cancer, general
Cancer, general
Cancer, general
Cancer, general
Keratosis

TABLE 6

API Gen. ric Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
NVP-SRA880	[(3R,4aR,10aR)-1,2,3,4,4a,5,10,10a-Octahydro-6-methoxy-1-methyl-benz[g]quinoline-3-carboxylic acid-4-(4-nitrophenyl)piperazine amide, hydrogen maleate			Neurological
NW-1029	(S)-(+)-2-[4-(2-fluorobenzoyloxy)benzylamino]propanamide methanesulfonate			Analgesic, other
NXY-059	CPI 22 [CAS]	168021-79-2	US 5780510	Neuroprotective
Nylidrin		447-41-6		
NZ-314	1-Imidazolidineacetic acid, 3-[(3-nitrophenyl)methyl]-2,4,5-trioxo- [CAS]	128043-99-2	EP 353198	Symptomatic antidiabetic
NZ-419	5-hydroxy-1-methylimidazolidine-2,4-dione		EP 412940	Urological
Obidoxime Chloride		114-90-9		
OC-108	OC 108 [CAS]	162602-62-2		Vasoprotective, topical
ocinaplon	Methanone, 2-pyridinyl[7-(4-pyridinyl)pyrazolo[1,5-e]pyrimidin-3-yl]- [CAS]	96804-21-6	EP 129847	Anxiolytic
Octabenz n		1843-05-6		
Octacaine		13912-77-1		
Octamoxin		4684-87-1		
Octav rine		549-68-8		
octenidine	1-Octanamine, N,N'-(1,10-decanediyl-1-(4H)-pyridinyl-4-ylidene)bis- [CAS]	70775-75-6 71251-02-0 86767-75-1	WO 8705501	Stomatological
Octodrine		543-82-8		
Oct pamin		104-14-3		
Octotiamin		137-86-0		
octreotide, Atrigel	L-Cysteinamide, D-phenylalanyl-L-cysteinyl-L-phenylalanyl-D-typtophyl-L-tyl-L-threonyl-N-[2-hydroxy-1-(hydroxymethyl)propyl]-, cyclic (2-7)-disulfide, [R-(R*,R*)]- [CAS]	83150-78-9		Formulation, fixed-dose combinations

TABLE 6

Example of Indication
Unspecified
Pain, general
Ischaemia, cerebral
Neuropathy, diabetic
Renal failure
Venous insufficiency
Generalized anxiety disorder
Periodontitis
Cancer, general

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Octyl Methoxycinnamate		5466-77-3		
ofloxacin	7H-Pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid, 9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-, (+)- [CAS]	82419-36-1	EP 47005	Quinolone antibacterial
o-tolod hippurate Sodium		133-17-5		
olanzapine	10H-Thieno(2,3-b)(1,5)benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- [CAS]	132539-08-1	EP 454436	Neuroleptic
Ol andrin		465-16-7		
olic Acid		112-80-1		
olmesartan medoxomil	1H-Imidazole-5-carboxylic acid, 4-(1'-hydroxy-1-methylethyl)-2-propyl-1-[(2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl]-, (5-methyl-2-oxo-1,3-dioxol-4-yl) methyl ester [CAS]	144689-63-4	EP 503785	Antihypertensive, renin system
olopatadine hydrochloride	11-[(Z)-3-(Dimethylamino)propylidene]-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid, monohydrochloride	113806-05-6 140462-76-6	EP 235796	Ophthalmological
olpadronic acid	Monosodium 3-dimethylamino-1-(hydroxypropylidene)-1,1-bisphosphonate	63132-39-8	WO 9619998	Osteoporosis treatment
olsalazine	Benzoic acid, 3,3'-azobis[6-hydroxy- [CAS]	15722-48-2 53200-51-4	US 4559330	GI Inflammatory/bowel disorders
olipraz	3H-1,2-Dithiole-3-thione, 4-methyl-5-pyrazinyl- [CAS]	64224-21-1	DE 2705641	Anticancer, other
OM-294DP	2-[3(R)-(Dodecanoyloxy)tetradecanamido]-N-(4-[3(R)-hydroxytetradecanamido]-5-(phosphonoxy)pentyl]-4-(phosphonoxy)butyramide			Anticancer, immunological

TABLE 6

Example of Indication
Schizophrenia
Hypertension, general
Conjunctivitis
Osteoporosis
Colitis, ulcerative
Cancer, general
Unspecified

TABLE 6

API Gen ric Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Omacor	ethyl (5Z,8Z,11Z,14Z,17Z)-eicos-5,8,11,14,17-pentaenoate + ethyl (4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoate	81926-94-5 86227-47-6		Hypolipaeic/Antiatherosclerosis
omapatrilat	7H-Pyrido(2,1-b)(1,3)thiazepine-7-carboxylic acid, octahydro-4-((2-mercapto-1-oxo-3-phenylpropyl)amino)-5-oxo, (4S-(4Alpha(R*),7Alpha,10aB))- [CAS]	167305-00-2	US 5508272	Antihypertensive, renin system
omeprazole	1H-Benzimidazole, 5-methoxy-2-(((4-methoxy-3,5-dimethyl-2-pyridinyl)methyl)sulfinyl)- [CAS]	73590-58-6	US 4255431	Antilulcer
omiloxetine	Ethanone, 2-((3R,4S)-3-((1,3-benzodioxol-5-yl)oxy)methyl)-4-(4-fluorophenyl)-1-piperidinyl]-1-(4-fluorophenyl)-, rel. [CAS]	176894-09-0		Antidepressant
omocozazole	1H-Imidazole, 1-[2-(2-(4-chlorophenoxy)ethoxy)-2-(2,4-dichlorophenyl)-1-methylethenyl]-, (Z)- [CAS]	74512-12-2	EP 8804	Antifungal
Onaprist ne		96346-61-1		
ondansetron	4H-Carbazol-4-one, 1,2,3,9-tetrahydro-9-methyl-3-((2-methyl-1H-imidazol-1-yl)methyl)- [CAS]	99614-01-4 99614-02-5	US 4847281	Antiemetic
ONO-3403	Benzoic acid, 4-((1E)-3-((2-ethoxy-2-oxoethyl)-2-propenylamino)-2-methyl-3-oxo-1-propenyl)-, 4-(aminominoethyl)phenyl ester, monomethanesulfonate [CAS]	181586-07-2		GI inflammatory/bowel disorders
ONO-4128	1,4,9-Triazaspiro(5,5)undecane-2,5-dione, 1-butyl-3-(cyclohexylmethyl)-9-((2,3-dihydro-1,4-benzodioxin-6-yl)methyl)- [CAS]	342394-93-8		Antiviral, anti-HIV
ONO-8815 Ly	L-lysine (Z)-7-((1R,2R,3R,5R)-5-chloro-3-hydroxy-2-((E)-(S)-4-(1-ethyl(cyclobutyl)-4-hydroxy-1-butenyl)cyclopentyl)-5-heptenoate			Labour inhibitor

TABLE 6

Example of Indication
Hypertriglyceridaemia
Hypertension, general
Ulcer, GI, general
Depression, general
Infection, dermatological
Chemotherapy-induced nausea and vomiting
Unspecified
Infection, HIV/AIDS
Labour, preterm

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
ONT-093			US 5756527	Radio/chemosensitizer
OPC-14523	2-(1H)-Quinolone, 1-[3-(4-(3-chlorophenyl)-1-piperazinyl)propyl]-3,4-dihydro-5-methoxy- [CAS]	145969-30-8	EP 512525	Antidepressant
OPC-31260	Benzamide, N-[4-[(5-(dimethylamino)-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)carbonyl]phenyl]-2-methyl-	137975-06-5	WO 9105549	Urological
OPC-51803	(5R)-2-[1-(2-chloro-4-(1-pyridinyl)benzoyl)-2,3,4,5-tetrahydro-1H-1-benzazepin-5-yl]-N-isopropylacetamide			Antidiabetic
OPC-6535	2-Pyridinecarboxylic acid, 6-[2-(3,4-dithoxyphenyl)-4-thiazolyl]- [CAS]	145739-56-6	WO 9209586	GI inflammatory/bowel disorders
Opiniazid		2779-55-7		
opioid analgesics, Adolor	2-(4-trifluoromethylphenyl)-N-methyl-1-phenyl-2-(1-pyridinyl)ethylacetamide			Analgesic, other
Opipramol		315-72-0		
Orazamide		2574-78-9		
orazipone	2,4-Pentanedione, 3-[(4-methylsulfonyl)phenyl]methylene)- [CAS]	137109-78-5	EP 440324	Antiasthma
Org-12962	Piperazine, 1-[6-chloro-5-(trifluoromethyl)-2-pyridinyl]-, monohydrochloride [CAS]	210821-63-9		Antidepressant
Org-24448			US 6166008	Neuroleptic
oritavancin	Vancomycin, 22-O-(3-amino-2,3,6-trideoxy-3-C-methyl-Alpha-L-arabino-hexopyranosyl)-N3'-[(4'-chloro[1,1'-biphenyl]-4-yl)methyl]- (4'P)- [CAS]	171099-57-3	US 5840684	Peptide antibiotic
orlistat	L-Leucine, N-formyl-, 1-[(3-hexyl-4-oxo-2-oxetanyl)methyl]dodecyl ester, [2S-[2Alpha(R*),3B]]- [CAS]	96829-58-2	EP 129748	Anorectic/Antiobesity
orneloxifene	Pyrolidone, 1-[2-(p-(7-methoxy-2,2-dimethyl-3-phenyl-4-chromanyl)phenoxy)ethyl]-, trans- [CAS]	31477-60-8	DE 2329201	Female contraceptive
Ornidazole		16773-42-5		

TABLE 6

Example of Indication
Cancer, general
Depression, general
Unspecified
Diabetes, insipidus
Inflammatory bowel disease
Pain, general
Unspecified
Depression, general
Schizophrenia
Infection, dermatological
Obesity
Contraceptive, female

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Ornipressin		3397-23-7		
Ornithin		70-26-8		
omoprostil	Prost-13-en-1-oic acid, 11,15-dihydroxy-17,20-dimethyl-9,9-dioxo-, methyl ester, (11Alpha,13E,15S,17S)- [CAS]	70667-26-4	US 4278688	Prostaglandin
Orotic Acid		65-86-1		
Orphenadrin		83-98-7		
Orthocaine		536-25-4		
Osalmid		526-18-1		
osanelant	Acetamide, N-[1-[3-[(3R)-1-benzoyl-3-(3,4-dichlorophenyl)-3-piperidinylpropyl]-4-phenyl-4-piperidinyl]-N-methyl- [CAS]	160492-56-8	EP 673928	Neuroleptic
osaterone acetate	2-Oxapregna-4,6-diene-3,20-dione, 17-(acetyloxy)-8-chloro- [CAS]	105149-00-6	EP 193871	Prostate disorders
oseltamivir	1-Cyclohexene-1-carboxylic acid, 4-(acetylamino)-5-amino-3-(1-ethoxypropoxy)-, ethyl ester, (3R-(3Alpha,4B,5Alpha))- [CAS]	196618-13-0	WO 9626933	Antiviral, other
OSI-7836	4'-Thio-β-D-arabinofuranosylcytosine			Anticancer, antimetabolite
	Pentanedioic acid, 2-[5-[(1,2-dihydro-3-methyl-1-oxobenzof[quinazolin-9-yl)methyl]amino]-1,3-dihydro-1-oxo-2H-isindol-2-yl]-, (S)- [CAS]	139987-54-5	WO 9119700	Formulation, optimized, liposomes
ospemilene	Ethanol, 2-[4-[(1Z)-4-chloro-1,2-diphenyl-1-butenyl]phenoxy]- [CAS]	128607-22-7	WO 9607402	Menopausal disorders
otilonium bromide	Ethanaminium, N,N-diethyl-N-methyl-2-[[4-[[2-(octyloxy)benzoyl]amino]benzoyloxy]-, bromide [CAS]	26095-59-0	GB 1181406	Antispasmodic
Ouabain		630-60-4		
Oxac prol		33996-33-7		
Oxacillin		66-79-5		
Oxaflozan		26629-87-8		

TABLE 6

Exempl of Indication
Ulcer, gastric
Schizophrenia
Benign prostatic hyperplasia
Infection, influenza virus
Cancer, general
Cancer, general
Osteoporosis
Irritable bowel syndrome

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
oxaliplatin	Platinum, (1,2-cyclohexanediamine-N,N')[ethanedioato(2-)-O,O']-, [SP-4-2-(1R-trans)]-, [CAS]	81825-94-3	EP 393575	Anticancer, alkylating
Oxalyt-C	1,2,3-Propanetricarboxylic acid, 2-hydroxy-, potassium sodium salt [CAS]	28060-67-5	DE 2249274	Urological
Oxamarin		15301-80-1		
Oxam tacine		27035-30-9		
Oxamniquin		21738-42-1		
oxandrolone	2-Oxaandrostane-3-one, 17-hydroxy-17-methyl-, (5 α), (17 β)- [CAS]	53-39-4	US 3128283	Reproductive/gonadal, general
Oxantol		36531-26-7		
Oxapranium iodide		541-66-2		
oxaprozin	2-Oxazolepropanoic acid, 4,5-diphenyl- [CAS]	21256-18-8	GB 1208403	Antiarthritic, other
oxatolamide	2H-Benzimidazol-2-one, 1-[3-[4-(diphenylmethyl)-1-piperazinyl]propyl]-1,3-dihydro- [CAS]	60607-34-3	GB 1579365	Antiallergic, non-asthma
oxazepam	7-Chloro-1,3-dihydro-3-hydroxy-5-phenyl-2H-1,4-benzodiazepin-2-one	604-75-1		Formulation, oral, orally-disintegrating
oxazolam	Oxazol[3,2-d][1,4]benzodiazepin-6(5H)-one, 10-chloro-2,3,7,11b-tetrahydro-2-methyl-11b-phenyl- [CAS]	27167-30-2	US 3772371	Anxiolytic
oxcarbazepine	5H-Dibenz[b,f]azepine-5-carboxamide, 10,11-dihydro-10-oxo- [CAS]	28721-07-5 29331-92-8	DE 2011087	Antiepileptic
Oxeladin		468-61-1		
Oxndolone		33765-68-3		
Oxthazaine		126-27-2		
Oxtorone		26020-55-3		
oxiconazole	Ethanone, 1-(2,4-dichlorophenyl)-2-(1H-imidazol-1-yl)-, O-[(2,4-dichlorophenyl)methyl]oxime, (Z)- [CAS]	64211-45-6	GB 1514870	Antifungal
Oxidronic Acid		15468-10-7		
Oxnilac Acid		2398-81-4		
Oxiracetam		62613-82-5		

TABLE 6

Example of Indication
Cancer, colorectal
Sex-chromosome abnormality, Turner's syndrome
Arthritis, osteo
Rhinitis, allergic, general
Anxiety, general
Epilepsy, general
Infection, fungal, general

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
oxitropium	3-Oxa-9-azoniatricyclo[3.3.1.0 ^{2,4}]nonane, 9-ethyl-7-(3-hydroxy-1-oxo-2-phenylpropoxy)-9-methyl-, bromide, [7(S)-(1 α ,2 β ,4 β ,5 α ,7 β)]- [CAS]	30286-75-0	GB 1178305	Antisthma
Oxolamine		959-14-8		
Ox linic Acid		14698-29-4		
Ox phenarsin		538-03-4		
Oxprenolol		6452-71-7		
Oxybenz n		131-57-7		
oxybutynin	Benzeneacetic acid, Alpha-cyclohexyl-Alpha-hydroxy-, 4-(diethylamino)-2-butyl ester- [CAS]	5633-20-5		Formulation, modified-release, other
Oxycinchoph n		485-89-2		
oxycodone	Morphinan-6-one, 4,5-epoxy-14-hydroxy-3-methoxy-17-methyl-, (5 α)	76-42-6		Formulation, transmucosal, nasal
Oxyf drine		15687-41-9		
Oxygent	Ocane, 1-bromo-1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8-heptadecafluoro- [CAS]	423-55-2		Haematological
Oxym steron		145-12-0		
Oxymetazolin		1491-59-4		
oxymetholone, Unimed	Androstan-3-one, 17-hydroxy-2-(hydroxymethylene)-17-methyl-, (5 α ,17 β)- [CAS]	434-07-1		Hormone
Oxymethurea	(5 α)4,5-Epoxy-3,14-dihydroxy-17-methylmorphinan-6-one [CAS]	140-95-4		Formulation, modified-release, immediate
oxymorphone		76-41-5		
Oxypendyl		5585-93-3		
Oxypertin		153-87-7		
Oxyph nbutazone		129-20-4		
Oxyph ncyclimine		125-53-1		
Oxyphenisatin		115-33-3		

TABLE 6

Example of Indication
Incontinence
Pain, general
Surgery adjunct
Anaemia, general
Pain, general

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Oxyph n nium		50-10-2		
Oxyph n camphone		10136-65-9		
oxypurinol	1H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione [CAS]	2465-59-0		Antigout
Oxytetracycline		79-57-2		
ozagrel	2-Propenoic acid, 3-[4-(1H-imidazol-1-ylmethyl)phenyl]-, (E)- [CAS]	78712-43-3 82571-53-7	GB 2025946	Antithrombotic
p- (B n zylsulf namido)ben zolic Acid		536-95-8		
P-100, Pharmacor			US 6313177	Antiviral, anti-HIV
P-1202	Pentanoic acid, 5-amino-4-oxo, methyl ester, hydrochloride [CAS]	79416-27-6	US 6034267	Dermatological
P32/98	DI-(3N)-(2S,3S)-2-amino-3-methyl-pentanoyl-1,3-thiazolidine)fumarate			Antidiabetic
PA-324			WO 9701562	Antimycobacterial
PACAP 38	Pituitary adenylate cyclase-activating peptide-38 [CAS]	128606-20-2	US 5128242	Neuroprotective
pacifitaxel	5B,20-Epoxy-1,2Alpha,4,7B,10B,13Alpha-hexahydroxytax-11-en-9-one-4,10-diacetate-2-benzoate-13-(Alpha-phenylthiopyrate)	33069-62-4		Formulation, optimized, nanoparticles
PADRE			US 6413935	Immunostimulant, other
pagoclone	1H-Isolindol-1-one, 2-(7-chloro-1,8-naphthyridin-2-yl)-2,3-dihydro-3-(5-methyl-2-oxohexyl)- (R)- [CAS]	133737-32-3	US 4960778	Anxiolytic
PAI inhibs, thrombosis, Xenova			WO 9404512	Antithrombotic
palindore fumarate	8H-1,4-dioxino[2,3-e]indol-8-one,2,3,7,9-tetrahydro-2-[(phenylmethyl)amino]methyl-, 2(S)-, (2E)-2-butendioate (1:1)	189881-71-8		Neuroleptic
Palivizumab		188039-54-5		

TABLE 6

Example f Indication
Hyperuricaemia
Vasospasm, cerebral
Infection, HIV/AIDS
Keratosis
Diabetes, Type II
Infection, tuberculosis
Nerve injury, general
Cancer, breast
Vaccine adjunct
Panic disorder
Thrombosis, venous
Schizophrenia

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
palonosetron	3aS-2-[(S)-1-Azabicyclo[2.2.2]oct-3-yl]-2,3,3a,4,5,6-hexahydro-1-oxo-1H-benz[de]isoquinoline hydrochloride	135729-62-3	US 5202333	Antiemetic
Pamabrom		606-04-2		
Pamaquine		491-92-9		
pamocogrel	1H-Pyrrole-1-acetic acid, 2-[4,5-bis(4-methoxyphenyl)-2-thiazolyl]-, ethyl ester [CAS]	101001-34-7	EP 159677	Antithrombotic
pamidronate	(3-Amino-1-hydroxypropylidene)diphosphonic acid- [CAS]	40391-99-9		Formulation, implant
Pamidronic Acid		40391-99-9		
p-Aminobenzoic Acid		150-13-0		
p-Amin hippuric Acid		61-78-9		
p-Amin propi phenone		70-69-9		
p-Amin salicylic Acid		65-49-6		
Panavir	4,4'-isopropylidenedithiobis-2,6-di-t-butylphenol			Neuroprotective
Pancur nitum		15500-66-0		
Panipen m		87726-17-8		
Pantethin		16816-67-4		
pantoprazole	1H-Benzimidazole, 5-(difluoromethoxy)-2-[[[3,4-dimethoxy-2-pyridinyl)methyl]sulfinyl]- [CAS]	102625-70-7	EP 166287	Antilulcer
Pant thenic Acid		79-83-4		
Papain, Urea				
Papaverine		58-74-2		
paracetamol	Acetamide, N-(4-hydroxyphenyl)- [CAS]	103-90-2		Formulation, oral, other, modified-release
Parafutizid		1580-83-2		
Paraldehyde		123-63-7		
Paramethadi ne		115-67-3		
Paramethason		53-33-8		
Paranyline		1729-61-9		

TABLE 6

Example of Indication
Chemotherapy-induced nausea and vomiting
Thrombosis, cerebral
Hypercalcaemia of malignancy
Vasospasm, cerebral
Ulcer, duodenal
Pain, general

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Parathyrin	Propanamide, N-[(4-(5-methyl-3-phenyl-4-isoxazolyl)phenyl)sulfonyl]-, sodium salt [CAS]	9002-64-6		
parecoxib		198470-85-8	WO 9738986	Analgescic, NSAID
Parethoxycaine		94-23-5		
Pargyline		555-57-7		
paricalcitol	18-Nor-9,10-secosteroid-5,7,22-triene-1,3,25-triol, (1 α ,3 β ,7 β ,22 β)- [CAS]	131918-61-1	EP 387077	Hormone
paromomycin	O-2-Amino-2-deoxy-Alpha-D-glucopyranosyl-(1-4)-O-[O-2,6-diamino-2,6-dideoxy-8-L-idopyranosyl-(1-3)-8-D-ribofuranosyl-(1-5)]-2-deoxy-D-streptamine	7542-37-2		Protozoacide
paroxetine	Piperidine, 3-[(1,3-benzodioxol-5-yl)oxy)methyl]-4-(4-fluorophenyl)-, (3S-trans)- [CAS]	61869-08-7	EP 223403	Antidepressant, formulation, oral, orally-disintegrating
Paroxypropion		70-70-2		
Parsalmide		30653-83-9		
Patrin-2	4-Bromomethylguanidine			Radio/chemosensitizer
Pazinaclone		103255-66-9		
pazufloxacin	7H-Pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid, 10-(1-aminocyclopropyl)-9-fluoro-2,3-dihydro-3-methyl-7-oxo-, (S)- [CAS]	127045-41-4 127046-45-1 136905-87-8	DE 3913245	Quinolone antibacterial
p-Bromoacetanilide		103-88-8		
PC-NSAIDs, GrassRoots			US 4918063	Formulation, other
PD-0166285	6-(2,6-Dichlorophenyl)-2-(4-(diethylaminoethoxy)-phenylamino)-8-pyrido[2,3-D]pyrimidine-7-one			Anticancer, other
P clloclin		19504-77-9		
pelloxacin	3-Quinolonecarboxylic acid, 1-ethyl-6-fluoro-1,4-dihydro-7-(4-methyl-1-piperazinyl)-4-oxo- [CAS]	70458-92-3	GB 1598915	Quinolone antibacterial

TABLE 6

Example of Indication
Pain, post-operative
Hyperparathyroidism
Infection, leishmaniasis
Depression, general
Cancer, melanoma
Infection, general
Arthritis, general
Cancer, general
Infection, urinary tract

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
pegvisomant	Somatotropin (18-aspartic acid, 21-asparagine, 120-lysine, 167-asparagine, 168-alanine, 171-serine, 172-arginine, 174-serine, 179-threonine (human), pegylated [CAS])	216620-50-9		Somatostatin
P ifletirin		4396-1-4		
Pem tr x d		137281-23-3		
pemetrexed	L-Glutamic acid, N-[4-{2-(2-amino-4,7-dihydro-4-oxo-1H-pyrazolo[2,3-d]pyrimidin-5-yl)ethyl}benzoyl]-, disodium salt [CAS]	137281-23-3 150398-23-8	US 5248775	Anticancer, antimetabolite
penicilast	4H-Pyrido[1,2-a]pyrimidin-4-one, 9-methyl-3-(1H-tetrazol-5-yl)- [CAS]	100299-08-9 69372-19-6	US 4457932	Antiasthma
Pemoline		2152-34-3		
Pemipidine		79-55-0		
PEN-203			US 5955446	Antiviral, other
Penam cillin		983-85-7		
penbutolol	2-Propanol, 1-(2-cyclopentylphenoxy)-3-[[[1,1-dimethyl(ethyl)amino]- (S)-, sulfate (2:1) (salt) [CAS]	38363-32-5 38363-40-5	GB 1215751	Antihypertensive, adrenergic
Penbutolol		38363-40-5		
peniclovir	6H-Purin-6-one, 2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)butyl]- [CAS]	39809-25-1	JP 60058982	Antiviral, other
Pen thamate		808-71-9		
penfluridol	4-Piperidinol, 1-[4,4-bis(4-fluorophenyl)butyl]-4-[4-chloro-3-(trifluoromethyl)phenyl]- [CAS]	26864-56-2	DE 2040231	Neuroleptic
P nicillamin		52-67-5		
Penicillin G		61-33-6		
Penicillin G Benzathine		1538-09-6		
Penicillin G Pr caine		6130-64-9		
Penicillin N		525-94-0		
Penicillin O		87-09-2		

TABLE 6

Example of Indication
Acromegaly
Cancer, mesothelioma
Asthma
Infection, human papilloma virus
Infection, herpes simplex virus

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Penicillin V		87-08-1		
Penimepicycline		4599-60-4		
Pentius			US 4221778	Formulation, modified-release, other
Penta rythritol Chloral		78-12-6		
Penta rythritol		2209-86-1		
Dicli rohydrin				
P nta rythrit I		597-71-7		
P ntagastrin		5534-95-2		
Pentag str n		7001-56-1		
Pentalife	Starch, 2-hydroxyethyl ether [CAS]	9005-27-0	US 5407428	Plasma substitute
Pentamethonium		541-20-8		
pentamidine	Benzenecarboximidamide, 4,4'-(1,5-pentanediyldi(bis(oxy))bis- [CAS]	100-33-4		Formulation, inhalable, systemic
Pentazocine		359-83-1		
P ntetat		12111-24-9		
P nt tic Acid		67-43-6		
Pentetr otide		138661-02-6		
Penthenate		60-44-6		
Pentifylline		1028-33-7		
P ntigetide		62087-72-3		
P ntisomide		78833-03-1		
Pentobarbital		76-74-4		
Pent linium		52-62-0		
Pentor x		434-43-5		
pentosan polysulfate	Xylan, hydrogen sulfate, sodium salt [CAS]	37319-17-8	US 5180715	Urological
pentosatin	imidazo[4,5-d][1,3]diazepin-8-ol, 3-(2-deoxy-β-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydro-, (R)- [CAS]	53910-25-1	US 3923785	Anticancer, antimetabolite
pentoxifylline	1H-Purine-2,6-dione, 3,7-dihydro-3,7-dimethyl-1-(5-oxohexyl)- [CAS]			Neuroprotective
P nt xyl		147-61-5		
Pentritr I		1607-17-6		
Pentylene t trazole		54-95-5		

TABLE 6

API Gen ric Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
peplomycin	Bleomycinamide, N1-[3-[(1-phenylethyl)amino]propyl]-, (S)- [CAS]	68247-85-8	US 4195018	Anticancer, antibiotic
Perazin		84-97-9		
Perflubron		423-55-2		
Perflubron		62435-42-1; 39800-16-3 (unspecified)		
pergolide	Ergoline, 8-[(methylthio)methyl]-6-propyl-, (8S)-, monomethanesulfonate- [CAS]	66104-22-1 66104-23-2	US 4797405	Antiparkinsonian
Perhexiline		6621-47-2		
Percyazin		2622-26-6		
perifosine	Piperidinyl, 4- [[hydroxy(octadecyloxy)phosphinyl]oxy]-1,1-dimethyl-, inner salt [CAS]	157716-52-4	EP 594999	Anticancer, other
perillyl alcohol	1-Cyclohexene-1-methanol, 4-(1-methylethenyl)- [CAS]	538-59-4	US 5110832	Anticancer, other
Perimethazine		13093-88-4		
perindopril	1H-Indole-2-carboxylic acid, 1-[2-[[1-(ethoxycarbonyl)butyl]amino]-1-oxopropyl]octahydro-, [2S-[1R*(R'),2Alpha,3aB,7aB]]-, compd. with 2-methyl-2-propanamine (1:1) [CAS]	107133-36-8 82834-16-0 95153-31-4	EP 49658	Antihypertensive, renin system
Peritidin		53586-99-5		
Piraric acid		2055-44-9		
perisoxal	1-Piperidineethanol, Alpha-(5-phenyl-3-isoxazolyl)-, 2-hydroxy-1,2,3-propanetricarboxylate (2:1) (salt) [CAS]	2139-25-5	JP 04217925	Anti-inflammatory
Piraric acid		1977-11-3		
Piraric acid		52645-53-1		
perospirone	1H-Isindole-1,3(2H)-dione, 2-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]butyl]hexahydro-, cis- [CAS]	129273-38-7 150915-41-6	CA 2167004	Neuroleptic
Perphenazine		58-39-9		
Piraric acid		8030-30-6		

TABLE 6

Exemplary Indication
Parkinson's disease
Cancer, prostate
Cancer, breast
Hypertension, general
Schizophrenia

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
PH-10			US 6331286	Antipsoriasis
Phanquinon		84-12-8		
Pharmaprojects No. 4994			WO 9638482	Immunological
Pharmaprojects No. 5325			WO 9703986	Neuroleptic
Pharmaprojects No. 5972			WO 0204426	Antiasthma
Pharmaprojects No. 6362			US 6057346	Antiviral, anti-HIV
	(R)-N-[4-[2-[[2-Hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-[4-(trifluoromethyl)phenyl]thiazol-2-yl]benzenesulfonamide			
Pharmaprojects No. 6446				Anorectic/Antiobesity
Pharmaprojects No. 6590			WO 0206223	Psychostimulant
Pharmaprojects No. 6656			US 6455026	Genomics-based drug discovery
Pharmaprojects No. 6691			US 6299900	Formulation, other
	3-(6-Aminopyridin-3-yl)-N-methyl-N-[(1-methyl-1H-indol-2-yl)methyl]acrylamide			
Pharmaprojects No. 6743				Antibacterial, other
	1,2,3,4,10,14b-Hexahydro-6-methoxy-2-methylidibenzo[c, f]pyrazino[1,2-a]azepin			Antidepressant
Pharmaprojects No. 6748		620-99-5		
Phenacain				
Hydr chloride		63-98-9		
Phenacemid		62-44-2		
Phenac tin		467-84-5		
Ph nadox n		115-43-5		
Ph nallymal		3819-34-9		
Phenam t		127-35-5		
Phenazocin		136-40-3		
Phenazopyridine				
Hydrochloride		3149-00-6		
Phenbutamide		77-10-1		
Phencyclidine		634-03-7		
Phendimetrazine				
Ph nelzin		51-71-8		

TABLE 6

[illegible]

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Phenesterine		3546-10-9		
Ph netharbital		357-67-5		
Phenethicillin Potassium		132-93-4		
Pheneturide		90-49-3		
Phenformin		114-86-3		
Ph nglutarimide		1156-05-4		
Ph nindamin		82-88-2		
Phenindion		83-12-5		
Pheniprazin		55-52-7		
Pheniramine		86-21-5		
Ph nm trazine		134-49-6		
Ph n barbital		50-06-6		
Ph n buti dill		554-24-5		
Phenocoll		103-97-9		
Phenoclide		78-05-7		
Phen lphthal in		77-09-8		
Phenolphthalol		81-92-5		
Phen lsulfonphthalein		143-74-8		
Ph n it trachlorophthal in		639-44-1		
Ph nop ridine		562-26-5		
Phen sulfaz I		515-54-8		
Phen xybenzamine		59-96-1		
Phenoxypipazine		3818-37-9		
Phenprobamat		673-31-4		
Phenproc um n		435-97-2		
phenserine	Pyrrolo(2,3-b)indol-5-ol, 1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethyl-, phenylcarbamate (ester), (3aS-cis)- [CAS]	101246-66-6		Cognition enhancer
Phensuximid		86-34-0		
Phentermine		122-09-8		
Phentermine				

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Phentetiothaleln Sodium		18265-54-8		
Phent lamine		50-60-2		
phenotolamine mesylate, Zonagen	Phenol, 3-(((4,5-dihydro-1H-imidazol-2-yl)methyl)(4-methylphenyl)amino)-, monomethanesulfonate (salt) [CAS]	65-28-1		Formulation, oral, other
phenotolamine mesylate, Novartis	Phenol, 3-(((4,5-dihydro-1H-imidazol-2-yl)methyl)(4-methylphenyl)amino)-, monomethanesulfonate (salt) [CAS]	65-28-1		Formulation, oral, other
Ph nyl Acetylsalicylate		134-55-4		
Phenyl Amin salicylate		133-11-9		
Phenyl Salicylate		118-55-8		
Phenylbutaz ne		50-33-9		
Phenylephrin		61-76-7		
Hydrochloride				
Phenyl than lamine		7568-93-6		
Phenylmercury Borate		102-98-7		
Ph nylm thylbarbituric Acid		76-94-8		
Ph nylpropanolamine		14838-15-4		
phenylpropanolamine, Alza	Benzenemethanol, Alpha-(1-aminoethyl)-, (R*,S*)-(+/-) [CAS]	14838-15-4		Anorectic/Antibesity
phenylpropanolamine, Difluca	Benzenemethanol, Alpha-(1-aminoethyl)-, (R*,S*)-(+/-) [CAS]	14838-15-4		Formulation, optimized, microparticles
phenylpropanolamine, KV	Benzenemethanol, Alpha-(1-aminoethyl)-, (R*,S*)-(+/-) [CAS]	14838-15-4		Formulation, other
phenylpropanolamine, Verex	Benzenemethanol, Alpha-(1-aminoethyl)-, (R*,S*)-(+/-) [CAS]	14838-15-4		Formulation, modified-release, other
Phenylpr pylmethylamin		93-88-9		
Phenylt l xamine		92-12-6		
Ph nyramidol		553-69-5		
Phenytoln		57-41-0		

TABLE 6

Example of Indication
Impotence
Impotence
Obesity
Cough
Obesity

TABLE 6

API Gen ric Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
phenytoin, Sirus	2,4-Imidazolidinedione, 5,5-diphenyl- [CAS]	57-41-0		Formulation, oral, other
Pheth nylate S dium		510-34-9		
Phlor glucin I		108-73-6		
Pholcodine		509-67-1		
Ph I drin		370-14-9		
Phosphocreatine		67-07-2		
Ph sph cysteamine		5746-40-7		
Ph sphoryich line		107-73-3		
Phthalylsulfacetamide		131-69-1		
Phthalylsulfathiazole		85-73-4		
p-Hydroxyeph drine		365-26-4		
Phylloquinone		84-80-0		
Phys stigmin		57-47-6		
Phytic Acid		83-86-3		
PI-88	D-Mannose, O-6-O-phosphono-Alpha-D-mannopyranosyl-(1-3)-O-Alpha-D-mannopyranosyl-(1-3)-O-Alpha-D-mannopyranosyl-(1-3)-O-Alpha-D-mannopyranosyl-(1-2)-hydrogen sulphate [CAS]	185077-23-0		Anticancer, other
Piberaline		39640-15-8		
piboserod	2H-(1,3)Oxazino(3,2-a)indole-10-carboxamide, N-((1-butyl-4-piperidinyl)methyl)-3,4-dihydro- [CAS]	152811-62-6	WO 9318036	Antiarrhythmic
Piboser d		152811-62-6		
Picilor x		62510-56-9		
Picloxydine		5636-92-0		
Pic p rin		21755-66-8		
Picosulfat S dium		10040-45-6		
Picotamid		32828-81-2		
Picumast		39577-19-0		
pidotimod	4-Thiazolidinecarboxylic acid, 3-[(5-oxo-2-pyrrolidinyl)carbonyl]- [CAS]	121808-62-6	EP 276752	Immunomodulator, anti-infective
Pidotimod		121808-62-6		

TABLE 6

API Gen ric Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Pitamine		56208-01-6		
piketoprofen	Benzeneacetamide, 3-benzoyl-Alpha-methyl-N-(4-methyl-2-pyridinyl)- [CAS]	60576-13-8	GB 1436502	Anti-inflammatory, topical
Pik t pr f n		60576-13-8		
Pildralazine		64000-73-3		
Pilocarpin		92-13-7		
pilocarpine, Alza	2(3H)-Furanone, 3-ethyldihydro-4-[(1-methyl-1H-imidazol-5-yl)methyl]-, (3S-cis)- [CAS]	92-13-7		Formulation, implant
pilocarpine, MGI	2(3H)-Furanone, 3-ethyldihydro-4-[(1-methyl-1H-imidazol-5-yl)methyl]-, (3S-cis)- [CAS]	92-13-7		Stomatological
Piloplex	2-Propenoic acid, 2-methyl-, dodecyl ester, polymer with 2-propenoic acid, compd. with (3S-cis)-3-ethyldihydro-4-[(1-methyl-1H-imidazol-5-yl)methyl]-2(3H)-furanone [CAS]	62783-28-2	DE 2636559	Formulation, mucosal, topical
Plisicainide		88069-67-4		
plisicainide hydrochloride	1H-Pyrolizine-7a(5H)-acetamide, N-(2,6-dimethylphenyl)tetrahydro-, monohydrochloride [CAS]	88069-49-2 88069-67-4	US 4564624	Antiarrhythmic
Pimeclon		534-84-9		
pimecrolimus	15,19-Epoxy-3H-pyrido(2,1-c)(1,4)oxazacyclotricosine-1,7,20,21(4H,23H)-tetrone, 3-(2-(4-chloro-3-methoxycyclohexyl)-1-methylethenyl)-8-ethyl-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-5,19-dihydroxy-14,16-dimethoxy-4,10,12,18-tetramethyl-(3S-(3R'E(1S',3S',4R')), 4S',5R',8S',9E',12R',14R',5S',16R',18S,8,19S',26aR'))- [CAS]	137071-32-0	EP 626385	Antipruritic/inflam, allergic
Pimecrolimus		137071-32-0		
Pimefylline		10001-43-1		

TABLE 6

Example of Indication
Xerostomia
Glaucoma
Arrhythmia, general
Eczema, atopic

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
pimilprost	Acetic acid, [2-(octahydro-5-hydroxy-6-(3-hydroxy-5-methyl-1-nonenyl)-2-pentalenyl)ethoxy]-, methyl ester, [2R-(2A)pha,3Apha,4Alpha(1E,3S*,5S*),5B,6a Alpha]]- [CAS]	139403-31-9		Dermatological
Pimin din		13495-09-5		
Pimobendan		74150-27-9		
pimozide	2H-Benzimidazol-2-one, 1-[1-[4,4-bis(4-fluorophenyl)butyl]-4-piperidinyl]-1,3-dihydro- [CAS]	2062-78-4	FR M3695	Neuroleptic
Pimozid		2062-78-4		
Pimozide				
Pinacidil		85371-64-8		
pinaverium bromide	Morpholinium, 4-[(2-bromo-4,5-dimethoxyphenyl)methyl]-4-[2-[2-(6,6-dimethylbicyclo[3.1.1]hept-2-yl)ethoxy]ethyl]-, bromide- [CAS]	53251-94-8 59995-85-2	EP 406743	Antispasmodic
Pinaverium Br mide		53251-94-8		
pinazepam	2H-1,4-Benzodiazepin-2-one, 7-chloro-1,3-dihydro-5-phenyl-1-(2-propenyl)-[CAS]	52463-83-9	DE 2339790	Anxiolytic
Pinazepam		52463-83-9		
Pindolol		13523-86-9		
Pliglitazon		111025-46-8		
pioglitazone hydrochloride	2,4-Thiazolidinedione, 5-[[4-[2-(6-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-, monohydrochloride (+/-) [CAS]	111025-46-8 112529-15-4	EP 193256	Antidiabetic
Pioglitazone Hydrochloride				
Pipacyncln		1110-80-1		
Pipamazin		84-04-8		
Pipamp ron		1893-33-0		
Pipaz that		2167-85-3		
Pipebuzone		27315-91-9		
Pipecurium Bromide		52212-02-9		

TABLE 6

Exemplification of Indication
Ulcer, general
Irritable bowel syndrome
Diabetes, Type II

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
pilocarpinium bromide	Pilocarpinium, 4,4'- [[28,3Alpha,5Alpha,16B,17B)-3,17- bis(aceylloxy)androstane-2,16-diy]bis(1,1)- dimethyl-, dibromide [CAS]	52212-02-9 68399-57-5	GB 1398050	Muscle relaxant
pipemidic acid	Pyrido[2,3-d]pyrimidine-6-carboxylic acid, 8- ethyl-5,8-dihydro-5-oxo-2-(1-piperazinyl)- [CAS]	51940-44-4	GB 1451911	Antibacterial, other
Pip midic Acid		51940-44-4		
Pipenz late Br mide		125-51-9		
Pip racetazin		3819-00-9		
piperacillin	4-Thia-1-azabicyclo[3.2.0]heptane-2- carboxylic acid, 6-[[[(4-ethyl-2,3-dioxo-1- piperazinyl)carbonylamino]phenyl]acetyl]a- mino]-3,3-dimethyl-7-oxo-, [2S- [2Alpha,5Alpha,6B(S*)]]- [CAS]	59703-84-3 61477-96-1	GB 1508062	Penicillin, injectable
Piperacilin		61477-96-1		
piperacillin, KRKA	4-thia-1-azabicyclo[3.2.0]heptane-2- carboxylic acid, 6-[[[(4-ethyl-2,3-dioxo-1- piperazinyl)carbonylamino]phenyl]acetyl]a- mino]-3,3-dimethyl-7-oxo-, monosodium salt, [2S, [2Alpha,5Alpha,6B(S*)]]	59703-84-3 61477-96-1		Penicillin, injectable
Piperazin Adipate		142-88-1		
Piperidione		77-03-2		
Piperidolate		82-98-4		
Piperilate		4546-39-8		
piperine analogues, BTG			WO 002544	Dermatological
Piperocaine		136-82-3		
Pip r nal		120-57-0		
Piperoxan		59-39-2		
Pip ryl ne		4/6/2531		
Pip br man		54-91-1		
Piposulfan		2608-24-4		
Pipotiazine		39860-99-6		

TABLE 6

Examp ^l of Indication
Anaesthesia, adjunct
Infection, urinary tract
Infection, general
Infection, general
Vitiligo

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
pipotiazine palmitate	Hexadecanoic acid, 2-[[3-[[2-[[dimethylamino)sulfonyl]-10H-phenothiazin-10-yl]propyl]-4-piperidinyl]ethyl ester [CAS]	37517-26-3 39860-99-6	US 4782077	Neuroleptic
Pip x lan Hydrochloride		18174-58-8		
Pipradrol		467-60-7		
piprozolin	Acetic acid, [3-ethyl-4-oxo-5-(1-piperidinyl)-2-thiazolidinylidenel, ethyl ester [CAS]	17243-64-0	US 3971794	GI inflammatory/bowel disorders
Piproz lin		17243-64-0		
Pirac tam		7491-74-9		
pirarubicin	5,12-Naphthacenedione, 10-[[3-amino-2,3,6-trideoxy-4-O-(tetrahydro-2H-pyran-2-yl)-Alpha-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, [8S-[8Alpha,10Alpha(S*)]]- [CAS]	72496-41-4	US 4303785	Anticancer, antibiotic
Pirarubicin		72496-41-4		
Pirazolac		71002-09-0		
pirbuterol	2,6-Pyridinedimethanol, Alpha-[[[(1,1-dimethylethyl)amino]methyl]-3-hydroxy-, monoacetate (salt) [CAS]	38029-10-6 38677-81-5 65652-44-0	US 3786160	Antiasthma
Pirbut r l		38677-81-5		
Pir n xin		1043-21-6		
pirenzepine	6H-Pyrido[2,3-b][1,4]benzodiazepin-6-one, 5,11-dihydro-11-[(4-methyl-1-piperazinyl)acetyl]- [CAS]	28797-61-7 29868-97-1	FR 1505795	Antitumor
Pirenz pine		28797-61-7		
pirenzepine, Valley Forge	6H-Pyrido[2,3-b][1,4]benzodiazepin-6-one, 5,11-dihydro-11-[(4-methyl-1-piperazinyl)acetyl]- [CAS]	28797-61-7 29868-97-1		Formulation, mucosal, topical
piretanide	Benzolic acid, 3-(aminosulfonyl)-4-phenoxy-5-(1-pyrrolidinyl)- [CAS]	55837-27-9	US 4010273	Antihypertensive, diuretic
Piretanide		55837-27-9		

TABLE 6

Example of Indication
Motility dysfunction, GI, general
Cancer, breast
Asthma
Myopia
Hypertension, general

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
pirfenidone	2-(1H)-Pyridinone, 5-methyl-1-phenyl- [CAS]	53179-13-8		Respiratory
piribedil	Pyrimidine, 2-[4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl]- [CAS]	3805-01-4	US 3299067	Vasodilator, peripheral
Piribedil		1/4/3605		
Pirid caline		87-21-8		
Pirifibrat		55285-45-5		
Piritramide		302-41-0		
Piritr xim		72732-56-0		
pirindole	1H-Pyrazino[3,2,1-k]carbazole, 2,3,3a,4,5,6-hexahydro-8-methyl- [CAS]	16154-78-2 60762-57-4	SU 276060	Antidepressant
pirmenol	(2-Pyridinemethanol, Alpha-[3-(2,6-dimethyl-1-piperidinyl)propyl]-Alpha,phenyl, cis-(+)- [CAS]	61477-94-9 68252-19-7	US 4112103	Antiarrhythmic
Pirmenol		68252-19-7		
Piroctone		50650-76-5		
Pir heptin		16378-21-5		
Piromidic Acid		19562-30-2		
piroxicam	2H-1,2-Benzothiazine-3-carboxamide, 4-hydroxy-2-methyl-N-2-pyridinyl-, 1,1-dioxide [CAS]	36322-90-4	US 3862319	Anti-Inflammatory
Piroxicam		36322-90-4		
piroxicam betadex	B-Cyclodextrin, compd. with 4-hydroxy-2-methyl-N-2-pyridinyl-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide- [CAS]	121696-62-6 96984-39-8	EP 153998	Formulation, other
piroxicam cinnamate	2-Propenoic acid, 3-phenyl-, 2-methyl-3-[(2-pyridinylamino)carbonyl]-2H-1,2-benzothiazin-4-yl ester, S,S-dioxide [CAS]	87234-24-0	EP 79639	Antiarthritic, other
piroxicam suppositories	2H-1,2-Benzothiazine-3-carboxamide, 4-hydroxy-2-methyl-N-2-pyridinyl-, 1,1-dioxide [CAS]	36322-90-4		Formulation, transmucosal, systemic
piroxicam, Douglas	2H-1,2-Benzothiazine-3-carboxamide, 4-hydroxy-2-methyl-N-2-pyridinyl-, 1,1-dioxide [CAS]	36322-90-4		Formulation, oral, other

TABLE 6

Example of Indication
Fibrosis, pulmonary
Parkinson's disease
Depression, general
Tachycardia, supraventricular
Pain, musculoskeletal
Inflammation, general
Inflammation, general
Inflammation, general

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
pivoxicam, KRKA	2H-1,2-Benzothiazine-3-carboxamide, 4-hydroxy-2-methyl-N-2-pyridinyl-, 1,1-dioxide [CAS]	36322-90-4		Formulation, other
pivoxicam, Zydus	2H-1,2-Benzothiazine-3-carboxamide, 4-hydroxy-2-methyl-N-2-pyridinyl-, 1,1-dioxide [CAS]	36322-90-4		Formulation, oral, orally-disintegrating
Pir zadil		54110-25-7		
Pirprofen		31793-07-4		
pitavastatin	6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, calcium salt (2:1), [S-(R*, S*-(E))]- [CAS]	147526-32-7	EP 304063	Hypolipaeic/Antiatherosclerosis
pivagabine	N-trimethylacetyl-4-aminobutyric acid	69542-93-4		Neurological
pivaloyloxymethyl butyrate	Butanoic acid, (2,2-dimethyl-1-oxopropoxy)methyl ester [CAS]	122110-53-6	EP 302349	Anticancer, other
Pivalylbenzhydrazine		306-19-4		
Pivampicillin		33817-20-8		
pivampicillin/pivmecillinam		98445-47-7		Penicillin, oral
Pivcefalexin		63836-75-9		
pivmecillinam	4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[hexahydro-1H-azepin-1-yl)methylene]amino]-3,3-dimethyl-7-oxo-, (2,2-dimethyl-1-oxopropoxy)methyl ester, [2S-(2Alpha,5Alpha,6B)]- [CAS]	32886-97-8	GB 1293590	Penicillin, oral
pivantone	Benz[<i>g</i>]isoquinoline-5,10-dione, 6,9-bis[(2-aminoethoxy)amino]-, (2Z)-2-butenedioate(1:2) [CAS]	144675-97-8	EP 503537	Anticancer, other
pizotifen	4-(9,10-dihydro-4H-benzo[4,5]cyclohepta[1,2-b]thien-4-ylidene)-1-methylpiperidine	15574-96-6	DE 2346747	Antimigraine
Pizotyline		15574-96-6		
PKI-166	Phenol, 4-(4-((1R)-1-phenylethylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl)- [CAS]	187724-61-4		Anticancer, other
p-Lactoph n tide		539-08-2		

TABLE 6

Exempl	Indication
	Arthritis, rheumatoid
	Arthritis, osteo
	Hyperlipidaemia, general
	Anxiety, general
	Cancer, lung, non-small cell
	Infection, general
	Infection, general
	Cancer, lymphoma, non-Hodgkin's
	Cancer, general

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Platibrid		63394-05-8		
Plasminogen activator, Asahi	Plasminogen activator [CAS]	105913-11-9	EP 151996	Fibrinolytic
Plasmocid		551-01-9		
Platonin		3571-88-8		
Plaunotol		64218-02-6		
PLD-118	Cyclohexanecarboxylic acid, 2-amino-4-methylene-, (1R,2S)- [CAS]	198022-65-0	EP 805145	Antifungal
PLD-147	(OC-6-43)-Bis(acetato)(1-adamantylamine)amine-dichloroplatinum (IV)			Anticancer, alkylating
pleconaril	1,2,4-Oxadiazole, 3-(3,5-dimethyl-4-(3-(3-methyl-5-isoxazolyl)propoxy)phenyl)-5-(trifluoromethyl)- [CAS]	153168-05-9	US 5484848	Antiviral, other
PI conaril		153168-05-9		
Plicamycin		18378-89-7		
p- Methyldiphenhydramine		19804-27-4		
PMS-601			WO 0001677	Antiviral, anti-HIV
Pneumococcal Vaccine, Diphtheria Conjugate				
Pneumococcal Vaccine, Polyvalent				
PNU-288034	N-[[[(5s)-3-[4[(1,1-dioxido-4-thiomorpholinyl)3,5-difluorophenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide]			Antibiotic, other
P d phyll toxin		518-28-5		
polaprezinc	Zinc, bis[(N-β-alanyl-L-histidinato-N3,O'Alpha)-(T-4)- [CAS]	107667-60-7	EP 303380	Antilucer
Polaprezinc		107667-60-7		

TABLE 6

Exemplar Indication
Infection, myocardial
Infection, Candida, general
Cancer, general
Infection, respiratory tract, general
Infection, HIV/AIDS
Infection, general
Ulcer, duodenal

TABLE 6

API Gen ric Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Polidine Methylsulfate		545-80-2		
Polir sulen		2/3/9011		
Polidexide		9064-92-0		
Polid can I		9002-92-0		
polidocanol, BTG	Polyethylene glycol monododecyl ether	3055-99-0		Vasoprotective, systemic
Poliovirus Vaccine Inactivated				
poly-ADPRT inhibitors, Isotech			WO 9845253	Anticancer, other
Poly stradiol Phosphate		28014-46-2		
Polyphenon E	Polyphenon E [CAS]	188265-33-0		Antiviral, other
P lythiazide		346-18-9		
porimer sodium	Photrin [CAS]	87806-31-3	US 4882234	Anticancer, other
P rir mycin		801-52-5		
posaconazole	O-threo-Pentitol, 2,5-anhydro-1,3,4-trideoxy-2-C-(2,4-difluorophenyl)-4-((4-(4-(1(S,2S)-1-ethyl-2-hydroxypropyl)-1,5-dihydro-5-oxo-4H-1,2,4-triazol-4-yl)phenyl)-1-piperazinyl)phenoxy)methyl)-1-(1H-1,2,4-triazol-1-yl)- [CAS]	171228-49-2	US 5714490	Antifungal
P saconazole		171228-49-2		
Posatir lin		78664-73-0		
potassium chloride, Amarin	Potassium chloride (KCl) [CAS]	7447-40-7		Formulation, oral, enteric-coated
potassium chloride, Liquitard	Potassium chloride (KCl) [CAS]	7447-40-7	US 4259315	Formulation, oral, other
potassium chloride, Microcap	Potassium chloride (KCl) [CAS]	7447-40-7		Formulation, optimized, microencapsulate
Potassium Gluconate		299-27-4		
P tassium		1321-14-8		
Gualac Isulfonate				

TABLE 6

Example of Indication
Venous insufficiency
Cancer, general
Infection, human papilloma virus
Cancer, lung, non-small cell
Infection, fungal, general
Nutrition
Nutrition

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Potassium p-Amin benz at		138-84-1		
Potassium Permanganat		7722-64-7		
Povidone		9003-39-8		
Povidone-Iodine		25655-41-8		
PP-117	3-Pyridinemethanol, hydrofluoride [CAS]	62756-44-9	DE 2633028	Formulation, oral, other
PR-2699	(-)-(E)-[4-(2,4-dichlorophenyl)-1,3-dithiolan-2-ylidene]-1-imidazolylacetone nitrile			Antifungal
PR-608	(S)-(-)-1-[4,4-bis(4-fluorophenyl)butyl]-4-(2-hydroxy-3-phenylaminopropyl)piperazine trihydrochloride			Antiparkinsonian
Practol I		6673-35-4		
Pralmalin		35080-11-6		
Pralid xim Chloride		51-15-0		
pralnacasan	6H-Pyridazino(1,2-a)(1,2)diazepine-1-carboxamide, N-[(2R,3S)-2-ethoxytetrahydro-5-oxo-3-furanyl]octahydro-9-[(1-isoquinolinylcarbonyl)amino]-6,10-dioxo-, (1S,8S)- [CAS]	192755-52-5		Antiarthritic, immunological
pramipexole	2,6-Benzothiazolediamine, 4,5,6,7-tetrahydro-N6-propyl-, (S)- [CAS]	104632-26-0	EP 186087	Antiparkinsonian
Pramip xole		104632-26-0		
pramiracetam	1-Pyrrolidineacetamide, N-[2-bis(1-methylethyl)amino]ethyl-2-oxo-, monohydrochloride [CAS]	68497-62-1 72869-16-0 75733-60-5	US 4145347	Cognition enhancer
Pramiracetam		68497-62-1		
Pramiverin		14334-40-8		
pramilitide	1,2-Dithia-5,8,11,14,17-pentaazacycloicosane, cyclic peptide deriv. [CAS]	151126-32-8	US 5124314	Antidiabetic
Pramilitid		151126-32-8		

TABLE 6

Example of Indication
Unspecified
Infection, fungal, general
Parkinson's disease
Arthritis, rheumatoid
Parkinson's disease
Amnesia
Diabetes, Type I

TABLE 6

API Gen ric Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Pramoxin		140-65-8		
pranidipine	3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, methyl 3-phenyl-2-propenyl ester, (E)- [CAS]	99522-79-9	EP 173126	Antihypertensive, other
Pranlukast		103177-37-3		
Pran profen		52549-17-4		
pranoprofen, Senju	5H-[1]Benzopyrano[2,3-b]pyridine-7-acetic acid, Alpha-methyl- [CAS]	52549-17-4		Formulation, mucosal, topical
Prasteron		53-43-0		
prasterone, Nippon Organon	Androst-5-en-17-one, 3-hydroxy-, (3B)- [CAS]	53-43-0		Labour inducer
prazosin	4(3H)-Cycloheptimidazolone, 5,6,7,8-tetrahydro-2-propyl-3-[[2-(1H-tetrazol-5-yl)]1,1'-biphenyl]-4-ylmethyl- [CAS]	153804-05-8	US 5409947	Antihypertensive, renin system
pravastatin	1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro-8,8a-delta,6-trihydroxy-2-methyl-8-(2-methyl-1-oxobutoxy)-, monosodium salt, [1S- [1Alpha(8S*,deltaS*),2Alpha,6Alpha,8B(R*),8aAlpha]]- [CAS]	81089-37-0 81131-70-6	US 4346227	Hypolipaeic/Antiatherosclerosis
Pravastatin S dium		81131-70-6		
pravastatin, Zydys	Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro-8,8a-delta,6-trihydroxy-2-methyl-8-(2-methyl-1-oxobutoxy)-, monosodium salt, [1S- [1Alpha(8S*,deltaS*),2Alpha,6Alpha,8B(R*),8aAlpha]]- [CAS]	81089-37-0 81131-70-6		Formulation, oral, other
Przepam		2955-38-6		
praziquantel	4H-Pyrazino[2,1-a]isoquinolin-4-one, 2-(cyclohexylcarbonyl)-1,2,3,6,7,11b-hexahydro- [CAS]	55268-74-1	US 4001411	Schistosomicide
Praziquantel		55268-74-1		
prazosin	Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)- [CAS]	19216-56-9 19237-84-4	US 4092315	Antihypertensive, adrenergic
Prazosin		19216-56-9		

TABLE 6

Example of Indication
Hypertension, general
Ocular disorder, general
Hypertension, general
Atherosclerosis
Atherosclerosis
Hypertension, general

TABLE 6

API Gen ric Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
prazosin, Alza	Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)-[CAS]	19216-56-9		Formulation, modified-release, other
Pr dnicarbat		73771-04-7		
prednimustine	Pregna-1,4-diene-3,20-dione, 21-(4-[4-bis(2-chloroethyl)amino]phenyl)-1-oxobutoxy]-11,17-dihydroxy-, (11B)- [CAS]	29069-24-7	GB 1272841	Anticancer, alkylating
Pr dnmustin		29069-24-7		
Pr dnis l n		50-24-8		
Prednisolone 21-Diethylaminacetate		5626-34-6		
prednisolone farnesil	Pregna-1,4-diene-3,20-dione, 11,17-dihydroxy-21-[(3,7,11-trimethyl-1-oxo-2,6,10-dodecatrifenyloxy)]-, [11B,21(2E,6E)]- [CAS]	118244-44-3	EP 332143	Antiarthritic, other
Prednisolone Sodium Phosphate		125-02-0		
Prednisone		53-03-2		
Prednival		15180-00-4		
Pr dnylden		599-33-7		
pregabalin	Hexanoic acid, 3-(aminomethyl)-5-methyl, (S)- [CAS]	148553-50-8		Antiepileptic
Pr gabalin		148553-50-8		
Pregnan-3 α -ol-20-one		128-20-1		
Premarin + trimegestone	Estra-4,9-dien-3-one, 17-(2-hydroxy-1-oxopropyl)-17-methyl-, [17B (S)]- [CAS]	74513-62-5		Menopausal disorders
prenalterol	Phenol, 4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]-, hydrochloride, (S)-[CAS]	57526-81-5 61260-05-7	GB 1470039	Cardio stimulant
Pr nalterol		57526-81-5		
Pren x diazine Hydrochloride		982-43-4		
Prenylamin		390-64-7		

TABLE 6

Exempl f Indication
Hypertension, general
Arthritis, rheumatoid
Epilepsy, general
Hormone replacement therapy

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
proprate copper acetate, gel	Cuprate(1-), (N2-(N-glycyl-L-histidyl)-L-lysinate)(N2-(N-glycyl-L-histidyl)-L-lysinate(2-))-, hydrogen, diacetate- [CAS]	130120-57-9		Veterinary
Pridin I		511-45-5		
Prifinium Br mide		4630-95-9		
Pril caline		721-50-6		
Primaquine		90-34-6		
Primidone		125-33-7		
Prin mastat		192329-42-3		
PRO-2000			US 5614599	Antiviral, anti-HIV
Prob necid		57-66-9		
Pr buc I		23288-49-5		
Procainamid		614-39-1		
Hydrochloride				
procainamide, Pfizer	Benzamide, 4-amino-N-[2-(diethylamino)ethyl]- [CAS]	51-08-9		Formulation, other
Procalne		59-46-1		
Procarbazine		671-16-9		
procaterol	2(1H)-Quinolone, 8-hydroxy-5-[1-hydroxy-2-[(1-methylethyl)amino]butyl]-, monohydrochloride [CAS]	59828-07-8 60443-17-6	GB 1496766	Antiasthma
Procaterol		72332-33-3		
procaterol, ML Labs		59828-07-8 60443-17-6		Formulation, inhalable, dry powder
Pr chl rperazine		58-38-8		
Prochlorperazine Maleate				
prochlorperazine maleate, IVAX	10H-Phenothiazine 2-chloro-10-[3-(4-methyl-1-piperazinyl)propyl]-, (Z)-2-butenedioate	58-38-8 84-02-6		Formulation, oral, other
procodazol				
Pr codaz le	1H-Benzimidazole-2-propanoic acid [CAS]	23249-97-0	ES 407882	Anticancer, immunological
Procyclidin		23249-97-0		
		77-37-2		

TABLE 6

Example of Indication
Wound healing
Infection, HIV prophylaxis
Arrhythmia, general
Asthma
Nausea and vomiting, general
Cancer, general

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Procyamat		13931-64-1		
Pr dipine		31314-38-2		
Proflavine		92-62-6		
Progabide		62666-20-0		
Pr gester ne		57-83-0		
progesterone, Dekk-Tec	Pregn-4-ene-3,20-dione [CAS]	57-83-0		Formulation, transmucosal, systemic
progesterone, Effik	Pregn-4-ene-3,20-dione [CAS]	57-83-0	US 5776495	Formulation, oral, solubility-enhanced
progesterone, I2R	Pregn-4-ene-3, 20-dione [CAS]	57-83-0		Formulation, modified-release, immediate
proglumetacin	1H-Indole-3-acetic acid, 1-(4-chlorobenzoyl)-5-methoxy-2-methyl-, 2-(4-(3-(4-(benzoylamino)-5-(dipropylamino)-1,5-dioxopentyl)oxy)propyl)-1-piperazinyl)ethyl ester, (+/-) [CAS]	57132-53-3 59209-40-4	GB 1467568	Anti-inflammatory
Pr glumetacin		57132-53-3		
proglumide	Pentanolic acid, 4-(benzoylamino)-5-(dipropylamino)-5-oxo-, (+/-) [CAS]	6620-60-6	DE 1518125	Antitumor
Pr glumide		6620-60-6		
Proheptazine		77-14-5		
Pr lacin		9002-62-4		
Pr lantan		493-92-5		
Prolonium iodide		123-47-7		
Promazine		58-40-2		
Pr medol		64-39-1		
Pr meg ston		34184-77-5		
promestriene	Estra-1,3,5(10)-triene, 17-methoxy-3-propoxy-, (17 β)- [CAS]	39219-28-8	GB 1337198	Reproductive/gonadal, general
Promethazine		60-87-7		
Pronethalol		54-80-8		
propacetamol	Glycine, N,N-diethyl-, 4-(acetylamino)phenyl ester [CAS]	66532-85-2 66532-86-3	US 4127671	Formulation, parenteral, other
Propac tamol		66532-85-2		

TABLE 6

Example f Indication
Amenorrhoea
Hormone replacement therapy
Amenorrhoea
Inflammation, general
Ulcer, gastric
Acne

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
propafenone	1-Propanone, 1-[2-[2-hydroxy-3-(propylamino)propoxy]phenyl]-3-phenyl- [CAS]	54063-53-5	GB 1307455	Antiarrhythmic
Pr pafen ne		54063-53-5		
Propagermanium		12758-40-6		
Propallylonal		545-93-7		
Pr pamidin		104-32-5		
propane-1,2-diol, Vinas	1,2-propanediol	57-55-6		Formulation, dermal, topical
Pr panlidid		1421-14-3		
Pr panth lin Bromide		50-34-0		
Pr paracain		499-67-2		
Propatyl Nitrat		2921-92-8		
propenidazole	ethyl trans-Alpha-acetyl-1-methyl-5-nitroimidazole-2-acrylate	76448-31-2		Antifungal
propentofylline	1H-Purine-2,6-dione, 3,7-dihydro-3-methyl-1-(5-oxohexyl)-7-propyl- [CAS]	55242-55-2	GB 1470220	Neuroprotective
Pr p nt fylin		55242-55-2		
Propicillin		551-27-9		
Propi mazin		362-29-8		
Pr plonic Acid		79-09-4		
propionyl L-carnitine, Sigma	1-Propanaminium, 3-carboxy-N,N,N-trimethyl-2-(1-oxopropoxy)-, chloride, (R)- [CAS]	119793-66-7 20084-19-1	GB 2008578	Vasodilator, peripheral
Propipocaine		3670-68-6		
Pr piram		15686-91-6		
Pr piverin		60569-19-9		
propiverine hydrochloride	2,2-diphenyl-2-(1-propoxy)acetic acid (1-methylpiperid-4-yl) ester hydrochloride	54556-98-8 60569-19-9		Urological
Pr pizepine		10321-12-7		
propofol	Phenol, 2,6-bis(1-methylethyl)- [CAS]	2078-54-8	US 4056635	Anaesthetic, injectable
Pr p fol		2078-54-8		
Propofol				

TABLE 6

Example of Indication
Fibrillation, ventricular
Infection, fungal, general
Infection, trichomoniasis
Ischaemia, cerebral
Peripheral vascular disease
Incontinence
Anaesthesia

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
propofol phosphate, Vyrex	Phenol, 2,6-bis(1-methylethyl)- phosphate		US 6254853	Anaesthetic, injectable
propofol, Maier	Phenol, 2,6-bis(1-methylethyl)- [CAS]	2078-54-8	GB 2359747	Formulation, optimized, microencapsulate
propofol, SkyePharma	Phenol, 2,6-bis(1-methylethyl)- [CAS]	2078-54-8		Formulation, optimized, microparticles
Pr poxycaine		550-83-4		
Hydrochloride				
Prop xyph n		469-62-5		
Propranolol		525-66-6		
Propranolol, Biovail	2-Propanol, 1-[(1-methylethyl)amino]-3-(1-naphthalenyloxy)- [CAS]	525-66-6		Formulation, modified-release, <=24hr
propranolol, Elan	2-Propanol, 1-[(1-methylethyl)amino]-3-(1-naphthalenyloxy)- [CAS]	525-66-6		Formulation, modified-release, <=24hr
propranolol, EUCAPS	2-Propanol, 1-[(1-methylethyl)amino]-3-(1-naphthalenyloxy)- [CAS]	525-66-6		Formulation, modified-release, other
propranolol, Forest	2-Propanol, 1-[(1-methylethyl)amino]-3-(1-naphthalenyloxy)- [CAS]	525-66-6		Formulation, modified-release, other
Propylh x drine		101-40-6		
Propylid ne		587-61-1		
Pr pythi uracil		51-52-5		
Propyph naz ne		479-92-5		
Proquaz n		22760-18-5		
Pr scillaridin		466-06-8		
Prostacyclin		35121-78-9		
Prostaglandin E ₁		745-65-3		
Prostaglandin E ₂		363-24-6		
Pr staglandin F _{2a}		551-11-1		
Prosultiamine		59-58-5		
Pr tein C		60202-16-6		
Protheobromine		50-39-5		
Pr thip ndyl		303-69-5		
Protiofat		58416-00-5		
Protonamid		14222-60-7		

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
protizinc acid	10H-Phenothiazine-2-acetic acid, 7-methoxy-Alpha, 10-dimethyl-, (+/-)- [CAS]	13799-03-6	US 3450698	Anti-inflammatory
Protizinic Acid		54323-85-2		
Protoan monin		108-28-1		
Prot kylol		136-70-9		
Prot p rphyrin IX		553-12-8		
Protriptylin		438-60-8		
Pr -Urokinas		82657-92-9		
Pr xaz I		9/3/5696		
Proxibarbal		2537-29-3		
proxigermanium	Propanoic acid, 3,3'-(1,3-dioxo-1,3-digermoxanedyl)bis- [CAS]	12758-40-6	FR 2005110	Antiviral, other
Pr xyphyllin		603-00-9		
Pr zapine		8/2/3426		
Prucalopride		179474-81-8		
prulifloxacin	1H,4H-[1,3]Thiazeto[3,2-a]quinoline-3-carboxylic acid, 6-fluoro-1-methyl-7-[4-[(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl]-1-piperazinyl]-4-oxo- [CAS]	123447-62-1	EP 315828	Quinolone antibacterial
Ps ud c cain		478-73-9		
Ps udceph drine		90-82-4		
pseudoephedrine + triprolidine	Benzenemethanol, Alpha-[1-(methylamino)ethyl]-, hydrochloride, [S-(R*, R*)]-, mixt with (E)-2-[1-(4-methylphenyl)-3-(1-pyrrolidinyl)-1-propenyl]pyridine monohydrochloride [CAS]	8054-27-1		Formulation, modified-release, other
pseudoephedrine, Alza	Benzenemethanol, Alpha-[1-(methylamino)ethyl]-, [S-(R*, R*)]- [CAS]	90-82-4		Formulation, oral, other
pseudoephedrine, Difluocap	Benzenemethanol, Alpha-[1-(methylamino)ethyl]-, [S-(R*, R*)]- [CAS]	90-82-4		Formulation, optimized, microparticles
pseudoephedrine, KV	Benzenemethanol, Alpha-[1-(methylamino)ethyl]-, [S-(R*, R*)]- [CAS]	345-78-8 90-82-4		Formulation, modified-release, other
pseudoephedrine, Phoenix	Benzenemethanol, Alpha-[1-(methylamino)ethyl]-, [S-(R*, R*)]- [CAS]	90-82-4		Formulation, fixed-dose combinations

TABLE 6

API Gen ric Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Psilocybin		520-52-5		
PSK-3841	Benzonitrile, 4-[3-(4-hydroxybutyl)-4,4-dimethyl-2,5-dioxo-1-imidazolidinyl]-2-(trifluoromethyl)- [CAS]	154982-24-2		Dermatological
p-Sulfanilylbenzylamine		4393-19-5		
PT-141			US 6051555	Male sexual dysfunction
Pteripterin		89-38-3		
Pur mycin		53-79-2		
PX-12	1-Methylpropyl 2-mercaptimidazoyl disulfide			Anticancer, other
Pyrantel		15686-83-6		
Pyrazinamid		98-96-4		
Pyridinol Carbamate		1882-26-4		
Pyridostigmin Bromide		101-26-8		
Pyridoxal 5-Phosphate		54-47-7		
Pyridoxine		58-56-0		
Hydr chlorid				
Pyrilamin		91-84-9		
Pyrimethamin		58-14-0		
Pyrinolin		1740-22-3		
Pyrisuccid anil		33605-94-6		
Pyritin		1121-30-8		
Pyritinylidion		77-04-3		
Pyritinol		1098-97-1		
Pyrocat ch I		120-80-9		
Pyrogall I		87-66-1		
Pyronardine		74847-35-1		
Pyr val r n		3563-49-3		
Pyroxylin		9004-70-0		
Pyrobutamine		91-82-7		
Pyrr caine		2210-77-7		

TABLE 6

API Gen eric Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Pyrolnitrin		1018-71-9		
Pyvinium Pamoate		3546-41-6		
quazepam	2H-1,4-Benzodiazepine-2-thione, 7-chloro-5-(2-fluorophenyl)-1,3-dihydro-1-(2,2,2-trifluoroethyl)- [CAS]	36735-22-5	US 3845039	Hypnotic/Sedative
Quazepam		36735-22-5		
Quercetin		117-39-5		
Quetiapin		111974-69-7		
quetiapine fumarate	Ethanol, 2-[2-(4-dibenzo[b,f][1,4]thiazepin-11-yl-1-piperazinyl)ethoxy]-, (E)-2-butenedioate (2:1) (salt) [CAS]	111974-69-7 111974-72-2	EP 240228	Neuroleptic
quetiapine fumarate, SR	Ethanol, 2-[2-(4-dibenzo[b,f][1,4]thiazepin-11-yl-1-piperazinyl)ethoxy]-, (E)-2-butenedioate (2:1) (salt) [CAS]	111974-69-7 111974-72-2		Formulation, modified-release, <=24hr
Quinacillin		1596-63-0		
Quinacrine		83-89-6		
quinacrine, CJD treatment	N-(6-Chloro-2-methoxy-9-acridinyl)-N,N-diethyl-1,4-pentanediamine + 10H-Phenothiazine-10-propanamine, 2-chloro-N,N-dimethyl			Neurological
quinagolid	Sulfamide, N,N-diethyl-N'-(1,2,3,4,4a,5,10,10a-octahydro-6-hydroxy-1-propylbenzo[g]quinolin-3-yl)-, (3A)pha,4aAlpha,10aB)- (<+>)- [CAS]	87056-78-8 94424-50-7 97805-49-7	EP 77754	Antiprolactin
Quinagolide		87056-78-8		
quinapril	3-Isoquinolinecarboxylic acid, 2-[2-{1-(ethoxycarbonyl)-3-phenylpropylamino}-1-oxopropyl]-1,2,3,4-tetrahydro-, [3S-[2(R*(R')),3R'']]- [CAS]	82586-55-8 85441-61-8 90243-99-5	EP 49605	Antihypertensive, renin system
Quinapril		85441-61-8		
Quinapril Hydrochloride				

TABLE 6

Exempl of Indication
Insomnia
Schizophrenia
Schizophrenia
Creutzfeldt-Jakob disease
Hyperprolactinaemia
Hypertension, general

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
quinaprilat	3-Isquinolinecarboxylic acid, 2-[2-[(1-carboxy-3-phenylpropyl)amino]-1-oxopropyl]-1,2,3,4-tetrahydro-, [3S-[2(R*(R*),3R*)]- [CAS]	82768-85-2	EP 46953	Antihypertensive, renin system
Quinapryramine		20493-41-8		
Quinbolone		2487-63-0		
Quin stradi l		1169-79-5		
Quin strol		152-43-2		
Quin thazon		73-49-4		
quinfamide	2-Furancarboxylic acid, 1-(dichloroacetyl)-1,2,3,4-tetrahydro-8-quinolinyl ester [CAS]	62265-68-3	US 3997542	Amoebicide
Quinamide		62265-68-3		
Quinidine		56-54-2		
quinidine bisulfate, Eurand	Cinchonan-9-ol, 6'-methoxy-, (9S)-, sulfate (1:1) (salt) [CAS]	747-45-5		Formulation, modified-release, other
Quinine		130-95-0		
Quin cide		525-61-1		
Quinupramine		31721-17-2		
Quinupristin		120138-50-3		
R-107500	cis-2,3,3a,8-tetrahydro-N,N'-dimethyldibenz[c,f]isoxazolo[2,3-a]azepine-2-methanamine		WO 9614320	Anxiolytic
R-667			WO 0204439	COPD treatment
Rabeprazole		117976-89-3		
rabeprazole sodium	1H-Benzimidazole, 2-[14-(3-methoxypropoxy)-3-methyl-2-pyridinyl]methylsulfanyl-, sodium salt- [CAS]	117976-89-3 117976-90-6	EP 268956	Antituber
Rabeprazole Sodium				
Rabeprazole Sodium				
racecadortil	Glycine, N-[2-[(acetylthio)methyl]-1-oxo-3-phenylpropyl]-, phenylmethyl ester, (+/-)- [CAS]	112573-72-5 81110-73-8	EP 38758	Antidiarrhoeal

TABLE 6

Example of Indication
Hypertension, general
Arrhythmia, general
Anxiety, general
Emphysema, general
Ulcer, gastric
Diarrhoea, general

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Racecad tril		81110-73-8		
Racemeth rphan		510-53-2		
Raloxifen		84449-90-1		
raloxifene hydrochloride	Methanone, [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl-, hydrochloride [CAS]	82640-04-8 84449-90-1	EP 62503	Osteoporosis treatment
ralitrexed	L-glutamic acid, N-[5-[(1,4-dihydro-2-methyl-4-oxo-6-quinazolinyl)methyl]methylamino]-2-thienyl[carbonyl]- [CAS]	112887-68-0	EP 239362	Anticancer, antimetabolite
Raltitrex d	9H-Carbazole-9-propanoic acid, 3-[[4-(fluorophenyl)sulfonylamino]-1,2,3,4-tetrahydro-, (R)- [CAS]	116649-85-5	EP 242518	Antiallergic, non-asthma
ramatroban		116649-85-5		
Ramatroban		3615-24-5		
Ramifenazon				
ramipril	Cyclopenta[b]pyrrole-2-carboxylic acid, 1-[2-[[1-(ethoxycarbonyl)-3-phenylpropylamino]-1-oxopropyl]octahydro-1,2S-[1(R*(R*))],2Alpha,3aB,6aB]-[CAS]	87269-97-4 87333-19-5	EP 79022	Antihypertensive, renin system
Ramipril		87333-19-5		
Ramipril				
Ram setron		132036-88-5		
ramosetron hydrochloride	Methanone, (1-methyl-1H-indol-3-yl)(4,5,6,7-tetrahydro-1H-benzimidazol-5-yl)-, monohydrochloride, (R)- [CAS]	132907-72-3	EP 381422	Antiemetic
ramosetron, WOWTAB	Methanone, (1-methyl-1H-indol-3-yl)(4,5,6,7-tetrahydro-1H-benzimidazol-5-yl)-, monohydrochloride, (R)- [CAS]	132907-72-3	EP 381422	Formulation, oral, orally-disintegrating
Ramot project No. 1097			US 5730992	Dermatological
Ranlmustin		58994-96-0		
ranitidine	1,1-Ethenediamine, N-[2-[[5-[[dimethylamino)methyl]-2-furanyl]methyl]thio]ethyl]-N'-methyl-2-nitro-[CAS]	66357-35-5	US 4128658	Antilucer

TABLE 6

Example of Indication
Osteoporosis
Cancer, colorectal
Rhinitis, allergic, perennial
Heart failure
Nausea and vomiting, general
Chemotherapy-induced nausea and vomiting
Unspecified
Ulcer, duodenal

TABLE 6

API G generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Ranitidine	1,2,3-Propanetricarboxylic acid, 2-hydroxy-bismuth(3+) salt (1:1), compd. with N-(2-(((5-((dimethylamino)methyl)-2-furanyl)methyl)thio)ethyl)-N'-methyl-2-nitroethenediamine (1:1))- [CAS]	66357-35-5		
ranitidine bismuth citrate		128345-62-0	EP 533281	Anticancer
ranitidine, Phoenix	1,1-Ethenediamine, N-[2-[[[5-((dimethylamino)methyl)-2-furanyl]methyl]thio]ethyl]-N'-methyl-2-nitro [CAS]	66357-35-5		Formulation, modified-release, other
ranolazine	1-Piperazineacetamide, N-(2,6-dimethylphenyl)-4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]-, (+)- [CAS]	95635-55-5 95635-56-6	EP 126449	Antianginal
Ranolazin		95635-55-5		
Ranpirnase		133737-98-9		
Rapacuronium Bromide		156137-99-4		
rasagiline mesylate	1H-Inden-1-amine, 2,3-dihydro-N-2-propynyl-, (R)-, methanesulfonate [CAS]	161735-79-1	US 5457133	Antiparkinsonian
Raubasine		483-04-5		
ravuconazole	Benzonitrile, 4-[2-((1R,2R)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl)-4-thiazolyl]- [CAS]	182760-08-1		Antifungal
raxofelast	2-Benzoturanacetic acid, 5-(acetoxy)-2,3-dihydro-4,6,7-trimethyl-, (+)- [CAS]	128232-14-4	US 4999350	Symptomatic antidiabetic
razoxane	2,6-Piperazinedione, 4,4'-(1-methyl-1,2-ethanediy)bis- [CAS]	21416-67-1	GB 1234935	Anticancer, other
Raz xan		21416-87-5		
RC-529	Tetradecanoic acid (1R)-1-(2-((2-deoxy-3-O-(3R)-1-oxo-3-(1-oxotetradecyl)oxy)tetradecyl)amino-4-O-phosphono-8-D-glucopyranosyl)oxy)ethyl)amino)-2-oxoethyl)dodecyl ester, compd. with N,N-diethylethanamine (1:1) [CAS]	216014-46-9		Immunostimulant, other

TABLE 6

Example f Indication
Ulcer, duodenal
Ulcer, GI, general
Angina, general
Parkinson's disease
Infection, meningitis, general
Nephropathy, diabetic
Cancer, general
Vaccine adjunct

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
rebamipide	4-Quinolonepropanoic acid, Alpha-[(4-chlorobenzoyl)amino]-1,2-dihydro-2-oxo- [CAS]	90098-04-7	DE 3324034	Antitumor
Rebamipide		90098-04-7		
rebimastat	L-Valinamide, N-[(2S)-2-mercapto-1-oxo-4-(3,4,4-trimethyl-2,5-dioxo-1-imidazolidinyl)butyl]-L-leucyl-N,3-dimethyl- [CAS]	259188-39-0		Anticancer, other
rebexetine	Morpholine, 2-[(2-ethoxyphenoxy)phenylmethyl]-, (R*,S*)- [CAS]	71820-89-8	US 4229449	Antidepressant
Reb x tine		98769-81-4		
Remacemide		128298-28-2		
remifentanyl	1-Piperidinepropanoic acid, 4-(methoxycarbonyl)-4-[(1-oxopropyl)phenylamino]-methyl ester- [CAS]	132539-07-2	EP 383579	Analgesic, other
R mif ntanil		132875-61-7		
remintant	Tricyclo[3.3.1.1 ^{3,7}]decane-2-carboxylic acid, 2-[[[1-(7-chloro-4-quinolinyl)-5-(2,6-dimethoxyphenyl)-1H-pyrazol-3-yl]carbonyl]amino]- [CAS]	146362-70-1	EP 699438	Neuroleptic
R m xiprid		80125-14-0		
renzapride	Benzamide, 4-amino-N-1-azabicyclo[3.3.1]non-4-yl-5-chloro-2-methoxy- [CAS]	109872-41-5 88721-77-1	JP 58188885	Gastroprokinetic
repaglinide	Benzoic acid, 2-ethoxy-4-[2-[[3-methyl-1-(2-(1-piperidinyl)phenyl]butyl]amino]-2-oxoethyl]-, (S)- [CAS]	135062-02-1	WO 9300337	Antidiabetic
Repaglinide		135062-02-1		
repertaxin L-lysine salt	2(R)-4-Isobutylphenylpropionylmethanesulfonamide L-lysine salt			
R pinotan		144980-29-0	WO 0024710	Cardiovascular

TABLE 6

Example of indication
Cancer, lung, non-small cell
Depression, general
Pain, general
Schizophrenia
Irritable bowel syndrome
Diabetes, Type II
Reperfusion injury

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
repinotan hydrochloride	1,2-Benzisothiazol-3(2H)-one, 2-(4-(((3,4-dihydro-2H-1-benzopyran-2-yl)methyl)amino)butyl)-, 1,1-dioxide, monohydrochloride [CAS]	144980-77-8	US 5137901	Neuroprotective
replirinast	4H-Pyran[3,2-c]quinoline-2-carboxylic acid, 5,6-dihydro-7,8-dimethyl-4,5-dioxo-, 3-methylbutyl ester [CAS]	73080-51-0	US 4298810	Antiasthma
Reprinat		73080-51-0		
Rep sal		3625-25-0		
reproterol	1H-Purine-2,6-dione, 7-[3-[[2-(3,5-dihydroxyphenyl)-2-hydroxyethyl]amino]propyl]-3,7-dihydro-1,3-dimethyl-, [CAS]	13055-82-8	FR M5969	Antiasthma
Reproterol		54063-54-6		
Rescimet I		73573-42-9		
Rescinnamine		24815-24-5		
Reserpiline		131-02-2		
Reserpine		50-55-5		
Resibufogenin		465-39-4		
resiquimod	1H-Imidazo(4,5-o)quinoline-1-ethanol((ethoxymethyl)-Alpha, Alpha-dimethyl-, [CAS]	144875-48-9	US 5389640	Antiviral, other
R s rcinol		108-46-3		
Reteplas		133652-38-7		
retigabine	Carbamic acid, (2-amino-4-(((4-fluorophenyl)methyl)amino)phenyl)-, ethyl ester [CAS]	150812-12-7	DE 4200259	Antiepileptic
retinoic acid, Antigenics	Retinoic acid [CAS]	302-79-4		Formulation, parenteral, other
Revimid			US 6281230	Anticancer, other
R-flurbiprofen	[1,1'-Biphenyl]-4-acetic acid, 2-fluoro-Alpha-methyl	5104-49-4		Anticancer, other
Rho (D) Immune Globulin (Human)				
Rho-kinase inhibitors, Kirin			WO 0156988	Antiasthma

TABLE 6

Example of Indication
Ischaemia, cerebral
Asthma
Infection, hepatitis-C virus
Epilepsy, general
Cancer, leukaemia, acute myelogenous
Cancer, myeloma
Cancer, prostate
Unspecified

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
ribavirin	1H-1,2,4-Triazole-3-carboxamide, 1-β-D-ribofuranosyl- [CAS]	36791-04-5	US 4211771	Antiviral, other
Ribavirin		36791-04-5		
<i>Ribavirin</i>				
<i>Ribavirin</i>				
ribavirin + Alpha-interferon, SP			US 6172046	Antiviral, other
Riboflavin		146-17-8		
M noph sphate				
	D-Streptamine, O-2,6-diamino-2,6-dideoxy-Alpha-D-glucopyranosyl-(1-4)-O-β-D-ribofuranosyl-(1-5)]-2-deoxy- [CAS]	25546-65-0	GB 1254883	Aminoglycoside antibiotic
Ribostamycin		25546-65-0		
Ricinolic Acid		141-22-0		
Ridogr		110140-89-1		
rifabutin	Rifamycin XIV, 1',4-didehydro-1-deoxy-1,4-dihydro-5'-(2-methylpropyl)-1-oxo- [CAS]	72559-06-9	US 4219478	Antimycobacterial
Rifabutin		72559-06-9		
	Rifamycin VIII, 1',4-didehydro-1-deoxy-1,4-dihydro-3'-hydroxy-5'-(4-(2-methylpropyl)-1-piperazinyl)-1-oxo- [CAS]	129791-92-0 129791-84-2 133633-12-2	EP 366914	Antimycobacterial
Rifalazil		129791-92-0		
rifametane	Rifamycin, 3-[[[1-(diethylamino)ethylidene]hydrazono]methyl]- [CAS]	94168-98-6	EP 119571	Antimycobacterial
Rifamide		2750-76-7		
	Rifamycin, 3-[[[4-methyl-1-piperazinyl]imino]methyl]-, mixt. with 5-[(3,4,5-trimethoxyphenyl)methyl]-2,4-pyrimidinediamine [CAS]	61498-94-0		Formulation, fixed-dose combinations
rifampicin + trimethoprim		13292-46-1		
Rifampin		6998-60-3		
Rifamycin SV				
rifapentine	Rifamycin, 3-[[[4-cyclopentyl-1-piperazinyl]imino]methyl]- [CAS]	61379-65-5	DE 2608218	Antibiotic, other

TABLE 6

Exempl of Indication:
Infection, haemorrhagic fever
Infection, hepatitis-C virus
Infection, general
Infection, Mycobacterium avium complex
Infection, tuberculosis
Infection, general
Infection, general
Infection, tuberculosis

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Rifapentine		61379-65-5		
	Epoxypentadeca[1,11,13]trienimino)benzofuro[4,5-e]pyrido[1,2-a]benzimidazole-1,15(2H)-dione, 25-(acetyloxy)-5,6,21,23-tetrahydroxy-27-methoxy-2,4,11,16,20,22,24,26-octamethyl-, [2S-(2R*,16Z,18E,20R*,22S*,23S*,24S*,25R*,26S*,27R*,28E)]	80621-81-4	GB 2079270	Antibiotic, other
Rifaximin		80621-81-4		
	4-deoxy-4'-methylpyrido[1',2'-1,2]imidazo[5,4-c]rifamycin SV	80621-81-4	BE 888995	Formulation, dermal, topical
Rilmazafin		99593-25-6		
	2-Oxazolamine, N-(dicyclopropylmethyl)-4,5-dihydro- [CAS]	54187-04-1 54249-57-9	DE 2362754	Antihypertensive, adrenergic
Rilmenidine		54187-04-1		
	2-Benzothiazolamine, 6-(trifluoromethoxy)- [CAS]	1744-22-5	EP 50551	Neuroprotective
Riluzole		1744-22-5		
Riluzol		13392-28-4		
Rimantadine				
	4H-Pyrido[1,2-a]pyrimidinium, 3-(ethoxycarbonyl)-6,7,8,9-tetrahydro-1,6-dimethyl-4-oxo-, methyl sulfate [CAS]	28610-84-6 35615-72-6	DE 2461349	Analgesic, NSAID
Rimazolium metilsulfate		28610-84-6		
Rimastatim Metilsulfate				
	Androst-1,4-dien-3-one, 11-hydroxy-16,17-dimethyl-17-(1-oxopropyl)-, (11B,16Alpha,17B)- [CAS]	49697-38-3	DE 2301317	Ophthalmological
Rimexolone		49697-38-3		
Rimexolone		32953-89-2		
Rimonabant	1H-Pyrazole-3-carboxamide, 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-1-piperidinyl-, monohydrochloride [CAS]	158681-13-1	US 5624941	Anorectic/Antiobesity

TABLE 6

Exempl of Indication
Infection, GI tract
Infection, dermatological
Hypertension, general
Amyotrophic lateral sclerosis
Inflammation, ocular
Obesity

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
ritodrine	1,3-Benzene-diol, 2,4,6-tri-iodo- [CAS]	19403-92-0	US 3755251	Antiviral, other
Rlopr still		77287-05-9		
risedronate sodium	Phosphonic acid, (1-hydroxy-2-(3-pyridinyl)ethylidene)bis-, monosodium salt	115436-72-1	EP 304961	Osteoporosis treatment
Risedronate Sodium				
Ris dronic Acid		105462-24-6		
	4H-Pyrido[1,2-a]pyrimidin-4-one, 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl- [CAS]	106266-06-2	EP 196132	Neuroleptic
risperidone				
Risperidone		106266-06-2		
	4H-Pyrido[1,2-a]pyrimidin-4-one, 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl- [CAS]	106266-06-2		Formulation, optimized, microencapsulate
risperidone, Medisorb				
	4H-Pyrido[1,2-a]pyrimidin-4-one, 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl- [CAS]			Formulation, oral, orally-disintegrating
risperidone, Quicklets				
Ritans rin		87051-43-2		
Ritipenem		84845-57-8		
ritodrine	Benzene-methanol, 4-hydroxy-Alpha-[1-[2-(4-hydroxyphenyl)ethyl]amino]ethyl]-, (R,S*)- [CAS]	23239-51-2 26652-09-5	US 3410944	Labour inhibitor
Rit drine		26652-09-5		
	2,4,7,12-Tetraazatridecan-13-oic acid, 10-(hydroxy-2-methyl-5-(1-methylethyl)-1-(2-(1-methylethyl)-4-thiazolyl)-3,6-dioxo-8,11-bis(phenylmethyl)-, 5-thiazolyl-methyl ester, (5S-(5R*,8R*,10R*,11R*))- [CAS]	155213-67-5 155213-67-5	WO 9414436	Antiviral anti-HIV
ritonavir				
Rit navir				
Ritonavir				

TABLE 6

Example of Indication
Paget's disease
Schizophrenia
Schizophrenia
Schizophrenia
Labour, preterm
Infection, HIV/AIDS

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
ritonavir, soft gel	2,4,7,12-Tetraazatridecan-13-olc acid, 10-hydroxy-2-methyl-5-(1-methylethyl)-1-(2-(1-methylethyl)-4-thiazolyl)-3,6-dioxo-8,11-bis(phenylmethyl)-, 5-thiazolyl-methyl ester, (5S-(5R*,8R*,10R*,11R*))-[CAS]	155213-67-5		Formulation, other
Rituximab		174722-31-7		
Rivastigmine		123441-03-2		
rivastigmine tartrate	Carbamic acid, ethylmethyl-, 3-[(dimethylamino)ethyl]phenyl ester, (S)-[CAS]	123441-03-2 129101-54-8	DE 3805744	Cognition enhancer
Rivastigmine Tartrate				
Rivastigmine Tartrate				
Rizatriptan		144034-80-0		
rizatriptan benzoate	1H-Indole-3-ethanamine, N,N-dimethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-, monobenzoate- [CAS]	145202-68-0 159778-67-7	EP 497512	Antimigraine
rizatriptan benzoate, Zydys	1H-Indole-3-ethanamine, N,N-dimethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-, monobenzoate- [CAS]			Formulation, oral, orally-disintegrating
RJR-2403	3-Buten-1-amine, N-methyl-4-(3-pyridinyl)-, (3E)-, (2E)-2-butenedioate (1:1) [CAS]	183288-99-5		Cognition enhancer
RNA Stealth Nucleosides, Koron	5-Formyluridine			Antiviral, other
Ro-0094889	2',3'-Di-O-acetyl-5'-vinylcytidine			Anticancer, antimetabolite
Ro-61-1790	2-Pyridinesulfonamide, N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-[2-(1H-tetrazol-5-yl)-4-pyridinyl]-4-pyrimidinyl]-5-methyl- [CAS]	180384-56-9	WO 9819459	Cardiovascular
R civerin		53716-44-2		
R curonlum		143558-00-3		

TABLE 6

Example of Indication
Infection, HIV/AIDS
Alzheimer's disease
Migraine
Migraine
Alzheimer's disease
Infection, hepatitis-C virus
Cancer, general
Haemorrhage, subarachnoid

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
rocuronium bromide	Pyridinium, 1-((2B,3Alpha,5Alpha,16B,17B)-17-(acetoxy)-3-hydroxy-2-(4-morpholinyl)androstan-16-yl)-1-(2-propenyl)-, bromide- [CAS]	104855-17-6 104884-91-5 119302-91-9	EP 287150	Muscle relaxant
rofecoxib	2-(5H)-Furanone, 4-(4-(methylsulfonyl)phenyl)-3-phenyl- [CAS]	162011-90-7	US 5474995	Analgesic, NSAID
Rofecoxib		162011-90-7		
roflumilast	Benzamide, 3-(cyclopropylmethoxy)-N-(3,5-dichloro-4-pyridinyl)-4-(difluoromethoxy)- [CAS]	162401-32-3	WO 9501338	COPD treatment
rokitamycin	Leucomycin V, 4B-butanolate 3B-propanoate [CAS]	74014-51-0	US 4242504	Macrolide antibiotic
Rokitamycin		74014-51-0		
R lipram		61413-54-5		
Rolitetracyclin		751-97-3		
R muride		78113-36-7		
R nifibrat		42597-57-9		
R pinir l		91374-21-9		
ropinirole hydrochloride	2H-Indol-2-one, 4-[2-(diethylamino)ethyl]-1,3-dihydro-, monohydrochloride- [CAS]	91374-20-8 91374-21-9	EP 268033	Antiparkinsonian
ropinirole, GEOMATRIX	2H-Indol-2-one, 4-[2-(diethylamino)ethyl]-1,3-dihydro-, monohydrochloride- [CAS]	91374-20-8 91374-21-9		Formulation, oral, other
ropivacaine	2-Piperidinecarboxamide, N-(2,6-dimethylphenyl)-1-propyl-, (S)- [CAS]	84057-95-4 98717-15-8	EP 239710	Anaesthetic, local
Ropivacaine		84057-95-4		
Roquinimex		84088-42-6		
rosaprostol	Cyclopentanepentanoic acid, 2-hexyl-5-hydroxy- [CAS]	56695-65-9	GB 1523355	Prostaglandin
R sapr st l		56695-65-9		
R saramicin		35834-26-5		
R se Bengal		632-68-8		
R siglitzone		122320-73-4		

TABLE 6

Exempl of Indication
Muscle spasm, general
Arthritis, osteo
Chronic obstructive pulmonary disease
Infection, general
Parkinson's disease
Parkinson's disease
Anaesthesia

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
rosiglitazone maleate	2,4-Thiazolidinedione, 5-((4-(2-(methyl-2-pyridinylamino)ethoxy)phenyl)methyl)-, (Z)-2-butenedioate (1:1) [CAS]	122320-73-4 155141-29-0	US 5002953	Antidiabetic
rosiglitazone maleate+metformin	Imidazolidinecarboxylic acid, N,N-dimethyl-, monohydrochloride + 2,4-Thiazolidinedione, 5-((4-(2-(methyl-2-pyridinylamino)ethoxy)phenyl)methyl)-, (Z)-2-butenedioate (1:1)			Formulation, modified-release, multi
rosuvastatin	3-Quinolonecarboxylic acid, 1-ethyl-1,4-dihydro-4-oxo-7-(4-pyridinyl)- [CAS]	40034-42-2	US 3753993	Quinolone antibacterial
Rosoxacin		40034-42-2		
rotoporfin	Tin, dichloro[ethyl 3,4,20,21-tetradehydro-4,9,14,19-tetraethyl-18,19-dihydro-3,8,13,18-tetramethyl-20-phorbinecarboxylate(2-)-kappaN23,kappaN24,kappaN25,kappaN26]-, (OC-6-13)- [CAS]	114494-17-8		Ophthalmological
rosuvastatin calcium	6-Heptenoic acid, 7-(4-(4-fluorophenyl)-6-(1-methylethyl)-2-(methyl(methylsulfonyl)amino)-5-pyridinyl)-3,5-dihydroxy- calcium salt (2:1) (S-(R*), S*-(E)) [CAS]	147098-20-2	JP 2648897	Hypolipemic/Antiatherosclerosis
rotigotine	1-Naphthalenol, 5,6,7,8-tetrahydro-6-[propyl(2-(2-thienyl)ethyl)amino]-, (S)- [CAS]	99755-59-6	US 4564628	Antiparkinsonian
Rotraxat		92071-51-7		
Roxarsone		121-19-7		
R xatidin Ac tate		78628-28-1		
roxatidine acetate HCl	Acetamide, 2-(acetyloxy)-N-[3-(1-piperidinylmethyl)phenoxy]propyl-, monohydrochloride [CAS]	78628-28-1 93793-83-0	EP 24510	Antitumor
roxibane acetate	L-Alanine, 3-(((3-(4-(aminomethyl)phenyl)-4,5-dihydro-5-(isoxazolyl)acetyl)amino)-N-(butoxycarbonyl)-, methyl ester, (R)-, monoacetate- [CAS]			
Roxind le		176022-59-6	US 5849736	Antithrombotic
		112192-04-8		

TABLE 6

Example of Indication
Diabetes, Type II
Diabetes, Type II
Infection, gonorrhoea
Macular degeneration
Hyperlipidaemia, general
Parkinson's disease
Ulcer, gastric
Thrombosis, general

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
roxithromycin	Erythromycin, 9-[O-[(2-methoxyethoxy)methyl]oxime] [CAS]	80214-83-1 80214-86-4	EP 33255	Macrolide antibiotic
Roxithromycin		80214-83-1		
RPR-109881A	Benzenepropanoic acid, B-(((1,1-dimethylethoxy)carbonyl)amino)-Alpha-hydroxy-			
	(1S,2S,4S,7R,8aR,9aS,10aR,12aS,12bR)-7,12a-bis(acefyoxy)-1-(benzoyloxy)-1,3,4,7,8,9a,10,10a,12,12a,12b-dodecahydro-2-hydroxy-5,13,13-trimethyl-8-oxo-2,6-methano-2H-cyclodeca(3,4) cyclopropa (4,5) benz (1,2-b) oxet-4-yl ester, dihydrate Alpha R, betaS [CAS]	192573-38-9		Anticancer, other
	4,9-Ethano-3aH-benz[fi]indole-3a-carboxylic acid, 1,2,3,4,9,9a-hexahydro-2-[2-(2-methoxyphenyl)-1-oxo-2-propenyl]-9-(4-methylphenyl)-, (3aR,4S,9S,9aR)-rel- [CAS]	210282-69-2	WO 9829390 US 6316456	Anticancer, other Anticancer, other
RPR-130401				
R-roscovitine	N,N'-bis(3-hydroxyphenyl)pyridazine-3,6-diamine			Neuroprotective
RS-0406				
RSR-13		131179-95-8		
Rubij rvin		79-58-3		
rubitecan	1H-Pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H,12H)-dione, 4-ethyl-4-hydroxy-10-nitro-, (S)- [CAS]	91421-42-0	US 6485514	Anticancer, other
Rubitecan		91421-42-0		
rubitecan, SkyePharma	1H-Pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H,12H)-dione, 4-ethyl-4-hydroxy-10-nitro-, (S)- [CAS]			Formulation, parenteral, other

TABLE 6

Example of Indication
Infection, general
Cancer, lung, general
Cancer, general
Cancer, lung, non-small cell
Alzheimer's disease
Cancer, pancreatic
Cancer, general

TABLE 6

API Gen ric Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
ruboxistaurin	9H,18H-5,21:12,17-Dimethenodibenzo(e,k)pyrrolo(3,4-h)(1,4,13)oxadiazacyclohexadecine-18,20(19H)-dione,9-((dimethylamino)methyl)-6,7,10,11-tetrahydro-, (S)- [CAS]	16999-94-0		Symptomatic antidiabetic
Rufinamide		106308-44-5		
rufloxacin	7H-Pyrido[1,2,3-de]-1,4-benzothiazine-6-carboxylic acid, 9-fluoro-2,3-dihydro-10-(4-methyl-1-piperazinyl)-7-oxo- [CAS]	101363-10-4 102052-47-1 106017-08-7	EP 165375	Quinolone antibacterial
Rufloxacin		101363-10-4		
rupatadine	5H-Benzo[5,6]cyclohepta[1,2-b]pyridine, 8-chloro-6,11-dihydro-11-[(5-methyl-3-pyridinyl)methyl]-4-piperidinylidene], trihydrochloride- [CAS]	156611-76-6	EP 0577957	Antiallergic, non-asthma
Rutin		153-18-4		
RWJ-54428	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[(2Z)-(2-amino-5-chloro-4-thiazolyl)(hydroxymino)acetyl(amino)-3-[(3-[(2-aminoethylthio)methyl]-4-pyridinylthio]-8-oxo-, (6R,7R)- [CAS]	189448-35-9	WO 9713772	Cephalosporin, injectable
S-0139	Olean-12-en-28-oic acid, 27-[[3-[5-hydroxy-2-[(4-methoxy-1,4-dioxo-2-butenyl)amino]phenyl]-1-oxo-2-propenyl]oxy]-3-oxo- [CAS]	193969-54-9	WO 9727314	Cardiovascular
S-15535	Piperazine, 1-(2,3-dihydro-1,4-benzodioxin-5-yl)-4-(2,3-dihydro-1H-inden-2-yl)- [CAS]	146998-34-7		Cognition enhancer
S-18886	1-Naphthalenepropanoic acid, 6-(((4-chlorophenyl)sulfonyl)amino)-5,6,7,8-tetrahydro-2-methyl [CAS]	165537-73-5		Antithrombotic
S-34730	7-chloro-6-sulfamoyl-2-(1H)-quinoleinone-3-phosphonic acid			Neuroprotective

TABLE 6

Exempl of Indication
Retinopathy, diabetic
Infection, general
Rhinitis, allergic, seasonal
Infection, beta-lactamase resistant
Ischaemia, cerebral
Cognitive disorder, general
Thrombosis, general
Unspecified

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
S-3578	7β-[2-(5-amino-1,2,4-thiadiazol-3-yl)-2(Z)-ethoxyiminoacetamido]-3-(1-(N-methylaminopropyl)-1H-imidazo[4,5-b]pyridinium-4-methyl-3-cephem-4-carboxylate monosulfate			Cephalosporin, injectable
S-36496	2-[N-(4-(Chlorophenyl)sulfonylamino)butyl]-N-{3-[(4-isopropylthiazol-2-yl)methoxy]benzyl}sulfamoylbenzoic acid			Antialsthma
S-36527	2-[N-(4-(Chlorophenyl)sulfonylamino)butyl]-N-{3-[2-(4-cyclobutylthiazol-2-yl)ethyl]benzyl}sulfamoylbenzoic acid			Antialsthma
S-5751	(1R,2R,3S,5S)-7-[2-(5-Hydroxybenzothiophen-3-ylcarboxamido)-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-5(Z)-heptenoic acid			Antiallergic, non-asthma
S-8510	Imidazo[4,5-d]pyrano[4,3-b]pyridine, 1,6,7,9-tetrahydro-2-(3-isoxazolyl)-, phosphate (1:1) [CAS]	151466-23-8	EP 556008	Cognition enhancer
S-8921	2-Naphthalenecarboxylic acid, 1-(3,4-dimethoxyphenyl)-3-(3-ethyl-1-oxopentyl)-4-hydroxy-6,7,8-trimethoxy-, methyl ester [CAS]	151165-96-7	WO 9308155	Hypolipaeic/Antiatherosclerosis
Sabcom line		159912-53-5		
Sabeluz le		104383-17-7		
S-Aden sylimethionine		29908-03-0		
salinamide	(S)-(+)-2-[4-(3-fluorobenzoyloxy)benzylamino]propanamide methansulfonate	133865-89-1	AU 711309	Antiepileptic
Salacetamide		487-48-9		
Salazosulfadimidine		8/4/2315		

TABLE 6

Example of Indication
Infection, general
Asthma
Asthma
Allergy, general
Alzheimer's disease
Hypercholesterolaemia
Epilepsy, general

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
salbutamol, AeroDose	1,3-Benzenedimethanol, Alpha1-[[[(1,1-dimethylethyl)amino]methyl]-4-hydroxy- [CAS]	18559-94-9		Formulation, inhalable, topical
salbutamol, Alza	1,3-Benzenedimethanol, Alpha1-[[[(1,1-dimethylethyl)amino]methyl]-4-hydroxy- [CAS]	18559-94-9		Formulation, modified-release, other
salbutamol, Clickhaler	1,3-Benzenedimethanol, Alpha1-[[[(1,1-dimethylethyl)amino]methyl]-4-hydroxy- [CAS]	18559-94-9		Formulation, inhalable, dry powder
salbutamol, Easi-Breathe	1,3-Benzenedimethanol, Alpha1-[[[(1,1-dimethylethyl)amino]methyl]-4-hydroxy- [CAS]	18559-94-9		Formulation, inhalable, solution
salbutamol, Easyhaler	1,3-Benzenedimethanol, Alpha1-[[[(1,1-dimethylethyl)amino]methyl]-4-hydroxy- [CAS]	18559-94-9		Formulation, inhalable, dry powder
salbutamol, HFA aerosol, 3M	1,3-Benzenedimethanol, Alpha1-[[[(1,1-dimethylethyl)amino]methyl]-4-hydroxy- [CAS]	18559-94-9		Formulation, inhalable, topical
salbutamol, Premaire	1,3-Benzenedimethanol, Alpha1-[[[(1,1-dimethylethyl)amino]methyl]-4-hydroxy- [CAS]	18559-94-9		Formulation, inhalable, solution
salbutamol, Pulvinal	1,3-Benzenedimethanol, Alpha1-[[[(1,1-dimethylethyl)amino]methyl]-4-hydroxy- [CAS]	18559-94-9	EP 451745	Formulation, inhalable, dry powder
salbutamol, Turbuhaler	1,3-Benzenedimethanol, Alpha1-[[[(1,1-dimethylethyl)amino]methyl]-4-hydroxy- [CAS]	18559-94-9		Formulation, inhalable, topical
Salicin		138-52-3		
Salicyl Alcohol I		90-01-7		
Salicylamide		65-45-2		
Salicylamide O-Acetic Acid		25395-22-6		
Salicylanilid		87-17-2		
Salicylic Acid		69-72-7		
Salicylsulfuric Acid		89-45-2		
Salinazid		495-84-1		
Salmeterol		89365-50-4		

TABLE 6

Example of Indication
Asthma
Asthma
Asthma
Asthma
Asthma
Asthma
Asthma
Asthma
Asthma
Asthma

TABLE 6

API Gen ric Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
salmeterol xinafoate	1,3-Benzenedimethanol, 4-hydroxy-Alpha1- [[[6-(4-phenylbutoxy)hexylamino]methyl]-, (±)- 1-hydroxy-2-naphthalenecarboxylate (salt)- [CAS]	89365-50-4 94749-08-3	WO 9006775	Antiasthma
Salsalat		552-94-3		
Salverin		6376-26-7		
Samarium ¹⁵³ Sm		154427-83-5		
Lexidronam				
	L-Tyrosine, N2-(methylsulfonyl)-L-lysyl-1- [(2S)-3-amino-2- carboxypropyl]cyclopentanecarbonyl- [CAS]	129981-36-8	EP 358398	Antihypertensive, renin system
sampatrilat		129981-36-8		
Sampatrilat		808-26-4		
Sancyclin		110588-57-3		
Sapropterin		62989-33-7		
sapropterin hydrochloride	4(1H)-Pteridinone, 2-amino-6-(1,2- dihydroxypropyl)-5,6,7,8-tetrahydro- dihydrochloride, [6R-[6R'(1R*,2S*)]]- [CAS]	69056-38-8	EP 191335	Antidepressant
	Butanediamide, N1-[3-[3-[(1,1- dimethylethyl)amino]carbonyl]octahydro- 2(1H)-isoquinolinyl]-2-hydroxy-1- (phenylmethyl)propyl]-2-[(2- quinolinylcarbonyl)amino]-, [3S- [2(1R*(R*),2S*),3Alpha,4aB,8aB]]- [CAS]	127779-20-8 127779-20-8	EP 432695	Antiviral, anti-HIV
Saquinavir				
Saquinavir				
Saquinavir Mesylate				

TABLE 6

Example of Indication
Asthma
Hypertension, general
Hyperphenylalaninaemia
Infection, HIV/AIDS

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
saquinavir, soft gel	Butanediamide, N1-[3-[3-[(1,1-dimethylethyl)amino]carbonyl]octahydro-2(1H)-isoquinolinyl]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinyl)carbonyl]amino)-, [3S-[2(1R*(R*),2S*,3Alpha,4aB,8aB)] [CAS]	127729-20-8		Formulation, oral, other
Saralasin		34273-10-4		
saredutant	Benzamide, N-[4-[4-(acetylamino)-4-phenyl-1-piperidinyl]-2-(3,4-dichlorophenyl)butyl]-N-methyl-, (S)- [CAS]	142001-63-6	EP 474561	Antiasthma
sarizotan hydrochloride	3-Pyridinemethanamine, N-[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]-5-(4-fluorophenyl)- [CAS]	177975-08-5		Antiparkinsonian
sarpogrelate	Butanedioic acid, mono[2-(dimethylamino)-1-[[2-[2-(3-methoxyphenyl)ethyl]phenoxymethyl]ethyl] ester [CAS]	125926-17-2	EP 398326	Antithrombotic
Satigrel		111753-73-2		
satraplatin	Platinum, bis(acetato-O)amminedichloro(cyclohexanamine)-, (OC-8-43)- [CAS]	129560-63-8	EP 328274	Anticancer, alkylating
Satumomab		144058-40-2		
SB-237376	N-[3-[2-(3,4-dimethoxyphenyl)ethyl]amino]propyl]-4-nitrobenzamide, HCl			Antiarrhythmic
SB-238039	(5-(2-phenylamino-4-pyrimidinyl)-4-(4-fluorophenyl)-1-(4-piperidinyl)imidazole			Anticancer, other
SB-277011	trans-N-[4-[2-(6-Cyano-1,2,3,4-tetrahydroisoquinolin-2-yl)ethyl]cyclohexyl]-4-quinolinecarboxamide			Neuroleptic
Scarlet Red		85-83-6		

TABLE 6

Exempl of Indication
Infection, HIV/AIDS
Asthma
Parkinson's disease
Cancer, prostate
Fibrillation, atrial
Cancer, general
Schizophrenia

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
SCH-00013	Benzonitrile, 4-[2-[3,6-dihydro-4-(1,4,5,6-tetrahydro-6-oxo-3-pyridazinyl)-1(2H)-pyridinyl]-1-hydroxyethyl]- [CAS]	217963-18-3	EP 618204	Cardio stimulant
Sch-23863	(2-[10,11-Dihydro-5-ethoxy-5H-dibenzo[a,d] cyclohepten-S-yl]-N, N-dimethylethanamine			Immunosuppressant
Sch-57790	1-Piperazineacetone nitrile, 4-cyclohexyl-alpha-[4-(S)-(4-methoxyphenyl)sulfinyl]phenyl]- [CAS]	221660-80-6		Cognition enhancer
Sch-63390	7H-Pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine, 2-(2-turanyl)-7-(3-phenylpropyl)- [CAS]	174648-45-4		Antiparkinsonian
Scillarenin		465-22-5		
Scopolamine		51-34-3		
Scopolamine N-Oxide		97-75-6		
scopolamine, Alza	Benzeneacetic acid, Alpha-(hydroxymethyl)-, 9-methyl-3-oxa-9-azatricyclo[3.3.1.0 ^{2,4}]non-7-yl ester, [7(S)-(1Alpha,2B,4B,5Alpha,7B)]- [CAS]	51-34-3	US 4262003	Formulation, transdermal, other
SCS technology			US 6046188	Antiasthma
secalciferol, Teva	9,10-Secosterolesta-5,7,10(19)-triene-3,24,25-triol, (3R,5Z,7E,24R)- [CAS]	55721-11-4	EP 301167	Osteoporosis treatment
secnidazole	1H-Imidazole-1-ethanol, Alpha,2-dimethyl-5-nitro- [CAS]	3366-95-8	FR M3270	Protozoacide
Secnidazole		3366-95-8		
Secobarbital Sodium		309-43-3		
selegiline	Benzeneethanamine, N,Alpha-dimethyl-N-2-propenyl-, (R)- [CAS]	14611-51-9	GB 1153578	Antiparkinsonian
Sel gilin		14611-51-9		
Selegiline				
Hydrochloride				
selegiline transdermal, Somers	Benzeneethanamine, N,Alpha-dimethyl-N-2-propenyl-, (R)- [CAS]			Formulation, transdermal, patch

TABLE 6

Example 1 Indication
Heart failure
Inflammation, general
Alzheimer's disease
Parkinson's disease
Nausea and vomiting, general
Unspecified
Osteodystrophy
Infection, trichomoniasis
Depression, general

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
selegiline, Zydys	Benzene ethanamine, N(Alpha-dimethyl)-N-2-propynyl-, (R)- [CAS]	14611-51-9		Formulation, oral, orally-disintegrating
Selenomethionine		1464-42-2		
Sematilid		101526-83-4		
Semotiadiil		116476-13-2		
seocalcitol	1,3-Cyclohexanediol, 5-((1-(6-ethyl-6-hydroxy-1-methyl-2,4-octadienyl)octahydro-7a-methyl-4H-inden-4-ylidene)ethylidene)-(1R-4-methylene-, (1R-(1Alpha(1R*,2E,4E),3aB,4E(1R*,3S*,5Z),7aAlpha))- [CAS]	134404-52-7	WO 9100855	Anticancer, other
Sepimostat		103926-64-3		
seratrovast	Benzeneheptanoic acid, zeta-(2,4,5-trimethyl-3,6-dioxo-1,4-cyclohexadien-1-yl)-, (+)- [CAS]	103187-07-1 112665-43-7	EP 232089	Antiasthma
S ratrodast		112665-43-7		
sertaconazole	1H-Imidazole, 1-[2-[(7-chlorobenzobiphen-3-yl)methoxy]-2-(2,4-dichlorophenyl)ethyl]- [CAS]	99592-32-2	EP 151477	Antifungal
Sertaconazol		99592-32-2		
sertindole	2-Imidazolidinone, 1-[2-[4-(5-chloro-1-(4-fluorophenyl)-1H-indol-3-yl)-1-piperidinyl]ethyl]- [CAS]	106516-24-9	EP 392959	Neuroleptic
Sertind le		106516-24-9		
sertraline	1-Naphthalenamine, 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-, (1S-cis)- [CAS]	79559-97-0 79617-96-2 79617-97-3	EP 30081	Antidepressant
S rtralin		79617-96-2		
Setastine		64294-95-7		
S velamer		52757-95-6		
sevelamer hydrochloride	2-Propen-1-amine polymer with (chloromethyl)oxirane, hydrochloride [CAS]	152751-57-0 52757-95-6	US 5496545	Urological
sevoflurane	Propane, 1,1,1,3,3,3-hexafluoro-2-(fluoromethoxy)- [CAS]	28523-86-6	DE 1954268	Anaesthetic, Inhalation
Sevoflurane		28523-86-6		

TABLE 6

Example of Indication
Parkinson's disease
Cancer, liver
Asthma
Infection, dermatological
Schizophrenia
Depression, general
Renal failure
Anaesthesia

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
SG-210	2H-1,4-Benzothiazine-2-acetic acid, 3,4-dihydro-3-oxo-4-[(4,5,7-trifluoro-2-benzothiazolyl)methyl]- [CAS]	143162-65-6		Symptomatic antidiabetic
sibutramine	Cyclobutanemethanamine, 1-(4-chlorophenyl)-N,N-dimethyl-Alpha-(2-methylpropyl)- [CAS]	106650-56-0 84485-00-7	GB 2098602	Anorectic/Antiobesity
Sibutramine	(4aS-(4aAlpha,6aAlpha,11bAlpha,13aR*,13bAlp	106650-56-0		
siccanin	ha))-1,2,3,4,4a,5,6a,11b,13b-decahydro-4,4,6a,9-tetramethyl-13H-benzo[a]furo[2,3,4-mn]xanthen-11-ol	22733-60-4	JP 37003548	Antifungal
Siccanin		22733-60-4		
Sildenafil		139755-83-2		
	Piperazine, 1-(3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo(4,3-d)pyrimidin-5-yl)-4-ethoxyphenyl)sulfonyl)-4-methyl-2-hydroxy-1,2,3-propanetricarboxylate- (1:1) [CAS]	171599-83-0	WO 9428902	Male sexual dysfunction
sildenafil citrate				
sildenafil	1H-Indole-7-carboxamide, 2,3-dihydro-1-(3-hydroxypropyl)-5-[(2R)-2-[(2-(2,2,2-trifluoroethoxy)phenoxy)ethyl]amino]propyl]- [CAS]	160970-54-7	EP 600675	Urological
Silv r Lactat		128-00-7		
Silv r Picrat		146-84-9		
silver sulfadiazine	N-2-pyrimidinylsulfanilamide monosilver salt	22199-08-2 68-35-9		Anti-infective, other
Sim trid		154-82-5		
Simfibrat		14929-11-4		
simvastatin	Butanoic acid, 2,2-dimethyl-, 1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl]-1-naphthalenyl ester, [1S-[1Alpha,3Alpha,7S,8S(2S*,4S*),8aB]]- [CAS]	79902-63-9	US 4444784	Hypolipemic/Antiatherosclerosis

TABLE 6

Example of Indication
Neuropathy, diabetic
Obesity
Impotence
Dysuria
Infection, general
Hyperlipidaemia, general

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Simvastatin		79902-63-9		
Sinvalid		25126-32-3		
Sintropium Bromide		79467-19-9		
Sis micin		32385-11-8		
Sitafi xacin		127254-12-0		
sitafloxacin hydrate	3-Quinolnecarboxylic acid, 7-(7-amino-5-azaspiro[2.4]hept-5-yl)-8-chloro-6-fluoro-1-(2-fluorocyclopropyl)-1,4-dihydro-4-oxo-, [1R-[1Alpha(S'),2Alpha]]-, hydrate	127254-12-0	EP 341493	Quinolone antibacterial
sitamaquine	1,6-Hexanediamine, N,N-diethyl-N'-(6-methoxy-4-methyl-8-quinoliny)-, [CAS]	5330-29-0 57695-04-2		Protozoacide
sitaxsantan sodium	N-(4-Chloro-3-methyl-5-isoxazolyl)-2-[(4,5-(methylenedioxy)-o-tolylacetyl]-3-thiophenesulfonamide			
Sivelestat		184036-34-8	US 5464853	Antihypertensive, other
sivelestat sodium hydrate	Glycine, N-[2-[[[4-(2,2-dimethyl-1-oxopropoxy)phenyl]sulfonylamino]benzoyl]]- [CAS]	127373-66-4	EP 347168	Respiratory
SJA-6017	Butanamide, 2-[[[4-(4-fluorophenyl)sulfonylamino]-N-[(1S)-1-formyl-3-methylbutyl]-3-methyl-, (2S)- [CAS]	190274-53-4	EP 771565	Ophthalmological
SL-65-1498	6-Fluoro-9-methyl-2-phenyl-4-pyrrolidin-1-ylcarbonyl)-2,9-dihydro-1H-pyrido[3,4-b]indole-1-one		EP 607076	Anxiolytic
SLV-306	(3S,2'R)-3-[1-[2'-(Ethoxycarbonyl)-4'-phenyl-butyl]-cyclopentan-1-carbonylamino]-2,3,4,5-tetra-hydro-2-oxo-1H-benzazepin-1-acetic acid			Antihypertensive, diuretic
SLV-308	2-(3H)-Benzoxazolone, 7-(4-methyl-1-piperazinyl)-, monohydrochloride	269718-83-4		Antiparkinsonian

TABLE 6

Example of Indication
Infection, general
Infection, leishmaniasis
Hypertension, pulmonary
Systemic inflammatory response syndrome
Cataract
Anxiety, general
Hypertension, general
Parkinson's disease

TABLE 6

Example of Indication
Dwarfism
Pain, cancer
Angina, general
Cancer, colorectal
Anxiety, general
Asthma

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
sobidofin	L-valinamide, N,N-dimethyl-L-valyl-N-[2-methoxy-4-[2-[(1-methoxy-2-methyl-3-oxo-3-[(2-phenylethyl)amino]propyl]-1-pyrrolidinyl]]-1-(2-methylpropyl)-4-oxobutyl]-N-methyl-, [2S-[1(R*(R*),2S*,2R*(1S*,2S*))]-[CAS]	149606-27-9	WO 9303054	Anticancer, other
S ber I		498-71-5		
sobuzoxane	Carbonic acid, 1,2-ethanedithylbis[(2,6-dioxo-4,1-piperazinediyl)methylene]bis(2-methylpropyl) ester [CAS]	98631-95-9	EP 140327	Anticancer, other
Sobuzoxane		98631-95-9		
Sodium Arsanilate		127-85-5		
S dium Arsph namine		1936-28-3		
Sodium Chloride				
S dium Dibunate		14992-59-7		
Sodium F lat		6484-89-5		
Sodium F maldehyd sulfoxylat		149-44-0		
S dium Glyceroph sphate		1334-74-3		
Sodium Hyaluronate				
Sodium Iodomethamate		519-26-6		
S dium Nitrite		7632-00-0		
S dium Nitroprusside		14402-89-2		
sodium oxybate	Butyric acid, 4-hydroxy monosodium salt [CAS]	502-85-2		Psychostimulant
Sodium Oxybate				
S dium Phen Isulfonate		1300-51-2		

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
sodium phenylbutyrate, Ucyclud	Butyric acid, 4-phenyl-, sodium salt- [CAS]	1716-12-7		Formulation, other
sodium phosphate, InKline	Sodium phosphate monobasic monohydrate + sodium phosphate dibasic anhydrous		US 6162464	Formulation, oral, other
sodium prasterone sulfate, Akzo	3B-hydroxy-5-androsten-17-one(sodium sulfate dihydrate)		EP 380036	Formulation, mucosal, topical
Sodium Pr pionate		137-40-6		
sodium salicylate, Amarin	Benzolic acid, 2-hydroxy-, monosodium salt [CAS]	54-21-7		Formulation, oral, solubility-enhanced
Sodium Tetradecyl Sulfate		139-88-8		
sotalone	Acetic acid, [5-[(3-methyl-2-butenyloxy]-2-[3-[4-[(3-methyl-2-butenyloxy)phenyl]-1-oxo-2-propenyl]phenoxy]- [CAS]	64506-49-6	GB 1523241	Antitumor
Sofalcone		64506-49-6		
S lasulf n		133-65-3		
solifenacin succinate	Butanedioic acid compd with (1S)-(3R)-1-azabicyclo(2.2.2)oct-3-yl 3,4-dihydro-1-phenyl-2(1H)-isouinolincarboxylate (1:1) [CAS]	242478-38-2		Urological
Sorbitol	D-Glucitol, hexa-3-pyridinecarboxylate [CAS]	6184-06-1	BE 883352	Hypolipemic/Antiatherosclerosis
S rivudin		50-70-4		
		77181-69-2		
sotalol	Methanesulfonamide, N-[4-[1-hydroxy-2-(1-methylethyl)amino]ethyl]phenyl]- [CAS]	3930-20-9 959-24-0		Antiarrhythmic
S talol		3930-20-9		
Sotalol Hydrochloride				
Sotalol Hydrochloride				
Soteranol		13642-52-9		
Soziodolic Acid		554-71-2		

TABLE 6

Example of Indication
Hyperammonaemia
Surgery adjunct
Labour, induction
Pain, general
Overactive bladder

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
sparglumic acid, ophthalmol	L-Glutamic acid, N-(N-acetyl-L-Alpha-aspartyl)- [CAS]	3108-85-2 80819-84-3		Formulation, mucosal, topical
sparfloxacin	3-Quinolincarboxylic acid, 5-amino-1-cyclopropyl-7-(3,5-dimethyl-1-piperazinyl)-6,8-difluoro-1,4-dihydro-4-oxo-, cis- [CAS]	110871-86-8	EP 221463	Quinolone antibacterial
Sparfloxacin		110871-86-8		
Spartine		90-39-1		
SPA-S-843	Candicin D, 18-decarboxy-40-demethyl-3,7-dideoxo-N3'-((dimethylamino)acetyl)-18-(((2-(dimethylamino)ethyl)amino)carbonyl)-3,7-dihydroxy-N47-methyl-5-oxo cyclic 15,19-hemiacetal, comp with L-ascorbic acid (1:2) [CAS]	202748-83-2	US 5298495	Antifungal
Spasmolyt I		25333-96-4		
SPD-754	2(1H)-Pyrimidinone, 4-amino-1-(2-(hydroxymethyl)-1,3-oxathiolan-4-yl)- (2R-cis)-	160707-69-7	US 6228860	Antiviral, anti-HIV
Spectin mycin		1695-77-8		
SPI-339	4-[3-(4-Oxo-4,5,6,7-tetrahydroindol-yl)propionylamino]benzoic acid ethyl ester			Cognition enhancer
Spiperone		749-02-0		
spirapril	1,4-Dithia-7-azaspiro[4.4]nonane-8-carboxylic acid, 7-[2-[[1-(ethoxycarbonyl)-3-phenylpropylamino]-1-oxopropyl]-, [8S-[7[R'(R*),8R']]- [CAS]	83847-97-6	EP 50800	Antihypertensive, renin system
Spirapril		83647-97-6		
Spirogmanium		41992-23-8		
Spironolactone		52-01-7		
spironolactone, oral, Searle	17Alpha-Pregn-4-ene-21-carboxylic acid, 17-hydroxy-7Alpha-mercapto-3-oxo-, Gamma-lactone, acetate [CAS]	52-01-7		Formulation, oral, other

TABLE 6

Example of Indication
Conjunctivitis
Infection, respiratory tract, general
Infection, fungal, general
Infection, HIV/AIDS
Alzheimer's disease
Hypertension, general
Hypertension, general

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
spironolactone, topical, Searle	Pregn-4-ene-21-carboxylic acid, 7-(acetylthio)-17-hydroxy-3-oxo-, Gamma-lactone, (7Alpha, 17Alpha)- [CAS]	52-01-7	EP 124147	Formulation, dermal, topical
SR-121463	Benzamide, N-(1,1-dimethylethyl)-4-[[cis-5'-ethoxy-4-[2-(4-morpholinyl)ethoxy]-2'-oxospiro[cyclohexane-1,3'-[3H]indol]-1'(2H)-yl]sulfonyl]-3-methoxy- [CAS]	185913-78-4	WO 9715556	Cardio stimulant
SR-144190	Morpholine, 4-benzoyl-2-(3,4-difluorophenyl)-2-[2-(4-[[[(dimethylamino)carbonyl]amino]-4-phenyl-1-piperidinyl]ethyl]-, (2R)- [CAS]	201152-86-5	WO 9623787	Anxiolytic
SR-146131	1H-Indole-1-acetic acid, 2-[[[4-(4-chloro-2,5-dimethoxyphenyl)-5-(2-cyclohexylethyl)-2-thiazolyl]amino]carbonyl]-5,7-dimethyl- [CAS]	221671-61-0	WO 9915525	Anorectic/Antiobesity
SR-271425	N-[1-[2-(diethylamino)ethylamino]-7-methoxy-9-oxo-9H-thioxanthen-4-ylmethyl]formamide			Anticancer, alkylating
SR-27897	1H-Indole-1-acetic acid, 2-[[[4-(2-chlorophenyl)-2-thiazolyl]amino]carbonyl]- [CAS]	136381-85-6	EP 432040	Anticancer, other
SR-31747	Cyclohexanamine, N-(3-(3-chloro-4-cyclohexylphenyl)-2-propenyl)-N-ethyl-, hydrochloride, (Z)- [CAS]	132173-07-0	EP 376850	Anticancer, other
SR-58611	Acetic acid, [(7S)-7-[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]-5,6,7,8-tetrahydro-2-naphthalenyl]oxy], ethyl ester, hydrochloride [CAS]	121524-09-2	EP 303546	GI Inflammatory/bowel disorders
SS732	(R)-(-)-2-(2,4-difluorophenyl)-1-(ethylsulfonyl)-1,1-difluoro-3-(1H-1,2,4-triazol-1-yl)-2-propanol		US 5385900	Formulation, mucosal, topical
SS-750	Propanamide, N, N'(dithiodi-2,1-ethanediy)bis(3-amino)- [CAS]	646-08-2	US 6083968	Antifungal
B-aethine				Anticancer, immunological

TABLE 6

Example of Indication
Acne
Heart failure
Anxiety, general
Obesity
Cancer, general
Cancer, pancreatic
Cancer, myeloma
Irritable bowel syndrome
Infection, ocular
Infection, fungal, general
Cancer, myeloma

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
SSR-149415	(2S,4R)-1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxyphenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-2-pyrrolidine carboxamide		WO 0155130	Antidepressant
SSR-180575	2-(7-chloro-5-methyl-4-oxo-3-phenyl-4,5-dihydro-3H-pyridazin-4,5,6-triindol-1-yl)-N,N-dimethylacetamide			Neuroprotective
SSR-181507	(3-Exo)-8-benzoyl-N-[(2S)-7-chloro-2,3-dihydro-1,4-benzodioxin-2-yl]methyl]-8-azabicyclo[3.2.1]octane-3-methanamine HCl		US 6221879	Neuroleptic
SSR-591813	(5aS,8S,10aR)-5a,6,9,10-tetrahydro, 7H,11H-8,10a-methanopyrido[2',3':5,6]pyrano[2,3-d]azepine			Dependence treatment
SST-101	D-Glucitol, 1,4:3,6-dianhydro-, dinitrate [CAS]	87-33-2		Formulation, transdermal, other
SSY-726	(-)-(R)-3-Methyl-3-(methylsulfonyl)-1-(1,2,4-triazol-1-yl)-2-[4-(trifluoromethyl)phenyl]-2-butanol		US 5147886	Antifungal
ST-200	1-Propanaminium, 2-(acetoxy)-3-carboxy-N,N,N-trimethyl-, chloride, (R)- [CAS]	5080-50-2	DE 3015635	Cognition enhancer
stachyfin			WO 9711947	Antiviral, other
Stallimycin		636-47-5		
Stampidine		15578-26-4	US 6350736	Antiviral, anti-HIV
Stann us				
Pyr ph sphate	(OC-6-13)-Dihydrogen dichloro[7,12-diethyl-3,8,13,17-tetramethyl-21H,23H-porphine-2,18-dipropionate(4-)-N21,N22,N23,N24]stannate(2-)			
stannosporfin		106344-20-1		Hepatoprotective

TABLE 6

Example of Indication
Depression, general
Unspecified
Schizophrenia
Addiction, nicotine
Angina, general
Infection, fungal, general
Dementia, senile, general
Infection, influenza virus
Infection, HIV/AIDS
Hyperbilirubinaemia

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Stanolon		521-18-6		
Stanozolol		10418-03-8 (2'H form); 302-96-5 (1'H form)		
Staph aureus ther, PhageTech			US 6376652	Genomics-based drug discovery
STAT4 Inhibitors, Tularik			WO 9628341	Immunosuppressant
stavudine	Thymidine, 2',3'-didehydro-3'-deoxy- [CAS]	3056-17-5	EP 501511	Antiviral, anti-HIV
Stavudin		3056-17-5		
stavudine, once-daily, BMS	Thymidine, 2',3'-didehydro-3'-deoxy- [CAS]	3056-17-5		Formulation, modified-release, <=24hr
St nbolon		5197-58-0		
steproin	Glycine, N-[1-oxo-2-[(2- thienylcarbonyl)thio]propyl]- [CAS]	72324-18-6	US 4242354	Antitussive
Stepronin		72324-18-6		
Stib captat		27279-76-1		
Stib phen		15489-16-4		
Stilbamidin		122-06-5		
stripentol	1-Penten-3-ol, 1-(1,3-benzodioxol-5-yl)-4,4- dimethyl- [CAS]	49763-86-4		Antiepileptic
Str ptod mas		37340-82-2		
Str pt mycin		57-92-1		
Strept nlc zid		5667-71-0		
Strept nigrin		3930-19-6		
Streptozocin		18883-66-4		
strontium ranelate	3-Thiopheneacetic acid, 5- [bis(carboxymethyl)amino]-2-carboxy-4- cyano-, strontium salt (1:2)- [CAS]	135459-87-9	EP 415850	Osteoporosis treatment
strontium-89 chloride	Strontium chloride (89SrCl2) [CAS]	38270-90-5		Analgesic, other
Succim r		304-55-2		
Succinimide		123-56-8		
Succinylch line		55-94-7		
Br mid				

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Succinylcholine		71-27-2		
Chl rid				
Succinylsulfathiazole		116-43-8		
Succsulf n		5934-14-5		
Suclofenide		30279-49-3		
	Aluminium, hexadeca- μ -hydroxytetraacosahydroxy(μ 8-(1,3,4,6-tetra-O-sulfo- β -D-fructofuranosyl-Alpha-D-glucopyranoside tetrakis(hydrogen sulfato)(8-)))hexadeca- [CAS]			
sucralfate		54182-58-0	JP 58208233	Antitumor
Sucralfat		54182-58-0		
	Aluminium, hexadeca- μ -hydroxytetraacosahydroxy(μ 8-(1,3,4,6-tetra-O-sulfo- β -D-fructofuranosyl Alpha-D-glucopyranoside tetrakis(sulfato-kappaO'))(8-)))hexadeca- [CAS]			Formulation, oral, other
sucralfate, APR		54182-58-0		
sufentanil	Propanamide, N-[4-(methoxymethyl)-1-[2-(2-thienyl)ethyl]-4-piperidinyl]-N-phenyl- [CAS]	56030-54-7	US 3998834	Anesthetic, other
Sufentanil		56030-54-7		
	Propanamide, N-[4-(methoxymethyl)-1-[2-(2-thienyl)ethyl]-4-piperidinyl]-N-phenyl- [CAS]	56030-54-7		Formulation, implant
sufentanil, S BioSystems				
	4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3,3-dimethyl-7-oxo-, 4,4-dioxide, (2S-cis)- [CAS]	68373-14-8	GB 2000138	Antibiotic, other
subactam		68373-14-8		
Subactam		117060-71-6	US 4234579	Antibiotic, other
subactam + ampicillin				
	4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3,3-dimethyl-7-oxo-6-[[phenylsulfonamido]amino]-, [2S-[(2A)alpha,5A]alpha,6B(S*)]]- [CAS]	28002-18-8 41744-40-5		Penicillin, injectable
subenclillin				
Subenclillin		41744-40-5		
Sulb nline		350-12-9		

TABLE 6

Example of Indication
Ulcer, general
Ulcer, general
Pain, general
Pain, general
Infection, general
Infection, general
Infection, pseudomonal

TABLE 6

API Gen ric Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
sulfabutamine	Propanoic acid, 2-methyl-, dithiobis[3-(1- [[[(4-amino-2-methyl-5- pyrimidinyl)methyl]formylamino]ethylidene]- 3,1-propanediyl] ester [CAS]	3286-46-2 67-16-3		Neurological
sulfonazole	1H-Imidazole, 1-[2-[[4- chlorophenyl)methyl]thio]-2-(2,4- dichlorophenyl)ethyl-, (+/-)- [CAS]	61318-90-9 61318-91-0	US 4055652	Antifungal
Sulc nazole		61318-90-9		
Sulesomab		167747-19-5		
Sulfabenzamide		127-71-9		
Sulfacetamide		144-80-9		
Sulfachl rpyridazine		80-32-0		
Sulfachrys idine		485-41-6		
Sulfacytine		17784-12-2		
Sulfadiazin		68-35-9		
Sulfadiazin		115-68-4		
Sulfadiazin		122-11-2		
Sulfadimethoxine		2447-57-6		
Sulfadoxin		94-19-9		
Sulfa thid le		57-67-0		
Sulfaguanidin		27031-08-9		
Sulfaguanole		152-47-6		
Sulfalene		14376-16-0		
Sulfal xic Acid		127-79-7		
Sulfamerazine		651-06-9		
Sulfamet r		57-68-1		
Sulfamethazine		144-82-1		
Sulfam thizole		3772-76-7		
Sulfam th midline		723-46-6		
Sulfam th xazole		80-35-3		
Sulfam thoxypyridazine				
Sulfametrole		32909-92-5		
Sulfamidochrysoldine		103-12-8		
Sulfam xol		729-99-7		

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Sulfanilamide		63-74-1		
Sulfanilic Acid		121-57-3		
Sulfanilylurea		547-44-4		
Sulfaperin		599-88-2		
Sulfaphazole		526-08-9		
Sulfapyridine		116-42-7		
Sulfapyrazine		116-44-9		
Sulfapyridine		144-83-2		
Sulfarsid		1134-98-1		
Sulfarsphenamine		618-82-6		
Sulfasalazine		599-79-1		
Sulfasalazine, Pharmacia	Benzoic acid, 2-hydroxy-5-[(4-[(2-pyridinylamino)sulfonyl]phenyl)azo]- [CAS]	599-79-1		Formulation, oral, enteric-coated
Sulfasomizole		632-00-8		
Sulfasymazine		1984-94-7		
Sulfathiazole		72-14-0		
Sulfathiourea		515-49-1		
Sulfinalol		66264-77-5		
Sulfonpyrazole		57-96-5		
Sulfiram		95-05-6		
Sulfisomidine		515-64-0		
Sulfisoxazole		127-69-5		
Sulfobromophthalic acid		71-67-0		
Sulfonmethane		76-20-0		
Sulfoniazide		3691-81-4		
Sulfonmethane		115-24-2		
Sulfonidazole		14759-06-9		
Sulfonamide Sodium		144-75-2		
Sulfonamide	cis-5-fluoro-2-methyl-1-[(p-methylsulfonyl)benzylidene]indene-3-acetic acid	38194-50-2	US 3725548	Anti-inflammatory
Sulfonamide		38194-50-2		

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Sulisatin		54935-03-4		
Sulisobenzonone		4065-45-6		
Sulmarin		29334-07-4		
Sulmaz 1		73384-60-8		
Suloctidil		54063-56-8		
Sulphan Blue		129-17-9		
Sulpirid		15676-16-1		
sulpride, Delagrange	Benzamide, 5-(aminosulfonyl)-N-[(1-ethyl-2-pyrrolidinyl)methyl]-2-methoxy-[CAS]	15676-16-1		Alimentary/Metabolic, other
sulprostone	5-Heptenamide, 7-[3-hydroxy-2-(3-hydroxy-4-phenoxy-1-butenyl)-5-oxocyclopentyl]-N-(methylsulfonyl)-, [1R-[1Alpha(Z),2B(1E,3R*),3Alpha]]-[CAS]	60325-46-4	US 4024179	Prostaglandin
Sulpr ston		60325-46-4		
sultamicillin	4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-((aminophenylacetyl)amino)-3,3-dimethyl-7-oxo-, ((3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)hept-2-yl)carbonyl)oxy)methyl ester, S, S-dioxide, (2S-(2.alpha.(2R*,5S*),5.alpha.,6.beta.(S*))-[CAS]	117060-71-8 76497-13-7	GB 2044255	Penicillin, oral
Sultamicillin		76497-13-7		
Sulthlame		61-56-3		
sultopride	Benzamide, N-[(1-ethyl-2-pyrrolidinyl)methyl]-5-(ethylsulfonyl)-2-methoxy-[CAS]	53583-79-2	FR M5916	Neuroleptic
Sultopride		53583-79-2		
Sult silic Acid		57775-26-5		
sumatriptole	4H-Imidazo[4,5,1-j]quinolin-2(1H)-one, 5,6-dihydro-5-(methylamino)-, (5R)-, (2Z)-2-butenedioate (1:1) [CAS]	179386-44-8	WO 9514020	Antiparkinsonian
Sumatriptan		103628-46-2		

TABLE 6

API Gen. ric Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
sumatriptan succinate	1H-Indole-5-methanesulfonamide, 3-[2-(dimethylamino)ethyl]-N-methyl-, butanedioate (1:1)- [CAS]	103628-46-2 103628-48-4	EP 147107	Antimigraine
sumatriptan, BEMA	1H-Indole-5-methanesulfonamide, 3-[2-(dimethylamino)ethyl]-N-methyl-, butanedioate (1:1)- [CAS]			Formulation, modified-release, other
sumatriptan, Intraject	1H-Indole-5-methanesulfonamide, 3-[2-(dimethylamino)ethyl]-N-methyl-, butanedioate (1:1)- [CAS]	103628-46-2 103628-48-4		Formulation, parenteral, needle-free
sumatriptan, WOWTAB	1H-Indole-5-methanesulfonamide, 3-[2-(dimethylamino)ethyl]-N-methyl-, butanedioate (1:1)- [CAS]	103628-46-2 103628-48-4		Formulation, oral, orally-disintegrating
SUN-N8075	1-(4-amino-2,3,5-trimethylphenoxy)-3-[4-[(4-fluorobenzyl)phenyl]piperazin-1-yl]propan-2(s)-ol dimethanesulfonate			Neuroprotective
suplatast tosylate	Sulfonium, [3-[[4-(3-ethoxy-2-hydroxypropoxy)phenyl]amino]-3-oxopropyl]dimethyl-, salt with 4-methylbenzenesulfonic acid (1:1) [CAS]	94055-76-2	JP 59167564	Antiasthma
Suplatast T slylate		94055-76-2		
Supr fen		40828-46-4		
Suramin S dium		129-46-4		
surfactant TA	Suractant [CAS]	108778-82-1	WO 9117766	Lung Surfactant
Suriclone		53813-83-5		
Suxibuz ne		27470-51-5		
SYM-1010			US 5830998	Antiepileptic
SYM-2081	L-Glutamic acid, 4-methyl-, (4R)- [CAS]	31137-74-3		Analgesic, other
SYM-2207	4-(Aminophenyl)-1-methyl-6,7-(methylenedioxy)-N-butyl-1,2-dihydrophthalazine-2-carboxamide			Neuroprotective
Symclosene		87-90-1		
Syn-1253	1-cyclopropyl-6-fluoro-8-methoxy-7-[3-(4-methyl-1,2,3-triazol-1-yl)pyrrolidin-1-yl]-4-oxo-1,4-dihydroquinoline 3-carboxylic acid			Quinolone antibacterial

TABLE 6

Example of Indication
Migraine
Migraine
Migraine
Migraine
Infarction, cerebral
Asthma
Respiratory distress syndrome, general
Epilepsy, general
Pain, general
Ischaemia, cerebral
Infection, peritoneum

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Sym-2190	1-Azaidinesulfonic acid, 3-[(2E)-[(1,4-dihydro-1,5-dihydroxy-4-oxo-2-pyridinyl)methoxyimino]-2-thienylacetyl]amino]-2-methyl-4-oxo, (2S,3S)- [CAS]	214963-75-4	WO 9847895	Antibacterial, other
Sym-2869	3H-1,2,4-Triazol-3-one, 4-(4-(4-(1R,2R)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl)-1-piperazinyl)phenyl)-2,4-dihydro-2[(4-(trifluoromethoxy)phenyl)methyl]- [CAS]	210562-98-4	US 6153616	Antifungal
Synephrine		94-07-5		
Syr sing pine		84-36-6		
T-1095	1-Propanone, 3-(5-benzofuran-1-yl)-2-hydroxy-6-((6-O-methoxycarbonyl)-8-D-glucopyranosyl)oxy)-4-methylphenyl- [CAS]	209746-59-8	EP 850948	Antidiabetic
T-1249	L-Phenylalaninamide, N-acetyl-L-tryptophyl-L-glutamyl-L-Alpha-glutamyl-L-tryptophyl-L-Alpha-glutamyl-L-glutamyl-L-lysyl-L-iso-leucyl-L-threonyl-L-alanyl-L-leucyl-L-leucyl-L-Alpha-glutamyl-L-glutamyl-L-alanyl-L-glutamyl-L-iso-leucyl-L-glutamyl-L-glutamyl-L-Alpha-glutamyl-L-lysyl-L-Alpha-glutamyl-asparaginyl-L-tyrosyl-L-Alpha-glutamyl-L-leucyl-L-glutamyl-L-lysyl-L-leucyl-L-Alpha-aspartyl-L-lysyl-L-tryptophyl-L-ananyl-L-seryl-L-leucyl-L-tryptophyl-L-Alpha-glutamyl-L-tryptophyl- [CAS]	251562-00-2	WO 9959615	Antiviral, anti-HIV
T-3912	1-cyclopropyl-8-methyl-7-[5-methyl-6-(methylamino)-3-pyridinyl]-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid			Quinolone antibacterial
T-588	Benzo(b)thiophene-5-methanol, Alpha-((2-(diethylamino)ethoxy)methyl)-, hydrochloride, (R)- [CAS]	142935-03-3	EP 565965	Cognition enhancer

TABLE 6

Example of Indication
Infection, general
Infection, Aspergillus
Diabetes, general
Infection, HIV/AIDS
Infection, dermatological
Alzheimer's disease

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
T-67	Benzenesulfonamide, 2,3,4,5,6-pentafluoro-N-(3-fluoro-4-methoxyphenyl)- [CAS]	195533-53-0		Anticancer, other
T-82			US 5190951	Cognition enhancer
TA-2005	2(1H)-Quinolone, 8-hydroxy-5-[1-hydroxy-2-[[2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-monohydrochloride, [R-(R*, R*)]- [CAS]	137888-11-0	US 4578854	Antihistamine
TA-2005, dry powder inhaler	Other 2(1H)-Quinolone, 8-hydroxy-5-[1-hydroxy-2-[[2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-monohydrochloride, [R-(R*, R*)]- [CAS]			Formulation, inhalable, dry powder
TA-2005, HFA Modulator, Chiesi	2(1H)-Quinolone, 8-hydroxy-5-[1-hydroxy-2-[[2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-monohydrochloride, [R-(R*, R*)]- [CAS]		WO 189480	Formulation, inhalable; solution
TA-893	1,5-Benzothiazepin-4(5H)-one, 3-(acetyloxy)-5-[2-(dimethylamino)ethyl]-2,3-dihydro-8-methyl-2-(4-methylphenyl)-, (2R,3R)-rel-(+), (2Z)-2-butenedioate [CAS]	122024-98-0	JP 01045376	Antithrombotic
tabimorelin	(R)-Alpha-[(E)-5-Amino-N,5-dimethyl-2-hexenamido]-N-methyl-N-[(R)-Alpha-(methylcarbamoyl)phenethyl]-2-naphthalenepropionamide	170851-70-4 193079-69-5		Releasing hormones
tacalcitol	9,10-Secocholesta-5,7,10(19)-triene-1,3,24-triol, (1Alpha,3R,5Z,7E,24R)- [CAS]	57333-96-7 93129-94-3	EP 129003	Antipsoriasis
Tacalcitol		57333-96-7		
TA-CD			WO 9630049	Dependence treatment
tacridinaline	Benzamide, 4-(acetylamino)-N-(2-aminophenyl)- [CAS]	112522-84-2	DE 3613571	Anticancer, other
tacrine	9-Acridinamine, 1,2,3,4-tetrahydro- [CAS]	1884-40-8 321-64-2	EP 332147	Cognition enhancer
Tacrine		321-64-2		
Tacrolimus		104987-11-3		

TABLE 6

Example of Indication
Cancer, liver
Alzheimer's disease
Asthma
Asthma
Asthma
Peripheral vascular disease
Growth hormone deficiency
Keratosis
Addiction, cocaine
Cancer, pancreatic
Alzheimer's disease

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
tadalafil	Pyrazino(1',2':1,6)pyrido(3,4-b)indole 1,4-dione, 6-(1,3-benzodioxol-5-yl)-2,3,6,7,12,12a-hexahydro-2-methyl-, (6R-trans) [CAS]	171596-29-5	US 6143746	Male sexual dysfunction
tafenoquine	1,4-Pentanediimine, N4-[2,6-dimethoxy-4-methyl-5-[3-(trifluoromethyl)phenoxy]-8-quinolyl]- [CAS]	106635-80-7 106635-81-8 80065-55-0	US 4617394	Antimalarial
Tafenoquine taliposide		106635-80-7 179067-42-6	WO 9612727	Anticancer, other
TAK-375	(S)-N-[2-(1,6,7,8-Tetrahydro-2H-indeno-[5,4-b]furan-8-yl)]propionamide			Hypnotic/Sedative
TAK-427	2-[6-[3-[4-(Diphenylmethoxy)-piperidino]imidazo[1,2-b]pyridazin-2-yl-2-methyl]propionic acid dihydrate			Antipruritic/Inflamm, allergic
TAK-559	(E)-4-{4-[5-Methyl-2-phenyl-1,3-oxazol-4-yl]methoxy}benzoyloxymino)-4-phenylbutyric acid			Antidiabetic
Taka-Diasfas		9001-19-8		
talampanel	7H-1,3-Dioxolo[4,5-h][2,3]benzodiazepine, 7-acetyl-5-(4-aminophenyl)-8,9-dihydro-8-methyl-, (8R)- [CAS]	161832-65-1	US 5639751	Antiepileptic
Talampanel		161832-65-1		
Talampicillin		47747-56-8		
talaporfin sodium	N-[(2S,3S)-18-Carboxy-2-(2-carboxyethyl)-13-ethyl-2,3-dihydro-3,7,12,17-tetramethyl-8-vinyl porphyrin-20-yl]acetyl-L-aspartic acid	220201-34-3		Radio/chemosensitizer
Talastine		16188-61-7		
Talbutal		115-44-6		
Talinol I		57460-41-0		
talipexole	4H-Thiazolo[4,5-d]azepin-2-amine, 5,6,7,8-tetrahydro-6-(2-propenyl)- [CAS]	101626-70-4 36085-73-1	DE 3503963	Antiparkinsonian

TABLE 6

Example of indication
Impotence
Infection, malaria
Cancer, general
Insomnia
Eczema, atopic
Diabetes, general
Epilepsy, general
Cancer, lung, general
Schizophrenia

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Talipexel	4-Quinolincarboxamide, 3-hydroxy-2-phenyl-N-[(1S)-1-phenylpropyl]- [CAS]	101626-70-4		
Talnetant		174636-32-9	WO 9532948	GI inflammatory/bowel disorders
Talinflumate	3-Pyridinecarboxylic acid, 2-[[3-(trifluoromethyl)phenylamino]-, 1,3-dihydro-3-oxo-1-isobenzotriazinyl ester [CAS]	66898-62-2	BE 858864	Anti-inflammatory
Talinflumate		66898-62-2		
Talitrelin	L-Prolinamide, N-[(hexahydro-1-methyl-2,6-dioxo-4-pyrimidinyl)carbonyl]-L-histidyl-, (S)- [CAS]	103300-74-9	JP 61033197	Neurological
Taltirellin		103300-74-9		
Tamoxifen	Ethanamine, 2-[4-(1,2-diphenyl-1-butenyl)phenoxy]-N,N-dimethyl-, (Z)- [CAS]	10540-29-1	US 4536516	Anticancer, hormonal
Tamoxifen		10540-29-1		
Tamoxifen, Douglas	Ethanamine, 2-[4-(1,2-diphenyl-1-butenyl)phenoxy]-N,N-dimethyl-, (Z)- [CAS]	10540-29-1		Formulation, other
Tamoxifen, liposomal, BTG	Ethanamine, 2-[4-(1,2-diphenyl-1-butenyl)phenoxy]-N,N-dimethyl-, (Z)- [CAS]	10540-29-1		Formulation, optimized, liposomes
Tamsulosin	Benzenesulfonamide, 5-[2-[(2-ethoxyphenoxy)ethyl]amino]propyl]-2-methoxy-, (R)- [CAS]	106133-20-4 80223-99-0	EP 34432	Prostate disorders
Tamsulosin		106133-20-4		
Tamsulosin, OCAS	Benzenesulfonamide, 5-[2-[(2-ethoxyphenoxy)ethyl]amino]propyl]-2-methoxy-, (R)- [CAS]	106133-20-4 80223-99-0		Formulation, modified-release, other
Tamsulosin, immediate-release	Benzenesulfonamide, 5-[2-[(2-ethoxyphenoxy)ethyl]amino]propyl]-2-methoxy-, (R)- [CAS]	106133-20-4		Formulation, oral, orally-disintegrating
Tandospirone	4,7-Methano-1H-isindole-1,3(2H)-dione, hexahydro-2-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]- (3aAlpha,4b,7b,7aAlpha)-, 2-hydroxy-1,2,3- [CAS]	112457-95-1 87760-53-0	EP 82402	Anxiolytic
Tandospirone	propanetricarboxylate (1:1) [CAS]	87760-53-0		

TABLE 6

Exempl of Indication
Irritable bowel syndrome
Inflammation, ocular
Dyskinesia, general
Cancer, breast
Cancer, breast
Benign prostatic hyperplasia
Benign prostatic hyperplasia
Benign prostatic hyperplasia
Anxiety, general

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Tann f rm		9010-29-1		
Tapr st ne		108945-35-3		
tariquidar	3-Quinolincarboxamide, N-[2-[[4-[2-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)ethyl]phenyl]amino]carbonyl]-4,5-dimethoxyphenyl]- [CAS]	208873-63-4	WO 9817648	Radio/chemosensitizer
TAS-103	6-[[2-(Dimethyl-amino)ethyl]amino]-3-hydroxy-7H-indeno[2,1-c]quinolin-7-one dihydrochloride	174634-09-4	WO 9532187	Anticancer, other
Tasosartan		145733-36-4		
Taur ch lic Acid		81-24-3		
Taurolidin		19388-87-5		
tazanolast	Acetic acid, oxo[[3-(1H-tetrazol-5-yl)phenyl]amino]-, butyl ester [CAS]	82989-25-1	US 4778816	Antisthma
Tazanolast		82989-25-1		
tazarotene	3-Pyridinecarboxylic acid, 6-[(3,4-dihydro-4,4-dimethyl-2H-1-benzothiopyran-6-yl)ethynyl]-, ethyl ester [CAS]	118292-40-3	EP 284288	Antipsoriasis
Tazarot ne		118292-40-3		
Taz bactam		89786-04-9		
tazobactam + piperacillin			JP 58225091	Antibiotic, other
TBC-3711		374680-51-0		Cardiovascular
TCH-346	N-Methyl-N-propargyl-10-aminomethyl-dibenzo(b,f)oxepin			Neuroprotective
tebipenem	5-Hexenoic acid, 4-hydroxy-, polymer with 4-ethenyl-1H-imidazole [CAS]	82200-24-6		Beta-lactam antibiotic
tecadenoson	Adenosine, N-[(3R)-tetrahydro-3-furanyl]- [CAS]	204512-90-3	WO 9808855	Antiarrhythmic
tecstemizole	1H-Benzimidazol-2-amine, 1-((4-fluorophenyl)methyl)-N-4-piperidinyl- [CAS]	75970-99-9	US 4219559	Antiallergic, non-asthma
Technetium ^{99m} Tc Biscate		121281-41-2		

TABLE 6

Exempl f Indication
Cancer, lung, non-small cell
Cancer, lung, non-small cell
Psoriasis
Infection, general
Heart failure
Amyotrophic lateral sclerosis
Infection, streptococcal
Tachycardia, supraventricular
Rhinitis, allergic, seasonal

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
T chnetium ^{99m} Tc Mertiatid		125224-05-7; 104348-91-6		
T chn tium ^{99m} Tc Sestamibi		109581-73-9		
Techntium ^{99m} Tc Tebrothiazide		104716-22-5		
Tecizan		5/4/4267		
tedisamil	Spirocyclopentane-1,9'- [3,7]diazabicyclo[3.3.1]nonane], 3',7'- bis(cyclopropylmethyl)- [CAS]	5560-78-1		
T disamil		90961-53-8	EP 102833	Antiarrhythmic
T flurane		124-72-1		
tegafur	2,4-(1H,3H)-Pyrimidinedione, 5-fluoro-1- (tetrahydro-2-furanyl)- [CAS]	17902-23-7	GB 1188391	Anticancer, antimetabolite
T gafur		17902-23-7		
tegafur + uracil, Taiho	2,4-(1H,3H)-Pyrimidinedione, 5-fluoro-1- (tetrahydro-2-furanyl)-, mixt. with 2,4-(1H,3H)-pyrimidinedione- [CAS]	74578-38-4	EP 224885	Anticancer, antimetabolite
T gas rod		145158-71-0		
tegaserod maleate	Hydrazinecarboximidamide, 2-[(5-methoxy- 1H-indol-3-yl)methylene]-N-pentyl-, (Z)-2- butenedioate (1:1) [CAS]	189188-57-6		GI inflammatory/bowel disorders
T icoplanin		61036-64-4		
telbivudine	β-L-2'-deoxythymidine	3424-98-4		Antiviral, other
T lenzepine		80880-90-6		
telithromycin	3-De[(2,6-dideoxy-3-C-methyl-3-O-methyl- Alpha-L-ribo-hexopyranosyl)oxy]-11,12- dideoxy-8-O-methyl-3-oxo-12,11- (oxycarbonyl[(4-(4-(3-pyridinyl)-1H- imidazol-1-yl)butyl)imino])- [CAS]	191114-48-4	EP 680967	Macrolide antibiotic
T lithr mycin		191114-48-4		
telmestane	3,4-Thiazolidinedicarboxylic acid, 3-ethyl ester, (R)- [CAS]	122946-43-4		COPD treatment

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
telmisartan	(1,1'-Biphenyl)-2-carboxylic acid, 4'-((1,4-dimethyl-2-propyl(2,6'-bi-1H-benzimidazol)-1'-yl)methyl)- [CAS]	144701-48-4	EP 502314	Antihypertensive, renin system
Telmisartan		144701-48-4		
telomerase inhibitors, Chugai			WO 9941261	Anticancer, other
temazepam	7-chloro-1,3-dihydro-3-hydroxy-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one	846-50-4	US 3197467	Hypnotic/Sedative
Temazepam		846-50-4		
temiverine hydrochloride hydra	Benzeneacetic acid, Alpha-cyclohexyl-Alpha-hydroxy-, 4-(diethylamino)-1,1-dimethyl-2-butanyl ester, hydrochloride [CAS]	129927-33-9	GB 2222828	Urological
temocapril	1,4-Thiazepine-4(5H)-acetic acid, 6-[[1-(ethoxycarbonyl)-3-phenylpropylamino]tetrahydro-5-oxo-2-(2-thienyl)-, [2S-(2Alpha,6B(R*))]] [CAS]	102090-90-4 110221-44-8 111902-57-9	US 4495188	Antihypertensive, renin system
Tem capril		111902-57-9		
Temocillin		66148-78-5		
temoporfin	Phenol, 3,3',3''-(2,3-dihydro-21H,23H-porphine-5,10,15,20-tetrayl)tetrakis- [CAS]	122341-38-2	EP 337601	Radio/chemosensitizer
Temoporfin		122341-38-2		
temozolomide	Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3,4-dihydro-3-methyl-4-oxo- [CAS]	85622-93-1	DE 3231255	Anticancer, alkylating
Tem z l mid		85622-93-1		
temozolomide, StrykePharma	Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3,4-dihydro-3-methyl-4-oxo- [CAS]			Formulation, parenteral, other
tenaloprazole	1H-Imidazo(4,5-b)pyridine, 5-methoxy-2-(((4-methoxy-3,5-dimethyl-2-pyridinyl)methyl)sulfinyl)- [CAS]	113712-98-4	US 4808596	Antilucer
Tenect phase		191588-94-0		
Tenidap		120210-48-2		

TABLE 6

Example of Indication
Hypertension, general
Cancer, general
Insomnia
Pollakiuria
Hypertension, general
Cancer, head and neck
Cancer, brain
Cancer, general
Ulcer, gastric

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
teniposide	Furo[3,4':6,7]naphtho[2,3-d]-1,3-dioxol-6(5aH)-one, 5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)-9-[[4,6-O-(2-thienylmethylene)-8-D-glucopyranosyl]oxy]-, [5R-[5Alpha,5aB,8aAlpha,9b(R')]]- [CAS]	29767-20-2	US 3524844	Anticancer, other
T n ip sid		29767-20-2		
tenofovir	Phosphonic acid, (((1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy)methyl)- [CAS]	147127-20-6		Antiviral, anti-HIV
T nofovir		147127-20-6		
tenofovir disoproxil fumarate	2,4,6,8-tetraoxa-5-phosphanonanedioic acid, 5-(2-(6-amino-9H-purin-9-yl)-1-methylethoxymethyl) bis(1-methylethylester, 5-oxide (R)-, (E)-2-butenedioate (1:1)	202138-50-9		Antiviral, anti-HIV
Tenofovir Disoproxil Fumarate				
T nonitroz		3810-35-3		
tenoxicam	2H-Thieno[2,3-e]-1,2-thiazine-3-carboxamide, 4-hydroxy-2-methyl-N-2-pyridinyl-, 1,1-dioxide [CAS]	59804-37-4	GB 1519811	Antiarthritic, other
T n xicam		59804-37-4		
T nuaz nic Acid		610-88-8		
teprenone	5,9,13,17-Nonadecatetraen-2-one, 6,10,14,18-tetramethyl- [CAS]	3796-83-2		Antitumor
T pr n n		6809-52-5		
terazosin	Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-[(tetrahydro-2-furanyl)carbonyl]- [CAS]	63074-08-8 63590-64-7 70024-40-7	US 4112097	Antihypertensive, adrenergic
Teraz sin		63590-64-7		
terbinafine	1-Naphthalenemethanamine, N-(6,6-dimethyl-2-hepten-4-ynyl)-N-methyl-, (E)- [CAS]	78628-80-5 91161-71-6	EP 24587	Antifungal
T rbinafin		91161-71-6		

TABLE 6

Exempl of Indication
Cancer, lymphoma, non-Hodgkin's
Infection, HIV/AIDS
Infection, HIV/AIDS
Hypertension, general
Infection, dermatological

TABLE 6

API Gen ric Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Terbutaline	1,3-Benzenediol, 5-[2-[(1,1-dimethylethyl)amino]-1-hydroxyethyl]- [CAS]	23031-25-6		
terbutaline gel, Columbia		23031-25-6		Formulation, mucosal, topical
terconazole	Piperazine, 1-[4-[[2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-4-(1-methylethyl)-, cis- [CAS]	67915-31-5	US 4358449	Antifungal
T rc naz le		67915-31-5		
terfenadine	1-Piperidinebutanol, Alpha-[4-(1,1-dimethylethyl)phenyl]-4-(hydroxydiphenylmethyl)- [CAS]	50679-08-8	US 3878217	Antiallergic, non-asthma
Terf nadin		50679-08-8		
terguride	Urea, N,N-diethyl-N'-(8Alpha)-6-methylergolin-8-yl)- [CAS]	37686-84-3	EP 159522	Antiprolactin
Terguride		37686-84-3		
T rlipr ssin		14636-12-5		
Terodiline		15793-40-5		
Terofenamat		29098-15-5		
Terpin		80-53-5		
tertatolol	2-Propanol, 1-[(3,4-dihydro-2H-1-benzothiopyran-8-yl)oxy]-3-[(1,1-dimethylethyl)amino]-, hydrochloride, (+)- [CAS]	33580-30-2 83688-84-0	GB 1308191	Antihypertensive, adrenergic
Tertat l l		34784-64-0		
tert-Pentyl Alcohol		75-85-4		
tesagitazar	(2S)-2-ethoxy-3-[4-[2-[4-[(methylsulfonyl)oxy]phenyl]ethoxy]phenyl]propanoic acid			Antidiabetic
tesmilifene hydrochloride	Ethanamine, N,N-Diethyl-2-(4-(phenylmethyl)phenoxy)- hydrochloride [CAS]	92981-78-7		Radio/chemosensitizer
T st lact ne		968-93-4		
Testosteron		58-22-0		
Testosterone				

TABLE 6

Example of Indication
Dysmenorrhoea
Vaginitis
Hyperprolactinaemia
Hypertension, general
Diabetes, Type II
Cancer, breast

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
testosterone undecanoate, Schering		5949-44-0		Formulation, other
testosterone, TDS	androst-4-en-3-one, 17-hydroxy-, (17 β)-[CAS]			Formulation, transdermal, systemic
tetabamate		60763-47-5	DE 2748794	Anxiolytic
T trabarbitol		76-23-3		
T trab nazin		58-46-8		
T tracain		136-47-0		
Hydrochlorid				
Tetrachloroethylene		127-18-4		
tetracine, percutaneous	Benzoic acid, 4-(butylamino)-, 2-(dimethylamino)ethyl ester [CAS]	94-24-6		Formulation, transdermal, systemic
T tracyclin		60-54-8		
tetracycline, Actisite	2-Naphthacene-carboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, [4S-(4 α), 4a α], 5a α , 6 β , 12a α]-[CAS]	60-54-8		Formulation, oral, other.
tetracycline, Procter & Gamble	2-Naphthacene-carboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, [4S-(4 α), 4a α], 5a α , 6 β , 12a α]-[CAS]	60-54-8		Formulation, other
Tetrahydroz line		84-22-0		
Tetrandrine		518-34-3		
T trant in		52094-70-9		
T trazepam		10379-14-3		
Tetrofosmin		127502-06-1		
tetoxoprim	2,4-Pyrimidinediamine, 5-[[3,5-dimethoxy-4-(2-methoxyethoxy)phenyl]methyl]-[CAS]	53808-87-0 74515-38-1	US 3992379	Trimethoprim and analogues
T tr xoprim		53808-87-0		
T venel®		4302-95-8		
tezacitabine	Cytidine, 2'-deoxy-2'-(fluoromethylene)-, (2E)- [CAS]	130306-02-4	US 5616702	Anticancer, antimetabolite

TABLE 6

Example of Indication
Hormone replacement therapy
Hormone replacement therapy
Addiction, alcohol
Pain, general
Infection, oral
Acne
Infection, general
Cancer, colorectal

TABLE 6

API Gen. rlc Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
tezosentan	2-Pyridinesulfonamide, N-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-(2-(1H-tetrazol-5-yl)-4-pyridinyl)-4-pyrimidinyl)-5-(1-methylethyl)- [CAS]	180384-57-0		Cardio stimulant
Thalidomide		50-35-1		
thalidomide, Celgene	1H-Isindole-1,3(2H)-dione, 2-(2,6-dioxo-3-piperidinyl)- [CAS]	50-35-1		Dermatological
Thenaldine		86-12-4		
Th nyldiamin		91-79-2		
Theobromin		83-67-0		
Theofibrate		54504-70-0		
Th phylline		58-55-9		
theophylline, 3M	1H-Purine-2,6-dione, 3,7-dihydro-1,3-dimethyl- [CAS]	58-55-9		Formulation, modified-release, other
theophylline, Altana	1H-Purine-2,6-dione, 3,7-dihydro-1,3-dimethyl- [CAS]	58-55-9		Formulation, modified-release, <=24hr
theophylline, Amarin	1H-Purine-2,6-dione, 3,7-dihydro-1,3-dimethyl- [CAS]	5967-84-0		Formulation, modified-release, other
theophylline, bioMérieux-Pier	1H-Purine-2,6-dione, 3,7-dihydro-1,3-dimethyl- [CAS]	58-55-9		Formulation, other
theophylline, Biovail	1H-Purine-2,6-dione, 3,7-dihydro-1,3-dimethyl- [CAS]	58-55-9		Formulation, modified-release, other
theophylline, Diffutab	1H-Purine-2,6-dione, 3,7-dihydro-1,3-dimethyl- [CAS]	58-55-9		Formulation, modified-release, <=24hr
theophylline, Eisal	1H-Purine-2,6-dione, 3,7-dihydro-1,3-dimethyl- [CAS]	58-55-9		Formulation, modified-release, other
theophylline, Elan	1H-Purine-2,6-dione, 3,7-dihydro-1,3-dimethyl- [CAS]	58-55-9		Formulation, modified-release, <=24hr
theophylline, Elan PharmaZome	1H-Purine-2,6-dione, 3,7-dihydro-1,3-dimethyl- [CAS]	58-55-9		Formulation, optimized, microparticles
theophylline, Forest	1H-Purine-2,6-dione, 3,7-dihydro-1,3-dimethyl- [CAS]	58-55-9		Formulation, modified-release, other
theophylline, Gebro	1H-Purine-2,6-dione, 3,7-dihydro-1,3-dimethyl- [CAS]	58-55-9		Formulation, modified-release, other
theophylline, Key	1H-Purine-2,6-dione, 3,7-dihydro-1,3-dimethyl- [CAS]	58-55-9		Formulation, modified-release, other

TABLE 6

Exempl f Indication
Oedema, general
Infection, dermatological
Asthma
Asthma
Asthma
Asthma
Asthma
Asthma
Asthma
Asthma
Asthma
Asthma
Asthma
Bronchitis, chronic
Asthma

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
theophylline, Klinge	1H-Purine-2,6-dione, 3,7-dihydro-1,3-dimethyl- [CAS]	59-55-9		Formulation, other
theophylline, KV	1H-Purine-2,6-dione, 3,7-dihydro-1,3-dimethyl- [CAS]	59-55-9		Formulation, modified-release, other
theophylline, Liquidard	1H-Purine-2,6-dione, 3,7-dihydro-1,3-dimethyl- [CAS]	58-55-9		Formulation, modified-release, <=24hr
theophylline, Mayne	1H-Purine-2,6-dione, 3,7-dihydro-1,3-dimethyl- [CAS]	58-55-9		Formulation, modified-release, <=24hr
theophylline, Mundipharma	1H-Purine-2,6-dione, 3,7-dihydro-1,3-dimethyl- [CAS]	58-55-9		Formulation, modified-release, other
theophylline, Napp	1H-Purine-2,6-dione, 3,7-dihydro-1,3-dimethyl- [CAS]	58-55-9		Formulation, modified-release, other
theophylline, Scherer	1H-Purine-2,6-dione, 3,7-dihydro-1,3-dimethyl- [CAS]	58-55-9		Formulation, modified-release, other
theophylline, Schering-Plough	1H-Purine-2,6-dione, 3,7-dihydro-1,3-dimethyl- [CAS]	58-55-9		Formulation, other
Thiabendazole		148-79-8		
Thiacetazone		104-06-3		
thiacymerine	Carbamic acid, [4-(1-methylethyl)phenyl]-, (3aS,8aS)-3,3a,8,8a-tetrahydro-3a,8-dimethyl-2H-thieno[2,3-b]indol-5-yl ester [CAS]	145209-51-4		Cognition enhancer
Thialbarbital		467-36-7		
Thiamine		59-43-8		
Thiamin Diphosphate		154-87-0		
Thiamin Disulfide		67-16-3		
Thiamiprin		5581-52-2		
Thiamphenic I		15318-45-3		
Thiamylal		77-27-0		
Thiazim		5845-26-1		
Thiazinamium		58-34-4		
Methylsulfat				
Thiazolinobutazone		54749-86-9		
Thiaz isulfone		473-30-3		
Thibenzaz line		6028-35-9		
Thiethylperazine		1420-55-9		

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Thimerf nate Sodium		5964-24-9		
Thimerosal		54-64-8		
Thiobarbital		77-32-7		
Thi butabarbital		2095-57-0		
Thiocarbamazine		91-71-4		
Thi carbars ne		120-02-5		
Thiocolchicin		2730-71-4		
Thiocr s l		26445-03-4		
Thi ctic Acid		62-46-4		
Thioglycerol		96-27-5		
Thi guanine		154-42-7		
Thiomreg	L-Thietyrosinyl-glycyl-glycine			Anticancer, immunological
Thiopental Sodium		71-73-8		
Thiopropazat		84-06-0		
Thiopr perazine		316-81-4		
Thi ridazine		50-52-2		
Thioridazine				
Hydrochloride				
Thiothix ne		5591-45-7		
Thiothixene				
Thiothixene				
Thiothixene				
Thiovir	Thiophosphonoformic acid			Antiviral, anti-HIV
Thiphenamil		82-99-5		
Thiram		137-26-8		
Th nylamin		63-56-9		
Hydr chl rid				
Th zalinon		655-05-0		
Thromboplastin		9035-58-9		
Thurfyl Nicotinate		70-19-9		
thymectacin			US 6245750	Anticancer, other

TABLE 6

API Gen eric Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Thym i		89-83-8		
Thymopentin		69558-55-0		
Thymyl N-Is amylcarbamate		578-20-1		
Thyropropic Acid		51-26-3		
Thyroxin		51-48-9		
Tiadenol		6964-20-1		
tiagabine	3-Piperidinecarboxylic acid, 1-[4,4-bis(3-methyl-2-thienyl)-3-butenyl]-, (R)- [CAS]	115103-54-3	WO 8700171	Antiepileptic
Tiagabine		115103-54-3		
Tiam nidin		31428-61-2		
tianeptine	Haplanolic acid, 7-[(3-chloro-6,11-dihydro-6-methyl(dibenzofc,fl[1,2]thiazepin-11-yl)amino]-, S,S-dioxide [CAS]	72797-41-2	GB 1269551	Antidepressant
Tianeptin		66981-73-5		
tiapride	Benzamide, N-[2-(diethylamino)ethyl]-2-methoxy-5-(methylsulfonyl)- [CAS]	51012-32-9	GB 1394563	Neuroleptic
Tiapride		51012-32-9		
tiaprofenic acid	2-Thiopheneacetic acid, 5-benzoyl-Alpha-methyl- [CAS]	33005-95-7	GB 1331505	Antiarthritic, other
Tiaprofenic Acid		33005-95-7		
Tiaramid		32527-55-2		
tiazofurin	4-Thiazolecarboxamide, 2-B-D-ribofuranosyl- [CAS]	60084-10-8	EP 54432	Anticancer, antimetabolite
Tiazofurin		60084-10-8		
Tib z nium l dide		54663-47-7		
tibolone	19-Norpregn-5(10)-en-20-yn-3-one, 17-hydroxy-7-methyl-, (7Alpha,17Alpha)- [CAS]	5630-53-5	EP 389035	Menopausal disorders
Tib l n		5630-53-5		
Ticarcillin		34787-01-4		
ticlopidine	Thieno[3,2-c]pyridine, 5-[(2-chlorophenyl)methyl]-4,5,6,7-tetrahydro- [CAS]	53885-35-1 55142-85-3	GB 1554424	Antithrombotic

TABLE 6

Example of Indication
Epilepsy, general
Depression, general
Cancer, leukaemia, chronic myelogenous
Hormone replacement therapy

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Ticlopidin		55142-85-3		
Ticrynafen		40180-04-9		
Tiemonium iodide		144-12-7		
Tiemonium metilsulfate	4-(3-hydroxy-3-phenyl-3-thien-2-yl-propyl)-4-methylmorpholinium methylsulfate	6252-82-2		Antispasmodic
Tigecycline	2-Naphthacene-carboxamide, 4,7-bis(dimethylamino)-9-[[[1,1'-dimethylethyl]amino]acetyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S,4aS,5aR,12aS)- [CAS]	220620-09-7	EP 582829	Tetracycline
Tigemnam		102507-71-1		
Tiglidin		495-83-0		
Tilidine		20380-58-9		
Tilisolol		85136-71-6		
Tilmaoxib	Benzenesulfonamide, 4-(4-cyclohexyl-2-methyl-5-oxazolyl)-2-fluoro- [CAS]	180200-68-4	WO 9619463	Alimentary/Metabolic, other
Tiludronic acid	Phosphonic acid, [[4-chlorophenyl]thio]methylene]bis- [CAS]	89987-06-4	EP 100718	Osteoporosis treatment
Tiludronic Acid		89987-06-4		
Timentin		86482-18-0		Antibiotic, other
Timepidium bromide	Piperidinium, 3-(di-2-thienylmethylene)-5-methoxy-1,1-dimethyl-, bromide- [CAS]	35035-05-3	GB 1358446	Antispasmodic
Timepidium Bromide		35035-05-3		
Timipron		57648-21-2		
Timolol		26839-75-8		
timolol maleate	(-)-1-(1-butylamino)-3-[(4-morpholino-1,2,5-thiadiazol-3-yl)oxy]-2-propanolmaleate (1:1) salt	26839-75-8 26921-17-5	GB 1253709	Antihypertensive, adrenergic
timolol maleate, Wakamoto	2-Propanol, 1-(tert-butylamino)-3-[(4-morpholino-1,2,5-thiazol-3-yl)oxy, (-)-maleate (1:1) (salt) [CAS]	26921-17-5		Formulation, mucosal, topical

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
timolol, antiglaucoma	2-Propanol, 1-[(1,1-dimethylethyl)amino]-3-[[4-(4-morpholinyl)-1,2,5-thiadiazol-3-yl]oxy]-, (S)-, (Z)-2-butenedioate (1:1) (salt) [CAS]	26839-75-8 26921-17-5		Antiglaucoma
timolol, ophthalmic	2-Propanol, 1-[(1,1-dimethylethyl)amino]-3-[[4-(4-morpholinyl)-1,2,5-thiadiazol-3-yl]oxy]-, (S)- [CAS]	26839-75-8		Antiglaucoma
timolol, topical, Senju	2-Propanol, 1-[(1,1-dimethylethyl)amino]-3-[[4-(4-morpholinyl)-1,2,5-thiadiazol-3-yl]oxy]-, (S)-, (Z)-2-butenedioate (1:1) (salt) [CAS]			Formulation, mucosal, topical
Tim nalc		444-27-9		
Tin Ethyl Eti purpurin		113471-15-1		
tinazoline	1H-Indole, 3-[(4,5-dihydro-1H-imidazol-2-yl)thio]- [CAS]	62882-99-9	US 3376311	Vasodilator, peripheral
Tindazole		19387-91-8		
Tin ridin		24237-54-5		
Ti caride		910-86-1		
Tioclomarol		22619-35-8		
tiocanazole	1H-Imidazole, 1-[2-(2-chloro-3-thienyl)methoxy]-2-(2,4-dichlorophenyl)ethyl]- [CAS]	61875-64-7 65899-73-2	US 4062966	Antifungal
Tioc nazole		65899-73-2		
tiopronin	Glycine, N-(2-mercapto-1-oxopropyl)- [CAS]	1953-02-2	US 3246025	Urological
Tiopronin		2/2/1953		
tiotropium bromide	3-Oxa-9-azoniatricyclo(3.3.1.0 ^{2,4})nonane, 7-((hydroxydi-2-thienylacetyl)oxy)-9,9-dimethyl-, bromide (1Alpha,2B,4B,5Alpha,7B) [CAS]	136310-93-5	EP 418716	COPD treatment
Ti tr plum Bromide		136310-93-5		
Tioxolone		4991-65-5		
Tipepidine		5169-78-8		

TABLE 6

Example of Indication
Glaucoma
Infection, fungal, general
Homocystinuria
Chronic obstructive pulmonary disease

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
tipranavir	2-(1H)-Quinolone, 6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl [CAS]	192185-68-5 192185-72-1	WO 9716443	Anticancer, other
tipranavir	N-[3-(1(R)-[4-Hydroxy-2-oxo-6(R)-(2-phenylethyl)-6-propyl-5,6-dihydro-2H-pyran-3-yl]propylphenyl]-5-(trifluoromethyl)pyridine-2-sulfonamide	174484-41-4		Antiviral, anti-HIV
tiqizium bromide	2H-Quinolizinium, 3-(di-2-thienylmethylene)octahydro-5-methyl-, bromide, trans- [CAS]	71731-58-3	US 4205074	Antispasmodic
Tiquizium Bromide		71731-58-3		
tiropazamine	1,2,4-Benzotriazin-3-amine, 1,4-dioxide- [CAS]	20028-80-2 27314-97-2 5424-06-6	DE 2204574	Radio/chemosensitizer
Tirapazamin		27314-97-2		
Tiratricol		51-24-1		
Tirilazad		110101-66-1		
tiirilazad mesylate	Pregna-1,4,9(11)-triene-3,20-dione, 21-[4-(2,6-di-1-pyrrolidinyl-4-pyrimidinyl)-1-piperazinyl]-16-methyl-, (16Alpha)-, monomethanesulfonate- [CAS]	110101-65-0 110101-67-2	WO 8701706	Neuroprotective
Tirolifiban		144494-65-5		
tirolifiban hydrochloride	L-Tyrosine, N-(butylsulfonyl)-O-[4-(4-piperidinyl)butyl]-, monohydrochloride- [CAS]	142373-60-2	EP 478363	Antithrombotic
Tirolifiban Hydrochloride				
tiropamide	Benzenepropanamide, Alpha-(benzoylamino)-4-[2-(diethylamino)ethoxy]-N,N-dipropyl-, (+)- [CAS]	55837-29-1	DE 2503992	Antispasmodic
Tiropamid		55837-29-1		
Titanium Sulfate		13825-74-6		
Tixacortol		61951-99-3		

TABLE 6

Example of Indication
Cancer, breast
Infection, HIV/AIDS
Cancer, lung, non-small cell
Haemorrhage, subarachnoid
Infarction, myocardial
Muscle spasm, general

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
flucocortol pivalate	Pregn-4-ene-3,20-dione, 21-[(2,2-dimethyl-1-oxopropyl)thio]-11,17-dihydroxy-, (11R)-[CAS]	55560-96-8 61951-99-3	GB 1475795	Antiallergic, non-asthma
flucocortol pivalate enema	Pregn-4-ene-3,20-dione, 21-[(2,2-dimethyl-1-oxopropyl)thio]-11,17-dihydroxy-, (11R)-[CAS]	55560-96-8	US 4014909	Formulation, mucosal, topical
flizanidine	2,1,3-Benzothiadiazol-4-amine, 5-chloro-N-(4,5-dihydro-1H-imidazol-2-yl)[CAS]	51322-75-9	GB 1429926	Muscle relaxant
Tizanidin		51322-75-9		
TLK-199	Glycine, L-Gamma-glutamyl-S-(phenylmethyl)-L-cysteinyl-2-phenyl-, diethyl ester, (2R)- [CAS]	168682-53-9	US 5679643	Immunostimulant, other
TLK-286	Glycine, L-Gamma-glutamyl-3-[[2-[[bis(2-chloroethyl)amino]phosphinyloxy]ethyl]sulfonyl]-L-alanyl-2-phenyl-, (2R)- [CAS]	158382-37-7	US 5545621	Anticancer, other
TNF- β analogue, SRC VB			RU 2035185	Anticancer, immunological
TNP-470		129298-91-5		
TO-186	Pregna-1,4-diene-3,20-dione, 9-fluoro-11 β ,17,21-trihydroxy-16 β .beta.-methyl-, 17-butyrate 21-propionate [CAS]	5534-02-1		Antipruritic/inflamm, allergic
Tobramycin		32986-56-4		
tobramycin, Nektar	O-3-amino-3-deoxy-Alpha-D-glucopyranosyl-(1-6)-O-(2,6-diamino-2,3,6-trideoxy-Alpha-D-ribo-hexopyranosyl-(1-4))-2-deoxy- [CAS]	32986-56-4		Formulation, inhalable, topical
tobramycin, Pathogenesis	O-3-amino-3-deoxy-Alpha-D-glucopyranosyl-(1-6)-O-(2,6-diamino-2,3,6-trideoxy-Alpha-D-ribo-hexopyranosyl-(1-4))-2-deoxy- [CAS]	32986-56-4		Formulation, inhalable, solution
tocainide	Propanamide, 2-amino-N-(2,6-dimethylphenyl)- [CAS]	41708-72-9	US 4218477	Antiarrhythmic
T cainid		41708-72-9		
T camphyl		5634-42-4		

TABLE 6

Example of Indication
Rhinitis, allergic, general
Colitis, ulcerative
Spastic paralysis
Myelodysplastic syndrome
Cancer, ovarian
Cancer, general
Infection, respiratory tract, general
Infection, respiratory tract, lower
Fibrillation, ventricular

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
tolcladesine	8-Chloroadenosine 3'5'-cyclic phosphate	41941-56-4		Anticancer, other
T c r tinate		40516-48-1		
Todralazine		14679-73-3		
T fenacin		15301-93-6		
	5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-e]pyridine, 9-cyclopentyl-7-ethyl-6,9-dihydro-3-(2-thienyl)-			
tofilmist		185954-27-2		Antiasthma
	5H-2,3-Benzodiazepine, 1-(3,4-dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-4-methyl-[CAS]	22345-47-7	GB 1334271	Anxiolytic
tofisopam		22345-47-7		
T fisopam		1156-19-0		
Tolazamide		59-98-3		
Tolazoline		64-77-7		
T lbutamid				
tolcapone	Methanone, (3,4-dihydroxy-5-nitrophenyl)(4-methylphenyl)- [CAS]	134308-13-7	EP 237829	Antiparkinsonian
Tolcapone		134308-13-7		
tolciclate	Carbamothioic acid, methyl(3-methylphenyl)-, O-(1,2,3,4-tetrahydro-1,4-methanonaphthalen-6-yl) ester [CAS]	50838-36-3	GB 1364407	Antifungal
Tolciclate		50838-36-3		
T lyclamide		664-95-9		
tolvamer sodium	Benzenesulfonic acid, 4-ethenyl-, homopolymer, sodium salt	28038-50-8		Antibacterial, other
tolfenamic acid	Benzoic acid, 2-[(3-chloro-2-methylphenyl)amino]- [CAS]	13710-19-5	DE 1543295	Anti-inflammatory
T lfenamic Acid		13710-19-5		
Tolindat		27877-51-6		
T liprolol		2933-94-0		
Tolmetin		26171-23-3		

TABLE 6

Example of Indication
Cancer, colorectal
Asthma
Anxiety, general
Parkinson's disease
Infection, dermatological
Infection, Clostridium, general
Inflammation, general

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Tolnaftat		2398-96-1		
T Ionidine		4201-22-3		
Tolonium Chloride		92-31-9		
toloxatone	2-Oxazolidinone, 5-(hydroxymethyl)-3-(3-methylphenyl)- [CAS]	29218-27-7	GB 1250538	Antidepressant
T I xaton		29218-27-7		
Tolperison		728-88-1		
T Ipropamine		5632-44-0		
T Ir stat		82964-04-3		
tolserine	Carbamic acid, (2-methylphenyl)-, (3aS,8aR)-1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethylpyrrolo[2,3-b]indol-5-yl ester [CAS]	145209-30-9		Cognition enhancer
tolterodine	Phenol, 2-(3-(bis(1-methylethylamino)-1-phenylpropyl)-4-methyl-, (R)- [CAS]	124937-51-5	EP 325571	Urological
Tolt rodin	Phenol, 2-(3-(bis(1-methylethylamino)-1-phenylpropyl)-4-methyl-, (R)- [CAS]	124937-51-5		
tolterodine, extended-release				Formulation, modified-release, <=24hr
tolvaptan	Benzamide, N-[4-[(7-chloro-2,3,4,5-tetrahydro-5-hydroxy-1H-1-benzazepin-1-yl)carbonyl]-3-methylphenyl]-2-methyl- [CAS]	150683-30-0	EP 450097	Cardiovascular
T lycain		3686-58-6		
topiramate	β-D-Fructopyranose, 2,3,4,5-bis-O-(1-methylethylidene)-, sulfamate [CAS]	97240-79-4	EP 533483	Antiepileptic
T plamat		97240-79-4		
topoisomerase inhibitors, BTG			US 5733880	Anticancer, other
topotecan	1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione, 9-[(dimethylamino)methyl]-4-ethyl-4,10-dihydroxy-, (S)- [CAS]	123948-87-8	EP 321122	Anticancer, other
T p t can		123948-87-8		
topotecan TCS, Inex	1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione, 9-[(dimethylamino)methyl]-4-ethyl-4,10-dihydroxy-, (S)- [CAS]	123948-87-8		Formulation, optimized, liposomes

TABLE 6

Example of Indication
Alzheimer's disease
Incontinence
Incontinence
Heart failure
Epilepsy, generalized, tonic-clonic
Cancer, general
Cancer, ovarian
Cancer, general

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
torasemide	3-Pyridinesulfonamide, N-[(1-methylethyl)amino]carbonyl-4-[(3-methoxyphenyl)amino]- [CAS]	56211-40-6	US 4018929	Antihypertensive, diuretic
torcetrapib	ethyl (2R,4S)-4-[(3,5-bis(trifluoromethyl)benzyl(methoxycarbonyl)amino)-2-ethyl-6-(trifluoromethyl)-3,4-dihydroquinoline-1(2H)-carboxylate	262352-17-0		Hypolipemic/Antiatherosclerosis
torcitabine	8-L-2'Deoxyglycidine			Antiviral, other
torsemide	Ethanamine, 2-[4-(4-chloro-1,2-diphenyl-1-butenyl)phenoxy]-N,N-dimethyl-, (Z)-[CAS]	89778-26-7 56211-40-6 208921-02-2 100490-36-6	EP 95875	Anticancer, hormonal
T remif n				
Torsemid				
Tositumomab				
Tosufi xacin				
tosufloxacin tosilate	1,8-Naphthyridine-3-carboxylic acid, 7-(3-amino-1-pyrrolidinyl)-1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-4-oxo-, mono(4-methylbenzenesulfonate)- [CAS]	100490-36-6 115964-29-9	US 4704459	Quinolone antibacterial
tramadol	Cyclohexanol, 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)-, cis-(+)-[CAS]	27203-92-5 36282-47-0		Analgesic, other
Tramadol		27203-92-5		
tramadol + acetaminophen, Ortho	Cyclohexanol, 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)-, cis-(+)- + Acetamide, N-(4-hydroxyphenyl)-			Formulation, fixed-dose combinations
tramadol SR, Ethypharm	Cyclohexanol, 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)-, cis-(+)-[CAS]	27203-92-5 36282-47-0		Formulation, modified-release, other
tramadol, Biocell	Cyclohexanol, 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)-, cis-(+)- [CAS]	27203-92-5 36282-47-0		Formulation, modified-release, <=24hr

TABLE 6

Example of indication
Hypertension, general
Atherosclerosis
Infection, hepatitis-B virus
Cancer, breast
Infection, urinary tract
Pain, general
Pain, general
Pain, general
Pain, general

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
tramadol, Flashtab	Cyclohexanol, 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)-, cis-(+)- [CAS]	27203-92-5 36282-47-0		Formulation, oral, orally-disintegrating
tramadol, Labopharm	Cyclohexanol, 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)-, cis-(±) [CAS]	27203-92-5 36282-47-0		Formulation, modified-release, <=24hr
tramadol, Purdue	Cyclohexanol, 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)-, cis-(±) [CAS]	27203-92-5 36282-47-0		Formulation, modified-release, other
Tramazoline		1082-57-1		
trandolapril	1H-Indole-2-carboxylic acid, 1-[2-[(1-carboxy-3-phenylpropyl)amino]-1-oxopropyl]octahydro-, [2S-[1(R*(R*))], 2Alpha, 3aAlpha, 7aB]]- [CAS]	87679-71-8	DE 3151690	Antihypertensive, renin system
Trandolapril		87679-37-6 82-53-9 87679-71-8		
trandolapril + verapamil, Aven				Formulation, fixed-dose combinations
tranexamic acid	Cyclohexanecarboxylic acid, 4-(aminomethyl)-, trans- [CAS]	1197-18-8	US 3950405	Antifibrinolytic
Tranexamic Acid		1197-18-8		
tranilast	Benzoic acid, 2-[(3-(3,4-dimethoxyphenyl)-1-oxo-2-propenyl)amino]- [CAS]	53902-12-8	US 3940422	Vulnery
Tranilast		53902-12-8		
trans-retinoic acid, NIH	Retinoic acid [CAS]	302-79-4		Anticancer, other
Tranlycypyr mine		155-09-9		
trapidil	[1,2,4]Triazole[1,5-a]pyrimidin-7-amine, N,N-diethyl-5-methyl- [CAS]	15421-84-8	DD 55956	Vasodilator, coronary
Trapidil		15421-84-8		
Trastuzumab		180288-69-1		
Trastuzumab				

TABLE 6

Example f Indication
Pain, general
Pain, general
Pain, general
Hypertension, general
Hypertension, general
Menstrual disorder, general
Wound healing
Cancer, general

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
travoprost, Alcon	5-Heptenoic acid, 7-(3,5-dihydroxy-2-(3-hydroxy-4-(3-(trifluoromethyl)phenoxy)-1-butenyl)cyclopentyl)-, 1-methylethylester (1R(1Alpha(Z),2R(1E,3R*),3Alpha,5Alpha) [CAS]	157283-68-6		Formulation, mucosal, topical
Traxanox	1-Piperidineethanol, 4-hydroxy-Alpha-(4-hydroxyphenyl)-8-methyl-4-phenyl-, (AlphaS,8S)-methanesulfonate [CAS]	58712-69-9		
traxoprodil mesylate	1,2,4-Triazolo[4,3-a]pyridin-3(2H)-one, 2-[4-(3-chlorophenyl)-1-piperazinyl]propyl-, [CAS]	134234-12-1 188591-67-5		Analgescic, other
trazodone		19794-93-5 25332-39-2	US 4215104	Antidepressant
Trazodone		19794-93-5		
Tramazepam		155576-45-7		
Tramazepam		10161-33-8		
Tramazepam		5192-84-7		
treosulfan	1,2,3,4-Butanetetrol, 1,4-dimethanesulfonate, [S-(R*,R*)] [CAS]	299-75-2	WO 8401506	Anticancer, alkylating
trebutone	Benzenebutanoic acid, 2,4,5-triethoxy-Gamma-oxo- [CAS]	41826-92-0	GB 1387733	Antispasmodic
Trinitrophenol		41826-92-0		
treprostinol	Prosta-5,13-dien-1-ol-ic acid, 6,9-epoxy-11,15-dihydroxy-, [5Z,9Alpha,11Alpha,13E,15S]- [CAS]	35121-78-9 61849-14-7	US 6054486	Formulation, parenteral, other
Retinoin, Connetics	Retinoic acid [CAS]	302-79-4		Formulation, dermal, topical
Retinoin, Ortho	Retinoic acid [CAS]	302-79-4	US 4247547	Antiacne
Retinoin, Roche	Retinoic acid- [CAS]	302-79-4		Anticancer, other
Retinoin	6,7-Isoquinolinediol, 1,2,3,4-tetrahydro-1-[(3,4,5-trimethoxyphenyl)methyl]-, (S)- [CAS]	18559-59-6 30418-38-3	ZA 6802416	Antialsthma
Retinoin		21650-42-0		
Trinitrophenol		24305-27-9		
TRH		226214-49-9		Antithrombotic
TRI-50b, IV	TRI 50b [CAS]	226214-49-9		Antithrombotic
TRI-50b, oral	TRI 50b [CAS]	226214-49-9		Antithrombotic

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Triacetin		102-76-1		
Triamcinolon		124-94-7		
Triamcinolon		76-25-5		
Acetonide				
	Pregna-1,4-diene-3,20-dione, 8-fluoro-11,21-dihydroxy-16,17-[(1-methylethylidene)bis(oxy)]-, (11B,16Alpha)-[CAS]	76-25-5		Formulation, inhalable, topical
triamcinolone acetonide, Astra				
	Pregna-1,4-diene-3,20-dione, 9-fluoro-11,21-dihydroxy-16,17-[(1-methylethylidene)bis(oxy)]-, (11B,16Alpha)-[CAS]	76-25-5		Formulation, transdermal, enhanced
triamcinolone acetonide, IDEA				
	Pregna-1,4-diene-3,20-dione, 9-fluoro-11,21-dihydroxy-16,17-[(1-methylethylidene)bis(oxy)]-, (11B,16Alpha)-[CAS]	76-25-5		Formulation, other
triamcinolone acetonide, Teij				
Triamcinolone		31002-79-6		
Benetonide		5611-51-8		
Triamcin lone				
H xacet nld		396-01-0		
Triamterene		236392-58-6	US 6458816	Anticancer, antimetabolite
Triapine	Triapine [CAS]	68-76-8		
Triaziqu n				
triazolam	8-chloro-6-(2-chlorophenyl)-1-methyl-4H-[1,2,4]-triazolo[4,3-a][1,4]benzodiazepine	28911-01-5	US 3980780	Hypnotic/Sedative
Triaz lam		28911-01-5		
	4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-6-(2-chlorophenyl)-1-methyl- [CAS]	28911-01-5		Formulation, transmucosal, nasal
triazolam intranasal, Questcor				
	4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-6-(2-chlorophenyl)-1-methyl- [CAS]	28911-01-5		Formulation, transmucosal, systemic
triazolam, Dumex-Alpha				
Triben sid		10310-32-4		
Trichl rf n		52-68-6		
Trichlormethiazide		133-67-5		

TABLE 6

Example f Indication
Asthma
Eczema, general
Ulcer, aphthous
Cancer, leukaemia, general
Insomnia
Insomnia
Insomnia

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Trichloromethine		555-77-1		
Trichlorothylene		79-01-6		
Triclobisonium Chloride		79-90-3		
Triclocarban		101-20-2		
Triclofenol Piperazine		5714-82-9		
Triclosan		306-52-5		
Triclosan		3380-34-5		
Triclosan		85-90-5		
Tridihexethyl iodide		125-99-5		
Triclinin		112-24-3		
Triclinin	1,2-Ethanediamine, N,N2-bis(2-aminoethyl)-, dihydrochloride [CAS]	38260-01-4		Metabolic and enzyme disorders
Triethyleneglycol		102-71-6		
Triethyleneglycol		51-18-3		
Triethyleneglycol		545-55-1		
Triethyl phosphoramide		52-24-4		
Triethyl phosphoramide		117-89-5		
Triethyl phosphoramide				
Triethyl phosphoramide		749-13-3		
Triethyl phosphoramide		146-54-3		
Triethyl phosphoramide	Thymidine, Alpha, Alpha, Alpha-trifluoromethyl- [CAS]	70-00-8	US 3201387	Antiviral, other
Triethyl phosphoramide	Benzoic acid, 2-(acetoxy)-4-(trifluoromethyl)- [CAS]	322-79-2	US 4096252	Antithrombotic
Triethyl phosphoramide		322-79-2		
Triethyl phosphoramide		52-49-3		

TABLE 6

API Gen ric Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
trilostane	Androst-2-ene-2-carbonitrile, 4,5-epoxy-3,17-dihydroxy-, (4Alpha,5Alpha,17B)- [CAS]	13647-35-3	US 3296255	Anticancer, hormonal
Trilostane		13647-35-3		
Trimaz sin		35795-16-5		
Trimebutin		39133-31-8		
trimebutine maleate	Benzic acid, 3,4,5-trimethoxy-, 2-(dimethylamino)-2-phenylbutyl ester, (Z)-2-butenedioate (1:1) [CAS]	34140-59-5	DE 2151716	Antispasmodic
Trimecaine		616-68-2		
Trim prazine		84-96-8		
Trimetazidine		5011-34-7		
Trimethadione		127-48-0		
Trimethaphan		68-91-7		
Camsylate				
Trimeth benzamide		138-56-7		
Trimethoprim		738-70-5		
Trimetozin		635-41-6		
Trimetr xat		52128-35-5		
trimetrexate glucuronate	2,4-Quinolinediamine, 5-methyl-6-[[[(3,4,5-trimethoxyphenyl)amino]methyl]- [CAS]	52128-35-5 82952-64-5	US 4391809	Antifungal
Trimipramine		739-71-9		
trimipramine maleate	5H-Dibenz[b,f]azepine-5-propanamine, 10,11-dihydro-N,N,B-trimethyl-, (Z)-2-butenedioate (1:1) [CAS]	521-78-8 739-71-9		Antidepressant
Trimopr stil		69900-72-7		
Trioxsal n		3902-71-4		
tripamide	Benzamide, 3-(aminosulfonyl)-4-chloro-N-(octahydro-4,7-methano-2H-isoindol-2-yl)-, (3aAlpha,4Alpha,7aAlpha)- [CAS]	73803-48-2	JP 7305585	Antihypertensive, diuretic
Tripamide		73803-48-2		
Triparan l		78-41-1		
Tripelennamin		91-81-6		

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Tripr lidin		486-12-4		
triptorelin	Luteinizing hormone-releasing factor (pig), 6-D-tryptophan- [CAS]	124508-66-3 57773-63-4	US 4010125	Releasing hormones
Triptorelin		57773-63-4		
Trithiozin		35619-65-9		
trithiozine	Morpholine, 4-[thioxo(3,4,5-trimethoxyphenyl)methyl]- [CAS]	35619-65-9	US 3862138	Anticancer
Tritoqualine		14504-73-5		
TRK-530	Phosphonic acid, [[(4-(methylthio)phenyl]thio]methylene]bis-, disodium salt [CAS]	151425-92-2	WO 9410181	Antiarthritic, other
TRK-820	2-Propenamide, N-[(5 α ph, 6 β)-17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinan-6-yl]-3-(3-turanyl)-N-methyl-, monohydrochloride, (2E)- [CAS]	152658-17-8	WO 9315081	Antipruritic/inflam, non-allergic
Troclosen Potassium		2244-21-5		
troflosamide	3,2-(chloroethyl)-2-bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorin 2-oxide	22089-22-1	GB 1188159	Anticancer, alkylating
Trof sfamid		22089-22-1		
Tr glitazone		97322-87-7		
Troleand mycin		9/9/2751		
Trolnitrat Ph sphate		588-42-1		
tromantidine	N-(1-adamantyl)-2-(2-dimethylamine ethoxy)acetamide	53783-83-8	DE 1941218	Antiviral, other
Tr mantadin		53783-83-8		
Tr methamine		77-86-1		
Tropacine		6878-98-4		
Tropesin		65189-78-8		
Tr picamide		1508-75-4		
tropine indometacinlate, Spofa	1H-Indole-3-acetic acid, 1-(4-chlorobenzoyl)-5-methoxy-2-methyl-, 2-carboxy-2-phenylethyl ester, (+/-)- [CAS]	65189-78-8		Antiarthritic, other

TABLE 6

Example f Indication
Cancer, prostate
Arthritis, rheumatoid
Pruritus
Infection, herpes simplex virus

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
tropisetron	1H-Indole-3-carboxylic acid, 8-methyl-8-azabicyclo[3.2.1]oct-3-yl ester, endo-[CAS]	89565-68-4	GB 2125398	Antiemetic
Tr pils tr n		89565-68-4		
Tr spect mycin		88669-04-9		
tropium chloride	3Alpha-Hydroxyspiro[1AlphaH,5AlphaH-nortropane-8,1'-pyrrolidinium] chloride benzilate	10405-02-4		Urological
Tropium Chloride		10405-02-4		
	3Alpha-Hydroxyspiro[1AlphaH,5AlphaH-nortropane-8,1'-pyrrolidinium] chloride benzilate			
tropium chloride, extended re		10405-02-4		Formulation, modified-release, other
	3Alpha-Hydroxyspiro[1AlphaH,5AlphaH-nortropane-8,1'-pyrrolidinium] chloride benzilate			
tropium chloride, Pfizer		10405-02-4		Formulation, parenteral, other
Tr vafloxacin		147059-72-1		
	1,8-Naphthyridine-3-carboxylic acid, 7-(8-amino-3-azabicyclo[3.1.0]hex-3-yl)-1-(2,4-difluorophenyl)-8-fluoro-1,4-dihydro-4-oxo-, (1Alpha,5Alpha,6Alpha)-, monomethanesulfonate- [CAS]	147059-72-1 147059-75-4	US 5184402	Quinolone antibacterial
trovafloxacin mesilate				
troxactabine	2(1H)-Pyrimidinone, 4-amino-1-(2-(hydroxymethyl)-1,3-dioxolan-4-yl)-, (2S-cis)-[CAS]	145918-75-8		Anticancer, other
Tr x rutin		7085-55-4		
troxipide	Benzamide, 3,4,5-trimethoxy-N-3-piperidinyl-, (+/-)- [CAS]	30751-05-4	US 3647805	Antitumor
Troxipid		99777-81-8		
Trypan R d		574-64-1		
Tryparsamide		554-72-3		
Trypt phan		73-22-3		
TSH		9002-71-5		

TABLE 6

Example of Indication
Chemotherapy-induced nausea and vomiting
Poliakisuria
Poliakisuria
Poliakisuria
Infection, respiratory tract, general
Cancer, leukaemia, acute myelogenous
Ulcer, gastric

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
TSN-09	6,14-Ethenomorphinan-7-methanol, 17-(cyclopropylmethyl)-Alpha-(1,1-dimethylethyl)-5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy-Alpha-methyl-, [5Alpha,7Alpha,(S)]- [CAS]	52485-79-7		Formulation, transdermal, patch
TU-2100	Nonanedic acid, bis[(2-(ethoxycarbonyl)phenyl] ester		US 6180669	Antiacne
Tuaminoheptane		123-82-0		
Tub rcidin		69-33-0		
Tub curarin Chloride		57-94-3		
tulobuterol	Benzenemethanol, 2-chloro-Alpha-[(1,1-dimethylethyl)amino]methyl-, [CAS]	41570-61-0	DE 2244737	Antiasthma
Tulobuterol		41570-61-0		
TV-3326	N-(Propargyl-(3R)aminoindan-5-yl)-ethyl methyl carbamate			Cognition enhancer
TY-11223	Acetic acid, [2-[2,3,3a,6,7,7a-hexahydro-2-hydroxy-1-(3-hydroxy-4,4-dimethyl-1,6-nonadienyl)-1H-inden-5-yl]ethoxy]-, [1S-[1Alpha(R*),2S,3aAlpha,7aAlpha]]- [CAS]	140694-43-5	US 4837342	Antithrombotic
TY-12533	6,7,8,9-Tetrahydro-2-methyl-5H-cyclohepta[b]pyridine-3-carbonylguanidine maleate			
TYB-3215	D-Glucitol, 1,4:3,6-dianhydro-, dinitrate [CAS]	87-33-2		Formulation, modified-release, other
Tybamat		4268-36-4		
Tyl xapol		25301-02-4		
tyloxapoi, Discovery	4-(1,1,3,3-Tetramethylbutyl)phenol polymer with formaldehyde and oxirane [CAS]	25301-02-4		Formulation, inhalable, topical
Tymaz line		24243-97-8		
Tyramine		51-67-2		

TABLE 6

Example of Indication
Pain, cancer
Acne
Asthma
Alzheimer's disease
Unspecified
Unspecified
Angina, general
Cystic fibrosis

TABLE 6

API Gen ric Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Tyr pan ate Sodium		7246-21-1		
Ubenimex		58970-76-6		
ufenamate	Benzoic acid, 2-[[3-(trifluoromethyl)phenyl]amino]-, butyl ester [CAS]	67330-25-0	BE 861852	Antipruritic/inflamm, non-allergic
Undecylenic Acid		112-38-9		
Un pr st ne		120373-36-6		
UR-8880	4-(4-Chloro-5-(3-fluoro-4-methoxyphenyl)imidazol-1-imidazol-1-yl)benzenesulfonamide- [CAS]			Anti-inflammatory
Uracil Mustard		66-75-1		
Uralyt-U	1,2,3-Propanetricarboxylic acid, 2-hydroxy-, potassium sodium salt (5:6:6), hydrate [CAS]	55049-48-4	US 4400535	Urological
urapidil	2,4-(1H,3H)-Pyrimidinedione, 6-[[3-(4-(2-methoxyphenyl)-1-piperazinyl)propyl]amino]-1,3-dimethyl- [CAS]	34661-75-1	GB 1309324	Antihypertensive, adrenergic
Urapidil		34661-75-1		
Urea, Kabi Pharmacia	Urea [CAS]	57-13-6		Antipsoriasis
urea, Vinas	Urea [CAS]	57-13-6		Antipruritic/inflamm; allergic
Uredepa		302-49-8		
Urethan		51-79-6		
Uridine 5'-Triphosphate		63-39-8		
uridine, Polifarma	Uridine [CAS]	58-96-8	EP 348360	Formulation, other
Urinastatin		80449-31-6		
ursodeoxycholic acid, Axcan	3Alpha,7B-dihydroxy-5B-cholan-24-olc acid [CAS]	128-13-2		Formulation, other
ursodeoxycholic acid, Axcan-2	3Alpha,7B-dihydroxy-5B-cholan-24-olc acid [CAS]	128-13-2		Formulation, other
ursodeoxycholic acid, Mitsub	3Alpha,7B-dihydroxy-5B-cholan-24-olc acid [CAS]	128-13-2		Formulation, oral, other
ursodeoxycholic acid, Novartis	3Alpha,7B-dihydroxy-5B-cholan-24-olc acid [CAS]	128-13-2		Gallstone therapy
Ursodi I		128-13-2		

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
<i>Drasdiol</i>				
Ushercell			US 6063773	Formulation, mucosal, topical
Uzarin		20231-81-6		
valaciclovir	L-Valine, 2-[(2-amino-1,6-dihydro-8-oxo-9H-purin-9-yl)methoxy]ethyl ester [CAS]	124832-26-4	EP 308065	Antiviral, other
Valacycl vir		124832-26-4		
valdecoxib	Benzenesulfonamide, 4-(5-methyl-3-phenyl-4-isoxazolyl)- [CAS]	181695-72-7	US 5859257	Antiarthritic, other
Vald tamide		512-48-1		
Valethamate Bromide		90-22-2		
valganciclovir	L-Valine, 2-[(2-amino-1,6-dihydro-8-oxo-9H-purin-9-yl)methoxy]-3-hydroxypropyl ester [CAS]	175865-59-5 175865-60-8	EP 694547	Antiviral, other
Valganciclovir vir		175865-60-8		
Valnoctamid		4171-13-5		
valmaciclovir stearate	L-Valine (3R)-3-[(2-amino-1,6-dihydro-8-oxo-9H-purin-9-yl)methyl]-4-[(1-oxooctadecyl)oxy]butyl ester [CAS]	195156-77-5		Antiviral, other
valproate semisodium	Pentanoic acid, 2-propyl-, sodium salt (2:1) [CAS]	76584-70-8	US 4988731	Antiepileptic
valproate semisodium, ER	Pentanoic acid, 2-propyl-, sodium salt (2:1) [CAS]	76584-70-8		Formulation, modified-release, <=24hr
valproate sodium, Nikken	Pentanoic acid, 2-propyl-, sodium salt- [CAS]	1069-66-5		Formulation, modified-release, <=24hr
valproate sodium, Sanofi-Synth	Valeric acid, 2-propyl-, sodium salt [CAS]	1069-66-5		Formulation, modified-release, <=24hr
Valproic Acid		99-66-1		
Valpr mid		2430-27-5		
valroacemide	Pentanamide, N-(2-amino-2-oxoethyl)-2-propyl- [CAS]	92262-58-3	US 5585358	Antiepileptic
valrubicin	Pentanoic acid, 2-(1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-((2,3,6-trideoxy-3-(trifluoroacetyl)amino)-Alpha-L-lyxo-hexopyranosyl)oxy)-2-naphthaceny)-2-oxoethyl ester (2S-cis)- [CAS]	56124-62-0	US 4035566	Anticancer, antibiotic
Valrubicin		56124-62-0		

TABLE 6

Example of Indication
Contraceptive, female
Infection, herpes simplex virus
Arthritis, rheumatoid
Infection, cytomegalovirus
Infection, herpes simplex virus
Epilepsy, generalized, tonic-clonic
Migraine
Epilepsy, general
Epilepsy, general
Epilepsy, general
Cancer, bladder

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
valsartan	L-Valine, N-(1-oxopentyl)-N-[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl- [CAS]	137862-53-4	EP 443983	Antihypertensive, renin system
Valsartan		137862-53-4		
Valspodar		121584-18-7		
varidenafil	Piperazine, 1-(3-(1,4-dihydro-5-methyl-(4-oxo-7-propylimidazo(5,1-f)(1,2,4)-triazin-2-yl)-4-ethoxyphenyl)sulfonyl)-4-ethyl- [CAS]	224785-90-4		Male sexual dysfunction
varspladib sodium	Acetic acid, ((3-(aminooxocetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl)oxy)- [CAS]	172732-88-2 172733-42-5	EP 675110	Septic shock treatment
<i>Varicella Virus Vaccine, Live</i>				
vatandipine hydrochloride	3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 2-[4-(4-(diphenylmethyl)-1-piperazinyl)phenyl]ethyl methyl ester, dihydrochloride- [CAS]	116308-55-5 133743-71-2	EP 257618	Neuroprotective
VEA, Peregrine			US 6007817	Radio/chemosensitizer
vecuronium bromide	Piperidinium, 1-[[28,3Alpha,5Alpha,16B,17B)-3,17-bis(acetoxy)-2-(1-piperidinyl)androstan-16-yl]-1-methyl-, bromide [CAS]	50700-72-6	US 4237126	Muscle relaxant
V cur nium Bromide		50700-72-6		
V Inacrin		104675-29-8		
Venlafaxine		93413-69-5		
venlafaxine hydrochloride	Cyclohexanol, 1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]-, hydrochloride [CAS]	93413-69-5 99300-78-4	GB 2227743	Antidepressant
venlafaxine XR	Cyclohexanol, 1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]-, hydrochloride [CAS]	99300-78-4		Formulation, modified-release, <=24hr
venlafaxine, Phoenix	Cyclohexanol, 1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]-, hydrochloride [CAS]	99300-78-4		Formulation, modified-release, other
V raliprid		66644-81-3		

TABLE 6

Example of Indication
Hypertension, general
Sexual dysfunction, male, general
Sepsis
Hypertension, general
Cancer, general
Anaesthesia, adjunct
Depression, general
Depression, general
Depression, general

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Verapamil		52-53-9		
	Benzeneacetoneitrile, Alpha-[3-[[2-(3,4-dimethoxyphenyl)ethyl]methylamino]propyl]-3,4-dimethoxy-Alpha-(1-methylethyl)-[CAS]			
verapamil SR, Ethypharm		52-53-9		Formulation, modified-release, other
	Benzeneacetoneitrile, Alpha-[3-[[2-(3,4-dimethoxyphenyl)ethyl]methylamino]propyl]-3,4-dimethoxy-Alpha-(1-methylethyl)-[CAS]			
verapamil, Elan		52-53-9	US 4863742	Formulation, oral, other
	Benzeneacetoneitrile, Alpha-[3-[[2-(3,4-dimethoxyphenyl)ethyl]methylamino]propyl]-3,4-dimethoxy-Alpha-(1-methylethyl)-[CAS]			
verapamil, Mylan		52-53-9		Formulation, modified-release, other
	Benzeneacetoneitrile, Alpha-[3-[[2-(3,4-dimethoxyphenyl)ethyl]methylamino]propyl]-3,4-dimethoxy-Alpha-(1-methylethyl)-[CAS]			
verapamil, Orion-Farnos		52-53-9		Formulation, modified-release, <=24hr
	Benzeneacetoneitrile, Alpha-[3-[[2-(3,4-dimethoxyphenyl)ethyl]methylamino]propyl]-3,4-dimethoxy-Alpha-(1-methylethyl)-[CAS]			
verapamil, OROS, Alza		52-53-9		Formulation, modified-release, other
	Benzeneacetoneitrile, Alpha-[3-[[2-(3,4-dimethoxyphenyl)ethyl]methylamino]propyl]-3,4-dimethoxy-Alpha-(1-methylethyl)-[CAS]			
verapamil, Verex		52-53-9	US 4461759	Formulation, modified-release, <=24hr
	23H,25H-Benzof[b]porphine-9,13-dipropionic acid, 18-ethenyl-4,4a-dihydro-3,4-bis(methoxycarbonyl)-4a,8,14,19-tetramethyl-, monomethyl ester, trans-[CAS]			
verteporfin		129497-78-5	US 5238940	Ophthalmological
Verteporfin		129497-78-5		
vesnarinone	Piperazine, 1-(3,4-dimethoxybenzoyl)-4-(1,2,3,4-tetrahydro-2-oxo-6-quinolyl)-[CAS]	81840-15-5	GB 2086896	Cardio stimulant
V snarinone		81840-15-5		
V trabutin		3735-45-3		
VF-233	Benzene carboximidamide, N,3,4,5-tetrahydroxy- [CAS]	95933-74-7	US 4623659	Cardiovascular
VI-0134			US 6403597	Male sexual dysfunction

TABLE 6

Example f Indication
Hypertension, general
Hypertension, general
Hypertension, general
Tachycardia, supraventricular
Hypertension, general
Hypertension, general
Macular degeneration
Heart failure
Reperfusion injury
Premature ejaculation

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
vidarabine	9H-Purin-6-amine, 9-β-D-arabinofuranosyl- [CAS]	24356-66-9 5536-17-4	GB 1159280	Antiviral, other
Vidarabine		5536-17-4		
vigabatrin	5-Hexenoic acid, 4-amino- [CAS]	68506-86-5	GB 1472525	Antiepileptic
Vigabatrin		60643-86-9		
vilazodone	2-Benzoteturancarboxamide, 5-[4-{4-(5-cyano-1H-indol-3-yl)butyl}-1-piperazinyl]- [CAS]	163521-12-8	EP 648767	Antidepressant
Viloxazine		46817-91-8		
Vimin 1		21363-18-8		
Vinbarbital Sodium		125-44-0		
Vinblastine		865-21-4		
vinburnine	Ebumamenin-14(15H)-one, (3Alpha,16Alpha)- [CAS]	474-00-0 4880-88-0	DE 1932245	Cognition enhancer
Vincamin		1617-90-9		
Vinc nate		70704-03-9		
Vincristin		57-22-7		
vincristine solution	Vincalculoblastine, 22-oxo-, sulfate (1:1) (salt) [CAS]	2088-78-2	EP 207831	Formulation, parenteral, other
vincristine, Alza	Vincalculoblastine, 22-oxo- [CAS]	57-22-7		Formulation, optimized, liposomes
vincristine, bioMérieux-Pierre	Vincalculoblastine, 22-oxo- [CAS]	57-22-7		Formulation, parenteral, other
vindesine	Vincalculoblastine, 3-(aminocarbonyl)-O4-deacetyl-3-de(methoxycarbonyl)- [CAS]	53643-48-4 59917-39-4	GB 1463575	Anticancer, other
Vindesine		53643-48-4		
vinflunine	Aspidospermidine-3-carboxylic acid, 4-(acetyloxy)-6,7-didehydro-15-[(2R,4R,6S,8S)-4-(1,1-difluoroethyl)-1,3,4,5,6,7,8,9-octahydro-8-(methoxycarbonyl)-2,6-methano-2H-azecino[4,3-b]indol-8-yl]-3-hydroxy-16-methoxy-1-methyl-, methyl ester, (2S,3S,4S,5Alpha,12B,19Alpha) - [CAS]	162652-95-1	FR 2707988	Anticancer, other
vinorelbine	C'-Norvincalculoblastine, 3',4'-didehydro-4'-deoxy- [CAS]	71486-22-1	EP 10458	Anticancer, other

TABLE 6

Exempl f Indication
Infection, herpes virus, general
Epilepsy, partial (focal, local)
Depression, general
Cancer, general
Cancer, lymphoma, Hodgkin's
Cancer, general
Cancer, leukaemia, acute lymphocytic
Cancer, general
Cancer, lung, non-small cell

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
vinorelbine, oral	C'-Norvincaleukoblastine, 3',4'-didehydro-4'-deoxy- [CAS]	71486-22-1		Formulation, oral, other
vinpocetine	Ebumenine-14-carboxylic acid, ethyl ester, (3Alpha, 16Alpha)- [CAS]	42971-09-5	GB 1405127	Cognition enhancer
Vinp cetin		42971-09-5		
Vinyl Ether		109-93-3		
Vinylbital		2430-49-1		
Viquidil		84-55-9		
Viridin		3306-52-3		
Vismadin		477-32-7		
Vitamin A		68-26-8		
Vitamin B12, Nascet	Vitamin B12 [CAS]	68-19-9		Formulation, transmucosal, nasal
Vitamin C, Alza	L-Ascorbic acid [CAS]	50-81-7		Formulation, modified-release, <=24hr
Vitamin D ₂		50-14-6		
Vitamin D ₃		67-97-0		
Vitamin K ₃		83-70-5		
Vitamins, Prenatal				
VLA-4 antagonists, Aventis	((R,S)-4-(4-(Amino-imino-methyl)-phenyl)-3-((4-biphenyl)-methyl)-4-methyl-2,5-dioximidazolidin-1-yl)-acetyl-L-N-methyl-aspartyl-L-phenylglycine		EP 842943	Antiasthma
VNP-40101M	1,2-Bis(methylsulfonyl)-1-(2-chloroethyl)-2-(methylamino)carbonylhydrazine		US 6040338	Anticancer, alkylating
voglibose	D-epi-Inositol, 3,4-dideoxy-4-[[2-hydroxy-1-(hydroxymethyl)ethyl]amino]-2-C-(hydroxymethyl)- [CAS]	83480-29-9	EP 56194	Antidiabetic
Voglibose		83480-29-9		
voriconazole	4-Pyrimidineethanol, Alpha-(2,4-difluorophenyl)-5-fluoro-8-methyl-Alpha-(1H-1,2,4-triazol-1-ylmethyl)-, (R-(R*,S*))-[CAS]			
V ric naz l		137234-62-9	EP 440372	Antifungal
		137234-62-9		

TABLE 6

Example 1 Indication
Cancer, lung, non-small cell
Cognitive disorder, general
Anaemia, general
Nutrition
Asthma
Cancer, general
Diabetes, Type II
Infection, fungal, general

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Vorozole	7-[3-[4-(2-Quinolinylmethyl)-1-piperazinylpropoxy]-3,4-dihydro-2H-1,4-benzothiazine-3-one	129731-10-8		
VUF-K-8788				Antisthma
Warfarin		81-81-2		
WF-10	Tetrachlorodecaoxide [CAS]	92047-76-2		Radio/chemoprotective
WMC-79	2-[3-[4-(3-(6-oxo-6H-2,10b-diaza-acenanthren-5-ylamino)propyl)-piperazin-1-yl]propyl]-5-nitro-2-azaphenylene-1,3-dione			Anticancer, other
wound healing matrix, IPM, LAM			US 5897880	Formulation, transdermal, patch
WP-170			US 6531121	Cytokine
Xalipr den		135354-02-8		
xaliprodan hydrochloride	Pyridine, 1,2,3,6-tetrahydro-1-[2-(2-naphthalenyl)ethyl]-4-[3-(trifluoromethyl)phenyl]-, hydrochloride [CAS]	90494-79-4	EP 101381	Neuroprotective
xamoterol	4-Morpholinecarboxamide, N-[2-[[2-hydroxy-3-(4-hydroxyphenoxy)propylamino]ethyl]-, (+)- [CAS]	73210-73-8 81801-12-9	GB 2002748	Cardio stimulant
Xam ter I		81801-12-9		
Xan m lin		131986-45-3		
Xanthinol Niacinate		437-74-1		
Xemilofiban		149820-74-6		
X nbucin		959-10-4		
Xibenolol		81584-06-7		
xibornol	Phenol, 4,5-dimethyl-2-(1,7,7-trimethylbicyclo[2.2.1]hept-2-yl), exo- [CAS]	13741-18-9	GB 1208774	Antibacterial, other
Xiborn I		13741-18-9		

TABLE 6

Exempl of Indication
Asthma
Chemotherapy-induced injury, bone marrow, general
Cancer, colorectal
Ulcer, diabetic
Unspecified
Atrophic lateral sclerosis
Heart failure
Infection, general

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
ximelagatran	Glycine, N-((R)-cyclohexyl-2-((2S)-2-(((4-(hydroxyamino)iminomethyl)phenyl)methyl)amino)carbonyl)-1-azetidinyl)2-oxoethyl ester [CAS]	192939-46-1		Antithrombotic
Ximoprofen		56187-89-4		
xipamide	Benzamide, 5-(aminosulfonyl)-4-chloro-N-(2,6-dimethylphenyl)-2-hydroxy- [CAS]	14293-44-8	US 3567777	Antihypertensive, diuretic
Xipamide		14293-44-8		
xorphanol	Morphinan-3-ol, 17-(cyclobutylmethyl)-8-methyl-6-methylene-, (8R)- [CAS]	77287-89-9		Analgesic, other
XR-5118	2,5-Piperazinedione, 3-[[5-[[2-(dimethylamino)ethyl]thio]-2-(thienyl)methylene]-6-(phenylmethylene)-, monohydrochloride, (3Z,6Z)- [CAS]	174766-49-5	WO 9532190	Anticancer, other
XR-5944	N,N'-(1,2-Ethanediyl)bis(mino-2,1-ethanediyl)bis(9-methylphenazine-1-carboxamide)		EP 934278	Anticancer, other
Xylom tazolin		526-36-3		
Xylose		58-86-6		
YH-1885	2-Pyrimidinamine, 4-(3,4-dihydro-1-methyl-2(1H)-isoquinolyl)-N-(4-fluorophenyl)-5,6-dimethyl-, monohydrochloride [CAS]	178307-42-1	WO 9605177	Antulcer
YM-511	Benzonitrile, 4-[[[(4-bromophenyl)methyl]-4H-1,2,4-triazol-4-ylamino]- [CAS]	148869-05-0	WO 9305027	Anticancer, hormonal
YM-598	potassium(E)-N-[6-methoxy-5-(2-methoxyphenoxy)-2-(pyrimidin-2-yl)pyrimidin-4-yl]-2-phenylethanesulfonamide			Anticancer, other
Y himbine		146-48-5		
YT-146	Adenosine, 2-(1-octynyl)- [CAS]	90598-75-1	US 5270304	Anti-inflammatory
Z-321	Thiazolidine, 3-((2,3-dihydro-1H-inden-2-yl)acetyl)-4-(1-pyrrolidinylcarbonyl)-, (R)- [CAS]	130849-58-0	EP 372484	Cognition enhancer

TABLE 6

Example of Indication
Thrombosis, venous
Pain, cancer
Cancer, general
Cancer, general
Ulcer, GI, general
Cancer, breast
Cancer, prostate
Inflammation, general
Dementia, senile, general

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Z-335	(1H-Indene-5-acetic acid, 2[[[(4-chlorophenyl)sulfonylamino]methyl]-2,3-dihydro, monosodium salt] [CAS]	146731-14-8	JP 92506077	Antithrombotic
zafirlukast	Carbamic acid, [3-[[2-methoxy-4-[[[(2-methylphenyl)sulfonylamino]carbonyl]phenyl]methyl]-1-methyl-1H-indol-5-yl]-, cyclopentyl ester [CAS]	107753-78-6	EP 199543	Antiasthma
Zafirlukast		107753-78-6		
<i>Zafirlukast</i>				
zalcitabine	Cytidine, 2',3'-dideoxy- [CAS]	7481-89-2	US 4879277	Antiviral, anti-HIV
Zalcitabine		7481-89-2		
<i>Zalcitabine</i>				
Zaldarid		109826-26-8		
zaleplon	Acetamide, N-[3-(3-cyanopyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-N-ethyl- [CAS]	151319-34-5	EP 776898	Hypnotic/Sedative
Zalpl n		151319-34-5		
zaltoprofen	Dibenzof[b,f]thiepin-2-acetic acid, 10,11-dihydro-Alpha-methyl-10-oxo- [CAS]	74711-43-6	JP 55053282	Anti-inflammatory
Zaltoprof n		74711-43-6		
zanamivir	5-Acetamido-2,6-anhydro-3,4,5-trideoxy-4-guanidino-D-glycero-D-galacto-non-2-enonic acid [CAS]	139110-80-8	WO 9116320	Antiviral, other
Zanamivir		139110-80-8		
<i>Zanamivir</i>				
zanapezil	1-Propanone, 3-(1-(phenylmethyl)-4-piperidinyl)-1-(2,3,4,5-tetrahydro-1H-1-benzazepin-8-yl)- [CAS]	142852-50-4	EP 487071	Cognition enhancer
Zat bradine		85175-67-3		
ZD-0473	Platinum, aminedichloro(2-methylpyridine)- (SP-4-3)- [CAS]	181630-15-9	EP 727430	Anticancer, alkylating
ZD-0947	N-acetylcolchicinol-O-phosphate		WO 9528388	Urological
ZD-6126				Anticancer, other
ZD-9331	1H-Tetrazole-5-butanonic acid, Alpha-((4-(((1,4-dihydro-2,7-dimethyl-4-oxo-6-quinazolinyl)methyl)-2-propynylamino)-2-fluorobenzoyl)amino) (S)- [CAS]	153537-73-6	GB 2264946	Anticancer, antimetabolite

TABLE 6

Exempl of Indication
Peripheral vascular disease
Asthma
Infection, HIV/AIDS
Insomnia
Infection, influenza virus
Alzheimer's disease
Cancer, ovarian
Overactive bladder
Cancer, general
Cancer, pancreatic

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
zebularine	2(1H)-Pyrimidinone, 1-β-D-ribofuranosyl- [CAS]	3690-10-6		Anticancer, other
zelandopam hydrochloride	7,8-Isoquinolinediol, 4-(3,4-dihydroxyphenyl)-1,2,3,4-tetrahydro-, hydrochloride, (S)- [CAS]	138086-00-7	JP 03190818	Vasodilator, renal
Z nar stat		112733-06-9		
Zic n tide		107452-89-1		
zidovudine	Thymidine, 3'-azido-3'-deoxy- [CAS]	30516-87-1	US 4724232	Antiviral, anti-HIV
Zid vudine		30516-87-1		
zidovudine				
zidovudine				
zidovudine, Verex	Thymidine, 3'-azido-3'-deoxy- [CAS]	30516-87-1		Formulation, modified-release, <=24hr
zileuton	Urea, N-(1-benzob[thien-2-ylethyl)-N-hydroxy- [CAS]	111406-87-2	EP 278263	Antiasthma
Zileuton		111406-87-2		
Zimeldin		56775-88-3		
zinc acetate, basic	hexakis(μ-acetato)μ ₄ -oxotetrazinc	12129-82-7		Antiviral, other
zinc acexanate	Hexanoic acid, 6-(acetylaminio)-, zinc salt (2:1)- [CAS]	70020-71-2	EP 369088	Anticancer
zinc ibuprofenate, Vinas		78416-80-5		Anti-inflammatory, topical
Zinc p-Phen Isulfonate		127-82-2		
Zinc Salicylat		16283-36-6		
Zin statin		2/29014		
zinostatin stimalamer		123760-07-6	EP 136791	Anticancer, antibiotic
Zipepr I		34758-83-3		
ziprasidone	2H-Indol-2-one, 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro- [CAS]	122883-93-6 146939-27-7	EP 281309	Neuroleptic
Ziprasidon		146939-27-7		
zofenopril	L-Proline, 1-[3-(benzoylthio)-2-methyl-1-oxopropyl]-4-(phenylthio)-, 1,1 (R*), 2Alpha, 4Alpha)- [CAS]	75176-37-3 81872-10-8 81938-43-4	GB 2028327	Antihypertensive, renin system

TABLE 6

Example f Indication
Cancer, general
Hypertension, general
Infection, HIV/AIDS
Infection, HIV/AIDS
Asthma
Infection, herpes simplex virus prophylaxis
Ulcer, duodenal
Inflammation, dermal
Cancer, liver
Schizophrenia
Hypertension, general

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
zofenopril + HCTZ	L-Proline, 1-(3-(benzoylthio)-2-methyl-1-oxopropyl)-4-(phenylthio)-, [1(R*), 2Alpha, 4Alpha]- + 6-Chloro-3,4-dihydro-2H-1,2,4-benzothiazide-7-sulfonamide 1,1-dioxide [CAS]			Formulation, fixed-dose combinations
zoledronic acid	Phosphonic acid, [1-hydroxy-2-(1H-imidazol-1-yl)ethylidene]bis- [CAS]	118072-93-8	EP 531253	Osteoporosis treatment
Zoledronic Acid		118072-93-8; 165800-06-6 (monohydrate)		
zolimidine	2-(p-methylsulfonylphenyl)imidazo[1,2-a]pyridine	1222-57-7	US 3318880	Antitumor
Zolimidin		1222-57-7		
zolmitriptan	2-Oxazolidinone, 4-((3-(2-(dimethylamino)ethyl)-1H-indol-5-yl)methyl), (S)- [CAS]	139264-17-8	WO 9118897	Antimigraine
Zolmitriptan		139264-17-8		
zolmitriptan, DuraSolv	2-Oxazolidinone, 4-((3-(2-(dimethylamino)ethyl)-1H-indol-5-yl)methyl), (S)- [CAS]	139264-17-8		Formulation, modified-release, immediate
Zolpidem		82626-48-0		
zolpidem tartrate	Imidazo[1,2-a]pyridine-3-acetamide, N,N,6-trimethyl-2-(4-methylphenyl)-(R-(R*), R*))-, 2,3-dihydroxybutanedioate (2:1) [CAS]	99294-93-6	EP 50563	Hypnotic/Sedative
Zolpidem Tartrate				
zolpidem tartrate MR	Imidazo[1,2-a]pyridine-3-acetamide, N,N,6-trimethyl-2-(4-methylphenyl)-(R-(R*), R*))-, 2,3-dihydroxybutanedioate (2:1)	99294-93-6		Formulation, modified-release, other
zolpidem tartrate, Flash Dose	Imidazo[1,2-a]pyridine-3-acetamide, N,N,6-trimethyl-2-(4-methylphenyl)-(R-(R*), R*))-, 2,3-dihydroxybutanedioate (2:1) [CAS]	99294-93-6		Formulation, optimized, microparticles
Zolpidem		33369-31-2		
zonampanel	1(2H)-Quinoxalineacetic acid, 3,4-dihydro-7-(1H-imidazol-1-yl)-6-nitro-2,3-dioxo- [CAS]	210245-80-0		Neuroprotective

TABLE 6

Exemplification of Indication
Hypertension, general
Hypercalcaemia of malignancy
Gastritis
Migraine
Migraine
Insomnia
Insomnia
Insomnia
Ischaemia, cerebral

TABLE 6

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
zoniporide mesylate	1H-pyrazole-4-carboxamide, N-(aminolimo methyl)-5-cyclopropyl-1-(5-quinolinyl)-, monomethanesulfonate	249296-45-5		Cardiovascular
zonisamide	1,2-Benzisoxazole-3-methanesulfonamide [CAS]	68291-97-4 68291-98-5	GB 2025931	Antiepileptic
Z nisamide		68291-97-4		
zopiclone	1-Piperazinecarboxylic acid, 4-methyl-, 6-(5-chloro-2-pyridinyl)-6,7-dihydro-7-oxo-5H-pyrrolo[3,4-b]pyrazin-5-yl ester [CAS]	43200-80-2	GB 1358680	Hypnotic/Sedative
Zopiclon		43200-80-2		
Zopolrestat		110703-94-1		
Zorubicin		54083-22-6		
zosuquidar trihydrochloride	1-Piperazineethanol, 4-(1,1-difluoro-1,1a,6,10b-tetrahydrodibenzof[a,e]cyclopropa[cyclohepten-6-yl)-Alpha-(5-quinolinyl)oxy)methyl]-, trihydrochloride, [6(R)- (1aAlpha,6Alpha,10bAlpha)]-, [CAS]	167465-36-3		Radio/chemosensitizer
zotepine	Ethanamine, 2-[(8-chlorodibenzo[b,f]thiepin 10-yl)oxy]-N,N-dimethyl-, [CAS]	26615-21-4	GB 1247067	Neuroleptic
Zotepine		26615-21-4		
ZP-123			WO 0162775	Antiarrhythmic
Z-tamoxifen	Ethanamine, 2-[4-(1,2-diphenyl-1-butenyl)phenoxy]-N,N-dimethyl-, (Z)-, [CAS]	10540-29-1		Anticancer, hormonal
zuclopenthixol	1-Piperazineethanol, 4-[3-(2-chloro-9H-thioxanthen-9-ylidene)propyl]-, (Z)-, [CAS]	53772-83-1 982-24-1	EP 270282	Neuroleptic
zuclopenthixol acetate	1-Piperazineethanol, 4-[3-(2-chloro-9H-thioxanthen-9-ylidene)propyl]-, acetate (ester), (Z)-, [CAS]	85721-05-7		Neuroleptic
zuclopenthixol decanoate	Decanoic acid, 2-[4-[3-(2-chloro-9H-thioxanthen-9-ylidene)propyl]-1-piperazinyl]ethyl ester, (Z)-, [CAS]	64053-00-5		Neuroleptic

TABLE 6

Example f Indication
Unspecified
Epilepsy, generalized, tonic-clonic
Insomnia
Cancer, leukaemia, acute myelogenous
Schizophrenia
Arrhythmia, general
Cancer, colorectal
Psychosis, general
Schizophrenia
Schizophrenia

CLAIMS:

1. A pharmaceutical composition comprising a propylene glycol solvate of an API.
2. A composition according to claim 1, wherein the mole ratio of propylene glycol to API in the solvate is in the range 0.25 to 2.
3. A composition according to claim 1, wherein the solvate is in a crystalline form.
4. A composition according to claim 3, comprising a powder X-ray diffraction spectrum which differs from the corresponding powder X-ray diffraction spectrum of the unsolvated API by at least one property selected from
 - (i) a loss of at least one peak;
 - (ii) shifting of more than half the peaks at the 2-theta angle by at least 0.3°;
and
 - (iii) formation of at least one new peak.
5. A composition according to claim 1, wherein the solvate is stable to temperatures of up to 50 degrees C under a stream of gas in a thermogravimetric analysis apparatus.
6. A composition according to claim 1, wherein the API is in the form of a metal salt.
7. A composition according to claim 6, wherein the metal is an alkali metal or an alkaline earth metal.
8. A composition according to claim 7, wherein the metal is selected from Na, K, Li, Ca and Mg.

9. A composition according to claim 1, wherein the API is selected from the group consisting of celecoxib, naproxen, methyl prednisolone succinate ester, impinem/cilastatin, fomivirsen sodium, cerivastatin sodium, dalfopristin/quinopristin, gonadorelin HCl (decapeptide), clindamycin phosphate (ester prodrug), famciclovir, cyanocobalamin, tolcapone, epirubicin HCl, colestipol HCl (anion exc.), penicillin G potassium, bacitracin (peptide), fluvastatin sodium, diclofenac sodium, pilocarpine HCl, bethanechol chloride, trientine 2 (HCl), montelukast sodium, mechloroethamine HCl, hydrocortisone phosphate ester, dexamethasone phosphate ester, chromolyn sodium, pyridostigmine bromide, phentermine HCl, telmisartan, daunorubicin HCl, praziquantel, and entosan polysulfate sodium.
10. A composition according to claim 1, wherein the API has low aqueous solubility and is selected from the group consisting of steroid drugs.
11. A composition according to claim 1, which further comprises a pharmaceutically-acceptable diluent, excipient or carrier.
12. A propylene glycol solvate of a sodium salt of celecoxib, which comprises peaks at 2-theta angles of approximately 3.8°, 7.6°, 8.2°, 11.3° and 20.6°, in a powder X-ray diffraction spectrum.
13. A propylene glycol solvate of a potassium salt of celecoxib, which comprises peaks at 2-theta angles of approximately 3.8°, 7.5°, 11.3° and 18.3°, in a powder X-ray diffraction spectrum.
14. A propylene glycol solvate of a sodium salt of naproxen, which comprises peaks at 2-theta angles of approximately 6.7°, 9.7°, 15.8°, 18.6°, 20.8° and 22.8°, in a powder X-ray diffraction spectrum.

15. A method for preparing a propylene glycol solvate of an API, which method comprises:
- (a) contacting propylene glycol with an API in solution;
 - (b) crystallizing a propylene glycol solvate of the API from the solution; and
 - (c) isolating the solvate.
16. A method according to claim 15, wherein the step of crystallizing the solvate comprises changing the pH of the solution to precipitate the solvate.
17. A method according to claim 16, wherein the pH is raised to render the solution alkaline.
18. A method according to claim 15, wherein the step of isolating the solvate includes separating the solution phase from the solvate.
19. A method according to claim 18, wherein crystalline solvate is dried to remove excess solution phase.
20. A method for decreasing the hygroscopicity of an API, which method comprises
- (a) contacting the API with propylene glycol in solution;
 - (b) crystallizing a propylene glycol solvate of the API from the solution; and
 - (c) isolating the solvate, wherein the solvate has decreased hygroscopicity as compared to the API.
21. A method for increasing the aqueous solubility of an API, which method comprises
- (a) contacting the API with propylene glycol in solution;
 - (b) crystallizing a propylene glycol solvate of the API from the solution; and
 - (c) isolating the solvate, wherein the solvate has increased aqueous solubility as compared to the API.

22. A method according to claim 15, wherein the solvate has a powder X-ray diffraction spectrum which differs from the corresponding powder X-ray diffraction spectrum of the unsolvated API by at least one property selected from
- (i) a loss of at least one peak;
 - (ii) shifting of more than half the peaks at the 2-theta angle by at least 0.3°; and
 - (iii) formation of at least one new peak.
23. A method according to claim 15, wherein the solvate is stable to temperatures of up to 50 degrees C under a stream of gas in a thermogravimetric analysis apparatus.
24. A method according to claim 15, wherein the API is in the form of a metal salt.
25. A method according to claim 24, wherein the metal is an alkali metal or an alkaline earth metal.
26. A method according to claim 25, wherein the metal is selected from Na, K, Li, Ca and Mg.
27. A method according to claim 1, wherein the API comprises, celecoxib, naproxen, methyl prednisolone succinate ester, impinem/cilastatin, fomivirsen sodium, cerivastatin sodium, dalfopristin/quinopristin, gonadorelin HCl (decapeptide), clindamycin phosphate (ester prodrug), famciclovir, cyanocobalamin, tolcapone, epirubicin HCl, colestipol HCl (anion exc.), penicillin G potassium, bacitracin (peptide), fluvastatin sodium, diclofenac sodium, pilocarpine HCl, bethanechol chloride, trientine 2 (HCl), montelukast sodium, mechlorethamine HCl, hydrocortisone phosphate ester, dexamethasone phosphate ester, chromolyn sodium, pyridostigmine bromide, phentermine HCl, telmisartan, daunorubicin HCl, praziquantel, and pentosan polysulfate sodium.

28. A method according to claim 1, wherein the API has low aqueous solubility and is selected from the group consisting of steroid drugs.

29. A composition according to claim 1, wherein the API is olanzapine and the composition is characterized by a PXRD pattern comprising peaks expressed in terms of 2 theta angles, wherein:

- (i) said form is a propylene glycol solvate of olanzapine and said PXRD pattern comprises peaks at 8.3, 15.6 and 21.4 degrees;
- (ii) said form is a propylene glycol solvate of olanzapine and said PXRD pattern comprises peaks at 8.9, 11.7, 22.0, and 23.6 degrees;
- (iii) said form is a propylene glycol solvate of olanzapine and said PXRD pattern comprises peaks at 11.5, 18.0, 19.2, 19.6, and 20.6 degrees; or
- (iv) said form is a propylene glycol solvate of olanzapine and said PXRD pattern comprises peaks at 8.3, 8.9, 11.5, 11.7, 15.6, 18.0, 19.2, 19.6, 20.6, 21.4, 22.0, and 23.6 degrees.

30. A method according to claim 15, wherein the API is olanzapine.

31. A composition according to claim 1, wherein the API is cortisone acetate and the composition is characterized by a PXRD pattern comprising peaks expressed in terms of 2 theta angles, wherein:

- (i) said form is a propylene glycol solvate of cortisone acetate and said PXRD pattern comprises peaks at 10.7, 14.6 and 18.5 degrees;
- (ii) said form is a propylene glycol solvate of cortisone acetate and said PXRD pattern comprises peaks at 5.3, 15.7, 21.4, and 23.5 degrees; or
- (iii) said form is a propylene glycol solvate of cortisone acetate and said PXRD pattern comprises peaks at 5.3, 10.7, 14.6, 15.7, 18.5, 21.4, and 23.5 degrees.


32. A method according to claim 15, wherein the API is cortisone acetate.

FIG. 1

File: G:\Data\OSC\mal\tr33\mal33-07-00-12.01
 Operator: MLT
 Run Date: 21-Mar-03 10:21


DEC

Sample: mal33-07-00-12
 Size: 2.6910mm
 Modulus: 1000
 Consistent: 1000



Sample: 57_26_13
 Size: 2.0000 mg
 Method: Hi-Res - Dynamic
 Comment: TP133304

TGA



100% CHLOROPOLYMERIZATION OF STYRENE, 100% CHLOROPOLYMERIZATION OF STYRENE

100% CHLOROPOLYMERIZATION OF STYRENE, 100% CHLOROPOLYMERIZATION OF STYRENE




FIG. 3

Sample: mo-116-49b-celecoxib-LIOH
Size: 1.5600 mg
Method: Ramp

DSC

File: \\...mo-116-49b_celecoxib-LIOH_in2.001
Operator: MAO
Run Date: 06-Dec-02 11:28




FIGURE 4

Sample: MO-116-49b_celecoxib-LI
Size: 8.2290 mg
Method: Ramp

TGA

File: \\...MarkOlmo-116-49b_celecoxib-LI.001
Operator: MAO
Run Date: 08-Dec-02 16:36




FIGURE 5




FIGURE 6




FIGURE 7

Sample: mo-116-49a-celecoxib-KOH
Size: 1.1190 mg
Method: Ramp

DSC

File: \\mo-116-49a_celecoxib-KOH_inN2.001
Operator: MAC
Run Date: 06-Dec-02 10:55




FIGURE 8

Sample: MO-116-49a_celecoxib-K
Size: 5.9890 mg
Method: Stepwise Isothermal

TGA

File: \\...MarkO\mo-116-49a_celecoxib-K.001
Operator: MAO
Run Date: 06-Dec-02 11:35




FIGURE 9




FIGURE 10




FIGURE 11

Sample: Celecoxib Na pg from Et2O
 Size: 3.0430 mg
 Method: Ramp

TGA

File: MT_114_118_A; Celecoxib Na pg
 Operator: MDT
 Run Date: 26-Nov-02 19:30
 Instrument: TGA Q500 V4.7 Build 151




FIGURE12




FIGURE 13

Sample: MT_114_139_C; Colecodb K pg
 Size: 5.5520 mg
 Method: Ramp
 Comment from E20

TGA

File: I:_ITA\Data\TGA\MTawa\MT_114_139_C.001
 Operator: MDT
 Run Date: 20-Dec-02 14:19
 Instrument: TGA Q500 V4.7 Build 151




FIGURE 14




FIGURE 15

Sample: Celecoxib LI pg
Size: 3.4520 mg
Method: Ramp
Comment: from Et2O with tBuLi

TGA

File: \\...IT\DATA\TGA\MTewa\MT_114_141_A.001
Operator: MDT
Run Date: 23-Dec-02 15:39
Instrument: TGA Q500 V4.7 Build 151




FIGURE 16

Sample: MT_114_128_A; Naproxen Na pg
Size: 3.0340 mg
Method: Ramp
Comment: from Et2O

TGA

File: \\...IT\DATA\TGA\MTewa\MT_114_128_A.001
Operator: MDT
Run Date: 10-Dec-02 16:44
Instrument: TGA Q500 V4.7 Build 151




FIGURE 17




FIGURE 18




FIGURE 21A




FIGURE 19




FIGURE 20




FIGURE 21B

0




FIGURE 22

Sample: JR_81_143_A_DSC
 Size: 2.2280 mg
 Method: Ramp

DSC

File: T:\Data\BSC\JitesR\JR_81_143_A.DSC.
 Operator: JFR
 Run Date: 25-Feb-03 04:14
 Instrument: DSC Q1000 V6.19 Build 227




FIGURE 23




FIGURE 24A




FIGURE 24B

Sample: cortisone acetate from PG_IPAC
Size: 0.9280 mg
Method: Ramp

TGA

File: T:\Data\TGA\JulesRU\JulesWT_81_134_G
Operator: MDT
Run Date: 24-Dec-02 14:11
Instrument: TGA Q500 V4.7 Build 151




FIGURE 25

Sample: JR_81_135_A_NB150_8
Size: 1.1900 mg
Method: Ramp

DSC

File: T:\DSC\mesRJR_81_135_A_NB150_8
Operator: JFR
Run Date: 28-Mar-03 03:10
Instrument: DSC Q1000 V6.19 Build 227




FIGURE 26